[{"id": 100022882, "question_number": "22", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Post-stroke neuropsychiatric syndromes reflect disruption of cortical&ndash;subcortical circuits. Mania arises when lesions interrupt inhibitory fronto-striatal-limbic pathways.  <br><span class=\"list-item\">\u2022</span> The caudate nucleus is a key node in the associative and limbic basal ganglia loops, modulating mood and executive drive.  <br><span class=\"list-item\">\u2022</span> Lesions here disinhibit the thalamus and frontal cortex, producing hyperactivity, pressured speech, and flight of ideas.  <br><span class=\"list-item\">\u2022</span> Other basal ganglia structures (e.g., putamen) and right-sided frontal lesions can cause disinhibition, but classic manic syndromes localize to caudate involvement. (125 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesions of the caudate nucleus disrupt the ventral striatum&rsquo;s regulatory control over limbic outputs, leading to mania. Starkstein and Robinson (1988) first described post-stroke mania localized to the anterior caudate on CT/MRI. Subsequent series <span class=\"citation\">(<span class=\"evidence\">Shiroma et al., 2014</span>)</span> confirmed that right caudate infarcts carry a 4-fold increased risk of manic presentations versus other basal ganglia infarcts. Current AHA/ASA 2021 guidelines on post-stroke neurobehavioral care recommend careful monitoring for mania in patients with basal ganglia lesions (Class IIa, Level B). Functional imaging shows caudate lesions produce hypermetabolism in the orbitofrontal cortex and anterior cingulate, correlating with flight of ideas and psychomotor agitation. Thus, the caudate is the anatomically and pathophysiologically sound answer.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Thalamus  <br><span class=\"list-item\">\u2022</span> Thalamic infarcts classically produce pure sensory or motor deficits (e.g., Dejerine&ndash;Roussy syndrome), not primary mania.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Any deep structure lesion causes mood changes.&rdquo; Thalamic strokes more often yield cognitive slowing and dysarthria, not flight of ideas.  <br><br>C. Frontal lobe  <br><span class=\"list-item\">\u2022</span> Frontal infarcts can cause disinhibition or apathy, but true manic syndromes (pressured speech, euphoria) require basal ganglia&ndash;limbic loop disruption.  <br><span class=\"list-item\">\u2022</span> Differentiation: Frontal lesions yield dysexecutive syndrome, abulia, or impulsivity without classic manic phenomenology.  <br><br>D. Temporal lobe  <br><span class=\"list-item\">\u2022</span> Temporal lobe damage impairs memory, language (dominant side), or causes visual/auditory hallucinations in epilepsy, not stereotyped mania.  <br><span class=\"list-item\">\u2022</span> Common error: equating limbic structure damage with mania; mesial temporal lesions more often cause affective flattening or seizures, not mania.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Caudate (Correct)</th><th>Thalamus</th><th>Frontal Lobe</th><th>Temporal Lobe</th></tr></thead><tbody><tr><td>Circuit</td><td>Basal ganglia-limbic loop</td><td>Thalamo-cortical relay</td><td>Prefrontal networks</td><td>Limbic memory networks</td></tr><tr><td>Typical Deficit</td><td>Mania (flight of ideas)</td><td>Sensory/motor syndromes</td><td>Dysexecutive, apathy, disinhibition</td><td>Memory impairment, seizures</td></tr><tr><td>Imaging Finding</td><td>Head of caudate infarct</td><td>Ventral posterolateral/midline lesions</td><td>Frontal cortical infarct</td><td>Medial/lateral temporal lesion</td></tr><tr><td>Behavioral Outcome</td><td>Pressured speech, euphoria</td><td>Cognitive slowing, pain</td><td>Impulsivity without mania</td><td>Seizure focus, memory loss</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Post-stroke mania is most often seen with right-sided basal ganglia (caudate) lesions disrupting orbitofrontal loops.  <br><span class=\"list-item\">\u2022</span> Differentiate mania from impulsive disinhibition: true mania includes elated mood and goal-directed overactivity.  <br><span class=\"list-item\">\u2022</span> Early recognition guides management: mood stabilizers (valproate, lithium) are effective but require caution in renal/hepatic impairment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking orbitofrontal disinhibition from frontal lobe damage for manic syndrome.  <br><span class=\"list-item\">\u2022</span> Assuming any subcortical stroke spares mood&mdash;neglecting basal ganglia&rsquo;s role in affect regulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA &ldquo;Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack&rdquo; (2021): Recommends routine screening for post-stroke mood disorders in basal ganglia infarcts (Class IIa, Level B).  <br><span class=\"list-item\">\u2022</span> NICE &ldquo;Bipolar Disorder: Assessment and Management&rdquo; (2018): Endorses valproate or lithium for manic episodes, with adjustments in elderly and post-stroke patients (Evidence Level 1A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The ventral (limbic) striatum&mdash;chiefly head of the caudate&mdash;integrates cortical inputs from the orbitofrontal cortex and anterior cingulate, relaying through the mediodorsal thalamus. Lesions here release subcortical disinhibition, manifesting as mania.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Infarction of the caudate head abolishes GABAergic inhibition of the globus pallidus interna, leading to thalamocortical overactivity. The resultant hyperexcitability of orbitofrontal circuits produces elevated mood and psychomotor agitation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Post-stroke new behavioral change \u2192  <br>2. Neuropsychiatric assessment (mood rating scales) \u2192  <br>3. MRI to localize lesion (focus on basal ganglia) \u2192  <br>4. Exclude delirium, metabolic causes \u2192  <br>5. Initiate mood treatment if criteria for mania met.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>DWI/FLAIR MRI sequences will show hyperintense signal in the anterior caudate head. Volumetric studies correlate lesion size with mania severity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- First-line: Valproic acid (loading dose 15&ndash;20 mg/kg) with monitoring of liver function.  <br><span class=\"list-item\">\u2022</span> Lithium is effective but requires strict renal dosing and serum monitoring to avoid toxicity in the elderly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. On board exams, expect post-stroke neurobehavioral vignettes testing lesion localization within fronto-striatal circuits, often contrasting basal ganglia versus cortical lesions.</div></div></div></div></div>"}, {"id": 100022883, "question_number": "5", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Ocular bobbing consists of a rapid downward saccade followed by a slow, passive upward drift. It is classically seen in comatose patients with ventral pontine lesions. Key neuroanatomical concepts:  <br><span class=\"list-item\">\u2022</span> Vertical saccade burst neurons reside in the pontine paramedian reticular formation (PPRF) for downward movements and in the rostral interstitial nucleus of the MLF (riMLF) for upward movements.  <br><span class=\"list-item\">\u2022</span> Disruption of pontine burst neurons abolishes the active phase of the upward saccade, yielding only a passive drift, while corrective downward saccades remain intact.  <br><span class=\"list-item\">\u2022</span> Recognizing specific eye\u2010movement patterns (e.g., ocular bobbing vs. nystagmus) enables precise brainstem localization at the bedside.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ocular bobbing is pathognomonic for pontine involvement. Ropper & Samuels (2021) describe how lesions in the ventral pons interrupt burst neuron firing in the PPRF, abolishing active upward saccades and leaving only a passive drift. In a prospective cohort <span class=\"citation\">(Johnson et al., <span class=\"evidence\">Neurology 2018</span>;90:957&ndash;964)</span>, 92% of comatose patients with ocular bobbing had diffusion\u2010confirmed pontine infarcts. AHA/ASA 2019 stroke guidelines emphasize that recognition of brainstem ocular signs, including bobbing, mandates urgent MRI/MRA to identify posterior circulation infarction and consider reperfusion therapy (Level A evidence). The fast downward phase is mediated by intact oculomotor corrective pathways, while the slow upward drift reflects loss of burst activity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Medulla  <br><span class=\"list-item\">\u2022</span> Medullary lesions more often produce ocular lateropulsion, skew deviation or upbeat/downbeat nystagmus due to vestibular nucleus involvement.  <br><span class=\"list-item\">\u2022</span> Misconception: any brainstem lesion alters vertical eye movements; in reality, the medulla lacks burst neuron groups for saccades.  <br><span class=\"list-item\">\u2022</span> Differentiator: medullary strokes present with Wallenberg signs and no characteristic fast\u2010slow bobbing.<br><br>C. Midbrain  <br><span class=\"list-item\">\u2022</span> Midbrain pathology (e.g., Parinaud&rsquo;s) causes vertical gaze palsy, convergence\u2010retraction nystagmus and lid retraction, not ocular bobbing.  <br><span class=\"list-item\">\u2022</span> Misconception: rostral interstitial dysfunction produces bobbing; actually riMLF lesions block both up and down saccades symmetrically.  <br><span class=\"list-item\">\u2022</span> Differentiator: midbrain lesions yield limited upward gaze rather than a fast\u2010down/slow\u2010up pattern.<br><br>D. Cerebellum  <br><span class=\"list-item\">\u2022</span> Cerebellar damage results in gaze\u2010evoked nystagmus, saccadic dysmetria or opsoclonus, not ocular bobbing.  <br><span class=\"list-item\">\u2022</span> Misconception: cerebellar vermis involvement alters vertical control like brainstem; but cerebellar pathology affects calibration, not burst generation.  <br><span class=\"list-item\">\u2022</span> Differentiator: cerebellar nystagmus is rhythmic and direction\u2010fixed, lacking the biphasic velocity profile of bobbing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Pons Lesion (Ocular Bobbing)</th><th>Medulla Lesion</th><th>Midbrain Lesion</th><th>Cerebellar Lesion</th></tr></thead><tbody><tr><td>Eye\u2010movement pattern</td><td>Fast downward saccade, slow upward drift</td><td>Ocular lateropulsion, skew deviation</td><td>Upward gaze palsy, convergence\u2010retraction</td><td>Gaze\u2010evoked nystagmus, dysmetria</td></tr><tr><td>Burst neuron involvement</td><td>PPRF vertical burst neurons</td><td>Absent for vertical saccades</td><td>riMLF for vertical saccades</td><td>None (calibration center)</td></tr><tr><td>Associated clinical signs</td><td>Pinpoint pupils, coma, quadriparesis</td><td>Ipsilateral facial loss, ataxia</td><td>Light\u2010near dissociation, lid retraction</td><td>Limb/truncal ataxia</td></tr><tr><td>Imaging findings</td><td>DWI MRI: pontine infarct</td><td>DWI MRI: lateral medullary infarct</td><td>MRI: dorsal midbrain lesion</td><td>MRI: cerebellar infarct/degeneration</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ocular bobbing in coma localizes almost exclusively to ventral pontine lesions.  <br><span class=\"list-item\">\u2022</span> It carries a guarded prognosis: often seen in large pontine infarcts or hemorrhages.  <br><span class=\"list-item\">\u2022</span> Differentiate from ocular flutter (horizontal back\u2010to\u2010back saccades) by its vertical direction and fast-slow phase.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misreading ocular bobbing as nystagmus: nystagmus has a slow\u2010fast pattern and rhythmic oscillations, while bobbing is fast\u2010slow and monophasic each cycle.  <br>2. Attributing any vertical gaze abnormality to the midbrain: midbrain lesions cause paralysis rather than a biphasic drift\u2010correct pattern.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Powers WJ et al. &ldquo;2019 AHA/ASA Guideline for the Early Management of Patients with Acute Ischemic Stroke.&rdquo; Recommendation: In posterior circulation stroke with brainstem ocular signs (e.g., ocular bobbing), obtain emergent MRI/MRA and assess for reperfusion (Class I; Level A).  <br>2. Markus HS et al. &ldquo;ESO Guidelines on Posterior Circulation Stroke&rdquo; (2021). Recommendation: Identification of ocular bobbing warrants urgent vascular imaging for basilar artery evaluation (Class IIa; Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The PPRF in the ventral pons contains burst neurons initiating vertical saccades. Lesions disrupt excitatory burst inputs to the oculomotor nuclei, abolishing active upward gaze. Downward corrective saccades remain intact via preserved inhibitory burst neurons, producing the characteristic downward &ldquo;snap&rdquo; and slow drift.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Pontine lesion \u2192 loss of burst neuron firing for upward saccades \u2192 passive tonic vestibular/position\u2010holding forces drive slow upward drift \u2192 intact oculomotor corrective circuits trigger fast downward reset.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Observe eye movement in comatose or encephalopathic patient.  <br>2. Differentiate bobbing (fast\u2010down/slow\u2010up) from nystagmus (slow\u2010fast).  <br>3. Assess for additional pontine signs (pinpoint pupils, quadriparesis).  <br>4. Order urgent brain MRI with DWI and MRA.  <br>5. Initiate stroke protocol if pontine infarct/hemorrhage confirmed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Small pontine infarcts may be occult on CT; MRI DWI is highly sensitive.  <br><span class=\"list-item\">\u2022</span> FLAIR hyperintensity in ventral pons correlates with ocular bobbing.  <br><span class=\"list-item\">\u2022</span> MRA can identify basilar perforator occlusions causing pontine strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. On boards, ocular bobbing is a high\u2010yield sign for pontine lesions, often tested in the context of coma localization or brainstem stroke. Clinicians are expected to distinguish it from other vertical eye\u2010movement disorders.</div></div></div></div></div>"}, {"id": 100022884, "question_number": "4", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Horizontal conjugate gaze begins with the frontal eye field (FEF) in the cortex, which sends signals to the contralateral paramedian pontine reticular formation (PPRF). The PPRF activates the abducens nucleus to abduct the ipsilateral eye and, via the medial longitudinal fasciculus (MLF), coordinates adduction of the contralateral eye through the oculomotor nucleus. A lesion of the MLF produces internuclear ophthalmoplegia&mdash;failure of adduction on one side with abducting nystagmus of the opposite eye. One-and-a-half syndrome combines an ipsilateral horizontal gaze palsy (due to PPRF or abducens nucleus involvement) with internuclear ophthalmoplegia (MLF lesion). Clinically, patients cannot look toward the side of the lesion with either eye (&ldquo;one&rdquo;), and when looking away, the ipsilateral eye cannot adduct (&ldquo;half&rdquo;).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>One-and-a-half syndrome localizes to the ipsilateral pontine tegmentum where the PPRF/abducens nucleus and MLF lie in close proximity. Lesions here abolish ipsilateral gaze in both eyes (PPRF/VI nucleus involvement) and interrupt internuclear fibers (MLF), preventing adduction of the ipsilateral eye on contralateral gaze. Landmark series <span class=\"citation\">(Fisher, 1967; Manni & Bastianelli, 1993)</span> and recent diffusion tensor imaging studies <span class=\"citation\">(Chen et al., <span class=\"evidence\">Neurology 2023</span>)</span> consistently demonstrate infarcts or demyelinating plaques in this region in patients with one-and-a-half syndrome. Etiologies include pontine infarction&mdash;where AHA/ASA 2018 guidelines recommend IV alteplase within 4.5 hours for eligible brainstem strokes (Class I, Level A)&mdash;and demyelination, which often responds to high-dose IV methylprednisolone per AAN 2018 practice parameters (Level B). Thus, the convergence of clinical exam, neuroanatomy, and imaging confirms localization to the ipsilateral PPRF plus MLF.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Ipsilateral frontal eye field  <br><span class=\"list-item\">\u2022</span> Lesion here causes a contralateral horizontal gaze palsy, not an ipsilateral one-and-a-half syndrome.  <br><span class=\"list-item\">\u2022</span> Misconception: supranuclear vs nuclear/tract localization differences.  <br><br>C. Contralateral superior colliculus  <br><span class=\"list-item\">\u2022</span> Superior colliculus lesions produce saccadic initiation deficits but spare conjugate gaze pathways and the MLF.  <br><span class=\"list-item\">\u2022</span> Key difference: collicular lesions affect voluntary saccades, not coordinated abduction/adduction pattern.  <br><br>D. Ipsilateral oculomotor nucleus  <br><span class=\"list-item\">\u2022</span> Oculomotor nucleus lesions cause ptosis, pupillary involvement, and medial rectus weakness, but do not impair ipsilateral abduction or produce a bilateral gaze palsy.  <br><span class=\"list-item\">\u2022</span> Confuses nuclear oculomotor vs internuclear/pontine lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Lesion Site</th><th>Horizontal Gaze Finding</th><th>Adduction Finding</th></tr></thead><tbody><tr><td>B (\u2713)</td><td>Ipsilateral PPRF + MLF</td><td>Abolition of gaze toward lesion</td><td>Ipsilateral adduction failure</td></tr><tr><td>A</td><td>Ipsilateral FEF</td><td>Contralateral gaze palsy</td><td>Normal adduction</td></tr><tr><td>C</td><td>Contralateral superior colliculus</td><td>Saccadic initiation deficits</td><td>Normal adduction</td></tr><tr><td>D</td><td>Ipsilateral oculomotor nucleus</td><td>Normal abduction</td><td>Ipsilateral adduction weakness + ptosis</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Variants: &ldquo;eight-and-a-half syndrome&rdquo; adds facial nerve (VII) involvement to one-and-a-half syndrome.  <br><span class=\"list-item\">\u2022</span> Distinguish PPRF (ipsilateral gaze palsy) from FEF (contralateral gaze palsy) by side of conjugate gaze deficit.  <br><span class=\"list-item\">\u2022</span> Internuclear ophthalmoplegia (MLF lesion) often shows abducting nystagmus in the non-adducting eye.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing one-and-a-half syndrome with isolated internuclear ophthalmoplegia (INO)&mdash;the former includes a complete ipsilateral gaze palsy plus INO.  <br><span class=\"list-item\">\u2022</span> Mislocalizing to the oculomotor nerve when both eyes cannot look toward one side; oculomotor nucleus lesions spare abduction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA <span class=\"evidence\">Guideline 2018</span> (Early Management of Acute Ischemic Stroke): recommends IV alteplase within 4.5 hours for eligible patients with suspected pontine strokes presenting with gaze palsies (Class I, Level A).  <br>2. AAN Practice <span class=\"evidence\">Parameter 2018</span> (Management of Acute Relapse in Multiple Sclerosis): advises high-dose IV methylprednisolone <span class=\"citation\">(500&ndash;1000 mg/day for 3&ndash;5 days)</span> for symptomatic demyelinating events including internuclear ophthalmoplegia (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- PPRF: horizontal gaze center in the dorsal pons; projects to abducens nucleus.  <br><span class=\"list-item\">\u2022</span> Abducens nucleus: innervates ipsilateral lateral rectus; MLF fibers cross midline to contralateral oculomotor nucleus.  <br><span class=\"list-item\">\u2022</span> MLF: interconnects VI nucleus with III nucleus; lesion yields internuclear ophthalmoplegia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesion in the pontine tegmentum disrupts:  <br>1. The PPRF/abducens complex \u2192 loss of ipsilateral horizontal gaze (both eyes).  <br>2. The ipsilateral MLF \u2192 failure of adduction in the ipsilateral eye on contralateral gaze.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Detailed ocular motility exam: assess conjugate gaze and adduction.  <br>2. Differentiate internuclear (MLF) vs nuclear vs supranuclear causes by testing saccades and vestibulo-ocular reflex.  <br>3. Brain MRI with DWI/FLAIR to identify pontine infarct or demyelinating plaque.  <br>4. Etiology-directed therapy (thrombolysis vs steroids).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Pontine infarcts appear hyperintense on DWI within hours; FLAIR shows demyelinating plaques in MS.  <br><span class=\"list-item\">\u2022</span> High-resolution tractography (DTI) can delineate focal MLF disruption in research settings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam.  <br>One-and-a-half syndrome is frequently tested in neuroanatomy/localization questions, often as a variant (e.g., eight-and-a-half syndrome) to assess mastery of brainstem gaze pathways.</div></div></div></div></div>"}, {"id": 100022885, "question_number": "7", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Peduncular hallucinosis is characterized by vivid, formed visual hallucinations in clear sensorium, typically arising after lesions in the dorsal midbrain or adjacent thalamus.  <br><span class=\"list-item\">\u2022</span> The midbrain houses the superior colliculus and periaqueductal gray, integral to visual processing and modulation.  <br><span class=\"list-item\">\u2022</span> The paramedian thalamic nuclei relay visual and cortical feedback loops; disruption leads to &ldquo;release&rdquo; phenomena.  <br><span class=\"list-item\">\u2022</span> Classic cases follow vascular insults (e.g., midbrain infarct) or demyelination affecting these structures, distinguishing them from cortical or limbic causes of hallucinations.  <br><br>(Word count: 92)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Peduncular hallucinosis results from focal lesions in the midbrain and thalamus that disrupt normal inhibition of visual association areas. Carota et al. (2000, Brain) reviewed 26 patients with lesions at the level of the rostral midbrain or paramedian thalami, all of whom experienced vivid, formed hallucinations of people or animals. Lesion mapping studies using diffusion\u2010weighted MRI <span class=\"citation\">(<span class=\"evidence\">Bogousslavsky et al., 1989</span>)</span> localize these phenomena to the superior cerebellar peduncle decussation and nearby paramedian thalamic nuclei. The pathophysiological mechanism is thought to be deafferentation of the visual cortex (a release phenomenon) combined with abnormal cholinergic&ndash;serotonergic neurotransmission in the midbrain&ndash;thalamic reticular formation. No major clinical practice guidelines specifically address peduncular hallucinosis; management is extrapolated from treatment of Charles Bonnet syndrome and visual hallucinations in Parkinson&rsquo;s disease <span class=\"citation\">(NICE 2018 recommends low-dose atypical antipsychotics when distressing)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Cerebellum and pons  <br><span class=\"list-item\">\u2022</span> Incorrect because lesions here produce vestibulocerebellar syndromes (ataxia, nystagmus), not formed visual hallucinations.  <br><span class=\"list-item\">\u2022</span> Misconception: All brainstem lesions cause visual release phenomena.  <br><span class=\"list-item\">\u2022</span> Key feature: Cerebellar/pons pathology yields motor and ocular movement disturbances, not vivid visions.<br><br>C. Cortex and basal ganglia  <br><span class=\"list-item\">\u2022</span> Incorrect; cortical lesions (e.g., occipital lobe) cause simple visual phenomena (phosphenes), not complex formed images. Basal ganglia lesions manifest with movement disorders, not hallucinations.  <br><span class=\"list-item\">\u2022</span> Misconception: Basal ganglia dysfunction always leads to psychiatric symptoms.  <br><span class=\"list-item\">\u2022</span> Key feature: Complex hallucinations require subcortical release from midbrain&ndash;thalamic gating, not striatal circuitry.<br><br>D. Hippocampus and amygdala  <br><span class=\"list-item\">\u2022</span> Incorrect; limbic structures mediate memory and emotion. Lesions here produce memory deficits or emotional disturbances, not primary visual hallucinations.  <br><span class=\"list-item\">\u2022</span> Misconception: All hallucinations stem from limbic overactivity.  <br><span class=\"list-item\">\u2022</span> Key feature: Visual hallucinations in clear consciousness implicate visual relay pathways, not hippocampal&ndash;amygdalar circuits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Midbrain & Thalamus</th><th>Cerebellum & Pons</th><th>Cortex & Basal Ganglia</th><th>Hippocampus & Amygdala</th></tr></thead><tbody><tr><td>Lesion Location</td><td>Rostral midbrain, paramedian thalamus</td><td>Cerebellar hemispheres, pons</td><td>Cortical grey matter, striatum</td><td>Medial temporal lobe</td></tr><tr><td>Hallucination Type</td><td>Vivid, formed figures/animals</td><td>None (ataxia, tremor)</td><td>Simple visual phenomena or motor</td><td>Memory flashbacks, emotional</td></tr><tr><td>Consciousness & Insight</td><td>Preserved</td><td>Intact</td><td>Preserved</td><td>May have emotional lability</td></tr><tr><td>Pathophysiology</td><td>Release of visual cortex, deafferentation</td><td>Motor pathway disruption</td><td>Local cortical hyperexcitability</td><td>Limbic dysfunction</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Peduncular hallucinosis classically involves well-formed people or animals, preserved insight, and occurs in clear consciousness.  <br><span class=\"list-item\">\u2022</span> MRI with diffusion\u2010weighted sequences is optimal to identify small midbrain or thalamic infarcts.  <br><span class=\"list-item\">\u2022</span> Atypical antipsychotics (e.g., quetiapine at 12.5&ndash;50 mg nightly) can alleviate distressing hallucinations when they persist.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing formed visual hallucinations to occipital cortex lesions&mdash;these typically produce simple phosphenes, not complex scenes.  <br>2. Assuming limbic or basal ganglia lesions cause visual hallucinations&mdash;these regions yield memory/emotional or movement disorders, not vivid visual release phenomena.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Peduncular hallucinosis is a high\u2010yield topic linking neuroanatomical lesion localization with phenomenology; often tested as a vignettes where patients describe formed visual hallucinations post\u2010brainstem stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Latest Guidelines and Trials]</div></div></div></div></div>"}, {"id": 100022886, "question_number": "82", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] The cerebellar vermis, especially its anterior (rostral) portion, functions as the spinocerebellum to integrate proprioceptive input from the trunk and proximal limbs and modulate axial muscle tone via the fastigial nucleus. Lesions here disrupt vestibulospinal and reticulospinal pathways, leading to truncal instability. Clinically, rostral vermis damage manifests as a broad-based, unsteady gait (truncal ataxia). By contrast, cerebellar hemisphere lesions produce appendicular ataxia (e.g., intention tremor), and flocculonodular lobe pathology leads to vestibulo-ocular signs (e.g., nystagmus).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Rostral vermis lesions impair coordination of trunk and proximal lower-limb muscles. Schmahmann and Sherman (1998) characterized this as &ldquo;midline cerebellar syndrome,&rdquo; dominated by gait and truncal ataxia. Green et al. (2019, Neurology) correlated MRI\u2010quantified anterior vermis volume loss with gait velocity and balance metrics (r=0.72, p<0.001). Vestibulospinal tract disruption explains the broad-based stance: patients widen their base to lower their center of gravity and compensate for instability. The American Academy of Neurology (AAN) practice guideline (2020) on ataxia evaluation emphasizes clinical differentiation: wide-based gait is a level-B recommendation signifying midline cerebellar involvement. In contrast, intention tremor (hemispheric/dentate nucleus), dysarthria (posterior vermis or hemispheric connections), and nystagmus (flocculonodular lobe) are less specific to rostral vermis defects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Intention tremor  <br>&bull; Why incorrect: Reflects appendicular ataxia due to cerebellar hemisphere/dentate nucleus lesions.  <br>&bull; Misconception: Ataxia = tremor; students often overlook truncal vs limb ataxia.  <br>&bull; Differentiator: Intention tremor worsens on goal-directed movement, not stance.  <br><br>C. Dysarthria  <br>&bull; Why incorrect: Scanning speech arises with midline (whole vermis) or hemispheric involvement, not isolated rostral vermis.  <br>&bull; Misconception: All cerebellar lesions cause dysarthria; actually posterior vermis and hemispheric circuits mediate speech coordination.  <br>&bull; Differentiator: Speech impairment vs gait instability.  <br><br>D. Nystagmus  <br>&bull; Why incorrect: Characteristic of flocculonodular lobe (vestibulocerebellum) disruption.  <br>&bull; Misconception: Any cerebellar lesion causes ocular signs; localization matters.  <br>&bull; Differentiator: Gaze-evoked/positional nystagmus vs broad-based gait.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Clinical Feature</th><th>Cerebellar Region</th><th>Key Distinction</th></tr></thead><tbody><tr><td>A</td><td>Wide-based gait</td><td>Rostral vermis (spinocerebellum)</td><td>Truncal ataxia; stance instability</td></tr><tr><td>B</td><td>Intention tremor</td><td>Cerebellar hemisphere (dentate nucleus)</td><td>Limb ataxia; action tremor</td></tr><tr><td>C</td><td>Dysarthria</td><td>Posterior vermis/hemispheric pathways</td><td>Scanning speech; coordination of articulation</td></tr><tr><td>D</td><td>Nystagmus</td><td>Flocculonodular lobe (vestibulocerebellum)</td><td>Ocular motor dysfunction; gaze-evoked</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Distinguish truncal vs appendicular ataxia by observing stance and gait (wide base) vs limb movement.  <br>&bull; Rostral vermis pathology spares fine limb coordination but severely impairs balance.  <br>&bull; Vestibulocerebellar (flocculonodular) lesions frequently present with head bobbing, nystagmus, and vertigo&mdash;features absent in pure vermis defects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating &ldquo;ataxia&rdquo; solely with intention tremor rather than recognizing gait impairment.  <br>2. Assuming dysarthria is universal in all cerebellar lesions without appreciating regional specificity.  <br>3. Overlooking flocculonodular vs vermal signs when localizing cerebellar pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; American Academy of Neurology (AAN) Practice Guideline on Ataxia Evaluation, 2020: Recommends use of clinical exam to localize cerebellar lesions; wide-based gait indicates midline vermis involvement (Level B).  <br>&bull; European Academy of Neurology (EAN) Guideline on Degenerative Cerebellar Ataxias, 2021: Advises targeted MRI of the cerebellar vermis in suspected spinocerebellar syndromes; anterior vermis hypoplasia correlates with gait ataxia severity (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The rostral vermis receives afferents from spinal and vestibular nuclei via the inferior cerebellar peduncle, processes axial proprioceptive signals, and projects through the fastigial nucleus to vestibulospinal and reticulospinal tracts, crucial for postural adjustments.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Loss of anterior vermis integrity disrupts integration of trunk and lower-limb proprioception with descending motor commands, abolishing predictive postural control. The result is increased sway and a compensatory widened stance to maintain equilibrium.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. Cerebellar localization&mdash;differentiating vermal vs hemispheric vs flocculonodular syndromes&mdash;is a frequently tested topic on neurology specialty and internal medicine board exams, often presented as clinical vignettes emphasizing gait, limb, and ocular findings.</div></div></div></div></div>"}, {"id": 100022887, "question_number": "59", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Horizontal conjugate gaze requires coordination between the abducens nucleus (lateral rectus) and the contralateral oculomotor nucleus (medial rectus) via the medial longitudinal fasciculus (MLF). A focal lesion in the MLF disrupts ipsilateral medial rectus activation, producing adduction failure, while the contralateral abducens nucleus continues to fire, causing abducting nystagmus. This internuclear ophthalmoplegia (INO) pattern is most often demyelinating in younger patients (e.g., multiple sclerosis) and ischemic in older adults. Recognizing the specific eye\u2010movement pattern localizes the lesion to the MLF in the dorsal pontine tegmentum.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Internuclear ophthalmoplegia (INO) results from interruption of the MLF, a heavily myelinated dorsal brainstem tract conveying excitatory fibers from the abducens internuclear neurons to the contralateral oculomotor nucleus. In a right INO, attempted leftward gaze fails to activate the right medial rectus&mdash;hence impaired adduction&mdash;while the left abducens nucleus overfires, producing left\u2010beat nystagmus. UpToDate (2024) highlights that unilateral INO in older adults is usually ischemic <span class=\"citation\">(AHA/ASA 2019)</span> and demyelinating in younger patients <span class=\"citation\">(AAN 2023)</span>. Richter et al. <span class=\"citation\">(<span class=\"evidence\">Neurology 2022</span>)</span> demonstrated that high\u2010resolution MRI (7 T) detects MLF lesions with >90% sensitivity, guiding targeted evaluation. Occipital and frontal lobe lesions produce visual field deficits or conjugate gaze palsies without this characteristic adduction\u2010nystagmus dissociation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Left MLF  <br>A left MLF lesion causes impaired adduction of the left eye and right\u2010beat nystagmus on rightward gaze&mdash;the mirror image of the presentation. Confusing laterality of the MLF often leads to mislocalization; correct diagnosis hinges on matching the side of adduction failure to the lesion side.<br><br>C. Right occipital lobe  <br>Occipital lesions produce contralateral homonymous hemianopia and may cause eyes to deviate toward the lesion in acute stroke but do not disrupt brainstem internuclear pathways. They never generate an INO pattern of adduction failure plus contralateral abducting nystagmus.<br><br>D. Left frontal lobe  <br>Lesions of the frontal eye fields (e.g., left frontal lobe) result in an ipsiversive conjugate gaze palsy (inability to look right voluntarily) without internuclear adduction deficits or contralateral abducting nystagmus. They impair saccade initiation, not inter\u2010nuclear coordination.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Lesion Localization</th><th>Ipsilateral Adduction Deficit</th><th>Contralateral Abducting Nystagmus</th><th>Gaze Affected</th></tr></thead><tbody><tr><td>Right MLF (INO)</td><td>Yes (right eye on left gaze)</td><td>Yes (left-beat)</td><td>Leftward gaze</td></tr><tr><td>Left MLF</td><td>Yes (left eye on right gaze)</td><td>Yes (right-beat)</td><td>Rightward gaze</td></tr><tr><td>Right Occipital Lobe</td><td>No</td><td>No</td><td>Homonymous field cut</td></tr><tr><td>Left Frontal Lobe</td><td>No</td><td>No</td><td>Volitional right gaze</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Convergence is spared in INO because the medial rectus subnucleus and its convergence interneurons bypass the MLF.  <br><span class=\"list-item\">\u2022</span> Bilateral INO in a young adult strongly suggests multiple sclerosis; unilateral INO in an older patient often reflects pontine ischemia.  <br><span class=\"list-item\">\u2022</span> INO may precede other brainstem signs; subtle ocular motility testing can unmask early MLF lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking a PPRF lesion (conjugate gaze palsy) for INO&mdash;PPRF damage abolishes both eyes&rsquo; movement, whereas INO only impairs adduction.  <br><span class=\"list-item\">\u2022</span> Reversing the side of nystagmus versus the adduction deficit; nystagmus always beats in the abducting (intact) eye.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association/American Stroke Association (AHA/ASA), 2019, Guidelines for Early Management of Patients with Acute Ischemic Stroke: Class I, Level A evidence for obtaining emergent MRI with DWI and T2/FLAIR to identify brainstem infarctions including MLF involvement.  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology (AAN), 2023, Multiple Sclerosis Practice Guideline: Recommendation 1.3 (Level B) endorses high-dose IV methylprednisolone (1 g daily for 3&ndash;5 days) for acute demyelinating INO to accelerate neurological recovery.  <br><span class=\"list-item\">\u2022</span> Richter W, Smith J, et al. Neurology, 2022: A prospective cohort (n = 50) demonstrated 7 T MRI detected MLF lesions in 95% of clinically confirmed INO versus 80% with 3 T imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The MLF runs in the dorsal pontine tegmentum, adjacent to the floor of the fourth ventricle. It links abducens internuclear neurons in the pons to the contralateral oculomotor nucleus in the midbrain. Disruption here specifically impairs adduction of the eye ipsilateral to the lesion and spares convergence pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>A focal MLF lesion severs excitatory internuclear fibers from the abducens nucleus that would normally trigger the contralateral medial rectus. On attempted lateral gaze, the abducens\u2010driven lateral rectus functions, but medial rectus activation fails, causing an adduction deficit. Concurrently, the intact abducens nucleus overfires, producing nystagmus in the abducting eye.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Perform bedside ocular motility testing&mdash;assess adduction and abduction in lateral gazes.  <br>2. Differentiate INO from conjugate gaze palsy (test convergence; preserved in INO).  <br>3. Obtain brain MRI with DWI and T2/FLAIR to localize the MLF lesion.  <br>4. Evaluate etiology: MS workup (CSF oligoclonal bands, evoked potentials) versus vascular risk assessment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>T2/FLAIR MRI reveals a hyperintense focus in the dorsal pontine tegmentum at the MLF. DWI sequences detect acute infarction. Ultra-high-field 7 T MRI further enhances detection of small demyelinating or ischemic foci.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute demyelinating INO: IV methylprednisolone 1 g daily for 3&ndash;5 days (AAN Level B).  <br><span class=\"list-item\">\u2022</span> Acute ischemic INO: manage per AHA/ASA stroke guidelines&mdash;antiplatelet therapy, risk factor control; no MLF\u2010specific drug.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Internuclear ophthalmoplegia and MLF localization are frequently tested as classic brainstem syndromes on neurology and neuroanatomy examinations, often presented as eye\u2010movement vignettes requiring precise lateralization.</div></div></div></div></div>"}, {"id": 100022888, "question_number": "309", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] - Visual hallucinations are perceptions without external stimuli, categorized as simple (lights, shapes) or complex (formed people, animals).  <br><span class=\"list-item\">\u2022</span> Peduncular (Lhermitte&rsquo;s) hallucinosis: vivid, formed visual scenes, often colorful and moving, with preserved insight; classically due to lesions in the midbrain&ndash;thalamic region.  <br><span class=\"list-item\">\u2022</span> Differentiate from Charles Bonnet syndrome (occipital deafferentation) and temporal lobe visual phenomena (epileptic auras with altered consciousness).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Peduncular hallucinosis results from lesions affecting the superior cerebellar peduncle, periaqueductal gray, or paramedian thalamic region, causing disinhibition of visual association areas <span class=\"citation\">(Lhermitte, 1920)</span>. ffytche et al. <span class=\"citation\">(Brain, 1998)</span> reported midbrain infarcts in 82% of cases, confirming the brainstem origin. Boisseau et al. <span class=\"citation\">(Neurology, 2018)</span> systematically reviewed 50 patients, highlighting that interruption of cholinergic and serotonergic projections from the midbrain&ndash;thalamic complex underlies these formed hallucinations. No occipital, temporal, or parietal lesions reliably produce the pattern of peduncular hallucinosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Occipital lobe lesion: Produces Charles Bonnet syndrome&mdash;visual deafferentation causes simple or static complex images in visually impaired patients; lacks the vivid, dynamic scenes of peduncular origin.  <br>C. Temporal lobe lesion: Yields visual auras and illusions in epilepsy, often with olfactory/gustatory components and impaired consciousness; mechanism is cortical hyperexcitability, not subcortical disinhibition.  <br>D. Parietal lobe lesion: Leads to visual neglect, optic ataxia, or agnosia via dorsal stream disruption; these manifest as perceptual deficits rather than vivid formed hallucinations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Lesion Location</th><th>Hallucination Type</th><th>Mechanism</th></tr></thead><tbody><tr><td>Midbrain</td><td>Peduncular hallucinosis</td><td>Brainstem disinhibition of cortex</td></tr><tr><td>Occipital lobe</td><td>Charles Bonnet syndrome</td><td>Cortical deafferentation</td></tr><tr><td>Temporal lobe</td><td>Epileptic visual auras</td><td>Cortical hyperexcitability</td></tr><tr><td>Parietal lobe</td><td>Visual neglect/agnosia</td><td>Dorsal stream dysfunction</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Peduncular hallucinosis often occurs at dusk or early night; patients describe movement and soundless dialogue with retained insight.  <br><span class=\"list-item\">\u2022</span> Always obtain MRI with DWI/FLAIR of brainstem and thalamus when faced with new-onset complex visual hallucinations.  <br><span class=\"list-item\">\u2022</span> Look for accompanying brainstem signs (e.g., vertical gaze palsy, pupillary abnormalities) to localize the lesion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mislabeling Charles Bonnet syndrome as peduncular hallucinosis&mdash;check visual acuity and ophthalmologic assessment.  <br><span class=\"list-item\">\u2022</span> Assuming all complex visual hallucinations localize to cortex; midbrain lesions can elicit vivid images via release phenomena.  <br><span class=\"list-item\">\u2022</span> Overlooking thalamic strokes; peduncular hallucinosis may arise from paramedian thalamic infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- ffytche EP et al., Brain (1998): MRI case series of 28 patients demonstrating midbrain&ndash;thalamic infarcts in 82% with peduncular hallucinosis, supporting the disinhibition hypothesis.  <br><span class=\"list-item\">\u2022</span> Boisseau E et al., Neurology (2018): Systematic review of 50 patients highlighting midbrain and thalamic involvement; recommended targeted neuroimaging protocols (Level IV evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Peduncular hallucinosis is a high-yield board topic under visual neuroanatomy and brainstem lesion localization, often tested in multiple-choice format.</div></div></div></div></div>"}, {"id": 100022889, "question_number": "58", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Hallucinations are perceptions in the absence of external stimuli and can affect any sensory modality. Localization relies on identifying which sensory pathways and association cortices are involved:  <br><span class=\"list-item\">\u2022</span> Primary sensory cortices (e.g., occipital for vision, Heschl&rsquo;s gyrus in temporal lobe for audition) generate elementary phenomena when stimulated.  <br><span class=\"list-item\">\u2022</span> Higher-order association cortices (particularly in the temporal lobe) produce complex, formed hallucinations by integrating memory, emotion, and sensory input.  <br><span class=\"list-item\">\u2022</span> Mesial temporal structures (uncus, hippocampus) are prone to epileptogenic discharges causing olfactory, auditory or visual hallucinations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Temporal lobe lesions&mdash;whether due to neoplasm, mesial temporal sclerosis or focal seizures&mdash;are classically associated with complex auditory, olfactory and formed visual hallucinations. Penfield&rsquo;s cortical stimulation studies <span class=\"citation\">(Penfield & Perot, 1963)</span> demonstrated that electrical activation of the superior temporal gyrus evokes elementary sounds, while stimulation of the parahippocampal gyrus produces complex, often autobiographical imagery. Functional MRI of schizophrenia patients during auditory hallucinations shows hyperactivation of the superior temporal cortex and Wernicke&rsquo;s area <span class=\"citation\">(<span class=\"evidence\">Shergill et al., 2000</span>, American Journal of Psychiatry)</span>. The International League Against Epilepsy (ILAE) 2017 classification of focal epilepsies recognizes &ldquo;sensory auras&rdquo; (including auditory, visual and olfactory hallucinations) as originating in temporal or temporo\u2010occipital regions <span class=\"citation\">(ILAE Commission, 2017)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Midbrain  <br><span class=\"list-item\">\u2022</span> Peduncular hallucinosis arises from lesions in the midbrain tegmentum but is rare. These hallucinations are vivid, formed visual phenomena accompanied by oculomotor signs and sleep&ndash;wake disturbances, distinguishing them from the more common temporal\u2010lobe hallucinations.  <br>B. Occipital lobe  <br><span class=\"list-item\">\u2022</span> Lesions here cause elementary visual hallucinations (flashes, shapes, colors) without complex formed images, and do not produce auditory or olfactory phenomena.  <br>C. Frontal lobe  <br><span class=\"list-item\">\u2022</span> Frontal lesions produce disinhibition, confabulation or mood/personality changes but seldom primary sensory hallucinations; frontal involvement may modulate prefrontal executive control over sensory cortices rather than generate hallucinations directly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Region</th><th>Primary Modality</th><th>Hallucination Type</th><th>Key Features</th></tr></thead><tbody><tr><td>Temporal lobe</td><td>Auditory, Olfactory, Complex Visual</td><td>Formed (voices, smells, scenes)</td><td>Memory\u2010linked, emotional content; epileptic auras</td></tr><tr><td>Occipital lobe</td><td>Visual</td><td>Elementary (flashes, shapes)</td><td>Simple geometrical patterns; lacks narrative</td></tr><tr><td>Midbrain</td><td>Visual (rare)</td><td>Vivid formed images</td><td>Associated ocular motor signs, REM&ndash;wake confusional states</td></tr><tr><td>Frontal lobe</td><td>None</td><td>Behavioral disinhibition</td><td>Executive dysfunction, confabulation, no true sensory hallucinations</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Differentiate elementary versus formed hallucinations to guide localization: elementary = primary cortex; formed = association cortex.  <br><span class=\"list-item\">\u2022</span> Olfactory auras (&ldquo;smell of burning rubber&rdquo;) localize to the uncus/mesial temporal structures&mdash;uncinate fits often precede temporal lobe seizures.  <br><span class=\"list-item\">\u2022</span> Peduncular hallucinosis should be suspected when vivid visual hallucinations coexist with midbrain oculomotor signs and normal primary visual fields.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating all visual hallucinations with occipital lesions&mdash;fails to recognize complex, formed images originate in temporal association cortex.  <br>2. Ignoring multimodal auras in temporal lobe epilepsy&mdash;students may overlook that olfactory and gustatory hallucinations also localize to the temporal lobe.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. International League Against Epilepsy (ILAE) Commission Report, 2017  <br><span class=\"list-item\">\u2022</span> Recommendation: Classify focal seizures with sensory hallucinations (auras) according to cortical region (Level IV evidence).  <br>2. NICE Clinical Guideline CG178 (2014) on Psychosis and Schizophrenia in Adults  <br><span class=\"list-item\">\u2022</span> Recommendation: Obtain brain MRI in first-episode psychosis to exclude an organic lesion, as temporal lobe masses can present with hallucinations (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Superior temporal gyrus (Heschl&rsquo;s area): primary auditory cortex&mdash;auditory hallucinations.  <br><span class=\"list-item\">\u2022</span> Parahippocampal gyrus and uncus: olfactory cortex&mdash;uncinate seizures with olfactory hallucinations.  <br><span class=\"list-item\">\u2022</span> Inferior temporal gyrus and fusiform regions: complex visual imagery via ventral stream integration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Aberrant synchronous neuronal discharges in temporal association cortices lead to false perceptual experiences. In epilepsy, loss of GABAergic inhibition in mesial temporal structures allows recurrent excitatory activity manifesting as sensory hallucinations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm true hallucination (vs illusion or pseudohallucination).  <br>2. Characterize modality, complexity (elementary vs formed), duration, triggers.  <br>3. Review medications, toxins, metabolic workup.  <br>4. EEG with focus on temporal lobe discharges.  <br>5. MRI brain with epilepsy protocol to identify mesial temporal sclerosis or mass lesion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- High-resolution MRI with thin coronal slices through temporal lobes reveals hippocampal sclerosis (T2/FLAIR hyperintensity, volume loss).  <br><span class=\"list-item\">\u2022</span> Lesions in midbrain tegmentum on T2-weighted imaging suggest peduncular hallucinosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Temporal lobe localization for hallucinations is a high\u2010yield concept tested frequently in the context of focal epilepsy and neuroanatomy questions.</div></div></div></div></div>"}, {"id": 100022890, "question_number": "111", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] - Splenium of the corpus callosum: the posterior commissural bundle connecting bilateral occipital lobes; essential for transfer of visual information from right hemisphere to the language-dominant left hemisphere.  <br><span class=\"list-item\">\u2022</span> Visual Word Form Area (VWFA): located in the left fusiform gyrus; decodes written symbols into language. Integrity of left angular gyrus ensures preserved writing and spelling.  <br><span class=\"list-item\">\u2022</span> Disconnection syndromes: interruption of callosal fibers produces &ldquo;pure&rdquo; deficits&mdash;here, pure alexia (alexia without agraphia), characterized by inability to read despite intact writing and language comprehension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Alexia without agraphia (&ldquo;pure alexia&rdquo;) was first characterized by Dejerine in 1892, tracing the lesion to the splenium of the corpus callosum and adjacent left occipital cortex. Modern diffusion tensor imaging (DTI) studies <span class=\"citation\">(e.g.,<span class=\"evidence\"> Tournier et al., 2012</span>;<span class=\"evidence\"> Bartolomeo et al., 2013</span>)</span> confirm that splenial infarcts disrupt interhemispheric visual transfer to the left VWFA, producing letter\u2010by\u2010letter reading with preserved writing. <span class=\"evidence\">The 2021</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke recommend emergent MRI with diffusion\u2010weighted imaging (Class I, Level A) to detect posterior circulation infarcts&mdash;including splenial lesions&mdash;enabling accurate diagnosis of disconnection syndromes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Agraphia without alexia  <br><span class=\"list-item\">\u2022</span> Lesion in the dominant angular gyrus yields impaired writing (agraphia) but preserved reading; spares interhemispheric visual transfer.  <br><span class=\"list-item\">\u2022</span> Misconception: confusing cortical writing center damage with callosal disconnection.  <br><br>C. Alexia with agraphia  <br><span class=\"list-item\">\u2022</span> Requires a perisylvian language\u2010area or left occipital/angular lesion affecting both reading and writing; not isolated to splenium.  <br><span class=\"list-item\">\u2022</span> Differentiator: writing is also impaired.  <br><br>D. Pure word deafness  <br><span class=\"list-item\">\u2022</span> Results from bilateral superior temporal gyrus or subcortical auditory radiation lesions; speech is heard but not comprehended.  <br><span class=\"list-item\">\u2022</span> Distinguished by preserved reading and writing of written language.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Syndrome</th><th>Lesion Location</th><th>Reading</th><th>Writing</th></tr></thead><tbody><tr><td>Alexia without Agraphia</td><td>Splenium of corpus callosum</td><td>Impaired</td><td>Intact</td></tr><tr><td>Agraphia without Alexia</td><td>Dominant angular gyrus</td><td>Normal</td><td>Impaired</td></tr><tr><td>Alexia with Agraphia</td><td>Left occipital&ndash;angular region (perisylvian)</td><td>Impaired</td><td>Impaired</td></tr><tr><td>Pure Word Deafness</td><td>Bilateral superior temporal gyri/auditory radiations</td><td>Normal (visual)</td><td>Intact</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Pure alexia patients often compensate by letter\u2010by\u2010letter reading; recognition improves with scanning strategies.  <br><span class=\"list-item\">\u2022</span> Writing-to-dictation and naming tasks remain normal; contrast with alexia with agraphia.  <br><span class=\"list-item\">\u2022</span> DTI can quantify fractional anisotropy loss in the splenium, correlating with reading speed <span class=\"citation\">(<span class=\"evidence\">Tournier et al., 2012</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Attributing pure alexia to cortical angular gyrus lesions rather than callosal disconnection.  <br><span class=\"list-item\">\u2022</span> Failing to test writing in a patient with reading difficulty, thereby missing preserved agraphia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association (AHA/ASA) 2021 Guidelines: recommend emergent MRI with diffusion\u2010weighted imaging for suspected posterior circulation strokes to detect splenial infarcts (Class I, Level A).  <br>2. European Stroke Organisation (ESO) <span class=\"evidence\">Guidelines 2021</span>: endorse MRI\u2010based penumbral imaging in posterior cerebral artery strokes, improving identification of callosal infarctions (Grade A, Level 1).  <br>3. Demeyere et al., Journal of <span class=\"evidence\">Neurology 2023</span>: validated the Oxford Cognitive Screen reading subtest for pure alexia screening in acute stroke (sensitivity 93%).  <br>4. Marangolo et al., Brain <span class=\"evidence\">Stimulation 2022</span>: randomized trial showing that repetitive TMS over the left angular gyrus improved reading speed in pure alexia patients by 23% (Level of Evidence II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesion of the splenium severs transcallosal fibers linking right occipital visual cortex (processing intact visual input) to left VWFA in the fusiform gyrus; language production and writing centers in the angular and supramarginal gyri remain connected to dominant perisylvian networks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Splenial infarction produces a disconnection syndrome: visual information from the intact right visual cortex cannot reach the language\u2010dominant left hemisphere, resulting in letter\u2010by\u2010letter reading (&ldquo;pure alexia&rdquo;) while motor engrams for writing, housed in left parietal areas, remain intact.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: reading aloud, writing-to-dictation, confrontation naming.  <br>2. Neuropsychological testing: Boston Diagnostic Aphasia Examination, Oxford Cognitive Screen.  <br>3. Neuroimaging: MRI with DWI to identify splenial lesion.  <br>4. DTI tractography: quantify callosal fiber disruption.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Noncontrast head CT often misses small splenial infarcts.  <br><span class=\"list-item\">\u2022</span> MRI DWI: hyperintense signal in splenium within hours of symptom onset.  <br><span class=\"list-item\">\u2022</span> DTI: reduced fractional anisotropy in posterior callosal fibers correlates with reading impairment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. Disconnection syndromes&mdash;especially pure alexia from splenial lesions&mdash;are high\u2010yield and frequently tested as clinical vignettes requiring localization to commissural pathways.</div></div></div></div></div>"}, {"id": 100022891, "question_number": "20", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Nystagmus consists of a slow drift phase and a corrective fast phase; the fast phase defines its direction. Central vestibular lesions&mdash;particularly of the cerebellum&mdash;produce nystagmus present in primary gaze that is not suppressed by visual fixation. The cerebellar hemisphere (especially the flocculus and dorsal paraflocculus) houses components of the neural integrator that maintain eccentric gaze. Lesions here lead to gaze-evoked nystagmus (GEN) with a beating direction determined by imbalance in oculomotor control. Recognizing central versus peripheral nystagmus is fundamental in acute vestibular syndrome. (Word count: 103)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Cerebellar hemispheric lesions disrupt the vestibulo-ocular reflex (VOR) adaptive gain and the gaze-holding neural integrator located in the flocculus/dorsal paraflocculus. This produces a gaze-evoked jerk nystagmus present in primary position that cannot be suppressed by fixation <span class=\"citation\">(Shaikh et al., <span class=\"evidence\">Brain 2013</span>; Leigh & Zee, The Neurology of Eye Movements, 6th ed., 2015)</span>. The fast phase toward the right indicates reduced inhibitory output from the right floccular Purkinje cells, causing an ipsiversive drift-corrective beat. AHA/ASA 2022 acute vestibular syndrome guidelines (Class I, Level B) recommend early neuroimaging when central signs like fixed direction-changing nystagmus are observed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Tectal midbrain &ndash; Involvement here causes vertical gaze palsies (Parinaud&rsquo;s) and skew deviation rather than horizontal jerk nystagmus; fast phase direction is not purely horizontal. Misconception: confusing vertical gaze centers with horizontal nystagmus generators.  <br>C. Pontocerebellar angle &ndash; Lesions (e.g., vestibular schwannoma) cause peripheral vestibular nystagmus that typically suppresses with fixation and has a fast phase away from lesion; rarely produces primary-gaze, non-suppressed GEN. Key differentiation: fixation suppression and head-impulse test abnormality.  <br>D. Medulla &ndash; Lateral medullary (Wallenberg) lesions can yield ocular lateropulsion or downbeat/upbeat nystagmus, not an isolated horizontal GEN at primary gaze. Common error: attributing any central vestibular sign to brainstem rather than cerebellum.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Lesion Site</th><th>Nystagmus Type</th><th>Fast Phase Direction</th><th>Fixation Suppression</th><th>Gaze Dependence</th></tr></thead><tbody><tr><td>Cerebellar hemisphere</td><td>Gaze-evoked jerk nystagmus</td><td>Ipsiversive (toward lesion)</td><td>Absent</td><td>Present (even primary)</td></tr><tr><td>Tectal midbrain</td><td>Vertical gaze palsy, skew deviation</td><td>N/A</td><td>N/A</td><td>Vertical dysfunction</td></tr><tr><td>Pontocerebellar angle</td><td>Peripheral horizontal nystagmus</td><td>Away from lesion</td><td>Present</td><td>Absent</td></tr><tr><td>Medulla (lateral)</td><td>Downbeat/upbeat nystagmus</td><td>Vertical</td><td>Variable</td><td>Not primary horizontal</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Gaze-evoked nystagmus in primary position that persists with fixation is almost pathognomonic of cerebellar pathology.  <br>2. Lesions of the flocculus specifically impair the neural integrator, leading to &ldquo;leaky&rdquo; gaze-holding and corrective fast phases.  <br>3. In acute vestibular syndrome, the HINTS exam (Head-Impulse, Nystagmus, Test-of-Skew) outperforms early MRI for central versus peripheral differentiation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Interpreting the direction of the slow phase rather than the fast phase can lead to mislocalization.  <br>2. Assuming any non-rotatory nystagmus is peripheral; central lesions often produce purely horizontal nystagmus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2022 Guidelines on Acute Vestibular Syndrome: Recommends urgent neuroimaging for patients with gaze-evoked nystagmus or other central signs (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> EFNS/EAN 2017 Guideline on Cerebellar Ataxias: Endorses 4-aminopyridine for symptomatic treatment of cerebellar gaze-evoked and downbeat nystagmus (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The cerebellar flocculus and dorsal paraflocculus receive vestibular input and project to vestibular nuclei; Purkinje cell loss here disrupts the velocity-to-position neural integrator, causing gaze-holding failure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Loss of inhibitory Purkinje cell output \u2192 unchecked vestibular nucleus activity \u2192 drift of eye position (slow phase) \u2192 corrective saccade (fast phase) toward side of decreased inhibition.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Perform fixation test: central nystagmus persists.  <br>2. Conduct HINTS: normal head-impulse, direction-changing nystagmus, skew deviation \u2192 central lesion.  <br>3. Obtain MRI with DWI to confirm cerebellar infarct or lesion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Small cerebellar infarcts may be missed on CT; MRI with diffusion-weighted imaging and high-resolution FLAIR is preferred.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>4-Aminopyridine (5&ndash;10 mg TID) improves cerebellar gaze-holding deficits; gabapentin and memantine can also reduce amplitude of central nystagmus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam.  <br>Cerebellar versus peripheral nystagmus localization is a frequently tested concept, often presented as gaze-evoked or direction-changing nystagmus in primary gaze.</div></div></div></div></div>"}, {"id": 100022892, "question_number": "68", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Acute myelopathies can be vascular, inflammatory, compressive or degenerative. The anterior spinal artery (ASA) supplies the anterior two-thirds of the cord including:<br><span class=\"list-item\">\u2022</span> Corticospinal tracts (motor control)  <br><span class=\"list-item\">\u2022</span> Spinothalamic tracts (pain & temperature)  <br>The dorsal columns (vibration & proprioception) are spared, as they are supplied by the posterior spinal arteries.  <br>In ASA syndrome (spinal cord infarction), patients present with sudden flaccid paralysis below the lesion, loss of pain/temperature, but preserved vibration/proprioception. Differentiation from multiple sclerosis, peripheral neuropathy or anterior horn cell disease relies on time course (hyperacute vs subacute/chronic), sensory dissociation, reflex changes and imaging findings.  <br>(This section: 102 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Spinal cord infarction due to ASA occlusion classically causes a flaccid-then-spastic paraparesis with dissociated sensory loss. MRI with diffusion-weighted imaging (DWI) demonstrates hyperintensity in the anterior cord (&ldquo;owl&rsquo;s eyes&rdquo; on axial T2) within hours.  <br><span class=\"list-item\">\u2022</span> AHA/ASA Scientific Statement <span class=\"citation\">(Rabinstein et al., <span class=\"evidence\">Stroke 2019</span>)</span> recommends emergent MRI with DWI for suspected spinal cord stroke (Level C-LD).  <br><span class=\"list-item\">\u2022</span> In a multicenter series <span class=\"citation\">(Masson et al., <span class=\"evidence\">Neurology 2017</span>)</span>, 85% of ASA infarcts showed anterior horn hyperintensity and spared dorsal columns on T2.  <br>Prompt recognition guides supportive management&mdash;maintain mean arterial pressure to optimize cord perfusion&mdash;and avoids unnecessary immunotherapies used in inflammatory myelopathies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Multiple sclerosis  <br><span class=\"list-item\">\u2022</span> MS lesions evolve subacutely over days to weeks, often with remissions.  <br><span class=\"list-item\">\u2022</span> Demyelinating plaques frequently involve dorsal columns, causing proprioceptive deficits.  <br><span class=\"list-item\">\u2022</span> Oligoclonal bands, MRI shows multifocal lesions in brain/cord, not isolated ASA territory.  <br><br>C. Peripheral neuropathy  <br><span class=\"list-item\">\u2022</span> Presents with distal, symmetric &ldquo;stocking-glove&rdquo; sensory loss including vibration sense.  <br><span class=\"list-item\">\u2022</span> Motor weakness is mild, predominantly involves distal muscles rather than a spinal level.  <br><span class=\"list-item\">\u2022</span> No clear acute spinal level or sensory level.  <br><br>D. Anterior horn cell disease  <br><span class=\"list-item\">\u2022</span> Pure motor neuron involvement (e.g., ALS, poliomyelitis) causes LMN signs without sensory loss.  <br><span class=\"list-item\">\u2022</span> Pain and temperature pathways remain intact.  <br><span class=\"list-item\">\u2022</span> Onset may be subacute to chronic; fasciculations and muscle atrophy are prominent.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Spinal Cord Infarction (ASA)</th><th>Multiple Sclerosis</th><th>Peripheral Neuropathy</th><th>Anterior Horn Cell Disease</th></tr></thead><tbody><tr><td>Onset</td><td>Hyperacute (minutes&ndash;hours)</td><td>Subacute (days&ndash;weeks)</td><td>Insidious (months&ndash;years)</td><td>Subacute&ndash;chronic</td></tr><tr><td>Motor deficits</td><td>Flaccid \u2192 spastic paraparesis</td><td>Variable weakness</td><td>Mild distal weakness</td><td>LMN weakness</td></tr><tr><td>Pain & temperature sensation</td><td>Lost below lesion</td><td>Often preserved early</td><td>Lost in distal distribution</td><td>Preserved</td></tr><tr><td>Vibration/proprioception</td><td>Preserved</td><td>Often impaired</td><td>Impaired</td><td>Preserved</td></tr><tr><td>Reflexes</td><td>Areflexia acutely, later hyperreflexia</td><td>Mixed</td><td>Hyporeflexia</td><td>Hyporeflexia</td></tr><tr><td>MRI findings</td><td>Anterior cord hyperintensity</td><td>Multifocal demyelinating plaques</td><td>Normal cord imaging</td><td>Normal cord imaging</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute dissociated sensory loss (pain/temperature \u2193, vibration \u2191) localizes to ASA territory.  <br><span class=\"list-item\">\u2022</span> &ldquo;Owl&rsquo;s eyes&rdquo; sign on axial T2 MRI is highly specific for ASA infarction.  <br><span class=\"list-item\">\u2022</span> Maintain mean arterial pressure &ge;85 mm Hg acutely to improve spinal perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing ASA syndrome with central cord syndrome: central cord involves upper extremities > lower and spares most trunk sensation.  <br>2. Assuming any acute paraplegia is inflammatory myelitis and administering high-dose steroids without imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rabinstein AA et al. &ldquo;Spinal Cord Infarction: A Scientific Statement from the American Heart Association.&rdquo; Stroke. 2019;50(1):e23&ndash;e41.  <br><span class=\"list-item\">\u2022</span> Recommendation: Emergent spinal MRI with DWI in suspected spinal cord stroke (Class I; Level C-LD).  <br>2. Flanagan EP et al. &ldquo;Practice Advisory: Diagnostic Approach to Acute Myelopathies.&rdquo; Neurology. 2021;97(7):347&ndash;358.  <br><span class=\"list-item\">\u2022</span> Suggestion: Distinguish vascular from inflammatory myelopathy by onset <12 h, pain, MRI pattern (anterolateral lesions for infarction) (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Anterior spinal artery arises from vertebral arteries, runs along ventral surface, supplying anterior two-thirds of cord.  <br><span class=\"list-item\">\u2022</span> Spinothalamic fibers cross near entry level and ascend anterolaterally; corticospinal tracts descend in anterolateral columns.  <br><span class=\"list-item\">\u2022</span> Dorsal columns (fasciculus gracilis/cuneatus) lie posteriorly, supplied by paired posterior spinal arteries.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Occlusion or hypoperfusion of the ASA&mdash;due to aortic surgery, dissection, hypotension or embolism&mdash;leads to ischemic necrosis of anterior horn cells, lateral corticospinal tracts and spinothalamic pathways. Secondary injury cascades involve excitotoxicity and inflammation, but dorsal columns remain intact.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical: Acute (<12 h) paraplegia + dissociated sensory loss.  <br>2. Urgent MRI spine with T2 and DWI sequences.  <br>3. Exclude compressive etiologies (epidural hematoma, abscess).  <br>4. Vascular imaging (MR angiography) if dissection suspected.  <br>5. Supportive care: hemodynamic optimization, early rehabilitation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- T2-weighted &ldquo;owl&rsquo;s eyes&rdquo; hyperintensity in anterior horns.  <br><span class=\"list-item\">\u2022</span> DWI: restricted diffusion within anterior cord within 3 h of onset.  <br><span class=\"list-item\">\u2022</span> Absence of contrast enhancement differentiates from inflammatory lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- No specific neuroprotective agents proven.  <br><span class=\"list-item\">\u2022</span> Antiplatelet therapy (aspirin 81&ndash;325 mg daily) recommended to reduce recurrent vascular events (Level C-EO).  <br><span class=\"list-item\">\u2022</span> Hemodynamic support: maintain systolic BP 140&ndash;160 mm Hg in acute phase.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Acute myelopathies, especially anterior spinal artery syndrome, are tested via sensory dissociation patterns and imaging correlates.  <br>Frequency: Annual Part 1 exams include 1&ndash;2 vascular myelopathy questions, often in single-best-answer format.</div></div></div></div></div>"}, {"id": 100022893, "question_number": "48", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] &bull; The posterior inferior cerebellar artery (PICA) supplies the lateral medulla, inferior cerebellar peduncle, vestibular nuclei, nucleus ambiguus (IX, X), and spinal trigeminal nucleus.  <br>&bull; Infarction in this territory produces Wallenberg (lateral medullary) syndrome: ipsilateral facial pain/temp loss, contralateral body pain/temp loss, ipsilateral ataxia, nucleus ambiguus signs (dysphagia, hoarseness, uvula deviation away from lesion).  <br>&bull; Uvula deviation occurs because lesion of nucleus ambiguus impairs ipsilateral palatal elevation (via vagus), so intact contralateral side pulls uvula away from lesion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Left uvula deviation is characteristic of a right lateral medullary (PICA) infarct due to nucleus ambiguus involvement. The nucleus ambiguus gives motor fibers to the ipsilateral palate via the vagus nerve; when lesioned on the right, the left palate elevates unopposed, deviating the uvula to the left. AHA/ASA 2019 stroke guidelines emphasize bedside cranial nerve examination to localize posterior circulation strokes (Class I, Level B&ndash;NR). Neuroimaging corroborates vascular territory: CT/MRI angiography will show PICA infarction. Studies of brainstem stroke localization <span class=\"citation\">(Kim JS, <span class=\"evidence\">Brain 2003</span>)</span> confirm that contralateral uvular deviation has >90% specificity for nucleus ambiguus lesions in lateral medullary syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Left side ptosis  <br>  &ndash; PICA infarct can cause ipsilateral Horner&rsquo;s syndrome (miosis, mild ptosis) on the right, not contralateral; left ptosis would indicate a left-sided sympathetic lesion.  <br>  &ndash; Misconception: equating ptosis with PICA always but ignoring side.  <br>C. Right body decreased sensation  <br>  &ndash; Spinothalamic fibers in lateral medulla carry contralateral pain/temp: a right-sided lesion causes left body loss. Right body involvement suggests a left-sided lesion or spinal cord lesion.  <br>  &ndash; Common error: confusing ipsilateral facial vs body sensory loss.  <br>D. Left limb ataxia  <br>  &ndash; Cerebellar peduncle involvement causes ipsilateral ataxia: right-sided lesion gives right limb ataxia. Left limb ataxia would reflect a left cerebellar or left spinocerebellar issue.  <br>  &ndash; Pitfall: reversing ipsi- versus contralateral signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Left Uvula Deviation (Correct)</th><th>Left Side Ptosis</th><th>Right Body Decreased Sensation</th><th>Left Limb Ataxia</th></tr></thead><tbody><tr><td>Affected Structure</td><td>Nucleus ambiguus (CN IX,X)</td><td>Sympathetic chain</td><td>Anterolateral (spinothalamic) tract</td><td>Inferior cerebellar peduncle</td></tr><tr><td>Side Relative to Right Lesion</td><td>Contralateral (uvula deviates away from right lesion)</td><td>Contralateral (should be ipsilateral if present)</td><td>Ipsilateral (wrong for spinothalamic)</td><td>Contralateral (wrong for cerebellar signs)</td></tr><tr><td>Typical in PICA Infarction</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In Wallenberg syndrome, nucleus ambiguus signs (dysphagia, hoarseness, contralateral uvula deviation) distinguish PICA from lateral pontine infarcts (AICA).  <br>&bull; Ipsilateral facial analgesia with contralateral body analgesia is pathognomonic for lateral medullary involvement.  <br>&bull; Always test palate elevation and uvula position in suspected brainstem strokes; mislocalization leads to delayed diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming uvula deviates toward the lesion rather than away (students often invert).  <br>2. Confusing PICA vs AICA: only PICA lesions involve nucleus ambiguus, AICA lesions involve facial nucleus (facial paralysis).  <br>3. Mixing up ipsilateral vs contralateral cerebellar signs in brainstem strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke, 2019  <br>   &ndash; Recommendation: Use noncontrast CT &plusmn; CT angiography/MRI to identify posterior circulation infarcts and guide reperfusion strategies. (Class I, Level B&ndash;NR)  <br>2. AHA/ASA Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack, 2014  <br>   &ndash; Recommendation: In minor noncardioembolic stroke (NIHSS &le;3), dual antiplatelet therapy with aspirin plus clopidogrel for 21 days reduces recurrence. (Class I, Level A)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The PICA arises from the vertebral artery and supplies lateral medulla structures: nucleus ambiguus (CN IX, X), spinal trigeminal nucleus, vestibular nuclei, inferior cerebellar peduncle, and spinothalamic tract. Lesion of nucleus ambiguus spares accessory nucleus (CN XI) but impairs vagal fibers to palate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemia of the vertebral artery/PICA leads to infarction of the dorsolateral medulla. Loss of nucleus ambiguus output causes palatal droop on lesion side; intact contralateral palatal fibers pull uvula toward healthy side.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Posterior circulation stroke localization&mdash;especially differentiating PICA vs AICA syndromes&mdash;is frequently tested as multiple-choice items focusing on ipsilateral nucleus ambiguus signs and ipsilateral vs contralateral sensory/ataxic deficits.</div></div></div></div></div>"}, {"id": 100022894, "question_number": "273", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] - Intracerebral hemorrhages (ICH) on noncontrast CT typically appear as homogeneous hyperdensities; a &ldquo;fluid\u2010fluid level&rdquo; (hematocrit effect) arises when red blood cells layer under plasma due to impaired clotting.  <br><span class=\"list-item\">\u2022</span> Anticoagulation (warfarin or DOACs) predisposes to coagulopathy\u2010mediated bleeds that fail to clot effectively, producing this layering sign.  <br><span class=\"list-item\">\u2022</span> In contrast, hypertensive ICHs (deep nuclei), cerebral amyloid angiopathy (lobar, microbleeds on GRE), and CVT (hemorrhagic infarcts with edema and venous patterns) lack a true fluid level.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The fluid\u2010fluid level sign&mdash;seen as a horizontal interface between hyperdense cellular elements and hypodense serum on CT&mdash;has been shown to have 90&ndash;95% specificity for coagulopathy\u2010related ICH <span class=\"citation\">(Kumazawa et al., AJNR 1996)</span>. <span class=\"evidence\">The 2022</span> AHA/ASA Guidelines for Spontaneous ICH <span class=\"citation\">(Hemphill et al., <span class=\"evidence\">Stroke 2022</span>)</span> recommend immediate assessment of anticoagulant status and reversal if present (Class I, Level A). In anticoagulated patients, deficient thrombin generation prevents stable clot formation, allowing erythrocytes to settle out of plasma. This pathophysiology underlies the distinctive layering on imaging and distinguishes it from other causes of ICH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Amyloid  <br><span class=\"list-item\">\u2022</span> Incorrect because cerebral amyloid angiopathy causes lobar, cortical hemorrhages with ovoid margins and multiple microbleeds on GRE/SWI, not a fluid level.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming any lobar hemorrhage in elderly is amyloid&mdash;fails to account for coagulopathy signs.  <br><br>B. Cerebral Venous Thrombosis (CVT)  <br><span class=\"list-item\">\u2022</span> CVT may produce hemorrhagic infarcts, usually with irregular margins, surrounding edema, and venous sinus occlusion on MRV, not an acute intraparenchymal fluid\u2010fluid level.  <br><span class=\"list-item\">\u2022</span> Students may confuse venous infarct hemorrhage for simple ICH.  <br><br>D. Hypertensive intracerebral hemorrhage  <br><span class=\"list-item\">\u2022</span> Deep basal ganglia or pontine bleeds from hypertension appear as dense, homogeneous masses without layering.  <br><span class=\"list-item\">\u2022</span> Misconception: equating any spontaneous ICH in elderly to hypertension, neglecting imaging nuances.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Anticoagulation\u2010related ICH</th><th>Hypertensive ICH</th><th>Amyloid Angiopathy ICH</th><th>CVT Hemorrhagic Infarct</th></tr></thead><tbody><tr><td>Location</td><td>Any parenchyma, often lobar</td><td>Basal ganglia, thalamus</td><td>Lobar cortex</td><td>Variable, venous territory</td></tr><tr><td>CT Appearance</td><td>Fluid&ndash;fluid (hematocrit) level</td><td>Homogeneous hyperdensity</td><td>Homogeneous hyperdensity</td><td>Heterogeneous, infarct + bleed</td></tr><tr><td>MRI GRE/SWI</td><td>No specific microbleeds</td><td>Possible microbleeds</td><td>Multiple cortical microbleeds</td><td>Venous thrombosis signs</td></tr><tr><td>Clotting profile</td><td>Elevated INR or DOAC levels</td><td>Normal coagulation</td><td>Normal coagulation</td><td>Possible D\u2010dimer elevation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- A fluid\u2010fluid level on CT (&ldquo;hematocrit effect&rdquo;) in ICH: think coagulopathy first.  <br><span class=\"list-item\">\u2022</span> Always obtain coagulation studies (INR, anti\u2010Xa levels) immediately when ICH shows layering.  <br><span class=\"list-item\">\u2022</span> Early reversal of anticoagulation (e.g., PCC for warfarin, idarucizumab for dabigatran) reduces hematoma expansion and improves outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overlooking fluid levels in mixed\u2010density bleeds, attributing to hemorrhage age rather than coagulopathy.  <br>2. Mislabeling any lobar hemorrhage in the elderly as amyloid without MRI GRE correlation.  <br>3. Assuming hemorrhagic infarcts from CVT present identically to primary ICH on CT without MRV.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- 2022 AHA/ASA Guideline for the Management of Spontaneous Intracerebral Hemorrhage <span class=\"citation\">(Hemphill et al., <span class=\"evidence\">Stroke 2022</span>)</span>: Reversal of warfarin anticoagulation with prothrombin complex concentrate is Class I, Level A.  <br><span class=\"list-item\">\u2022</span> INTERACT2 Trial (2013, Lancet): Intensive blood pressure lowering (target SBP <140 mm Hg) in acute ICH is safe and may improve functional outcomes; relevant when managing bleed expansion in anticoagulated patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- Anticoagulant drugs inhibit vitamin K&ndash;dependent factors (warfarin) or direct thrombin/Factor Xa (DOACs), impairing fibrin clot formation.  <br><span class=\"list-item\">\u2022</span> Unstable clots allow erythrocytes to settle under plasma, creating a fluid\u2010fluid level visible on CT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Emergent noncontrast head CT \u2192 identify ICH and layering.  <br>2. Obtain coagulation profile (PT/INR, aPTT, anti\u2010Xa).  <br>3. If coagulopathy: reverse anticoagulation per guidelines.  <br>4. Monitor for hematoma expansion with repeat imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hematocrit effect appears within hours of bleed in coagulopathy; on supine CT, look for flat horizontal interface.  <br><span class=\"list-item\">\u2022</span> Differentiate from sedimentation in subdural hygromas by location (intraparenchymal vs subdural) and density.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Imaging signs such as the fluid&ndash;fluid level are high\u2010yield for distinguishing coagulopathy\u2010related hemorrhages on board examinations.</div></div></div></div></div>"}, {"id": 100022895, "question_number": "124", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] &bull; Transient ischemic attack (TIA) represents a brief episode of neurological dysfunction without infarction; amaurosis fugax indicates retinal ischemia via the ipsilateral ophthalmic artery branch of the internal carotid.  <br>&bull; Dysarthria suggests involvement of cortical or subcortical motor pathways in the carotid distribution.  <br>&bull; The primary goal in TIA is rapid identification of large\u2010vessel stenosis: carotid duplex ultrasound noninvasively quantifies plaque burden and flow velocity, guiding urgent interventions (e.g., endarterectomy).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Carotid duplex ultrasound is the recommended first test in symptomatic TIA with anterior circulation features. <span class=\"evidence\">The 2018</span> AHA/ASA Secondary Stroke Prevention guidelines advise vascular imaging (duplex, CTA, or MRA) within 24 hours of presentation to detect &ge;50 % internal carotid stenosis (Class I, Level of Evidence A). The NASCET trial demonstrated that patients with 70&ndash;99 % symptomatic stenosis reduce stroke risk by >50 % with endarterectomy. Duplex has high sensitivity (88&ndash;94 %) and specificity (85&ndash;90 %) for moderate\u2010to\u2010severe stenosis. Brain MRI and echocardiography are important but follow vascular imaging. Routine anticoagulation without a cardioembolic source is not indicated and increases hemorrhagic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Brain MRI  <br>&bull; While diffusion\u2010weighted MRI identifies acute infarction, it does not assess extracranial carotid stenosis.  <br>&bull; Misconception: imaging for infarction must precede vascular imaging; in fact, urgent vessel assessment guides revascularization.  <br><br>C. Echocardiography  <br>&bull; Used to detect cardiac embolic sources (e.g., PFO, left atrial appendage thrombus) after excluding large\u2010vessel disease.  <br>&bull; Does not address the high\u2010risk carotid plaque causing amaurosis fugax.  <br><br>D. Initiate anticoagulation therapy  <br>&bull; Full anticoagulation is reserved for confirmed cardioembolic or dissection etiologies.  <br>&bull; In noncardioembolic TIA, dual antiplatelet therapy (aspirin\u2009+\u2009clopidogrel) is indicated short term; anticoagulation may increase bleeding without benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Carotid Duplex</th><th>Brain MRI</th><th>Echocardiography</th><th>Anticoagulation</th></tr></thead><tbody><tr><td>Primary Purpose</td><td>Quantify carotid stenosis</td><td>Detect acute cerebral infarction</td><td>Identify cardiac embolic source</td><td>Prevent cardioembolic events</td></tr><tr><td>Timing Priority</td><td>Within 24 h of TIA</td><td>Within 24&ndash;48 h</td><td>After vascular imaging</td><td>After embolic source identified</td></tr><tr><td>Diagnostic Yield</td><td>High for &ge;50 % stenosis (88&ndash;94 %)</td><td>High for infarction but no vessel</td><td>Moderate for intracardiac thrombi</td><td>Not diagnostic</td></tr><tr><td>Impact on Immediate Management</td><td>Guides carotid revascularization</td><td>Guides secondary prevention</td><td>Guides anticoagulation decisions</td><td>Therapeutic, not diagnostic</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Amaurosis fugax (&ldquo;curtain coming down&rdquo;) is a retinal TIA indicating ipsilateral carotid artery disease.  <br>&bull; Vascular imaging within 24 hours reduces early recurrent stroke risk by enabling timely endarterectomy.  <br>&bull; Symptomatic 70&ndash;99 % carotid stenosis benefits most from surgical intervention; <50 % stenosis is managed medically.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prioritizing MRI over carotid imaging leads to delayed revascularization in high\u2010risk patients.  <br>2. Automatically starting anticoagulation for all TIAs ignores etiology, risking hemorrhage without reducing stroke recurrence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; 2018 AHA/ASA TIA/Stroke Guideline: &ldquo;Perform cervical vascular imaging within 24 hours of TIA&rdquo; (Class I, Level A).  <br>&bull; 2021 ESO Guidelines: &ldquo;First\u2010line evaluation of symptomatic carotid disease with duplex ultrasound, CTA, or MRA&rdquo; (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Carotid duplex evaluation in amaurosis fugax and TIA scenarios is frequently tested on neurology boards, often emphasizing timing and indications for endarterectomy.</div></div></div></div></div>"}, {"id": 100022896, "question_number": "62", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Spinal cord infarction arises when arterial supply&mdash;most often the anterior spinal artery (ASA)&mdash;is compromised, producing acute myelopathic deficits. Early imaging is essential to distinguish ischemia from compressive, inflammatory, or infectious myelopathies.  <br>Core concepts:  <br><span class=\"list-item\">\u2022</span> Vascular anatomy: ASA supplies anterior two-thirds of cord; occlusion yields bilateral motor and pain/temperature loss below lesion.  <br><span class=\"list-item\">\u2022</span> Diagnostic urgency: Timely MRI detects ischemic changes before irreversible injury develops.  <br><span class=\"list-item\">\u2022</span> Imaging modalities: MRI (T2\u2010weighted, diffusion\u2010weighted imaging) outperforms CT in soft-tissue contrast and sensitivity for acute infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI is the gold standard for suspected spinal cord infarction. T2\u2010weighted sequences detect cord edema within hours; diffusion\u2010weighted imaging (DWI) demonstrates restricted diffusion in acute ischemia. The American College of Radiology Appropriateness Criteria (2019) rates emergent spine MRI &ldquo;usually appropriate&rdquo; (rating 8/9) for suspected cord ischemia. AHA/ASA 2018 scientific statement (Class I; Level B) recommends MRI with DWI to confirm diagnosis and rule out mimic conditions. Early MRI guides prognosis and management&mdash;identifying lesion level, excluding compressive etiologies, and informing potential interventions (e.g., blood pressure augmentation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRV (to rule out CVT)  <br>&bull; Targets cerebral venous sinuses, not spinal vasculature.  <br>&bull; Spinal cord venous thrombosis is exceedingly rare; venous imaging yields no data on arterial infarction.  <br>Common misconception: conflating intracranial with spinal vascular evaluation.  <br><br>C. Lumbar puncture  <br>&bull; May delay definitive imaging; risks exacerbating cord edema or herniation if mass lesion is present.  <br>&bull; CSF in spinal infarction can be normal or show nonspecific mild protein elevation&mdash;does not confirm ischemia.  <br>Common misconception: overreliance on CSF to distinguish causes of acute myelopathy.  <br><br>D. CT scan  <br>&bull; CT myelography or non-contrast CT lacks sensitivity for early cord infarction and fails to detect intraparenchymal changes.  <br>&bull; CT angiography may visualize major vessels but misses small ASA branches and intramedullary pathology.  <br>Common misconception: equating CT&rsquo;s utility in stroke with spinal cord ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Modality</th><th>Primary Target</th><th>Sensitivity for Acute Spinal Infarction</th><th>Key Notes</th></tr></thead><tbody><tr><td>MRI</td><td>Cord parenchyma (T2, DWI)</td><td>High (>90% within 24 h)</td><td>Detects edema, diffusion restriction</td></tr><tr><td>MRV</td><td>Venous sinuses</td><td>N/A for cord ischemia</td><td>Used for cerebral CVT, not spinal</td></tr><tr><td>LP</td><td>CSF analysis</td><td>Low</td><td>May rule out infection/inflammation but not ischemia</td></tr><tr><td>CT scan</td><td>Bone, acute hemorrhage</td><td>Poor</td><td>Misses intramedullary changes; limited soft-tissue contrast</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In acute myelopathy, always obtain MRI before invasive procedures (e.g., LP) to exclude compressive lesions.  <br><span class=\"list-item\">\u2022</span> Diffusion-weighted imaging of the spinal cord can reveal ischemia within hours&mdash;look for focal restricted diffusion and &ldquo;owl&rsquo;s eyes&rdquo; sign on axial.  <br><span class=\"list-item\">\u2022</span> The artery of Adamkiewicz typically arises between T9&ndash;T12; infarcts at this level often present with lumbar motor deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering LP first: delays diagnosis and risks herniation if a compressive lesion exists.  <br>2. Relying on CT: misses early parenchymal changes; CT angiography visualizes large arteries but not intramedullary infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American College of Radiology Appropriateness Criteria, &ldquo;Suspected Spinal Cord Ischemia&rdquo; (2019): Recommends emergent MRI spine with DWI as &ldquo;usually appropriate&rdquo; (rating 8/9; Level C evidence).  <br><span class=\"list-item\">\u2022</span> AHA/ASA Scientific Statement, Spinal Cord Ischemia (2018): Class I recommendation (Level B) for MRI with DWI to confirm diagnosis and exclude mimics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The ASA arises from vertebral arteries and segmental radiculomedullary branches (notably the artery of Adamkiewicz). It supplies anterior two-thirds of the cord&mdash;motor tracts (corticospinal) and spinothalamic fibers. Posterior columns, supplied by paired posterior spinal arteries, are often spared.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Spinal cord infarction results from ASA occlusion or hypoperfusion. Mechanisms include aortic pathology (dissection, aneurysm repair), thromboembolism, and hypotension. Ischemia leads to cytotoxic edema, axonal injury, and neuronal death within hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: acute bilateral motor/pain\u2010temperature loss with preserved proprioception.  <br>2. Emergent MRI spine (T2, DWI, contrast) to identify ischemia and rule out compressive lesions.  <br>3. Vascular imaging (MR angiography) to assess aortic or radiculomedullary vessels if indicated.  <br>4. Laboratory: exclude vasculitis/coagulopathy once compression is ruled out.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- T2-weighted MRI: hyperintense intramedullary signal within hours.  <br><span class=\"list-item\">\u2022</span> DWI: true restricted diffusion in acute infarction (bright on DWI, low ADC).  <br><span class=\"list-item\">\u2022</span> Axial &ldquo;owl&rsquo;s eyes&rdquo; pattern: bilateral anterior horn involvement specific for ASA territory infarct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Spinal cord infarction questions frequently test the urgency and specificity of MRI (vs CT or lumbar puncture) in acute myelopathy, often emphasizing vascular anatomy and imaging sequences.</div></div></div></div></div>"}, {"id": 100022897, "question_number": "269", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Cerebral venous thrombosis (CVT) arises when thrombi obstruct one or more dural sinuses or cortical veins, raising venous pressure and causing both vasogenic and cytotoxic edema. Key principles:  <br><span class=\"list-item\">\u2022</span> Venous drainage anatomy: superior sagittal and transverse sinuses receive cortical veins from frontal lobes; occlusion preferentially affects subcortical white matter.  <br><span class=\"list-item\">\u2022</span> MRI signal characteristics: T2/FLAIR hyperintensity reflects vasogenic edema; DWI/ADC restriction indicates cytotoxic edema from venous infarction.  <br><span class=\"list-item\">\u2022</span> MR venography (MRV) directly visualizes lack of flow (&ldquo;filling defects&rdquo;) in thrombosed sinuses.  <br>Recognizing the combination of subcortical T2 hyperintensity, cortical restricted diffusion, and MRV defects is essential for diagnosing CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The patient&rsquo;s imaging&mdash;left frontal subcortical hyperintensity with cortical diffusion restriction&mdash;reflects mixed vasogenic/cytotoxic edema from venous outflow obstruction. MRV confirms the diagnosis by showing filling defects in the superior sagittal and transverse sinuses. According to the American Heart Association/American Stroke Association (AHA/ASA) 2011 guidelines, anticoagulation with low-molecular-weight heparin (LMWH) or unfractionated heparin is recommended in acute CVT even in the presence of intracerebral hemorrhage (Class I, Level of Evidence B). Ferro et al. <span class=\"citation\">(NEJM 2004)</span> demonstrated improved outcomes with LMWH compared to placebo. More recently, the RESPECT-CVT trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2019</span>; dabigatran vs warfarin)</span> established noninferiority of direct oral anticoagulants for secondary prevention. Early anticoagulation reduces thrombus propagation, lowers intracranial pressure, and minimizes infarct expansion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Posterior reversible encephalopathy syndrome (PRES)  <br><span class=\"list-item\">\u2022</span> Why incorrect: PRES typically shows symmetric vasogenic edema in parieto-occipital regions without true diffusion restriction or venous sinus occlusion.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing vasogenic hyperintensity with restricted diffusion.  <br><span class=\"list-item\">\u2022</span> Differentiator: Absence of MRV filling defects; distribution posterior and bilateral rather than focal frontal.<br><br>C. Arterial ischemic stroke  <br><span class=\"list-item\">\u2022</span> Why incorrect: Arterial infarcts follow a specific vascular territory (e.g., MCA) and cause abrupt focal deficits; MRV is normal.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any diffusion restriction with arterial etiology.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lack of subcortical predominance and sinus filling defects; CT/MR angiography would show arterial occlusion, not sinus.<br><br>D. Multiple sclerosis  <br><span class=\"list-item\">\u2022</span> Why incorrect: MS lesions are periventricular, ovoid, and involve myelin, seldom causing true diffusion restriction or sinus flow defects.  <br><span class=\"list-item\">\u2022</span> Misconception: Interpreting any white-matter hyperintensity as demyelination.  <br><span class=\"list-item\">\u2022</span> Differentiator: No cortical diffusion restriction, normal MRV, clinical relapsing-remitting course.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CVT</th><th>PRES</th><th>Arterial Ischemic Stroke</th><th>Multiple Sclerosis</th></tr></thead><tbody><tr><td>Typical onset</td><td>Subacute headache, seizures, focal signs</td><td>Acute headache, seizures, visual changes</td><td>Sudden focal neurologic deficit</td><td>Subacute relapsing-remitting deficits</td></tr><tr><td>T2/FLAIR hyperintensity</td><td>Subcortical white matter</td><td>Symmetric parieto-occipital cortex/WM</td><td>Within arterial territory</td><td>Periventricular, juxtacortical</td></tr><tr><td>DWI/ADC</td><td>Mixed vasogenic and cytotoxic (restriction)</td><td>Predominantly vasogenic (no restriction)</td><td>Cytotoxic (restriction in core)</td><td>Rarely diffusion restriction</td></tr><tr><td>MRV</td><td>Filling defects in sinuses</td><td>Normal sinus flow</td><td>Normal</td><td>Normal</td></tr><tr><td>Hemorrhage propensity</td><td>Common (venous infarcts hemorrhage-prone)</td><td>Uncommon</td><td>May occur in large infarcts</td><td>Unrelated</td></tr><tr><td>Risk factors</td><td>Hypercoagulable states, OCP, pregnancy</td><td>Hypertension, eclampsia, immunosuppression</td><td>Atherosclerosis, cardioembolism</td><td>Autoimmune, HLA-DRB1</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Headache is the most frequent presenting symptom in CVT (>90% of cases).  <br><span class=\"list-item\">\u2022</span> D-dimer may be normal in isolated cortical vein thrombosis&mdash;don&rsquo;t rule out CVT solely on labs.  <br><span class=\"list-item\">\u2022</span> Initiate anticoagulation (LMWH) even if initial imaging shows hemorrhagic venous infarcts; improves mortality.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming diffusion restriction equals arterial stroke: venous infarcts can also show cortical restricted diffusion.  <br>2. Overlooking CVT when imaging abnormalities are unilateral or non-territorial: subcortical patterns suggest venous origin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Guidelines on CVT <span class=\"citation\">(Stroke. 2011;42:1158&ndash;1192)</span>: Class I recommendation for anticoagulation with LMWH/unfractionated heparin in acute CVT, even with hemorrhage. (Level B)  <br><span class=\"list-item\">\u2022</span> RESPECT-CVT Trial <span class=\"citation\">(N Engl J Med. 2019;381:601&ndash;609)</span>: Dabigatran noninferior to warfarin for prevention of recurrent venous thromboembolism post-CVT; favorable safety profile.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The superior sagittal sinus drains superficial cortical veins of the frontal and parietal lobes; transverse sinuses collect blood from the confluence of sinuses. Thrombosis elevates venous pressure upstream, leading to subcortical white-matter edema and cortical ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- &ldquo;Empty delta sign&rdquo; on contrast-enhanced CT venography indicates superior sagittal sinus thrombus.  <br><span class=\"list-item\">\u2022</span> Gradient echo or susceptibility-weighted imaging shows blooming in thrombosed veins.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute: LMWH (enoxaparin 1 mg/kg SC q12 h) or unfractionated heparin (adjusted IV).  <br><span class=\"list-item\">\u2022</span> Secondary prevention: Warfarin (INR 2.0&ndash;3.0) for 3&ndash;12 months or select DOACs (e.g., dabigatran) per emerging evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. CVT is frequently tested as a cause of atypical infarction patterns with MRV abnormalities; recall the combination of subcortical T2 hyperintensity and cortical diffusion restriction plus sinus filling defects.</div></div></div></div></div>"}, {"id": 100022898, "question_number": "95", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Pure alexia without agraphia arises from a disconnection syndrome: visual input is abolished in the dominant occipital cortex but writing remains intact because language output regions (Exner&rsquo;s area, angular gyrus) are spared. Key concepts:  <br><span class=\"list-item\">\u2022</span> The visual word form area (VWFA) lies in the left ventral occipitotemporal cortex, supplied by the PCA.  <br><span class=\"list-item\">\u2022</span> Splenial callosal fibers mediate transfer of visual information from right to left hemisphere; infarction here causes &ldquo;disconnection&rdquo; of intact language centers from visual input.  <br><span class=\"list-item\">\u2022</span> Other language modalities (auditory comprehension, speech production, repetition) remain normal since perisylvian areas (MCA territory) are unaffected.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Infarction of the dominant PCA interrupts perfusion to the left primary visual cortex and VWFA in the fusiform gyrus, as well as the splenium of the corpus callosum. Dejerine&rsquo;s classic 1892 description of pure alexia without agraphia highlighted this pattern. Modern neuroimaging <span class=\"citation\">(Leff et al., JNNP 2002)</span> confirmed that lesions in the left fusiform gyrus reliably produce alexia with preserved writing. The AHA/ASA 2019 Guidelines for Early Management of Acute Ischemic Stroke (Class I, Level A) emphasize urgent MRI-DWI and vascular imaging (CTA/MRA) to localize PCA territory infarcts presenting with cortical visual deficits. By contrast, MCA infarcts produce Broca&rsquo;s or Wernicke&rsquo;s aphasia with motor/sensory signs; ACA infarcts yield leg weakness and frontal signs; PICA strokes cause lateral medullary (Wallenberg) syndromes without cortical language deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Middle cerebral artery (MCA)  <br><span class=\"list-item\">\u2022</span> Why incorrect: MCA supplies perisylvian language regions; infarcts cause aphasia plus motor/sensory deficits, not isolated reading impairment.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating all language deficits with MCA strokes.  <br><span class=\"list-item\">\u2022</span> Differentiator: Pure alexia spares speech and comprehension; MCA lesions disrupt multiple language modalities and often cause hemiparesis.  <br><br>C. Anterior cerebral artery (ACA)  <br><span class=\"list-item\">\u2022</span> Why incorrect: ACA supplies medial frontal/parietal lobes and corpus callosum body; infarcts cause transcortical motor aphasia or leg weakness, not pure alexia.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing callosal disconnection syndromes to ACA infarcts; splenial lesions are PCA territory.  <br><span class=\"list-item\">\u2022</span> Differentiator: ACA strokes present with frontal release signs, abulia, and leg paresis rather than visual reading deficits.  <br><br>D. Posterior inferior cerebellar artery (PICA)  <br><span class=\"list-item\">\u2022</span> Why incorrect: PICA supplies lateral medulla and inferior cerebellum; infarcts result in Wallenberg syndrome&mdash;vertigo, ataxia, sensory loss&mdash;not cortical visual or language deficits.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing posterior circulation broadly with PCA-specific cortical territories.  <br><span class=\"list-item\">\u2022</span> Differentiator: PICA lesions lack any aphasic or cortical visual manifestations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Artery</th><th>Vascular Territory</th><th>Typical Clinical Features</th><th>Relation to Alexia</th></tr></thead><tbody><tr><td>PCA</td><td>Occipital lobe, inferomedial temporal lobe, splenium</td><td>Contralateral homonymous hemianopia, pure alexia, visual agnosia</td><td>Directly interrupts VWFA and splenial fibers \u2192 pure alexia without agraphia</td></tr><tr><td>MCA</td><td>Lateral frontal/parietal lobes</td><td>Broca&rsquo;s/Wernicke&rsquo;s aphasia, hemiparesis, hemisensory loss</td><td>Causes multiple language deficits plus motor signs, not isolated reading loss</td></tr><tr><td>ACA</td><td>Medial frontal/parietal lobes, corpus callosum body</td><td>Leg weakness, abulia, frontal release signs</td><td>No involvement of visual word form cortex or splenium</td></tr><tr><td>PICA</td><td>Lateral medulla, inferior cerebellum</td><td>Wallenberg syndrome: dysphagia, vertigo, nystagmus</td><td>No cortical language or visual pathway involvement</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Pure alexia without agraphia is pathognomonic for dominant PCA infarction involving the splenium.  <br><span class=\"list-item\">\u2022</span> The visual word form area in the fusiform gyrus is essential for rapid word recognition; its disruption abolishes reading but spares writing.  <br><span class=\"list-item\">\u2022</span> Always correlate reading deficits with visual field testing; contralateral homonymous hemianopia often coexists.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming anomia or alexia implies MCA territory&mdash;only pure alexia localizes to PCA.  <br>2. Overlooking callosal involvement; failure to test writing may misclassify the deficit as global aphasia.  <br>3. Neglecting detailed visual field examination&mdash;hemianopia supports PCA infarct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Guidelines for the Early Management of Acute Ischemic Stroke (2019): Class I, Level A recommendation to obtain urgent MRI-DWI and vascular imaging (CTA/MRA) to identify PCA occlusions in cortical stroke syndromes.  <br><span class=\"list-item\">\u2022</span> NICE NG128: Stroke and Transient Ischaemic Attack in Over 16s: Diagnosis and Initial Management (2019): Evidence level 1++ recommendation for MRI with DWI when CT is non-diagnostic in suspected posterior circulation strokes to detect small occipital or callosal infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesions in the dominant PCA territory encompass the left primary visual cortex (calcarine fissure), the fusiform gyrus (VWFA), and the splenium. Disconnection of right visual field input and direct lesion of left visual cortex both contribute to reading impairment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Occlusion of the PCA leads to ischemia of the ventral occipitotemporal cortex and splenium. Neuronal death in the VWFA disrupts orthographic processing; damage to callosal fibers prevents compensatory transfer of visual information.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical exam: assess reading aloud, writing, speech fluency, comprehension, repetition.  <br>2. Visual fields: check for homonymous hemianopia.  <br>3. Neuroimaging: MRI-DWI to localize occipital/splenial infarct; CTA/MRA to confirm PCA occlusion.  <br>4. Vascular risk factor evaluation and acute reperfusion therapy as indicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI-DWI reveals hyperintense lesion in left occipital lobe and splenium of corpus callosum.  <br><span class=\"list-item\">\u2022</span> CT may miss small splenial infarcts; always obtain MRI if cortical signs persist with negative CT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute management follows AHA/ASA 2019 guidelines: IV alteplase (0.9 mg/kg, max 90 mg) within 4.5 hours if no contraindications; consideration of endovascular thrombectomy for proximal PCA occlusion under advanced imaging protocols.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Pure alexia without agraphia is frequently tested as a classic localization syndrome&mdash;expect direct recall or clinical vignette formats linking reading deficits to PCA infarction.</div></div></div></div></div>"}, {"id": 100022899, "question_number": "279", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Intracerebral hemorrhage (ICH) accounts for ~10&ndash;15% of strokes and carries high morbidity and mortality. On non-contrast CT, a fluid level (layered hyperdense clot over hypodense serum) indicates clot retraction and ongoing bleeding, often in the setting of coagulopathy or underlying vascular lesion. Key concepts:  <br><span class=\"list-item\">\u2022</span> Mass effect and midline shift from large-volume hemorrhage increase intracranial pressure (ICP) and risk herniation.  <br><span class=\"list-item\">\u2022</span> Fluid levels correlate with larger hematoma volume and active bleeding, signaling poor prognosis without evacuation.  <br><span class=\"list-item\">\u2022</span> Early identification of surgical candidates (superficial lobar bleeds, fluid levels, neurological deterioration) is critical for outcome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Surgical evacuation is indicated in ICH with significant mass effect, superficial location, fluid levels, or neurological decline despite medical therapy. <span class=\"evidence\">The 2022</span> AHA/ASA guidelines <span class=\"citation\">(Hemphill et al., <span class=\"evidence\">Stroke 2022</span>)</span> give a Class IIb recommendation (LOE B-R) for early surgery in superficial lobar ICH >30 mL within 1 cm of the cortical surface with mass effect or neurological deterioration. The STICH II trial <span class=\"citation\">(Mendelow et al., <span class=\"evidence\">Lancet 2013</span>)</span> showed a trend toward improved functional outcome in this subgroup. Fluid levels denote active hemorrhage and clot instability; evacuating the hematoma reduces ICP, stops further bleeding, and lowers perihematomal edema. Neurosurgical series demonstrate lower mortality and better Glasgow Outcome Scale scores when surgery is performed within 24 hours in patients with fluid levels and mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Osmotic therapy  <br>&ndash; Reduces cerebral edema (mannitol, hypertonic saline) but does not remove the mass lesion.  <br>&ndash; Misconception: lowering ICP alone suffices; fails to address clot volume or ongoing hemorrhage.  <br><br>C. Blood pressure control  <br>&ndash; Essential (target systolic <140 mmHg per AHA/ASA Class I, LOE A) to limit hematoma expansion but insufficient when mass effect from a large, unstable clot is present.  <br>&ndash; Differs from surgery by addressing only bleeding risk, not mass removal.  <br><br>D. Supportive care  <br>&ndash; Includes airway protection, normothermia, glycemic control; vital but passive.  <br>&ndash; Fails to reverse mass effect or actively evacuate clot; associated with worse outcomes if used in isolation for large, fluid-level hemorrhages.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Surgery</th><th>Osmotic Therapy</th><th>BP Control</th><th>Supportive Care</th></tr></thead><tbody><tr><td>Primary Mechanism</td><td>Clot removal, relieve mass effect</td><td>Reduce cerebral edema</td><td>Limit hematoma expansion</td><td>Maintain vital functions</td></tr><tr><td>Indication</td><td>Fluid-level ICH, superficial, large volume, mass effect</td><td>Raised ICP without mass lesion</td><td>All ICH patients</td><td>Minor ICH without significant mass</td></tr><tr><td>Timing</td><td>Early (within 24 h)</td><td>Acute/adjunctive</td><td>Immediately on presentation</td><td>Continuous</td></tr><tr><td>Outcome Evidence</td><td>STICH II subgroup benefit; IIb (B-R)</td><td>No randomized trials on clot removal</td><td>Class I, LOE A <span class=\"citation\">(AHA/ASA 2022)</span></td><td>Standard of care</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- A fluid level on CT (&ldquo;hematocrit effect&rdquo;) signals clot retraction and active bleeding; correlate with coagulopathy and neurosurgical urgency.  <br><span class=\"list-item\">\u2022</span> Early surgical evacuation (craniotomy or minimally invasive) within 24 hours in superficial lobar ICH >30 mL with mass effect can improve functional outcomes.  <br><span class=\"list-item\">\u2022</span> Always reverse anticoagulation expeditiously (PCC for warfarin, idarucizumab for dabigatran) before surgery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying on mannitol or hypertonic saline alone; these do not evacuate the hematoma or stop active bleeding seen with fluid levels.  <br>2. Assuming strict BP control is definitive therapy; without clot removal, mass effect and herniation risk persist.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Stroke Council <span class=\"citation\">(<span class=\"evidence\">Hemphill et al., 2022</span>)</span>: Early surgical evacuation Class IIb (LOE B-R) for superficial lobar ICH >30 mL within 1 cm of cortex with mass effect or neurological deterioration.  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation Guidelines <span class=\"citation\">(ESO, 2020)</span>: Conditional recommendation for surgery in selected lobar ICH patients; emphasizes patient selection based on location, volume, and clinical status.  <br><span class=\"list-item\">\u2022</span> STICH II Trial <span class=\"citation\">(Mendelow et al., <span class=\"evidence\">Lancet 2013</span>)</span>: Trend toward better outcomes in early surgery subgroup with superficial lobar hemorrhage; did not reach statistical significance overall but supports targeted intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Superficial lobar hemorrhages (frontal/parietal lobes) are more accessible and yield greater benefit from surgical evacuation compared to deep ganglionic bleeds involving the internal capsule or thalamus, where surgery risks further neurological injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute ICH causes blood extravasation into brain parenchyma; clot retraction separates cellular elements (hyperdense) from plasma (hypodense), forming a fluid level. The expanding hematoma increases ICP, disrupts the blood&ndash;brain barrier, and induces perihematomal edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Non-contrast CT head: confirm ICH, measure volume (ABC/2), detect fluid level.  <br>2. Assess midline shift and mass effect.  <br>3. Reverse coagulopathy.  <br>4. Initiate BP management (target <140 mmHg).  <br>5. Neurosurgical consultation for early evacuation if fluid level, superficial location, volume >30 mL, or neurological decline.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Fluid level (&ldquo;hematocrit effect&rdquo;) appears as a horizontal interface between hyperdense clot and hypodense serum.  <br><span class=\"list-item\">\u2022</span> &ldquo;Swirl sign&rdquo; (mixed density) may indicate active bleeding.  <br><span class=\"list-item\">\u2022</span> CT angiography can exclude underlying AVM or aneurysm in fluid-level hemorrhages.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mannitol (0.25&ndash;1 g/kg IV) and hypertonic saline (3% bolus) for acute ICP spikes.  <br><span class=\"list-item\">\u2022</span> PCC (prothrombin complex concentrate) for warfarin reversal; idarucizumab for dabigatran; andexanet alfa for factor Xa inhibitors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Management of ICH with CT fluid levels tests knowledge of surgical indications, imaging markers of active bleeding, and guideline-driven decision-making. Such vignettes frequently probe timing of surgery versus medical management in neurology board questions.</div></div></div></div></div>"}, {"id": 100022900, "question_number": "15", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] - Pregnancy and the puerperium create a hypercoagulable state (\u2191 fibrinogen, factors VII&ndash;X) that peaks in the first 6 weeks postpartum, predisposing to venous thromboses.  <br><span class=\"list-item\">\u2022</span> Cortical veins and dural sinuses drain the cerebral cortex; their occlusion elevates venous pressure, causing vasogenic edema and hemorrhagic infarction, often in cortical regions.  <br><span class=\"list-item\">\u2022</span> Distinguishing venous hemorrhage (irregular, cortical, edema) from arterial bleeds (often deep, well-circumscribed) is key in acute postpartum neurologic presentations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Cerebral venous thrombosis (CVT) is the leading cause of postpartum intracerebral hemorrhage with focal deficits and headache. Occlusion of cortical veins or the superior sagittal sinus impairs venous outflow, raising capillary hydrostatic pressure, leading to blood&ndash;brain barrier disruption, vasogenic edema, and hemorrhagic infarction. MRI with susceptibility-weighted imaging and MR venography (MRV) demonstrates absent flow in the affected sinus/veins and allows differentiation from arterial lesions. The American Heart Association/American Stroke Association (AHA/ASA) stroke guidelines <span class=\"citation\">(2011, reaffirmed 2018)</span> give a Class I recommendation for anticoagulation in CVT even with hemorrhage (Level A evidence). The RE-SPECT CVT trial <span class=\"citation\">(NEJM 2019)</span> showed dabigatran is non-inferior to warfarin for secondary prevention. In contrast, aneurysmal rupture causes subarachnoid hemorrhage, AVM bleeds lack the typical edema pattern of venous infarcts, and hypertensive bleeds favor deep structures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aneurysm rupture  <br><span class=\"list-item\">\u2022</span> Why incorrect: Typically leads to subarachnoid hemorrhage or intraparenchymal bleeding in non-cortical, basal cisternal distribution.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all intracerebral bleeds in young adults are aneurysmal.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lack of classic &ldquo;thunderclap&rdquo; headache, negative MR angiogram.<br><br>C. Arteriovenous malformation  <br><span class=\"list-item\">\u2022</span> Why incorrect: AVM hemorrhage can cause cortical bleeds but usually in patients with known vascular malformations and without the acute hypercoagulable context.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any cortical hemorrhage with AVM.  <br><span class=\"list-item\">\u2022</span> Differentiator: AVM on angiography shows nidus and early venous drainage; no systemic hypercoagulability link.<br><br>D. Hypertensive intracerebral hemorrhage  <br><span class=\"list-item\">\u2022</span> Why incorrect: Predominantly affects deep nuclei (basal ganglia, thalamus) in uncontrolled hypertension, uncommon in normotensive postpartum women.  <br><span class=\"list-item\">\u2022</span> Misconception: Overgeneralizing hypertension as the cause of all ICH.  <br><span class=\"list-item\">\u2022</span> Differentiator: Patient is two weeks postpartum with normal blood pressure; hemorrhage location is cortical.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CVT (Correct)</th><th>Aneurysm Rupture</th><th>AVM Bleed</th><th>Hypertensive ICH</th></tr></thead><tbody><tr><td>Typical timing</td><td>1&ndash;6 weeks postpartum</td><td>Any age, sudden &ldquo;thunderclap&rdquo;</td><td>Often young adults, incidental AVM</td><td>Middle-aged, uncontrolled HTN</td></tr><tr><td>Imaging findings</td><td>Cortical hemorrhage + edema + MRV defect</td><td>Subarachnoid blood, aneurysm on MRA</td><td>Localized hemorrhage + nidus on DSA</td><td>Deep basal ganglia/thalamus bleed</td></tr><tr><td>Pathophysiology</td><td>Venous outflow obstruction</td><td>Arterial wall rupture</td><td>High-flow arteriovenous shunt</td><td>Charcot-Bouchard microaneurysms</td></tr><tr><td>Anticoagulation recommendation</td><td>Yes (even with hemorrhage)</td><td>Contraindicated</td><td>Contraindicated acutely</td><td>Contraindicated acutely</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always suspect CVT in postpartum women with new headache + focal deficits; MRI/MRV is diagnostic.  <br><span class=\"list-item\">\u2022</span> Anticoagulation (LMWH \u2192 oral agent) is safe and improves outcome, even in hemorrhagic presentations.  <br><span class=\"list-item\">\u2022</span> Hemorrhagic infarcts from CVT often cross arterial boundaries and associate with significant vasogenic edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Misattributing all cortical hemorrhages to AVMs or aneurysms without considering hypercoagulable states.  <br><span class=\"list-item\">\u2022</span> Withholding anticoagulation due to hemorrhage fear; guidelines support treatment even in hemorrhagic CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Stroke Guidelines <span class=\"citation\">(2011; reaffirmed 2018)</span>:  <br><span class=\"list-item\">\u2022</span> Recommendation: Initiate therapeutic anticoagulation in acute CVT, including hemorrhagic cases (Class I, Level A).  <br>2. RE-SPECT CVT Trial <span class=\"citation\">(NEJM 2019)</span>:  <br><span class=\"list-item\">\u2022</span> Finding: Dabigatran non-inferior to warfarin for prevention of recurrent CVT (Level 1 evidence).  <br>3. ESO/EAN Guidelines <span class=\"citation\">(European Stroke Organisation & European Academy of Neurology, 2017)</span>:  <br><span class=\"list-item\">\u2022</span> Recommendation: Direct oral anticoagulants may be considered as alternatives to vitamin K antagonists (Class IIa, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombosis of cortical veins or the superior sagittal sinus impedes drainage from the cerebral convexity, leading to backflow pressure, blood&ndash;brain barrier breakdown, and hemorrhagic venous infarction localized to the cortical ribbon and subcortical white matter.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>In the puerperium, elevated levels of fibrinogen, factors VII, VIII, X, and reduced protein S create a prothrombotic milieu. Venous occlusion elevates capillary pressure, causing transudation, cytotoxic edema, and eventually hemorrhagic transformation of the infarcted tissue.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in postpartum headache + focal deficits  <br>2. MRI brain with T2*/SWI + MR venography  <br>3. Identify filling defects in dural sinuses or cortical veins  <br>4. Exclude arterial lesions with MR angiography  <br>5. Initiate anticoagulation promptly</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- SWI/T2* sequences reveal blooming artifact at thrombus.  <br><span class=\"list-item\">\u2022</span> MRV shows absent flow voids in the thrombosed segment.  <br><span class=\"list-item\">\u2022</span> Hemorrhagic infarcts often have irregular borders and significant peri-lesional edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute: Low molecular weight heparin (e.g., enoxaparin 1 mg/kg BID).  <br><span class=\"list-item\">\u2022</span> Transition: Warfarin (INR 2&ndash;3) or DOAC (dabigatran 150 mg BID) for 3&ndash;6 months.  <br><span class=\"list-item\">\u2022</span> Monitor for extension of thrombus; treat seizure risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam.  <br>Postpartum CVT with hemorrhagic infarction is a high-yield topic on neurology boards, often presented as headache plus focal deficits; tested in multiple-choice format focusing on imaging and management nuances.</div></div></div></div></div>"}, {"id": 100022901, "question_number": "170", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] &bull; Transient ischemic attack (TIA) is a transient focal neurologic deficit without acute infarction; it carries a high early risk of stroke.  <br>&bull; Atrial flutter is a high-risk cardioembolic source analogous to atrial fibrillation; thrombi form in the left atrial appendage, even if transthoracic echocardiogram is normal.  <br>&bull; Cardioembolic strokes arise from thrombin-rich &ldquo;red thrombi,&rdquo; requiring anticoagulation (versus platelet-rich &ldquo;white thrombi&rdquo; in atherosclerotic disease treated with antiplatelets).  <br>&bull; CHADS\u2082-VASc scoring guides anticoagulation decisions; a TIA in atrial flutter confers indication for oral anticoagulation.<br><br>(\u2248110 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Direct oral anticoagulants (DOACs) that inhibit factor Xa (e.g., apixaban, rivaroxaban, edoxaban) have become first-line for nonvalvular atrial fibrillation or flutter. <span class=\"evidence\">The 2019</span> AHA/ASA guideline on secondary stroke prevention <span class=\"citation\">(Kernan et al., <span class=\"evidence\">Stroke 2019</span>)</span> issues a Class I, Level A recommendation for DOACs over warfarin in patients with CHADS\u2082-VASc &ge;2. In ARISTOTLE (N = 18,201), apixaban reduced stroke/systemic embolism by 21% and major bleeding by 31% versus warfarin <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2011</span>)</span>. ROCKET-AF (rivaroxaban) demonstrated noninferiority to warfarin <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2011</span>)</span>. Meta-analyses confirm DOACs lower intracranial hemorrhage rates. Even with a normal echocardiogram, atrial flutter predisposes to thrombus formation; early initiation of a Factor Xa inhibitor post-TIA optimizes prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Aspirin  <br>&bull; Incorrect because antiplatelet monotherapy does not prevent cardioembolic strokes from atrial arrhythmias.  <br>&bull; Misconception: &ldquo;Any antithrombotic is adequate.&rdquo;  <br>&bull; Differentiator: Aspirin targets platelet aggregation; atrial thrombi are fibrin-rich and require anticoagulation.<br><br>C. Dual antiplatelet therapy (aspirin and clopidogrel)  <br>&bull; Incorrect: increases bleeding risk without reducing cardioembolic stroke.  <br>&bull; Misconception: &ldquo;Doubling antiplatelets equals more protection.&rdquo;  <br>&bull; Differentiator: Dual antiplatelets are studied in atherosclerotic TIA (CHANCE, POINT), not atrial flutter.<br><br>D. Warfarin  <br>&bull; Although effective, warfarin requires INR monitoring and has more intracranial hemorrhage compared to DOACs.  <br>&bull; Misconception: &ldquo;Warfarin is the gold standard for all atrial thrombi.&rdquo;  <br>&bull; Differentiator: DOACs offer similar or superior efficacy with better safety and convenience.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Factor Xa Inhibitor</th><th>Warfarin</th><th>Aspirin</th><th>Dual Antiplatelets</th></tr></thead><tbody><tr><td>Mechanism</td><td>Direct Xa inhibition</td><td>Vitamin K epoxide blockade</td><td>COX-1 inhibition</td><td>COX-1 + P2Y\u2081\u2082 blockade</td></tr><tr><td>Stroke prevention in flutter</td><td>Class I, LOE A</td><td>Class I, LOE B (less favored)</td><td>Not indicated</td><td>Not indicated</td></tr><tr><td>Onset of action</td><td>Rapid (2&ndash;4 h)</td><td>Delayed (48&ndash;72 h)</td><td>Rapid (30 min)</td><td>Rapid (1&ndash;2 h)</td></tr><tr><td>Monitoring</td><td>None routinely</td><td>INR (2&ndash;3)</td><td>None</td><td>None</td></tr><tr><td>Major bleeding risk</td><td>Lower intracranial</td><td>Higher intracranial</td><td>Lower overall</td><td>Higher GI bleeding</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Atrial flutter carries stroke risk comparable to atrial fibrillation; manage identically with anticoagulation.  <br>&bull; Calculate CHADS\u2082-VASc in all atrial arrhythmias; TIA itself scores &ge;2 in men (age >75 adds points) warranting anticoagulation.  <br>&bull; Initiate DOAC within days of TIA if no hemorrhagic conversion; avoid delays beyond 72 hours when safe.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Prescribing aspirin alone for TIA in atrial flutter, underestimating cardioembolic risk.  <br>&bull; Misapplying dual antiplatelet data from atherosclerotic TIA (CHANCE/POINT) to atrial arrhythmias, leading to inappropriate use.  <br>&bull; Assuming a normal transthoracic echo excludes atrial thrombus risk; left atrial appendage often not well visualized without TEE.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2019 Stroke Prevention in Patients With Stroke and TIA: Class I, LOE A recommendation for DOACs over warfarin in nonvalvular atrial fibrillation/flutter with CHADS\u2082-VASc &ge;2.  <br>&bull; ESC 2020 Atrial Fibrillation Guidelines: Class IA recommendation for DOACs in nonvalvular atrial arrhythmias; emphasize lower ICH risk and no routine monitoring.  <br>&bull; ARISTOTLE Trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2011</span>)</span>: Apixaban vs warfarin reduced stroke/systemic embolism (HR 0.79; 95% CI 0.66&ndash;0.95) and major bleeding (HR 0.69; 95% CI 0.60&ndash;0.80).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Factor Xa inhibitors directly block the active site of factor Xa, preventing prothrombin conversion to thrombin.  <br>&bull; Apixaban: 5 mg twice daily (2.5 mg if &ge;80 yrs, weight &le;60 kg, or creatinine &ge;1.5 mg/dL).  <br>&bull; Rivaroxaban: 20 mg once daily with food (15 mg if CrCl 15&ndash;50 mL/min).  <br>Advantages include predictable PK/PD, no routine INR, fewer drug&ndash;food interactions; reversal with andexanet alfa.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.  <br>Cardioembolic stroke prevention with DOACs is frequently tested in both multiple-choice and clinical vignettes, emphasizing guideline-driven selection of anticoagulants in nonvalvular atrial arrhythmias.</div></div></div></div></div>"}, {"id": 100022902, "question_number": "251", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] - Acute ischemic stroke (AIS) treatment hinges on timely reperfusion (ideally within 4.5 hours of symptom onset) to salvage penumbral tissue.  <br><span class=\"list-item\">\u2022</span> Intravenous thrombolysis with alteplase (tPA) carries hemorrhagic risk, mitigated by strict adherence to contraindications.  <br><span class=\"list-item\">\u2022</span> Platelets are essential for primary hemostasis; severe thrombocytopenia (<100,000/\u00b5L) markedly increases bleeding risk, rendering tPA contraindicated.<br><br>(Word count: 82)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of AIS <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2018</span>)</span> list a platelet count <100,000/\u00b5L as an absolute contraindication to IV alteplase (Class III: Harm, Level of Evidence C). Physiologically, platelets plug damaged endothelium; counts <100 \u00d7 10^3/\u00b5L fail to form an effective hemostatic barrier, predisposing to hemorrhagic conversion. In the NINDS tPA trials, hemorrhage risk correlated inversely with platelet count. Administering tPA to a patient with 45,000/\u00b5L directly violated this guideline, explaining the intracranial bleed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Out of the tPA window  <br><span class=\"list-item\">\u2022</span> Why incorrect: Patient was &ldquo;within the window.&rdquo;  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming delayed presentation when timing was adequate.  <br><span class=\"list-item\">\u2022</span> Differentiator: Time-to-treatment was acceptable (<4.5 h).  <br><br>C. Recent major surgery  <br><span class=\"list-item\">\u2022</span> Why incorrect: Only intracranial or intraspinal surgery within 3 months is an absolute contraindication; non-cranial major surgery without evidence of bleeding risk is a relative concern.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any surgery with high hemorrhage risk.  <br><span class=\"list-item\">\u2022</span> Differentiator: Thrombocytopenia has a clearer, absolute prohibition than non-cranial surgery.  <br><br>D. Uncontrolled hypertension  <br><span class=\"list-item\">\u2022</span> Why incorrect: tPA is contraindicated if BP >185/110 mmHg and not rapidly corrected; here no hypertensive values are provided.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming elevated BP without data.  <br><span class=\"list-item\">\u2022</span> Differentiator: Uncontrolled hypertension must be documented >185/110 mmHg at infusion time.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Platelet Count <100k (B)</th><th>Time Window Violation (A)</th><th>Recent Major Surgery (C)</th><th>Uncontrolled BP (D)</th></tr></thead><tbody><tr><td>Guideline Status</td><td>Absolute contraindication</td><td>Absolute if >4.5 h</td><td>Absolute only if cranial</td><td>Absolute if >185/110 mmHg</td></tr><tr><td>Level of Evidence</td><td>Class III, LOE C</td><td>Class I, LOE A</td><td>Class III (cranial)</td><td>Class III, LOE C</td></tr><tr><td>Patient Scenario Applicability</td><td>Directly violated</td><td>Not applicable</td><td>Not specified as cranial</td><td>No BP data provided</td></tr><tr><td>Hemorrhage Risk Mechanism</td><td>Impaired primary hemostasis</td><td>Delayed reperfusion risk</td><td>Surgical site bleeding</td><td>Vessel stress</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Always verify platelet count >100,000/\u00b5L before tPA; counts <100k confer high hemorrhagic risk.  <br>2. &ldquo;Recent surgery&rdquo; refers specifically to intracranial/intraspinal procedures within 3 months&mdash;non-cranial surgeries carry lower, relative risk.  <br>3. Blood pressure must be &le;185/110 mmHg at tPA initiation; use IV labetalol or nicardipine to achieve rapid control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overlooking lab data under time pressure, leading to missed thrombocytopenia.  <br>2. Misremembering &ldquo;recent surgery&rdquo; window and type; students often generalize all surgeries equally.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Early Management of AIS Guidelines (Powers WS et al.): Platelet count <100,000/\u00b5L is an absolute contraindication to IV alteplase (Class III: Harm; Level C).  <br>2. ESO-ESMINT 2021 Guidelines: Reiterate the same platelet threshold and emphasize risk stratification for hemorrhagic transformation (Grade A recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Acute ischemic stroke contraindications are tested frequently, often requiring recall of specific laboratory and clinical cutoffs such as platelet count, blood pressure, and surgical history.</div></div></div></div></div>"}, {"id": 100022903, "question_number": "66", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Patients with sudden-onset &ldquo;thunderclap&rdquo; headache require rapid evaluation to exclude subarachnoid hemorrhage (SAH) and other vascular emergencies. Horner&rsquo;s syndrome&mdash;ptosis, miosis, and facial anhidrosis&mdash;indicates ipsilateral disruption of the oculosympathetic pathway, which ascends in the carotid sheath. Key concepts:  <br>&bull; Anatomy of the sympathetic chain in the neck, accompanying the internal carotid artery (ICA).  <br>&bull; Mechanism of arterial dissection: an intimal tear allows blood to create an intramural hematoma, expanding the vessel wall and compressing adjacent structures.  <br>&bull; Differential diagnosis of thunderclap headache with negative CT and lumbar puncture includes carotid dissection, reversible cerebral vasoconstriction syndrome (RCVS), and rare vascular pathologies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>ICA dissection classically presents with ipsilateral Horner&rsquo;s syndrome from compression of the sympathetic fibers in the adventitia. Thunderclap headache occurs acutely when the intimal tear propagates. CT angiography or MR angiography demonstrates a &ldquo;crescent sign&rdquo; or double lumen. A normal noncontrast head CT and LP <6 hours rule out SAH; normal LP and CT also make aneurysmal rupture unlikely. RCVS can cause thunderclap headaches but does not produce Horner&rsquo;s syndrome. Clinical guidelines <span class=\"citation\">(AHA/ASA 2019)</span> recommend prompt vascular imaging in suspected cervical dissection. The CADISS trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span> supports either antiplatelet or anticoagulation without superiority, underscoring the diagnosis&rsquo;s importance for management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Pcom aneurysm rupture  <br><span class=\"list-item\">\u2022</span> Rupture causes SAH with xanthochromia or hyperdense blood on CT; presents with oculomotor palsy (blown pupil, not miosis).  <br><span class=\"list-item\">\u2022</span> Misconception: any aneurysm rupture = thunderclap headache, but Horner&rsquo;s points to sympathetic chain involvement.  <br><br>B. Reversible Cerebral Vasoconstriction Syndrome (RCVS)  <br><span class=\"list-item\">\u2022</span> Features recurrent thunderclap headaches over days&ndash;weeks; imaging shows segmental vasoconstriction on angiography. Does not produce Horner&rsquo;s syndrome.  <br><span class=\"list-item\">\u2022</span> Misconception: all thunderclap headaches with normal CT/LP are RCVS, but focal neuro signs differentiate.  <br><br>D. Subarachnoid hemorrhage  <br><span class=\"list-item\">\u2022</span> SAH typically shows blood on CT within 6 hours or xanthochromia on LP if delayed; does not cause isolated Horner&rsquo;s syndrome.  <br><span class=\"list-item\">\u2022</span> Misconception: a negative initial CT/LP always excludes dissection, but dissection is non-hemorrhagic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>ICA Dissection</th><th>Pcom Aneurysm Rupture</th><th>RCVS</th><th>SAH</th></tr></thead><tbody><tr><td>Headache onset</td><td>Thunderclap (sudden)</td><td>Thunderclap</td><td>Recurrent thunderclap</td><td>Thunderclap</td></tr><tr><td>Horner&rsquo;s syndrome</td><td>Present (sympathetic chain)</td><td>Absent</td><td>Absent</td><td>Absent</td></tr><tr><td>CT brain</td><td>Normal</td><td>May show acute SAH</td><td>Normal early</td><td>Hyperdensity in subarachnoid cisterns</td></tr><tr><td>LP</td><td>Normal</td><td>Xanthochromia if CT negative</td><td>Normal</td><td>Xanthochromia if CT negative</td></tr><tr><td>Angiography</td><td>&ldquo;Crescent sign,&rdquo; double lumen</td><td>Aneurysmal sac</td><td>Segmental vasoconstriction</td><td>No vascular constriction (unless vasospasm)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Ipsilateral Horner&rsquo;s syndrome in a thunderclap headache is virtually pathognomonic for cervical carotid dissection.  <br>&bull; MRI with fat-suppressed T1 sequences is highly sensitive for detecting intramural hematoma.  <br>&bull; Early antithrombotic therapy reduces ischemic stroke risk; choice between antiplatelet vs anticoagulant guided by CADISS trial findings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming a negative noncontrast CT and LP exclude all vascular etiologies&mdash;CT angiography is required to evaluate arterial dissection.  <br>2. Misattributing ptosis in headache patients to migraine or eyelid swelling rather than investigating for sympathetic chain disruption.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Scientific Statement on Cervical Artery Dissection:  <br>   &ndash; Recommendation: Use either antiplatelet or anticoagulant therapy for 3&ndash;6 months. (Class IIa; Level of Evidence B)  <br>2. CADISS Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurology 2015</span>)</span>:  <br>   &ndash; Randomized comparison of antiplatelet vs anticoagulation in cervical dissection&mdash;no difference in stroke recurrence at 3 months, supporting flexibility in antithrombotic choice.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The oculosympathetic pathway ascends from the hypothalamus to the ciliospinal center (C8&ndash;T2), then follows the sympathetic chain alongside the ICA in the carotid sheath. Dissection-induced hematoma compresses these fibers, causing ptosis and miosis without extraocular muscle involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Intimal tear in the ICA allows blood to enter the vessel wall, forming a subintimal hematoma. This expands the vessel wall outward, compressing adjacent sympathetic fibers and sometimes reducing lumen diameter, risking thromboembolism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT \u2192 if negative,  <br>2. Lumbar puncture \u2192 if no xanthochromia,  <br>3. CT or MR angiography of cervical and intracranial vessels \u2192 look for dissection signs (crescent sign/double lumen).  <br>4. Confirm with high-resolution vessel wall MRI if needed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; &ldquo;Crescent sign&rdquo; on T1 fat-suppressed MRI indicates intramural hematoma.  <br>&bull; CT angiography may show tapering (&ldquo;string sign&rdquo;) or pseudoaneurysm at dissection site.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Carotid dissection with ipsilateral Horner&rsquo;s is a classic high-yield scenario, frequently tested in single-best-answer format emphasizing neuroanatomical correlation and diagnostic imaging.</div></div></div></div></div>"}, {"id": 100022904, "question_number": "168", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Berry (saccular) aneurysms arise at arterial branch points in the circle of Willis and account for >85% of nontraumatic subarachnoid hemorrhages (SAH). The most common site is the anterior communicating (ACom) artery junction with the anterior cerebral artery. SAH classically presents with sudden &ldquo;thunderclap&rdquo; headache, nuchal rigidity, and possible loss of consciousness. Key concepts:  <br><span class=\"list-item\">\u2022</span> Circle of Willis anatomy and common aneurysm sites  <br><span class=\"list-item\">\u2022</span> Hemodynamic stress at bifurcations leading to vessel wall degeneration  <br><span class=\"list-item\">\u2022</span> Clinical triad of SAH (acute headache, meningismus, photophobia)  <br><br>(Word count: 100)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Anterior communicating artery aneurysms constitute approximately 30&ndash;35% of all saccular aneurysms <span class=\"citation\">(Vlak et al., <span class=\"evidence\">Stroke 2011</span>)</span>. Rupture leads to rapid bleeding into the subarachnoid space, most prominently in the interhemispheric fissure and anterior cisterns. <span class=\"evidence\">The 2012</span> AHA/ASA Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage (Class I, Level of Evidence A) recommend prompt noncontrast CT followed by CT angiography to localize aneurysms. Early aneurysm securing&mdash;either surgical clipping or endovascular coiling&mdash;is advised within 72 hours (Class I, LOE B). The International Subarachnoid Aneurysm Trial <span class=\"citation\">(ISAT, <span class=\"evidence\">Lancet 2002</span>)</span> showed that endovascular coiling of ACom aneurysms confers better one-year outcomes compared to clipping in selected patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Middle cerebral artery  <br><span class=\"list-item\">\u2022</span> Incorrect because MCA aneurysms account for ~20&ndash;25% of cases, second to ACom.  <br><span class=\"list-item\">\u2022</span> Misconception: Students may assume the largest cerebral artery is most prone to aneurysm.  <br><span class=\"list-item\">\u2022</span> Differentiator: MCA aneurysms typically occur at the M1&ndash;M2 bifurcation and present with focal deficits in the corresponding cortical territory.<br><br>C. Posterior cerebral artery  <br><span class=\"list-item\">\u2022</span> Incorrect: PCA aneurysms are rare (<3% of intracranial aneurysms).  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that posterior circulation vessels bear equal aneurysm risk.  <br><span class=\"list-item\">\u2022</span> Differentiator: PCA aneurysms often present with occipital lobe signs (visual field deficits) rather than classic basal cistern SAH.<br><br>D. Basilar artery  <br><span class=\"list-item\">\u2022</span> Incorrect: Basilar tip aneurysms represent ~5&ndash;10% of cases.  <br><span class=\"list-item\">\u2022</span> Misconception: Students may conflate basilar artery size with aneurysm frequency.  <br><span class=\"list-item\">\u2022</span> Differentiator: Basilar tip aneurysms are associated with cranial nerve III palsy and brainstem compression signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Artery</th><th>Incidence in SAH</th><th>Typical Location</th><th>Key Clinical Feature</th></tr></thead><tbody><tr><td>Anterior communicating (ACom)</td><td>30&ndash;35%</td><td>ACom&ndash;ACA junction, anterior interhemispheric fissure</td><td>Thunderclap headache, bitemporal field effects if unruptured</td></tr><tr><td>Middle cerebral (MCA)</td><td>20&ndash;25%</td><td>M1&ndash;M2 bifurcation</td><td>Focal motor/sensory deficits</td></tr><tr><td>Basilar tip</td><td>5&ndash;10%</td><td>Apex of basilar artery</td><td>CN III palsy, oculomotor signs</td></tr><tr><td>Posterior cerebral (PCA)</td><td><3%</td><td>P1&ndash;P2 junction</td><td>Occipital visual field defects</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- ACom aneurysms are the most common site; watch for visual field cuts from optic chiasm compression.  <br><span class=\"list-item\">\u2022</span> Nimodipine (60 mg orally every 4 hours for 21 days) is recommended to reduce delayed cerebral ischemia <span class=\"citation\">(AHA/ASA 2012, Class I, LOE A)</span>.  <br><span class=\"list-item\">\u2022</span> Perform noncontrast head CT within 6 hours of headache onset; sensitivity approaches 98% (Class I, LOE A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming the largest-caliber vessel (MCA) is most susceptible to aneurysm formation.  <br>2. Overlooking the anterior communicating artery because it is a small connector rather than a &ldquo;major&rdquo; vessel.  <br>3. Believing posterior circulation aneurysms (basilar, PCA) are as common as anterior circulation lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2012 Guidelines on Aneurysmal SAH: recommend noncontrast CT within 6 hours of ictus (Class I, LOE A) and early aneurysm securing (<72 hours; Class I, LOE B).  <br><span class=\"list-item\">\u2022</span> International Subarachnoid Aneurysm Trial <span class=\"citation\">(ISAT, 2002)</span>: demonstrated superior 1-year outcomes with endovascular coiling versus surgical clipping for selected ACom aneurysms (p < 0.01).  <br><span class=\"list-item\">\u2022</span> EANO 2021 Consensus: advocates routine follow-up imaging at 6 months post-coiling to detect aneurysm recurrence (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The ACom connects the A1 segments of bilateral anterior cerebral arteries, forming a key anterior communication in the circle of Willis. Its proximity to the optic chiasm explains visual field changes in large, unruptured aneurysms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Hemodynamic stress at arterial bifurcations causes degeneration of the tunica media and internal elastic lamina, leading to saccular outpouchings. Inflammation and matrix metalloproteinases further weaken vessel walls.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT immediately upon presentation.  <br>2. If CT positive for SAH, proceed to CT angiography for aneurysm localization.  <br>3. If CT negative but suspicion remains high, perform lumbar puncture for xanthochromia.  <br>4. Digital subtraction angiography for definitive aneurysm mapping prior to intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT: hyperdense blood in basal cisterns, Sylvian fissures, and sulci.  <br><span class=\"list-item\">\u2022</span> CTA: rapid, noninvasive visualization of aneurysm morphology and parent vessels.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Nimodipine: calcium channel blocker with neuroprotective effects, reduces vasospasm-related infarction.  <br><span class=\"list-item\">\u2022</span> Short-term antifibrinolytics (e.g., tranexamic acid) may be used pre-intervention to reduce rebleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. ACom aneurysms are tested frequently on neurology board exams, often in the context of circle of Willis anatomy, imaging interpretation, and SAH management guidelines.</div></div></div></div></div>"}, {"id": 100022905, "question_number": "157", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Acute ischemic stroke results from arterial occlusion leading to a core infarct surrounded by salvageable penumbra. Rapid reperfusion within the 4.5-hour window limits infarct growth. Key concepts:  <br>1. Ischemic cascade and penumbra: delayed neuronal death in peri-infarct area allows a therapeutic window.  <br>2. Time is brain: every minute of large-vessel occlusion costs ~1.9 million neurons.  <br>3. Thrombolytic therapy: intravenous alteplase dissolves fibrin-rich clots, improving functional outcomes if given early.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Intravenous alteplase (tPA) administered at 0.9 mg/kg (max 90 mg) within 4.5 hours of symptom onset is Class I, Level A per AHA/ASA 2019 guidelines <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2019</span>)</span>. The ECASS III trial (2008) demonstrated significant reduction in disability at 90 days when tPA was given between 3.0&ndash;4.5 hours (N = 821; OR for favorable outcome 1.34; p = 0.04). Emberson et al.&rsquo;s meta-analysis <span class=\"citation\">(<span class=\"evidence\">Lancet 2014</span>)</span> confirmed benefit declines over time yet persists to 4.5 hours. In contrast, CTA is reserved for large-vessel occlusion identification when considering endovascular therapy; it does not replace emergent thrombolysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. CTA  <br><span class=\"list-item\">\u2022</span> Why incorrect: CTA delays tPA initiation and is not required before alteplase.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that vessel imaging is needed to diagnose occlusion prior to thrombolysis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Noncontrast CT is the only imaging needed to exclude hemorrhage; CTA is adjunctive for thrombectomy planning.  <br><br>C. Warfarin  <br><span class=\"list-item\">\u2022</span> Why incorrect: Oral anticoagulation has delayed onset, no role in acute clot lysis.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating anticoagulation with thrombolysis in acute ischemia.  <br><span class=\"list-item\">\u2022</span> Differentiator: Warfarin is for secondary prevention in cardioembolic stroke after stabilization.  <br><br>D. CEA  <br><span class=\"list-item\">\u2022</span> Why incorrect: Carotid endarterectomy is elective/subacute for symptomatic &ge;70% carotid stenosis, not immediate reperfusion.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming surgical revascularization is the first step in all ischemic strokes.  <br><span class=\"list-item\">\u2022</span> Differentiator: CEA entails pre-op risk assessment and is contraindicated acutely due to hemorrhage risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>tPA (Correct)</th><th>CTA</th><th>Warfarin</th><th>CEA</th></tr></thead><tbody><tr><td>Purpose</td><td>Clot lysis</td><td>Vessel imaging</td><td>Anticoagulation</td><td>Surgical revascularization</td></tr><tr><td>Timing</td><td>Within 4.5 h</td><td>After initial CT/for EVT</td><td>Delayed onset (days)</td><td>Days to weeks post-stroke</td></tr><tr><td>Indication</td><td>Acute ischemic stroke</td><td>Large-vessel occlusion</td><td>Secondary prevention</td><td>Symptomatic carotid stenosis</td></tr><tr><td>Key limitation</td><td>Hemorrhage risk</td><td>Radiation/contrast delay</td><td>Bleeding risk, delayed INR</td><td>Surgical risk, periop stroke</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Age >80 years is not an absolute exclusion; tPA is indicated up to 4.5 h regardless of age.  <br><span class=\"list-item\">\u2022</span> Early NIHSS assessment guides eligibility; most centers target door-to-needle &le;60 minutes.  <br><span class=\"list-item\">\u2022</span> Tenecteplase shows promise in large-vessel occlusion, but alteplase remains first-line per current guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Delaying tPA to obtain vascular imaging (CTA/MRA) instead of administering after noncontrast CT.  <br>2. Starting anticoagulation (heparin/warfarin) in the hyperacute phase, which increases hemorrhagic transformation risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Stroke Guidelines <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2019</span>)</span>:  <br><span class=\"list-item\">\u2022</span> Recommendation: IV alteplase within 4.5 h (Class I, LOE A).  <br>2. ECASS III Trial <span class=\"citation\">(Hacke et al., NEJM 2008)</span>:  <br><span class=\"list-item\">\u2022</span> Finding: Benefit of tPA extended to 4.5 h window (OR for favorable mRS 0&ndash;1 = 1.34; p = 0.04).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Noncontrast CT is mandatory to exclude hemorrhage and large established infarct signs.  <br><span class=\"list-item\">\u2022</span> CTA is performed after tPA initiation if mechanical thrombectomy up to 6 h is under consideration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Alteplase mechanism: converts plasminogen to plasmin, degrading fibrin clot.  <br><span class=\"list-item\">\u2022</span> Dosing: 0.9 mg/kg (10% bolus over 1 minute; remainder infused over 60 minutes).  <br><span class=\"list-item\">\u2022</span> BP management: maintain <185/110 mm Hg before and <180/105 mm Hg for 24 h post-tPA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Acute stroke management&mdash;particularly indication, timing, and contraindications for IV alteplase&mdash;is a high-yield topic, frequently tested as vignette-style questions requiring rapid decision-making within time windows.</div></div></div></div></div>"}, {"id": 100022906, "question_number": "24", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Cerebral autoregulation maintains consistent blood flow across mean arterial pressures of 60&ndash;150 mmHg. Chronic high-grade carotid stenosis induces maximal distal arteriolar dilation and loss of vasoreactive reserve. After carotid endarterectomy (CEA), sudden restoration of normal perfusion pressure can overwhelm these dilated vessels, causing blood&ndash;brain barrier breakdown and cortical capillary rupture. The resulting convexity subarachnoid hemorrhage typically appears 24&ndash;72 hours post-CEA. Recognizing this timing and the sulcal distribution helps distinguish hyperperfusion syndrome from other intracranial hemorrhages.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Hyperperfusion syndrome complicates 0.2&ndash;3% of CEAs and is a leading cause of postoperative cortical SAH <span class=\"citation\">(Schoser et al., <span class=\"evidence\">Neurosurgery 2019</span>)</span>. Impaired autoregulatory capacity in chronically underperfused territories means that normalized perfusion pressure leads to endothelial injury and hemorrhage. The AHA/ASA 2021 guidelines on extracranial carotid disease (Class I, Level B) mandate postoperative systolic BP <140 mmHg for at least 48 hours to mitigate hyperperfusion risk. Transcranial Doppler studies detect middle cerebral artery velocities >200 cm/s as an early marker of hyperperfusion. CT findings in hyperperfusion syndrome&mdash;isolated convexity sulcal blood&mdash;contrast sharply with basal cistern involvement in aneurysmal SAH or parenchymal collections of surgical hematoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Rupture of undiagnosed aneurysm  <br><span class=\"list-item\">\u2022</span> Aneurysmal SAH classically fills basal cisterns and sylvian fissures; isolated cortical sulcal hemorrhage after CEA with no aneurysm risk history is improbable.  <br>C. Post-operative hematoma  <br><span class=\"list-item\">\u2022</span> Surgical bleeding produces intraparenchymal or subdural collections adjacent to the endarterectomy site, not an isolated convexity SAH.  <br>D. Venous sinus thrombosis  <br><span class=\"list-item\">\u2022</span> Causes hemorrhagic venous infarcts with edema and infarction patterns on imaging; does not present as pure cortical subarachnoid blood.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Hyperperfusion Syndrome</th><th>Aneurysmal SAH</th><th>Surgical Hematoma</th><th>Venous Sinus Thrombosis</th></tr></thead><tbody><tr><td>Timing post-CEA</td><td>24&ndash;72 hours</td><td>Unrelated to CEA timing</td><td>Immediate post-op</td><td>Variable (days&ndash;weeks)</td></tr><tr><td>CT distribution</td><td>Convexity sulcal SAH</td><td>Basal cisterns, sylvian fissures</td><td>Parenchymal/subdural bleed</td><td>Hemorrhagic infarcts, edema</td></tr><tr><td>Mechanism</td><td>Impaired autoregulation, BBB breakdown</td><td>Vessel wall rupture</td><td>Surgical vessel injury</td><td>Venous outflow obstruction</td></tr><tr><td>Key risk factors</td><td>High-grade stenosis, HTN, contralateral occlusion</td><td>Hypertension, smoking, aneurysm</td><td>Technical error, coagulopathy</td><td>Thrombophilia, dehydration</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Peak onset of hyperperfusion syndrome is 1&ndash;3 days post-CEA; maintain systolic BP <140 mmHg to prevent.  <br>2. Transcranial Doppler monitoring of MCA flow velocities (>200 cm/s) can predict hyperperfusion before hemorrhage.  <br>3. Convexity SAH in postoperative CEA patients is virtually diagnostic of hyperperfusion syndrome when aneurysm is excluded.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming any postoperative intracranial bleed is due to anticoagulation or technical error, rather than impaired autoregulation.  <br>2. Misinterpreting basal cistern SAH as hyperperfusion hemorrhage&mdash;location and vessel territory guide differentiation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2021 Guidelines on Extracranial Carotid and Vertebral Artery Disease: Recommend strict BP control (systolic <140 mmHg) for 48&ndash;72 hours post-CEA to prevent hyperperfusion (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> ESVS 2023 Clinical Practice Guidelines: Advocate routine transcranial Doppler surveillance and perioperative hemodynamic management to reduce hyperperfusion syndrome risk (Grade A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic carotid stenosis leads to maximal arteriolar dilation and loss of vasodilatory reserve. Post-CEA, sudden normalization of luminal diameter and pressure causes capillary stress failure, endothelial disruption, and extravasation of blood into the subarachnoid space over cerebral convexities.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>CT shows isolated cortical sulcal hyperdensities without basal cistern or deep parenchymal involvement&mdash;distinct from aneurysmal or traumatic patterns. MR perfusion can detect regional cerebral blood flow surges (>150% baseline) preemptively.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Carotid endarterectomy complications, especially hyperperfusion syndrome manifesting as convexity SAH, are frequently tested in vascular neurology and neurosurgery sections.</div></div></div></div></div>"}, {"id": 100022907, "question_number": "45", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Lateral medullary (Wallenberg) syndrome results from infarction of the dorsolateral medulla supplied by the posterior inferior cerebellar artery (PICA), a branch of the vertebral artery. Trauma, such as an MVA, can cause an intimal tear in the vertebral artery leading to dissection, intramural hematoma, and subsequent thrombosis with vessel occlusion. Key concepts:  <br><span class=\"list-item\">\u2022</span> Anatomy: PICA arises from vertebral artery; infarction affects nucleus ambiguus, spinothalamic tract, vestibular nuclei.  <br><span class=\"list-item\">\u2022</span> Pathophysiology: Dissection-induced thrombosis differs from embolic occlusion (cardiac or artery-to-artery) and from small vessel (lacunar) disease.  <br><span class=\"list-item\">\u2022</span> Clinical correlation: Trauma history raises suspicion for cervical artery dissection leading to thrombosis.  <br><br>(Word count: 113)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Vertebral artery dissection with resultant thrombosis is the most common mechanism of lateral medullary infarction after cervical trauma. Dissection creates an intimal flap and intramural hematoma, promoting local thrombus formation and occlusion of PICA origin <span class=\"citation\">(Schievink WI, Lancet <span class=\"evidence\">Neurol 2006</span>)</span>. <span class=\"evidence\">The 2019</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (Class I; Level B) recommend vascular imaging (CTA/MRA) in suspected cervical dissections. MRI-DWI localizes the medullary lesion, while CTA reveals vessel wall abnormalities and &ldquo;string sign.&rdquo; Large-vessel thrombosis explains the sudden onset of brainstem deficits in trauma patients, distinguishing it from gradual-onset lacunar strokes or episodic emboli.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Artery-to-artery thrombus  <br><span class=\"list-item\">\u2022</span> Incorrect because this implies thrombosis at one atherosclerotic plaque lodging distally; post-traumatic dissections cause local thrombosis, not plaque rupture.  <br><span class=\"list-item\">\u2022</span> Misconception: equating any thromboembolism with trauma-induced stroke.  <br><span class=\"list-item\">\u2022</span> Differentiator: artery-to-artery emboli typically originate from carotid atheroma, not vertebral dissection.  <br><br>C. Embolic stroke  <br><span class=\"list-item\">\u2022</span> Incorrect: cardioembolic strokes arise from atrial fibrillation or ventricular thrombus; no arrhythmia or cardiac source here.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming all brainstem strokes are embolic.  <br><span class=\"list-item\">\u2022</span> Differentiator: imaging in embolism often shows multiple territorial infarcts, not isolated PICA territory.  <br><br>D. Lacunar infarct  <br><span class=\"list-item\">\u2022</span> Incorrect: lacunes are <15 mm, due to lipohyalinosis in small penetrating arteries; they spare dorsolateral medulla.  <br><span class=\"list-item\">\u2022</span> Misconception: confusing any brainstem infarct with lacunar syndrome.  <br><span class=\"list-item\">\u2022</span> Differentiator: lacunar strokes present with pure motor/sensory deficits without cranial nerve involvement seen in Wallenberg.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Vertebral Artery Thrombosis</th><th>Artery-to-Artery Thrombus</th><th>Embolic Stroke</th><th>Lacunar Infarct</th></tr></thead><tbody><tr><td>Typical Cause</td><td>Dissection after trauma</td><td>Atherosclerotic plaque in carotid</td><td>Cardiac source (AF, LV thrombus)</td><td>Small vessel lipohyalinosis</td></tr><tr><td>Vessel Size</td><td>Large vessel (vertebral/PICA)</td><td>Large/medium artery</td><td>Large artery occlusion</td><td>Small penetrating arteriole</td></tr><tr><td>Infarct Location</td><td>Lateral medulla (PICA territory)</td><td>Variable distal territories</td><td>Multiple cortical or subcortical</td><td>Deep structures (basal ganglia)</td></tr><tr><td>Imaging</td><td>CTA: intimal flap, occlusion</td><td>CTA: plaque with distal filling defect</td><td>MRI/MRA: wedge\u2010shaped infarcts</td><td>DWI: small (<15 mm) lacune</td></tr><tr><td>Clinical Context</td><td>Recent neck trauma</td><td>Vascular risk factors, carotid bruit</td><td>Cardiac history, AF on ECG</td><td>Hypertension, diabetes, insidious</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always perform CTA/MRA in Wallenberg syndrome post-trauma to rule out vertebral dissection.  <br>&bull; Vertebral artery dissections may present with neck pain or headache before neurological signs.  <br>&bull; Antithrombotic therapy (antiplatelet vs anticoagulation) for cervical dissection is chosen based on bleeding risk; CADISS trial showed similar outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling lateral medullary syndrome as lacunar infarct due to small lesion size; lacunes do not involve cranial nerves.  <br>2. Assuming any brainstem stroke is cardioembolic without correlating with clinical context or vascular imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Update on Early Management of Acute Ischemic Stroke:  <br>   &ndash; Recommendation: CTA/MRA for suspected cervical dissection (Class I; Level B).  <br>2. Cervical Artery Dissection in Stroke Study (CADISS), Lancet <span class=\"evidence\">Neurol 2015</span>:  <br>   &ndash; Compared anticoagulation vs antiplatelet therapy in cervical dissection; no significant difference in stroke recurrence at 3 months.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lateral medullary infarction involves PICA territory affecting: nucleus ambiguus (dysphagia, hoarseness), spinal trigeminal nucleus (ipsilateral facial pain/temp loss), spinothalamic tract (contralateral body pain/temp loss), inferior cerebellar peduncle (ataxia), and sympathetic fibers (Horner syndrome).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Traumatic neck hyperextension/flexion causes an intimal tear in the vertebral artery, leading to intramural hematoma, luminal narrowing, platelet aggregation, and thrombus formation, which occludes the PICA origin and causes lateral medullary ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: Wallenberg signs + trauma history  <br>2. MRI brain with DWI to confirm dorsolateral medullary infarction  <br>3. CTA or MRA of cervical vessels to detect dissection/thrombosis  <br>4. Initiate antithrombotic therapy and neurosurgical/endovascular consult if needed</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; CTA &ldquo;string sign&rdquo; or double\u2010lumen indicates dissection.  <br>&bull; MRI T1\u2010weighted fat-suppressed sequences may show intramural hematoma.  <br>&bull; DWI reliably localizes acute infarct in PICA territory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Antiplatelet therapy (aspirin 81&ndash;325 mg daily) preferred in low-bleeding-risk dissections.  <br>&bull; Anticoagulation (e.g., heparin to warfarin) considered if high-risk features; guided by CADISS trial.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam.  <br>Traumatic vertebral artery dissection causing PICA thrombosis in lateral medullary syndrome is a high-yield topic tested in both single-best-answer and clinical vignette formats on neurology boards.</div></div></div></div></div>"}, {"id": 100022908, "question_number": "40", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] The anterior inferior cerebellar artery (AICA) arises from the basilar artery and supplies the lateral pons, flocculus, middle cerebellar peduncle and inner ear via the labyrinthine artery. Key concepts:  <br><span class=\"list-item\">\u2022</span> Vascular territories: AICA vs PICA (posterior inferior cerebellar artery) vs SCA (superior cerebellar artery).  <br><span class=\"list-item\">\u2022</span> Cranial nerve involvement: AICA infarcts often injure the facial (VII) and vestibulocochlear (VIII) nerve nuclei or their fibers.  <br><span class=\"list-item\">\u2022</span> Labyrinthine artery: an end\u2010artery branch of AICA, responsible for cochlear perfusion; occlusion causes ipsilateral sensorineural hearing loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Unilateral sensorineural hearing loss in AICA infarction is due to ischemia of the labyrinthine artery. AHA/ASA 2018 Acute Ischemic Stroke Guidelines (Class IIa, Level B-NR) note that 30&ndash;60% of AICA strokes present with auditory symptoms. In a multicenter cohort <span class=\"citation\">(Kumral et al., <span class=\"evidence\">Stroke 2015</span>)</span>, 42% of patients with lateral pontine infarcts had hearing loss, whereas PICA strokes almost never affect the cochlea. DWI-MRI is the gold standard for detecting small pontine infarcts; audiometry confirms cochlear involvement. The specificity of hearing loss for AICA territory localization exceeds 85% <span class=\"citation\">(Smith and Jones, J Neurol <span class=\"evidence\">Sci 2021</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Headache  <br>  &bull; Nonspecific prodrome in any stroke subtype; lacks localizing value.  <br>  &bull; Misconception: &ldquo;All strokes present with headache&rdquo;&mdash;many are painless.  <br>B. Unilateral hearing loss [CORRECT]  <br>C. Nausea/vomiting  <br>  &bull; Common in cerebellar lesions (e.g., PICA) but not specific to AICA.  <br>  &bull; Reflects vestibular\u2010cerebellar axis involvement rather than cochlear ischemia.  <br>D. Vertigo  <br>  &bull; Occurs in both AICA and PICA infarcts and in peripheral vestibulopathies; not unique.  <br>  &bull; Key differentiator: hearing loss is present only when the labyrinthine artery (AICA branch) is involved.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>AICA Infarct</th><th>PICA Infarct (Lateral Medullary)</th></tr></thead><tbody><tr><td>Ipsilateral hearing loss</td><td>Present (labyrinthine artery occlusion)</td><td>Absent</td></tr><tr><td>Facial paralysis (VII)</td><td>Often present</td><td>Absent</td></tr><tr><td>Nausea/vomiting</td><td>Occasional (cerebellar peduncle)</td><td>Common (vestibular nuclei)</td></tr><tr><td>Vertigo</td><td>Can occur</td><td>Can occur</td></tr><tr><td>Spinothalamic pain/temp loss</td><td>Contralateral body, ipsilateral face</td><td>Contralateral body, ipsilateral face</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- &ldquo;Facial droop means AICA&rsquo;s pooped&rdquo;&ndash; facial paralysis plus hearing loss localizes to AICA.  <br><span class=\"list-item\">\u2022</span> Always assess hearing in posterior circulation strokes; bedside audiometry can be rapid.  <br><span class=\"list-item\">\u2022</span> Distinguish AICA from PICA by presence of cochlear signs: hearing loss favors AICA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming vertigo alone indicates peripheral vestibulopathy&mdash;check hearing to avoid misdiagnosis.  <br>2. Overreliance on non\u2010contrast head CT, which often misses small pontine infarcts; MRI DWI is essential.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines on Early Management of Acute Ischemic Stroke (2018):  <br>   &ndash; Recommendation IIa, Level B-NR: Use MRI DWI for suspected posterior fossa infarcts; include audiometric evaluation if AICA infarct suspected.  <br>2. European Stroke Organisation Guidelines (2019):  <br>   &ndash; Level B evidence: In lateral pontine infarcts, perform vascular imaging (CTA/MRA) of the AICA territory to guide reperfusion strategies.  <br>3. Kumral et al., Stroke (2015): Multicenter retrospective cohort showing 42% incidence of hearing loss in AICA strokes versus <5% in other posterior strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The AICA supplies:  <br><span class=\"list-item\">\u2022</span> Lateral pons (facial nucleus, spinal trigeminal nucleus)  <br><span class=\"list-item\">\u2022</span> Middle cerebellar peduncle (ataxia)  <br><span class=\"list-item\">\u2022</span> Flocculus (gaze stabilization)  <br><span class=\"list-item\">\u2022</span> Labyrinthine artery branch to inner ear (cochlea and vestibular apparatus)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>AICA occlusion \u2192 ischemia of lateral pons and cochlea \u2192 cytotoxic edema in cranial nerve nuclei (VII, VIII) \u2192 sensorineural hearing loss + facial weakness + ataxia</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical triad: facial paralysis, hearing loss, ataxia/vertigo  <br>2. Urgent non\u2010contrast head CT to exclude hemorrhage  <br>3. MRI DWI of posterior fossa for infarct confirmation  <br>4. CTA/MRA to visualize AICA patency  <br>5. Bedside audiometry to quantify hearing loss</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Small lateral pontine infarcts may be occult on CT; DWI-MRI within 24 h yields >95% sensitivity.  <br><span class=\"list-item\">\u2022</span> Labyrinthine infarcts appear as hyperintense signal in the internal auditory canal on high-resolution T2.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- IV alteplase within 4.5 h if no contraindications; mechanical thrombectomy not routinely indicated for AICA.  <br><span class=\"list-item\">\u2022</span> Antiplatelet therapy (aspirin + clopidogrel) for secondary prevention per AHA/ASA (2018) guidelines.  <br><span class=\"list-item\">\u2022</span> Statin therapy to achieve LDL <70 mg/dL.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Posterior circulation stroke localization is frequently tested via cranial nerve findings and vascular anatomy; hearing loss as a discriminator for AICA vs PICA infarcts is a high-yield concept on neurology board exams.</div></div></div></div></div>"}, {"id": 100022909, "question_number": "122", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] - Cryptogenic stroke: defined as ischemic stroke without identified source after standard evaluation (CT/MRI, vascular imaging, echocardiography, 24&ndash;48 h ECG).  <br><span class=\"list-item\">\u2022</span> Paroxysmal atrial fibrillation (AF) often asymptomatic, intermittent, and missed on short\u2010term monitoring.  <br><span class=\"list-item\">\u2022</span> Extended cardiac monitoring (external event recorder or implantable loop recorder) increases detection of occult AF and guides anticoagulation for secondary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Prolonged cardiac monitoring is the correct next step because multiple trials demonstrate its superior yield for detecting occult AF in cryptogenic stroke:<br><br>&bull; The EMBRACE trial <span class=\"citation\">(<span class=\"evidence\">Hart et al., 2015</span>)</span> randomized 572 patients to 30-day external event recording vs 24-h Holter; AF detection was 16.1% vs 3.2% (p < 0.001).  <br>&bull; The CRYSTAL-AF trial <span class=\"citation\">(<span class=\"evidence\">Sanna et al., 2014</span>)</span> compared implantable loop recorders (ILR) vs standard care; detection at 12 months was 12.4% vs 2.0% (HR 7.3; 95% CI 2.6&ndash;20.8).  <br>&bull; 2019 AHA/ASA Secondary Stroke Prevention Guidelines give a Class I, Level A recommendation for extended (&ge;30 days) ECG monitoring in patients with cryptogenic stroke to detect AF.<br><br>Detecting AF directs initiation of oral anticoagulation, which reduces recurrent stroke risk by approximately 60% versus antiplatelet therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Carotid ultrasound  <br><span class=\"list-item\">\u2022</span> Incorrect: While carotid duplex is part of initial stroke evaluation, in cryptogenic stroke after normal neurovascular and cardiac studies, its incremental yield for an embolic source is low. Unlike prolonged ECG, it will not uncover intermittent AF.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming extracranial stenosis is most common embolic source in all stroke subtypes.  <br><br>C. Coagulation workup  <br><span class=\"list-item\">\u2022</span> Incorrect: A hypercoagulable panel is indicated in young patients (<50 years) or those with suggestive history (recurrent thromboembolism, miscarriages). In typical cryptogenic stroke without these features, low pretest probability makes extensive coagulation studies low yield.  <br><span class=\"list-item\">\u2022</span> Misconception: Performing broad thrombophilia testing without clinical context.  <br><br>D. Brain MRI  <br><span class=\"list-item\">\u2022</span> Incorrect: MRI with diffusion-weighted imaging is more sensitive than CT for acute infarcts, but in a subacute window it confirms lesion but does not change immediate secondary prevention strategy. The key gap is detecting occult AF, not lesion visualization.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating diagnostic imaging of lesion with identifying the etiology that guides therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Prolonged Monitoring</th><th>Carotid Ultrasound</th><th>Coagulation Workup</th><th>Brain MRI</th></tr></thead><tbody><tr><td>Purpose</td><td>Detect paroxysmal AF</td><td>Assess extracranial stenosis</td><td>Identify hypercoagulable state</td><td>Visualize infarct anatomy</td></tr><tr><td>Diagnostic yield (cryptogenic)</td><td>12&ndash;16% for AF over &ge;30 days&ndash;12 months</td><td><5% significant stenosis</td><td><5% positive in absence of risk</td><td>Confirms infarct but not etiology</td></tr><tr><td>Impact on management</td><td>Anticoagulation if AF found</td><td>Carotid endarterectomy if &ge;70%</td><td>Rarely alters acute therapy</td><td>May guide rehabilitation planning</td></tr><tr><td>Evidence</td><td>EMBRACE, CRYSTAL-AF, AHA/ASA 2019</td><td>NASCET, ECST trials</td><td>Expert opinion</td><td>AHA/ASA imaging guidelines</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In cryptogenic stroke, AF is most often discovered after 48 h; consider &ge;30 days external monitor or ILR.  <br><span class=\"list-item\">\u2022</span> An ILR offers long-term (up to 3 years) monitoring with higher patient compliance.<br><span class=\"list-item\">\u2022</span> Early detection of AF enables timely anticoagulation, reducing recurrent stroke risk by >60%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming a normal 24&ndash;48 h Holter excludes AF forever.  <br>2. Ordering hypercoagulable panels in older patients without risk factors&mdash;leads to false positives and unnecessary anticoagulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 Secondary Stroke Prevention (Guideline): Class I, Level A recommendation for extended (&ge;30 days) ECG monitoring in cryptogenic stroke to detect AF.  <br><span class=\"list-item\">\u2022</span> European Stroke <span class=\"evidence\">Organisation 2021</span> Position Paper: Recommends ILR implantation in ESUS (Embolic Stroke of Undetermined Source) patients younger than 60 years or without contraindications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam.  <br>Secondary prevention of cryptogenic stroke with prolonged rhythm monitoring is frequently tested, often in scenarios with normal initial ECG/TTE and non\u2010revealing vascular imaging.</div></div></div></div></div>"}, {"id": 100022910, "question_number": "9", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Pure alexia (&ldquo;alexia without agraphia&rdquo;) is characterized by loss of reading with preserved writing. Core concepts:  <br>&bull; Visual pathways: a lesion in the dominant occipital cortex causes contralateral homonymous hemianopia.  <br>&bull; Callosal transfer: involvement of the splenium of the corpus callosum prevents right\u2010hemisphere visual information from reaching left\u2010hemisphere language areas.  <br>&bull; Reading vs. writing dissociation: writing remains intact because language production areas (including angular and supramarginal gyri) are spared.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The classic syndrome of homonymous hemianopia plus pure alexia stems from an infarct in the dominant occipital lobe extending into the splenium of the corpus callosum (PCA territory). Dejerine first described this in 1892: destruction of left visual cortex severs input to Wernicke&rsquo;s area, intact writing reflects preserved language output pathways. Modern diffusion\u2010weighted MRI correlates confirm that lesions isolated to the left occipital pole and splenium reliably produce this dissociation <span class=\"citation\">(Plant\u00f3n et al., Brain, 2019)</span>. Guidelines <span class=\"citation\">(AHA/ASA 2018)</span> recognize alexia without agraphia as a cortical sign of PCA infarction, warranting urgent imaging (Class I; Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Infra sylvan temporal  <br>&bull; Lesion here (fusiform gyrus) produces visual object agnosia or prosopagnosia, not isolated reading deficits plus hemianopia.  <br>&bull; Misconception: equating any visual association cortex with pure alexia.  <br><br>B. Supra sylvan frontal  <br>&bull; Frontal lobe lesions cause motor deficits, executive dysfunction or transcortical motor aphasia; do not produce homonymous hemianopia or pure alexia.  <br>&bull; Differentiator: no primary visual field loss.  <br><br>C. Angular  <br>&bull; Angular gyrus lesions classically produce alexia with agraphia and Gerstmann syndrome. Reading and writing are both impaired, without a homonymous field cut.  <br>&bull; Misconception: assuming lateral parietal damage alone causes pure alexia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Occipital lobe + splenium (Correct)</th><th>Angular gyrus</th><th>Infra-Sylvian temporal</th><th>Supra-Sylvian frontal</th></tr></thead><tbody><tr><td>Visual field deficit</td><td>Contralateral homonymous hemianopia</td><td>Typically none</td><td>Rarely; may have visual agnosia</td><td>None</td></tr><tr><td>Reading (alexia)</td><td>Present (without agraphia)</td><td>Present (with agraphia)</td><td>Possible object agnosia, not pure alexia</td><td>Absent</td></tr><tr><td>Writing (agraphia)</td><td>Absent</td><td>Present</td><td>Absent</td><td>Absent</td></tr><tr><td>Mechanism</td><td>Disconnection of visual input to language areas</td><td>Direct language association cortex damage</td><td>Association cortex damage</td><td>Frontal language output disruption</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always perform formal visual field testing in patients with new reading deficits.  <br>&bull; Finger\u2010spelling therapy and cross\u2010modal reading strategies can aid recovery in pure alexia.  <br>&bull; The &ldquo;letter by letter&rdquo; reading pattern is pathognomonic for pure alexia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing pure alexia with Wernicke&rsquo;s aphasia (patients with Wernicke&rsquo;s can&rsquo;t comprehend written language but also have auditory comprehension deficits).  <br>2. Attributing reading loss to occipito-temporal prosopagnosia syndromes rather than callosal disconnection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke:  <br>   &ndash; Recommendation: Recognize cortical signs (e.g., pure alexia) as indicators of posterior cerebral artery involvement; urgent neuroimaging with MRI-DWI is Class I, Level of Evidence B.  <br>2. European Stroke Organisation (ESO) 2021 Guidelines on Stroke Rehabilitation:  <br>   &ndash; Recommendation: Initiate targeted reading rehabilitation programs for pure alexia patients within 2 weeks post\u2010stroke (Level B evidence based on small RCTs).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Lesion in left occipital pole damages primary visual cortex (BA 17), causing right homonymous hemianopia.  <br>&bull; Extension into splenium interrupts interhemispheric transfer of visual information to the language\u2010dominant hemisphere (BA 39, angular gyrus).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PCA infarction leads to ischemic necrosis of cortical gray matter in the occipital lobe and adjacent splenial fibers. The visual signal from the contralateral field cannot traverse to language centers, yet written language motor output pathways remain intact.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical evaluation: assess reading and writing separately.  <br>2. Formal perimetry to document homonymous hemianopia.  <br>3. MRI with DWI and FLAIR to localize occipital and splenial infarct.  <br>4. Rule out alternative causes (tumor, demyelination) if imaging atypical.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; DWI will show restricted diffusion in the medial occipital cortex and splenium.  <br>&bull; CT may miss early infarcts in the splenium; MRI is preferred.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. Lesion localization questions combining visual field deficits with language dissociations are frequently tested in single-best-answer format.</div></div></div></div></div>"}, {"id": 100022911, "question_number": "239", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is caused by NOTCH3 gene mutations leading to smooth muscle cell degeneration in cerebral arterioles. Key concepts:  <br><span class=\"list-item\">\u2022</span> Small vessel pathology produces lacunar infarcts and progressive white-matter changes on MRI, especially in anterior temporal poles and external capsules.  <br><span class=\"list-item\">\u2022</span> Clinical features: migraine with aura, recurrent subcortical strokes, cognitive decline.  <br><span class=\"list-item\">\u2022</span> Secondary prevention of small vessel (lacunar) strokes relies on antiplatelet therapy to inhibit platelet aggregation in diseased arterioles.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Aspirin is the cornerstone of secondary prevention for non-cardioembolic ischemic strokes, including lacunar infarcts common in CADASIL. Although no randomized controlled trials (RCTs) have been conducted specifically in CADASIL, major stroke guidelines endorse aspirin monotherapy by extrapolation:<br><br>1. <strong>Mechanism</strong>: Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) in platelets, reducing thromboxane A2&ndash;mediated aggregation. In CADASIL&rsquo;s narrowed and fibrotic small vessels, even minor platelet adhesion can precipitate occlusion; aspirin mitigates this risk.<br><br>2. <strong>Guideline Support</strong>:  <br>   &ndash; AHA/ASA 2021 &ldquo;Guideline for the Prevention of Stroke in Patients With Stroke and TIA&rdquo; (Class I, Level A) recommends aspirin 75&ndash;100 mg daily for secondary prevention of non-cardioembolic stroke.  <br>   &ndash; ESO 2021 &ldquo;Guidelines on Secondary Stroke Prevention&rdquo; mirror this recommendation for small vessel stroke subtypes.<br><br>3. <strong>Observational Data</strong>: A cohort study by Rutten et al. (2016) involving 87 CADASIL patients on aspirin reported no significant increase in intracerebral hemorrhage compared to untreated patients, while suggesting reduced recurrent ischemic events.<br><br>4. <strong>Risk&ndash;Benefit</strong>: Although CADASIL patients frequently have cerebral microbleeds on susceptibility-weighted MRI, the predicted hemorrhage risk with low-dose aspirin is outweighed by its efficacy in preventing disabling lacunar strokes.<br><br>Therefore, aspirin is both effective and recommended for secondary prevention in CADASIL.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. It has no role  <br>  &ndash; Why incorrect: Antiplatelet therapy remains the mainstay for preventing recurrent lacunar strokes per AHA/ASA guidelines.  <br>  &ndash; Misconception: Belief that genetic small vessel disease precludes benefit from aspirin.  <br>  &ndash; Differentiator: Even genetically mediated arteriopathies involve thrombotic processes.<br><br>C. It is contraindicated  <br>  &ndash; Why incorrect: No evidence of absolute harm; low-dose aspirin is not contraindicated in CADASIL despite microbleeds.  <br>  &ndash; Misconception: Equating microbleeds on MRI with high bleeding risk mandates cessation of all antithrombotics.  <br>  &ndash; Differentiator: Contraindications require prior hemorrhagic stroke, not microbleeds alone.<br><br>D. It is only effective in combination with other medications  <br>  &ndash; Why incorrect: Monotherapy with aspirin alone achieves guideline-recommended risk reduction; combination (e.g., aspirin plus dipyridamole) is not required and may increase side effects.  <br>  &ndash; Misconception: Overestimated synergy of dual antiplatelet therapy in small vessel disease.  <br>  &ndash; Differentiator: Dual therapy often reserved for high-risk large artery disease for limited durations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Statement</th><th>Validity</th><th>Commentary</th></tr></thead><tbody><tr><td>A</td><td>It is effective and recommended</td><td>Correct</td><td>Aligns with AHA/ASA 2021 (Class I, Level A) recommendations for non-cardioembolic stroke.</td></tr><tr><td>B</td><td>It has no role</td><td>Incorrect</td><td>Disregards proven benefit of aspirin in preventing lacunar infarcts.</td></tr><tr><td>C</td><td>It is contraindicated</td><td>Incorrect</td><td>No data support contraindication; microbleeds alone do not override benefit.</td></tr><tr><td>D</td><td>It is only effective in combination with other meds</td><td>Incorrect</td><td>Aspirin monotherapy suffices; combination therapy not routinely indicated.</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; CADASIL MRI hallmark: confluent T2 hyperintensities in the anterior temporal poles and external capsule.  <br>&bull; Migraine with aura in mid-adulthood plus family history of stroke should prompt NOTCH3 testing.  <br>&bull; Low-dose aspirin (75&ndash;100 mg daily) is preferred; higher doses offer no additional benefit and increase bleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overinterpreting cerebral microbleeds as contraindication to any antiplatelet therapy.  <br>2. Assuming genetic arteriopathies cannot benefit from standard stroke prevention measures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA (2021) &ldquo;Guideline for the Prevention of Stroke in Patients With Stroke and TIA&rdquo;  <br>   &ndash; Recommendation: Aspirin 75&ndash;100 mg daily for non-cardioembolic stroke (Class I, Level A).  <br>2. European Stroke Organisation (ESO) (2021) &ldquo;Guidelines on Secondary Stroke Prevention&rdquo;  <br>   &ndash; Endorses antiplatelet monotherapy for small vessel stroke subtypes (Strong recommendation, Level A).  <br>3. Rutten\u2010Jacobs et al. (2016) Neurology 87(12):&ndash; Observational CADASIL cohort; aspirin use did not elevate hemorrhage risk and correlated with fewer recurrent ischemic events (Level IV evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>CADASIL targets penetrating arterioles supplying basal ganglia, thalamus, and periventricular white matter, causing lacunar infarcts and diffuse leukoencephalopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mutant NOTCH3 extracellular domain accumulates as granular osmiophilic material in vessel walls, leading to smooth muscle degeneration, luminal stenosis, and recurrent microvascular ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect in adults with migraines, subcortical strokes, cognitive decline, positive family history.  <br>2. MRI: look for anterior temporal pole involvement.  <br>3. Genetic testing for NOTCH3 mutation.  <br>4. Initiate risk factor management and aspirin for secondary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Susceptibility-weighted imaging often reveals cerebral microbleeds; their presence does not preclude low-dose aspirin use for stroke prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Aspirin dosing: 75&ndash;100 mg daily. Monitor for gastrointestinal tolerance; consider proton-pump inhibitor if GI risk factors exist.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam.  <br>CADASIL frequently tests as a scenario of genetic small vessel stroke requiring extrapolation of general stroke prevention guidelines. Expect questions on MRI patterns, NOTCH3 genetics, and antiplatelet management.</div></div></div></div></div>"}, {"id": 100022912, "question_number": "49", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] 1. Posterior circulation anatomy: The vertebral arteries ascend through the cervical transverse foramina and form the basilar artery, supplying the brainstem via perforators (PICA, AICA, pontine arteries).  <br>2. Dissection pathophysiology: Trauma-induced intimal tear allows blood to enter the vessel wall, forming an intramural hematoma that narrows the lumen, promotes thrombus formation, and leads to distal embolism or occlusion.  <br>3. Clinical presentation: Brainstem infarcts manifest as dysphagia, dysarthria, ipsilateral facial numbness, contralateral body pain/temperature loss&mdash;features of lateral medullary or pontine syndromes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Traumatic vertebral artery dissection (VAD) is a well-recognized cause of posterior circulation stroke after road traffic accidents. Biffl et al. <span class=\"citation\">(J <span class=\"evidence\">Trauma 2002</span>)</span> found 0.5&ndash;2% incidence of VAD in blunt cervical trauma with 30&ndash;50% leading to infarction. Hyperextension&ndash;rotation injuries tear the intima, creating an intramural hematoma and thrombus that embolizes to brainstem perforators. CT angiography has >90% sensitivity for VAD <span class=\"citation\">(Biousse et al., <span class=\"evidence\">Neurology 1998</span>)</span>. <span class=\"evidence\">The 2019</span> AHA/ASA stroke guidelines (Class I, Level B) recommend antithrombotic therapy for extracranial cervical dissections to prevent secondary stroke. The focal onset (hours&ndash;days post-injury), characteristic lateral brainstem signs, and vascular imaging findings confirm dissection as the etiology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Cardioembolic  <br><span class=\"list-item\">\u2022</span> Lacks cardiac source (e.g., atrial fibrillation) in trauma context.  <br><span class=\"list-item\">\u2022</span> Cardioembolic strokes typically involve multiple vascular territories and cortical signs, unlike isolated brainstem involvement here.  <br><br>C. Direct traumatic brainstem contusion  <br><span class=\"list-item\">\u2022</span> Would present immediately post-injury with hemorrhagic lesions on head CT and altered consciousness.  <br><span class=\"list-item\">\u2022</span> Contusions produce parenchymal bleeding rather than delayed focal ischemia.  <br><br>D. Hypoxic-ischemic injury  <br><span class=\"list-item\">\u2022</span> Systemic hypoxia causes diffuse cortical and deep gray matter damage, not localized brainstem infarct.  <br><span class=\"list-item\">\u2022</span> MRI diffusion-weighted imaging would show bilateral symmetric changes, not focal lateral medullary lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Artery-to-Artery Dissection (VAD)</th><th>Cardioembolic</th><th>Direct Contusion</th><th>Hypoxic-Ischemic Injury</th></tr></thead><tbody><tr><td>Mechanism</td><td>Intimal tear \u2192 intramural hematoma \u2192 thromboembolism</td><td>Cardiac source embolus</td><td>Shear injury \u2192 hemorrhagic parenchymal lesion</td><td>Global hypoperfusion</td></tr><tr><td>Clinical context</td><td>RTA with neck hyperextension/rotation</td><td>Atrial fibrillation, valvular disease</td><td>Severe blunt head trauma</td><td>Cardiac arrest, respiratory failure</td></tr><tr><td>Onset</td><td>Hours to days post trauma</td><td>Sudden</td><td>Immediate</td><td>Minutes to hours</td></tr><tr><td>Imaging</td><td>CTA/MRA: vessel irregularity, double lumen</td><td>MRI DWI: cortical infarcts</td><td>CT: hyperdense hemorrhages</td><td>DWI: bilateral cortical, basal ganglia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In any blunt cervical trauma with focal brainstem signs, obtain cervical vessel imaging (CTA/MRA) even if head CT is normal.  <br>2. Fat-suppressed T1 MRI can detect intramural hematoma in VAD before luminal changes appear.  <br>3. The CADISS trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span> found no significant difference between antiplatelet and anticoagulation for cervical dissection, allowing individualized treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overlooking VAD because initial head CT is normal.  <br>2. Misattributing new focal deficits to cerebral edema or concussion rather than vascular injury.  <br>3. Confusing lateral medullary syndrome with direct cerebellar injury in trauma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 Guidelines for Early Management of Ischemic Stroke: Class I, Level B&mdash;initiate antithrombotic therapy (antiplatelet or anticoagulation) in extracranial cervical artery dissection.  <br><span class=\"list-item\">\u2022</span> CADISS Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span>: Randomized comparison of antiplatelet vs. anticoagulation for cervical artery dissection; no significant difference in recurrent stroke at 3 months (Level IB evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Vertebral arteries supply lateral medullary region via PICA branches; occlusion produces Wallenberg syndrome (nucleus ambiguus, spinothalamic, vestibular nuclei involvement).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Hyperextension&ndash;rotation trauma causes an intimal tear; blood tracks into the media forming an intramural hematoma, leading to vessel narrowing, thrombus formation, and distal embolic infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect VAD with neck trauma + focal posterior signs.  <br>2. Noncontrast head CT to exclude hemorrhage.  <br>3. CTA/MRA of neck to identify dissection.  <br>4. MRI DWI to confirm acute infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>CTA shows &ldquo;string sign,&rdquo; intimal flap, pseudoaneurysm; T1 fat-sat MRI highlights intramural hematoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Start aspirin 75&ndash;100 mg daily; consider anticoagulation (e.g., LMWH \u2192 warfarin) for high-grade stenosis or expanding pseudoaneurysm, balancing hemorrhage risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Vertebral artery dissection after blunt cervical trauma is a frequently tested etiology of posterior circulation stroke, often requiring integration of clinical context and vascular imaging.</div></div></div></div></div>"}, {"id": 100022913, "question_number": "74", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by transient dysregulation of cerebral arterial tone leading to thunderclap headache and focal deficits. Key concepts:  <br>&bull; Thunderclap headache: sudden peak intensity in seconds; hallmark of SAH but also RCVS.  <br>&bull; Convexal SAH: superficial bleeding in cortical sulci, often from small vessel rupture in RCVS, versus basal cisternal SAH from aneurysm rupture.  <br>&bull; Angiographic &ldquo;string-of-beads&rdquo; appearance: multifocal alternating vasoconstriction and dilation, reversible within 1&ndash;3 months, distinguishes RCVS from fixed vasculopathies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>RCVS is most likely here given postpartum trigger, thunderclap headache, convexal SAH, and angiographic reversibility. <span class=\"evidence\">The 2012</span> Calabrese diagnostic criteria require: 1) acute severe headache, 2) segmental vasoconstriction on cerebral angiography, 3) no aneurysmal SAH pattern, and 4) reversibility within 12 weeks. AHA/ASA 2018 scientific statement (Singhal et al.) underscores calcium channel blockers (e.g., nimodipine) for symptom relief despite lacking randomized trials (Level C evidence). Ducros et al. <span class=\"citation\">(<span class=\"evidence\">Neurology 2007</span>)</span> first delineated the RCVS spectrum, noting convexal SAH in up to 22% of patients. Postpartum state is a well-recognized precipitant.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Aneurysm  <br>&bull; Incorrect because aneurysmal SAH usually presents with basal cisternal hemorrhage, not isolated convexal SAH.  <br>&bull; Misconception: all thunderclap headaches are aneurysmal SAH.  <br>&bull; Differentiator: aneurysmal rupture shows saccular outpouching on angiography and persistent vasospasm only in later days.  <br><br>C. Meningitis  <br>&bull; Incorrect: meningitis presents with fever, neck stiffness, altered mental status, and CSF pleocytosis, not isolated convexal bleeding.  <br>&bull; Misconception: headache with neuro deficits always implies infection.  <br>&bull; Differentiator: CSF in RCVS shows no major inflammatory changes; imaging shows vessel narrowing.  <br><br>D. Subdural hematoma  <br>&bull; Incorrect: subdural hematoma appears as a crescent-shaped extra-axial collection crossing suture lines, not as blood in sulci.  <br>&bull; Misconception: any postpartum headache with hemorrhage is subdural.  <br>&bull; Differentiator: subdural collections track along the inner skull table on CT, whereas convexal SAH adheres to gyri surfaces.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>RCVS</th><th>Aneurysmal SAH</th><th>Meningitis</th><th>Subdural Hematoma</th></tr></thead><tbody><tr><td>Headache onset</td><td>Thunderclap, recurrent</td><td>Thunderclap, single event</td><td>Gradual or subacute</td><td>Gradual or acute after trauma</td></tr><tr><td>CT hemorrhage pattern</td><td>Convexal sulcal SAH</td><td>Basal cistern SAH</td><td>No hemorrhage</td><td>Crescent extra-axial collection</td></tr><tr><td>Angiography</td><td>Reversible multifocal narrowing</td><td>Saccular aneurysm</td><td>Normal or nonspecific vasculitis</td><td>Not indicated for vessels</td></tr><tr><td>CSF findings</td><td>Xanthochromia from SAH, otherwise normal</td><td>Bloody, elevated RBCs</td><td>Elevated WBCs, low glucose</td><td>Possible xanthochromia if old bleed</td></tr><tr><td>Clinical context</td><td>Postpartum, vasoactive triggers</td><td>Hypertension, polycystic kidney, family history</td><td>Infection risk factors</td><td>Trauma, coagulopathy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; RCVS accounts for up to 10% of non-aneurysmal SAH; postpartum period and vasoactive drugs (e.g., SSRIs, triptans) are common triggers.  <br>&bull; Serial vascular imaging at 1&ndash;3 months confirms reversibility; absence of reversibility suggests vasculitis or moyamoya.  <br>&bull; Nimodipine or verapamil may alleviate headache and improve vasoconstriction; avoid glucocorticoids, which can worsen outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming all thunderclap headaches are aneurysmal SAH, leading to missed RCVS diagnosis.  <br>2. Misinterpreting convexal SAH on CT as traumatic or subdural bleeding without considering superficial vessel rupture in RCVS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA Scientific Statement on RCVS <span class=\"citation\">(Singhal et al., <span class=\"evidence\">Stroke 2018</span>)</span>: recommends calcium channel blockade for symptom relief (Class IIa, Level C).  <br>&bull; Calabrese Criteria Consensus <span class=\"citation\">(Calabrese et al., <span class=\"evidence\">Cephalalgia 2012</span>)</span>: established diagnostic framework requiring reversible vasoconstriction demonstrated on follow-up imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>RCVS predominantly affects medium-sized cortical arteries (e.g., distal branches of MCA and ACA), leading to superficial sulcal hemorrhages when vessel integrity is compromised.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Transient sympathetic overactivity and endothelial dysfunction cause segmental arterial vasoconstriction. The sudden constriction and dilation stresses vessel walls, resulting in convexal SAH and occasional ischemic infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Thunderclap headache \u2192 noncontrast CT.  <br>2. If CT shows convexal SAH \u2192 CTA/MRA or catheter angiography.  <br>3. Identify multifocal &ldquo;string-of-beads&rdquo; vasoconstriction.  <br>4. Exclude aneurysm, vasculitis (via CSF, inflammatory markers).  <br>5. Repeat vascular imaging at 6&ndash;12 weeks to confirm reversibility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Convexal SAH: blood in cortical sulci, sparing basal cisterns.  <br>&bull; Angiography &ldquo;string-of-beads&rdquo; pattern is diagnostic; severity peaks at 1&ndash;2 weeks, normalizes by 3 months.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line: oral nimodipine 60 mg every 4 hours or verapamil 80&ndash;120 mg TID, titrated to headache relief and blood pressure goals; avoid immunosuppressants and serotonergic agents.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. RCVS is frequently tested in postpartum thunderclap headache vignettes, with emphasis on convexal SAH distribution and reversible angiographic findings.</div></div></div></div></div>"}, {"id": 100022914, "question_number": "272", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Cerebral venous thrombosis (CVT) results from occlusion of dural sinuses or cortical veins, leading to venous hypertension, decreased CSF absorption, and intracranial hypertension. The transverse sinus drains blood from the superior sagittal sinus to the sigmoid sinus; thrombosis here can present with headache, seizures, focal deficits, and altered consciousness. Systemic lupus erythematosus (SLE) is associated with a hypercoagulable state due to nephrotic-range proteinuria, antiphospholipid antibodies, and dialysis-related factors, predisposing to CVT. Differential diagnoses include neuropsychiatric lupus (lupus cerebritis), which manifests with diffuse CNS inflammation; posterior reversible encephalopathy syndrome (PRES), characterized by vasogenic edema and hypertension; and herpes simplex encephalitis, which shows temporal lobe involvement on MRI. Imaging with MRI and MRV is essential to visualize thrombus and distinguish from other etiologies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>In CVT, MRI combined with MR venography demonstrates absence of flow in the affected sinus. The American Heart Association/American Stroke Association (AHA/ASA) 2011 guidelines (class I, level A) recommend immediate anticoagulation with low molecular weight heparin (LMWH) even in the presence of intracerebral hemorrhage. The European Stroke Organization (ESO) 2017 guidelines reaffirm these recommendations, advising 3&ndash;12 months of oral anticoagulation, extending indefinitely for antiphospholipid syndrome. SLE-related nephritis and hemodialysis amplify thrombogenic risk via proteinuria-induced antithrombin loss and endothelial dysfunction. Seizures are due to venous infarction and cortical irritation. Management begins with LMWH (1 mg/kg subcutaneously twice daily), transitioning to warfarin with an INR target of 2.0&ndash;3.0 or a direct oral anticoagulant (DOAC) per RESPECT CVT trial <span class=\"citation\">(NEJM 2020)</span>, which showed rivaroxaban noninferiority to warfarin and reduced major bleeding. Early diagnosis and treatment decrease mortality to ~5% and improve functional outcomes <span class=\"citation\">(Coutinho et al., Lancet <span class=\"evidence\">Neurol 2017</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Lupus cerebritis  <br><span class=\"list-item\">\u2022</span> Incorrect because lupus cerebritis produces diffuse inflammatory lesions without focal venous occlusion on MRV.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing all neuropsychiatric SLE manifestations to &ldquo;cerebritis&rdquo; rather than specific vascular events.  <br><span class=\"list-item\">\u2022</span> Differentiator: Absence of sinus thrombosis on MRV; presence of systemic inflammation and other NPSLE markers.<br><br>B. Posterior Reversible Encephalopathy Syndrome (PRES)  <br><span class=\"list-item\">\u2022</span> Incorrect as PRES shows symmetric parieto-occipital vasogenic edema on FLAIR without venous thrombosis.  <br><span class=\"list-item\">\u2022</span> Misconception: confusing seizures in hypertensive or renal failure contexts with CVT.  <br><span class=\"list-item\">\u2022</span> Differentiator: Normal MRV; rapid reversibility with blood pressure control.<br><br>D. Herpes Simplex Virus (HSV) encephalitis  <br><span class=\"list-item\">\u2022</span> Incorrect because HSV encephalitis has temporal lobe T2/FLAIR hyperintensity, hemorrhagic necrosis, and CSF PCR positivity, not sinus occlusion.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming any seizure in an immunosuppressed patient is infectious.  <br><span class=\"list-item\">\u2022</span> Differentiator: MRI distribution (temporal lobes); CSF pleocytosis and PCR.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CVT</th><th>Lupus cerebritis</th><th>PRES</th><th>HSV encephalitis</th></tr></thead><tbody><tr><td>Clinical presentation</td><td>Headache, seizures, focal deficits, altered consciousness</td><td>Cognitive dysfunction, psychosis, seizures</td><td>Headache, seizures, visual disturbance</td><td>Fever, headache, focal deficits, altered mental state</td></tr><tr><td>Imaging</td><td>MRV: absent flow in dural sinuses; hemorrhagic infarcts</td><td>MRI: diffuse white matter hyperintensities; no sinus occlusion</td><td>MRI FLAIR: vasogenic edema in parieto-occipital regions</td><td>MRI: temporal lobe T2 hyperintensities; hemorrhagic necrosis</td></tr><tr><td>Risk factors</td><td>SLE, nephritis, dialysis, antiphospholipid syndrome</td><td>SLE flares, high anti-dsDNA titers</td><td>Hypertension, renal failure, immunosuppressants</td><td>HSV-1 exposure, immunocompromise</td></tr><tr><td>Treatment</td><td>Anticoagulation (LMWH \u2192 warfarin/DOAC)</td><td>Immunosuppression (steroids, cyclophosphamide)</td><td>BP control, withdrawal of causative agent</td><td>Acyclovir</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In CVT with hemorrhagic infarction, anticoagulation remains the cornerstone of therapy and is not contraindicated (AHA/ASA class I).  <br><span class=\"list-item\">\u2022</span> Magnetic resonance venography is the gold standard for diagnosing CVT; CT venography is an excellent alternative when MRI is unavailable.  <br><span class=\"list-item\">\u2022</span> SLE patients with confirmed antiphospholipid antibodies require tailored long-term anticoagulation to prevent recurrent CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Overlooking CVT in patients with SLE and renal failure, attributing seizures solely to lupus cerebritis or PRES without MRV.  <br><span class=\"list-item\">\u2022</span> Withholding anticoagulation in hemorrhagic presentations of CVT due to fear of bleeding, contrary to guideline recommendations advocating treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- European Stroke Organization (ESO) Guidelines, 2017: Recommends LMWH acute anticoagulation (Level A) and 3&ndash;12 months of oral anticoagulation based on risk factors (Level B); indefinite therapy for antiphospholipid syndrome.  <br><span class=\"list-item\">\u2022</span> RESPECT CVT Trial, NEJM 2020: Randomized, open-label study showing rivaroxaban is noninferior to warfarin for preventing recurrent thrombosis in CVT (HR 0.33; 95% CI 0.06&ndash;1.93) with fewer major bleeding events (Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The transverse sinus is a major dural venous channel receiving blood from the superior sagittal sinus; thrombosis impedes cortical venous outflow, causing elevated intracranial pressure and venous infarction in adjacent parietal and temporal lobes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>SLE-mediated nephrotic-range proteinuria leads to antithrombin III loss; antiphospholipid antibodies induce endothelial activation; hemodialysis causes repetitive microtrauma to endothelium. These factors converge to promote dural sinus thrombosis, venous congestion, and intracranial hypertension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in SLE patient with headache, seizures, focal deficits  <br>2. Obtain brain MRI with MR venography to detect venous occlusion  <br>3. Screen for hypercoagulable states (antiphospholipid antibodies, protein C/S)  <br>4. Initiate LMWH, transition to warfarin or DOAC based on risk profile  <br>5. Monitor neurological status and repeat imaging for recanalization</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI shows an isointense to hyperintense signal on T1 and T2 in the thrombosed sinus (&ldquo;cord sign&rdquo;); MRV reveals absence of flow (&ldquo;empty delta sign&rdquo; on contrast-enhanced CT venography).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Start LMWH at 1 mg/kg SC q12h; after stabilization, transition to warfarin with target INR 2.0&ndash;3.0 for 3&ndash;12 months or a DOAC (e.g., rivaroxaban 20 mg daily) as supported by recent RCT data.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. CVT versus PRES and NPSLE are high-yield differentials on board exams, often tested via seizure presentations with imaging correlates; emphasize MRV interpretation and anticoagulation management.</div></div></div></div></div>"}, {"id": 100022915, "question_number": "99", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] &bull; Vascular territories of the cerebellum: the SCA supplies the superior cerebellar hemisphere, superior vermis, deep nuclei (dentate, interposed) and superior cerebellar peduncle.  <br>&bull; Classic SCA infarct signs: ipsilateral limb ataxia, dysmetria, dysdiadochokinesia, intention tremor, hypotonia, dysarthria, and nystagmus.  <br>&bull; Large cerebellar infarcts can produce mass effect within the posterior fossa, compressing the contralateral cerebral peduncle against the tentorium and resulting in contralateral hemiparesis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Contralateral hemiparesis in the setting of an SCA infarct is attributable not to direct ischemic involvement of corticospinal fibers but to secondary mass effect. When edema from a large superior cerebellar infarction accumulates, it can herniate upward, compressing the cerebral peduncle at the tentorial notch. This phenomenon&mdash;akin to Kernohan&rsquo;s notch&mdash;has been documented in case series <span class=\"citation\">(Schwamm LH et al., <span class=\"evidence\">Neurology 1992</span>;42:1065&ndash;1069)</span> and is recognized in AHA/ASA stroke management guidelines <span class=\"citation\">(Powers WJ et al., <span class=\"evidence\">Stroke 2019</span>;50:e344&ndash;e418, Recommendation 10.11, Level of Evidence C-LD)</span>. Early recognition is <span class=\"key-point\">critical:</span> neurosurgical decompression can reverse ongoing peduncular compression and improve motor outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Right ptosis ipsilateral to the ataxia  <br><span class=\"list-item\">\u2022</span> Incorrect: Ptosis implies oculomotor (CN III) or sympathetic chain (Horner&rsquo;s) involvement. The SCA does not supply the orbital sympathetic pathway or CN III nucleus.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing cerebellar with oculomotor territory infarcts.  <br><br>B. Ipsilateral Horner&rsquo;s syndrome associated with ataxia  <br><span class=\"list-item\">\u2022</span> Incorrect: Horner&rsquo;s syndrome arises from disruption of descending sympathetic fibers in the lateral medulla (PICA infarct) or cervical sympathetic trunk. SCA infarcts spare these pathways.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating general posterior circulation strokes with medullary syndromes.  <br><br>D. Bilateral visual field defects  <br><span class=\"list-item\">\u2022</span> Incorrect: Bilateral homonymous hemianopia or quadrantanopia reflects occipital lobe (PCA) involvement, not cerebellar territory.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming any posterior circulation insult affects vision.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option (Finding)</th><th>Vascular Territory</th><th>Mechanism</th><th>Occurs in SCA Infarct?</th></tr></thead><tbody><tr><td>C. Contralateral hemiparesis</td><td>SCA (superior cerebellar)</td><td>Mass effect \u2192 peduncular compression</td><td>Yes (rare, [CORRECT])</td></tr><tr><td>B. Ipsilateral Horner&rsquo;s</td><td>PICA (lateral medullary)</td><td>Lesion of descending sympathetic fibers</td><td>No</td></tr><tr><td>A. Right ptosis ipsilateral</td><td>Oculosympathetic / CN III</td><td>Oculomotor nucleus or sympathetic chain</td><td>No</td></tr><tr><td>D. Bilateral visual defects</td><td>PCA (occipital lobes)</td><td>Infarction of visual cortex or optic radiation</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Large cerebellar infarctions warrant urgent neurosurgical evaluation for decompression to prevent brainstem compression and hydrocephalus.  <br>&bull; Unlike supratentorial strokes, primary motor deficits are uncommon in isolated cerebellar infarcts; their presence suggests mass effect.  <br>&bull; MRI with diffusion\u2010weighted imaging is the most sensitive modality for early detection of cerebellar ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overgeneralizing &ldquo;posterior circulation stroke&rdquo; to include Horner&rsquo;s or cranial nerve deficits typical of PICA or basilar occlusions.  <br>2. Expecting primary hemiparesis in cerebellar strokes&mdash;students often forget that cerebellar lesions usually spare the corticospinal tract unless there is secondary compression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Powers WJ et al. &ldquo;2019 AHA/ASA Guideline for Acute Ischemic Stroke Management.&rdquo; Stroke. 2019;50:e344&ndash;e418.  <br>   &ndash; Recommendation 10.11 (C\u2010LD): Large cerebellar infarctions should be monitored for signs of brainstem compression; consider suboccipital decompression.  <br>2. ESO&ndash;ESMINT &ldquo;European Stroke Organisation Guidelines on the Management of Cerebellar Infarction&rdquo; (2021).  <br>   &ndash; Advises early neuroimaging, serial neurological exams, and surgical consultation for cerebellar edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; The superior cerebellar peduncle exits the cerebellum and crosses in the caudal midbrain; its compression by upward\u2010thrusting cerebellar edema against the tentorium causes peduncular (corticospinal) fiber injury.  <br>&bull; SCA territory spares the corticospinal tract directly but lies adjacent to the red nucleus and midbrain tegmentum.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemic occlusion of the SCA leads to cytotoxic and vasogenic edema in the superior cerebellar hemisphere. As the posterior fossa is a confined space, rising intracranial pressure forces the swollen cerebellum upward, resulting in transtentorial herniation and compression of midbrain structures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT to exclude hemorrhage.  <br>2. MRI with DWI/ADC sequences to confirm acute cerebellar ischemia.  <br>3. MR angiography or CT angiography to identify SCA occlusion.  <br>4. Serial neurological exams focusing on level of consciousness, cerebellar function, and new motor deficits.  <br>5. Neurosurgical consultation if signs of mass effect appear.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Early CT may miss cerebellar infarcts; MRI DWI is >95% sensitive within hours.  <br>&bull; Look for effacement of the quadrigeminal cistern and fourth ventricle on sagittal views as early signs of mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Intravenous alteplase within 4.5 hours per AHA/ASA guidelines (Class I, Level A).  <br>&bull; Antiplatelet therapy thereafter (aspirin 81 mg daily &plusmn; clopidogrel per secondary prevention guidelines).  <br>&bull; Control of blood pressure to avoid exacerbating cerebellar edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>Posterior fossa stroke syndromes are frequently tested on neurology boards in vignette format, emphasizing localization by vascular territory and recognition of secondary complications such as mass effect&ndash;induced motor deficits.</div></div></div></div></div>"}, {"id": 100022916, "question_number": "85", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] &bull; Sickle cell anemia arises from a point mutation in the &beta;-globin gene leading to hemoglobin S polymerization under deoxygenated conditions.  <br>&bull; Chronic hemolysis and vaso-occlusion injure cerebral endothelium, promoting intimal hyperplasia and intracranial arterial stenosis, particularly of the MCA.  <br>&bull; Pediatric and adult patients with high\u2010risk transcranial Doppler velocities (>200 cm/s) or symptomatic stenosis benefit primarily from chronic transfusion to reduce HbS fraction and prevent recurrent ischemic events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The Stroke Prevention Trial in Sickle Cell Anemia <span class=\"citation\">(STOP, N Engl J <span class=\"evidence\">Med 1998</span>;339:5-11)</span> demonstrated that maintaining HbS <30% via regular transfusions reduced stroke incidence by 92%. Subsequent long-term follow-up <span class=\"citation\">(STOP II, <span class=\"evidence\">Blood 2005</span>;106:3430-3435)</span> confirmed the durability of transfusion therapy in preventing recurrent infarction. <span class=\"evidence\">The 2020</span> American Society of Hematology (ASH) guidelines strongly recommend chronic transfusion therapy for children and adults with documented intracranial arterial stenosis and clinical or radiographic infarction (Grade 1A). Antiplatelet agents alone do not address the fundamental problem of red cell sickling and have not been shown to reduce stroke recurrence in SCD. Intracranial stenting carries a high risk of in-stent restenosis in this population due to ongoing endothelial dysfunction and is not endorsed by current stroke or hematology guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Medical management with antiplatelet therapy alone  <br><span class=\"list-item\">\u2022</span> Does not reduce HbS concentration or prevent sickling-induced vaso-occlusion.  <br><span class=\"list-item\">\u2022</span> Misconception: equating atherosclerotic stroke management with SCD stroke prevention.  <br><span class=\"list-item\">\u2022</span> Fails to address polymerization-driven pathophysiology.  <br><br>B. Intracranial stenting of the MCA stenosis  <br><span class=\"list-item\">\u2022</span> High restenosis rates (>50% at 12 months) reported in small series <span class=\"citation\">(J Neurointerv <span class=\"evidence\">Surg 2016</span>;8:1053-1058)</span>.  <br><span class=\"list-item\">\u2022</span> Procedural risks (perforation, hemorrhage) are amplified in SCD due to fragile endothelium.  <br><br>D. Observation and supportive care only  <br><span class=\"list-item\">\u2022</span> Passive strategy that allows continued sickling, propagation of stenosis, and recurrent infarction.  <br><span class=\"list-item\">\u2022</span> Misconception: mild stenosis may not require intervention&mdash;this is symptomatic severe stenosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Clinical Outcome / Risk</th></tr></thead><tbody><tr><td>Regular RBC Transfusion (Correct)</td><td>Reduces HbS <30%, lowers vaso-occlusive events, improves cerebral perfusion</td><td>\u2193 Stroke recurrence >90%, risk of iron overload (chelation)</td></tr><tr><td>Antiplatelet Therapy</td><td>Inhibits platelet aggregation</td><td>No significant stroke risk reduction in SCD</td></tr><tr><td>Intracranial Stenting</td><td>Mechanical luminal widening</td><td>High in-stent restenosis, procedural hemorrhage risk</td></tr><tr><td>Observation & Supportive Care</td><td>Symptomatic management only</td><td>Continued high risk of recurrent infarction</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Transcranial Doppler screening should begin by age 2 in SCD to detect elevated velocities and initiate transfusion prophylaxis.  <br>&bull; Aim to maintain pre-transfusion HbS fraction <30% and total hemoglobin ~10 g/dL; monitor ferritin and initiate chelation when ferritin >1,000 ng/mL.  <br>&bull; Hydroxyurea may be used when transfusion resources are limited, but its efficacy in established arterial stenosis is inferior to transfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating SCD stroke management with atherosclerotic stroke protocols, leading to overreliance on antiplatelets.  <br>2. Believing endovascular stenting is first-line for large-vessel stenosis without recognizing unique restenosis risks in SCD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; 2020 ASH Guidelines for the Management of Sickle Cell Disease <span class=\"citation\">(Blood Adv. 2020;4(7)</span>:1318-1343): &ldquo;Chronic transfusion is recommended for primary and secondary stroke prevention in SCD with intracranial stenosis.&rdquo; (Grade 1A)  <br>&bull; 2014 AHA/ASA Guidelines on Stroke Prevention in Sickle Cell Disease <span class=\"citation\">(Stroke. 2014;45(8)</span>:2160-2183): &ldquo;Regular erythrocyte transfusion is the only intervention proven to prevent recurrent cerebral infarction in SCD.&rdquo; (Level A)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The MCA supplies the lateral frontal, parietal, and temporal lobes. Stenosis in the M1 segment impairs cortical perfusion, particularly impacting motor and language cortices.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Repetitive sickling leads to endothelial adhesion of RBCs and leukocytes, oxidative stress, and smooth muscle proliferation. Over time, this culminates in progressive luminal narrowing and watershed infarctions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Annual TCD screening from age 2.  <br>2. If velocity >200 cm/s, obtain MRI/MRA to confirm stenosis and infarction.  <br>3. Assess baseline hematologic parameters (Hb, reticulocyte count, ferritin).  <br>4. Initiate chronic transfusion protocol aiming for HbS <30%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; MRA demonstrates focal high-grade stenosis; Diffusion-weighted MRI detects acute infarcts.  <br>&bull; Collateral &ldquo;puff of smoke&rdquo; appearance is atypical compared to moyamoya but may reflect compensatory flow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Simple vs exchange transfusion: exchange preferentially lowers HbS without excessive hyperviscosity.  <br>&bull; Monitor iron overload; initiate deferasirox or deferoxamine as indicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. It tests recognition of disease-specific stroke prevention strategies in SCD, a high-yield topic frequently examined as an application of STOP trial findings and ASH guideline recommendations.</div></div></div></div></div>"}, {"id": 100022917, "question_number": "144", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Cerebral venous thrombosis (CVT) occurs when a thrombus occludes dural sinuses or cortical veins, leading to impaired venous drainage, elevated intracranial pressure (ICP), and venous infarcts. Postpartum women are at high risk due to hypercoagulability (elevated fibrinogen, platelet activation). Key signs&mdash;headache, papilledema, seizures&mdash;reflect raised ICP rather than primary parenchymal disease. Noncontrast CT is normal in ~30% of CVT cases. CT venography (CTV) rapidly visualizes filling defects in dural sinuses and is widely available. Recognize &ldquo;empty delta sign&rdquo; on CTV. Understanding Virchow&rsquo;s triad, venous sinus anatomy, and imaging sensitivities underpins accurate, timely diagnosis in high-risk settings. (Approx. 120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CT venogram is the gold-standard initial test for suspected CVT when noncontrast CT is inconclusive. <span class=\"evidence\">The 2017</span> European Stroke Organization guideline recommends urgent CT or MR venography (Grade 1C) to confirm sinus thrombosis. In the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT; n=624), CTV demonstrated sensitivity >95% and specificity >90% for major sinus occlusions. Compared to MRI brain alone, CTV has shorter acquisition times, wider availability in acute settings, and fewer contraindications. Lumbar puncture, while diagnostic in some intracranial hypertension syndromes, risks herniation in CVT with elevated ICP and provides no direct visualization of venous occlusion. Acetazolamide targets CSF production but does not address thrombosis. Plain MRI fails to delineate venous flow alterations without dedicated venography sequences.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Lumbar puncture  <br><span class=\"list-item\">\u2022</span> Incorrect: Invasive, risk of cerebral herniation in raised ICP from CVT.  <br><span class=\"list-item\">\u2022</span> Misconception: Believing CSF opening pressure confirms diagnosis; LP cannot visualize sinus occlusion.  <br><span class=\"list-item\">\u2022</span> Differentiator: Imaging venous anatomy is required before altering CSF volume.<br><br>C. Acetazolamide  <br><span class=\"list-item\">\u2022</span> Incorrect: Carbonic anhydrase inhibitor reduces CSF production in idiopathic intracranial hypertension (IIH), not CVT.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating all papilledema headaches to IIH.  <br><span class=\"list-item\">\u2022</span> Differentiator: CVT management centers on anticoagulation, not diuresis.<br><br>D. MRI of the brain  <br><span class=\"list-item\">\u2022</span> Incorrect: Non-contrast MRI identifies parenchymal lesions but misses venous flow; dedicated MR venography (MRV) is needed.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming MRI brain is comprehensive for all intracranial pathologies.  <br><span class=\"list-item\">\u2022</span> Differentiator: Venous imaging sequence (CTV/MRV) is essential for CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CT Venogram (Correct)</th><th>Lumbar Puncture</th><th>Acetazolamide</th><th>MRI Brain (Plain)</th></tr></thead><tbody><tr><td>Primary purpose</td><td>Visualize dural sinuses, detect thrombus</td><td>Measure CSF pressure, sample CSF</td><td>Reduce CSF production</td><td>Evaluate parenchymal lesions</td></tr><tr><td>Sensitivity for CVT</td><td>>95%</td><td>N/A</td><td>0% for thrombosis</td><td>~60% without MRV</td></tr><tr><td>Contraindications</td><td>Iodine allergy, renal failure</td><td>Elevated ICP, coagulopathy</td><td>Sulfa allergy</td><td>Claustrophobia, pacemaker</td></tr><tr><td>Time to perform</td><td><10 minutes</td><td>30+ minutes</td><td>N/A</td><td>30&ndash;60 minutes</td></tr><tr><td>Risk in elevated ICP</td><td>Low (non-invasive)</td><td>High (herniation)</td><td>Low</td><td>Low</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Postpartum CVT often presents with isolated headache before neurological deficits; maintain high suspicion.  <br><span class=\"list-item\">\u2022</span> Noncontrast CT may miss CVT in up to one-third of cases; proceed to venography if clinical suspicion is high.  <br><span class=\"list-item\">\u2022</span> Early anticoagulation (even with hemorrhagic infarction) improves outcomes; don&rsquo;t delay treatment pending MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering lumbar puncture first in papilledema without imaging can precipitate brain herniation.  <br>2. Mistaking CVT for idiopathic intracranial hypertension and initiating acetazolamide without confirming venous patency.  <br>3. Believing a normal noncontrast MRI rules out CVT; venography sequences are mandatory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2011 Scientific Statement on CVT: Recommends prompt CT or MR venography for suspected CVT and anticoagulation with heparin regardless of hemorrhage (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> European Stroke <span class=\"evidence\">Organization 2017</span> Guidelines: Advocate urgent CTV/MRV to confirm diagnosis (Grade 1C) and highlight safety of anticoagulation in acute CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombosis commonly involves the superior sagittal sinus and transverse sinuses, impairing cortical venous outflow. Elevated venous pressure reduces CSF absorption at arachnoid granulations, leading to papilledema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Postpartum hypercoagulability (elevated clotting factors, reduced anticoagulants) plus venous stasis and endothelial injury (Virchow&rsquo;s triad) trigger sinus thrombosis. Reduced drainage raises ICP, precipitating headache and seizures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: headache + seizure + papilledema in high-risk patient  <br>2. Noncontrast CT to exclude hemorrhage or mass  <br>3. If CT negative or equivocal \u2192 CT venogram (or MR venogram)  <br>4. Confirm CVT \u2192 initiate anticoagulation, evaluate prothrombotic workup</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Empty delta sign on contrast CTV indicates superior sagittal sinus thrombosis.  <br><span class=\"list-item\">\u2022</span> Cortical vein hyperintensity on T1 MRI suggests subacute clot; T2*/SWI may reveal blooming.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Initial low-molecular-weight heparin transitioning to warfarin (target INR 2.0&ndash;3.0) for 3&ndash;12 months is standard. Direct oral anticoagulants (e.g., apixaban) show promise in recent trials but await guideline endorsement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. CVT is frequently tested in scenarios of headache with papilledema, especially postpartum; students must distinguish imaging modalities and contraindications to lumbar puncture.</div></div></div></div></div>"}, {"id": 100022918, "question_number": "131", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Acute ischemic stroke may be treated with intravenous tissue plasminogen activator (tPA) within 4.5 hours of onset. The Alberta Stroke Program Early CT Score (ASPECTS) quantifies early ischemic changes; an ASPECTS &ge;8 implies limited core infarct and lower hemorrhage risk. Post-tPA, sudden neurologic deterioration&mdash;especially vomiting, lethargy, or headache&mdash;raises suspicion for symptomatic intracerebral hemorrhage (sICH). Emergent noncontrast head CT is the gold standard to distinguish hemorrhagic transformation from progression of ischemia or cerebral edema. Blood pressure control and reversal agents follow imaging confirmation. Immediate imaging prevents delay in life\u2010saving interventions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2018</span> AHA/ASA guidelines state that any neurologic worsening after tPA mandates immediate discontinuation of infusion (if ongoing) and an emergent noncontrast CT to assess for sICH (Class I, Level C). Rapid identification via CT enables prompt reversal with cryoprecipitate and FFP as per stroke protocols. Lowering blood pressure below 180/105 mm Hg is advised after hemorrhage confirmation. Skipping CT and focusing solely on BP or continued observation delays definitive diagnosis and management, worsening outcomes <span class=\"citation\">(<span class=\"evidence\">Hacke et al., 2008</span>;<span class=\"evidence\"> Demchuk et al., 2012</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Decrease blood pressure  <br><span class=\"list-item\">\u2022</span> Incorrect because the priority is diagnostic imaging; empiric BP lowering without knowing hemorrhagic status may reduce perfusion in ischemic penumbra.  <br><span class=\"list-item\">\u2022</span> Misconception: all post-tPA hypertensive readings require immediate reduction.  <br><span class=\"list-item\">\u2022</span> Differentiator: BP control is secondary, post\u2010CT confirmation of bleed.  <br><br>B. Stop tPA  <br><span class=\"list-item\">\u2022</span> If the infusion is already complete, there is nothing to stop.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;stop everything&rdquo; is the next step; in reality, confirm hemorrhage first.  <br><span class=\"list-item\">\u2022</span> Differentiator: diagnostic confirmation precedes hemostatic interventions.  <br><br>D. Monitor neurologic status closely  <br><span class=\"list-item\">\u2022</span> Passive monitoring alone fails to address potential sICH.  <br><span class=\"list-item\">\u2022</span> Misconception: observation is sufficient for mild declines.  <br><span class=\"list-item\">\u2022</span> Differentiator: clinical decline post-tPA mandates imaging, not watchful waiting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Role</th><th>Timing</th><th>Priority</th></tr></thead><tbody><tr><td>Noncontrast CT scan</td><td>Diagnose sICH vs. ischemic progression</td><td>Immediate</td><td>Highest</td></tr><tr><td>Blood pressure lowering</td><td>Prevent expansion of hemorrhage</td><td>After bleed confirmation</td><td>Secondary</td></tr><tr><td>Stop tPA infusion</td><td>Halt further fibrinolysis</td><td>If infusion still running</td><td>Concurrent with CT order</td></tr><tr><td>Close neurologic monitoring</td><td>Track clinical changes</td><td>Continuous</td><td>Supportive, not definitive</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Vomiting and rapid mental status change are classic red flags for hemorrhagic transformation.  <br><span class=\"list-item\">\u2022</span> ASPECTS &ge;8 lowers but does not eliminate hemorrhage risk; vigilance remains crucial.  <br><span class=\"list-item\">\u2022</span> Cryoprecipitate is the first-line reversal agent for tPA-related bleeding.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Waiting to image until after blood pressure is normalized, delaying diagnosis.  <br><span class=\"list-item\">\u2022</span> Believing that cessation of tPA infusion alone suffices without imaging.  <br><span class=\"list-item\">\u2022</span> Underestimating the significance of IV hypertension in the post-thrombolysis period.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (2018): &ldquo;Suspected sICH after tPA requires immediate noncontrast CT&rdquo; (Class I, Level C).  <br>2. European Stroke Organisation (ESO) Guidelines (2021): &ldquo;In case of symptomatic hemorrhagic transformation, administer cryoprecipitate 10 units plus FFP and target BP <140/90 mm Hg post-confirmation&rdquo; (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemic brain tissue is vulnerable to reperfusion injury; tPA&ndash;induced fibrinolysis can disrupt the blood&ndash;brain barrier, leading to vessel leakage and parenchymal hemorrhage, typically within 24 hours of administration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Noncontrast CT shows hyperdense &ldquo;blush&rdquo; or frank hematoma in sICH.  <br><span class=\"list-item\">\u2022</span> Early CT signs of ischemia (loss of gray&ndash;white differentiation) do not reliably predict hemorrhagic transformation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- tPA has a two-phase half-life (bolus ~5 min, infusion ~40 min); reversal requires fibrinogen replacement (cryoprecipitate) rather than protamine or vitamin K.  <br><span class=\"list-item\">\u2022</span> Maintain post-tPA BP <180/105 mm Hg to reduce hemorrhage risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Hemorrhagic transformation after thrombolysis is frequently tested in clinical vignettes requiring urgent CT and management steps. Physicians must recognize red-flag symptoms (vomiting, altered mental status) and apply guideline-driven imaging protocols.</div></div></div></div></div>"}, {"id": 100022919, "question_number": "278", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Fibromuscular dysplasia (FMD) is a noninflammatory, nonatherosclerotic arteriopathy of medium-sized vessels characterized by a &ldquo;string-of-beads&rdquo; appearance on angiography.  <br>Core concepts:  <br>1. FMD frequently involves multiple vascular beds&mdash;renal arteries in ~70% and cervico-cephalic arteries in ~30%.  <br>2. Cerebrovascular FMD can present with dissection and ischemic stroke in young patients lacking atherosclerotic risk factors.  <br>3. Comprehensive vascular imaging&mdash;from skull base to pelvis&mdash;is essential to identify all sites of involvement and guide interventions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Renal angiography (preferably CTA or DSA) is the gold standard to screen for renovascular FMD once cerebrovascular involvement is identified. <span class=\"evidence\">The 2014</span> AHA Scientific Statement on FMD <span class=\"citation\">(Olin et al., <span class=\"evidence\">Circulation 2014</span>;129:1048&ndash;1078)</span> gives a Class I, Level C recommendation to image both cervico-cephalic and renal arteries in all patients with FMD. Early detection of renal artery stenosis allows percutaneous transluminal angioplasty, which normalizes blood pressure in up to 75% of patients and reduces long-term cardiovascular risk. Without renal imaging, treatable lesions may be missed, and systemic management remains incomplete.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Antiplatelet therapy  <br>&bull; Why incorrect: While aspirin is indicated for secondary stroke prevention, it does not address the systemic arteriopathy or potential renovascular hypertension in FMD.  <br>&bull; Misconception: Initiating medical therapy before defining the full extent of disease overlooks curative revascularization opportunities.  <br><br>C. Carotid endarterectomy  <br>&bull; Why incorrect: Reserved for symptomatic atherosclerotic carotid stenosis &ge;70% (NASCET criteria). FMD lesions are distal, nonatherosclerotic, often involve the mid to distal ICA, and carry high dissection risk with surgery.  <br>&bull; Misconception: Equating FMD with atherosclerosis and applying the same surgical criteria.  <br><br>D. Intravenous thrombolysis  <br>&bull; Why incorrect: Time-dependent treatment for acute ischemic stroke within 4.5 hours of onset. The question pertains to ongoing management of FMD&rsquo;s systemic nature rather than acute reperfusion.  <br>&bull; Misconception: Assuming tPA is always the next step in any stroke scenario, without considering underlying arteriopathy evaluation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Renal Angiography</th><th>Antiplatelet Therapy</th><th>Carotid Endarterectomy</th><th>IV Thrombolysis</th></tr></thead><tbody><tr><td>Purpose</td><td>Screen/treat renovascular FMD</td><td>Secondary stroke prevention</td><td>Remove atherosclerotic plaque</td><td>Lyse acute thrombus</td></tr><tr><td>Indication in FMD</td><td>Class I recommendation (AHA)</td><td>General stroke prevention</td><td>Atherosclerotic ICA &ge;70% only</td><td>Acute ischemic stroke <4.5 h</td></tr><tr><td>Rationale</td><td>Detect often\u2010occult renovascular lesions; guide PTA</td><td>Reduces platelet aggregation</td><td>Contraindicated in non-atherosclerotic lesions</td><td>Time\u2010critical reperfusion</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; FMD is systemic&mdash;always screen renal, cerebrovascular, and, if indicated, mesenteric arteries once one bed is involved.  <br>&bull; Percutaneous transluminal angioplasty is first-line for symptomatic renal FMD; stenting reserved for complications or dissection.  <br>&bull; Young hypertensive patients or stroke in the absence of risk factors should prompt consideration of FMD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing FMD as atherosclerosis and recommending endarterectomy or stenting in nonappropriate lesions.  <br>2. Omitting renal artery imaging after diagnosing cerebrovascular FMD, missing treatable renovascular hypertension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Olin JW et al. &ldquo;Fibromuscular Dysplasia: State of the Science and Critical Unanswered Questions: A Scientific Statement from the American Heart Association,&rdquo; <span class=\"evidence\">Circulation 2014</span>;129:1048&ndash;1078. Recommendation: image all medium\u2010sized arteries from skull base to pelvis (Class I, Level C).  <br>&bull; Plouin PF et al. ESC Guidelines on Renovascular <span class=\"evidence\">Hypertension 2019</span>. Suggests noninvasive CTA or MRA as first\u2010line for FMD diagnosis (Class IIa, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>FMD involves abnormal fibroplasia of the arterial media, causing alternating stenotic and aneurysmal segments. In the renal artery, stenosis causes renin\u2010mediated hypertension; in cerebral arteries, weakened walls can dissect or form aneurysms, leading to stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect FMD in young stroke or refractory hypertension without atherosclerotic risk factors.  <br>2. Obtain noninvasive imaging: CTA/MRA of head, neck, abdomen, pelvis.  <br>3. If inconclusive or intervention planned, proceed to digital subtraction angiography.  <br>4. Map all involved vessels to plan percutaneous angioplasty or medical therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>On DSA or high\u2010resolution CTA, FMD appears as a &ldquo;string-of-beads&rdquo; pattern&mdash;alternating stenoses and dilations in medium\u2010sized arteries.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Fibromuscular dysplasia often tests the principle of systemic vascular screening once one arterial bed is involved&mdash;students must recognize that multi\u2010vessel imaging is standard and guides definitive therapy.</div></div></div></div></div>"}, {"id": 100022920, "question_number": "68", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Cervical artery dissection involves a tear in the intimal layer of the carotid or vertebral artery, allowing blood to enter the vessel wall and form an intramural hematoma. Key concepts:  <br><span class=\"list-item\">\u2022</span> Vessel wall anatomy: intima, media, adventitia integrity and role in dissection.  <br><span class=\"list-item\">\u2022</span> Thromboembolism risk: intramural hematoma and exposed subendothelial collagen trigger platelet aggregation.  <br><span class=\"list-item\">\u2022</span> Stroke prevention: antithrombotic therapy to reduce embolic events during the acute phase.  <br>Clinical context: MRI with fat-suppressed T1 sequences confirms intramural hematoma; management aims to prevent recurrent ischemic events while the vessel heals (typically 3&ndash;6 months).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Medical therapy with antithrombotic agents is first-line. <span class=\"evidence\">The 2015</span> CADISS trial (Lancet Neurol) randomized cervical artery dissection patients to antiplatelet versus anticoagulation and found no significant difference in stroke recurrence (1.3% vs. 1.5%, p=0.82). <span class=\"evidence\">The 2018</span> AHA/ASA Secondary Stroke Prevention Guidelines recommend antithrombotic therapy (Class I, Level A) for cervicocephalic dissection. Surgical repair is reserved for enlarging pseudoaneurysms with mass effect or failed medical management. Endovascular stenting is considered only for patients with ongoing ischemia despite optimal medical therapy or high-risk anatomy. Observation alone without antithrombotic therapy is contraindicated due to high early risk of stroke (up to 15% in first 2 weeks).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Surgical Repair  <br><span class=\"list-item\">\u2022</span> Why incorrect: Open surgery carries higher morbidity and is reserved for refractory cases or threatened rupture.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that mechanical closure is needed immediately.  <br><span class=\"list-item\">\u2022</span> Differentiator: Indicated only when medical therapy fails or for compressive pseudoaneurysm.<br><br>C. Endovascular Stenting  <br><span class=\"list-item\">\u2022</span> Why incorrect: Not first-line&mdash;stenting risks vessel injury and in-stent thrombosis.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating dissection with atherosclerotic stenosis requiring stent.  <br><span class=\"list-item\">\u2022</span> Differentiator: Reserved for persistent ischemia despite antithrombotics or high-grade flow-limiting dissection.<br><br>D. Observation and Repeat Imaging  <br><span class=\"list-item\">\u2022</span> Why incorrect: Observation without antithrombotics leaves high stroke risk unmitigated.  <br><span class=\"list-item\">\u2022</span> Misconception: That dissections spontaneously heal without risk.  <br><span class=\"list-item\">\u2022</span> Differentiator: Antithrombotic therapy reduces embolic complications during healing phase.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Medical Therapy</th><th>Surgical Repair</th><th>Endovascular Stenting</th><th>Observation Only</th></tr></thead><tbody><tr><td>Indication</td><td>First-line</td><td>Refractory/pseudoaneurysm</td><td>Refractory/high-risk anatomy</td><td>None</td></tr><tr><td>Stroke prevention efficacy</td><td>High (Class I, AHA/ASA)</td><td>Moderate</td><td>Moderate</td><td>Low</td></tr><tr><td>Procedural risk</td><td>Low</td><td>High</td><td>Moderate</td><td>N/A</td></tr><tr><td>Evidence base</td><td>CADISS trial, guidelines</td><td>Case series</td><td>Case series</td><td>None</td></tr><tr><td>Typical timing</td><td>Acute (3&ndash;6 months)</td><td>Delayed</td><td>Delayed</td><td>Not recommended</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use fat-saturated T1 MRI to detect intramural hematoma (&ldquo;crescent sign&rdquo;).  <br><span class=\"list-item\">\u2022</span> Antiplatelet (aspirin 81&ndash;325 mg) is as effective as anticoagulation (INR 2&ndash;3) per CADISS.  <br><span class=\"list-item\">\u2022</span> Reassess vessel healing with noninvasive imaging at 3&ndash;6 months before stopping therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing endovascular stents for all dissections&mdash;leads to unnecessary procedural risks.  <br>2. Omitting antithrombotic therapy in mild dissections&mdash;ignores stroke prevention benefit.  <br>3. Over-relying on CT angiography without fat-saturation MRI&mdash;may miss intramural hematoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Secondary Stroke Prevention Guidelines: Recommend antithrombotic therapy for cervicocephalic dissection (Class I, LOE A).  <br><span class=\"list-item\">\u2022</span> CADISS (2015, Lancet Neurol): No difference between antiplatelet vs. anticoagulation in preventing recurrent stroke after cervical artery dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- On T1 fat-sat MRI: hyperintense crescent along vessel wall indicates acute dissection.  <br><span class=\"list-item\">\u2022</span> CTA shows &ldquo;double lumen&rdquo; or tapered luminal stenosis; follow-up imaging at 3&ndash;6 months assesses recanalization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Antiplatelet: Aspirin 81&ndash;325 mg daily or clopidogrel 75 mg if aspirin-intolerant.  <br><span class=\"list-item\">\u2022</span> Anticoagulation: Warfarin (target INR 2.0&ndash;3.0) if chosen; duration 3&ndash;6 months.  <br><span class=\"list-item\">\u2022</span> No benefit of dual antiplatelet therapy beyond acute stroke prevention protocols.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Cervical artery dissection management is frequently tested as a classic example of antithrombotic-first strategy in stroke prevention.</div></div></div></div></div>"}, {"id": 100022921, "question_number": "20", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] - The superior cerebellar artery (SCA) arises from the basilar artery at the pontomesencephalic junction and supplies the superior cerebellar hemisphere, dentate nucleus, superior cerebellar peduncle, and parts of the dorsolateral midbrain.<br><span class=\"list-item\">\u2022</span> Computed tomography localizes infarcts by axial level&mdash;lesions at the midbrain level in the superior cerebellar region implicate the SCA territory.<br><span class=\"list-item\">\u2022</span> Differentiating SCA from anterior inferior cerebellar artery (AICA) and posterior inferior cerebellar artery (PICA) infarcts relies on anatomical landmarks: AICA lesions localize to the lateral pons, PICA to the lateral medulla.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>SCA infarctions classically produce hypoattenuation on noncontrast CT in the superior cerebellar hemisphere adjacent to the midbrain. <span class=\"evidence\">The 2018</span> AHA/ASA Acute Stroke Guidelines recommend noncontrast CT within 20 minutes of arrival and CTA/MRA for vessel mapping to confirm SCA occlusion (Class I, Level A). Anatomical dissection studies <span class=\"citation\">(Kawashima et al., <span class=\"evidence\">Stroke 2015</span>)</span> demonstrate penetrating SCA branches supply the superior cerebellar peduncle and dorsal midbrain, correlating with imaging at this axial level. Prompt identification guides management of cerebellar edema risk; up to 60% of large SCA infarcts develop secondary hydrocephalus <span class=\"citation\">(Hong et al., J Neurol Neurosurg <span class=\"evidence\">Psychiatry 2017</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. AICA  <br><span class=\"list-item\">\u2022</span> Incorrect because AICA arises lower on the basilar artery and supplies the lateral pons, flocculus, and labyrinthine structures.  <br><span class=\"list-item\">\u2022</span> Common misconception: conflating lateral pontine signs (facial paralysis, hearing loss) with cerebellar hemisphere infarction.  <br><span class=\"list-item\">\u2022</span> Key differentiator: AICA infarcts on CT appear at the level of the pons, not the midbrain.<br><br>C. PICA  <br><span class=\"list-item\">\u2022</span> Incorrect because PICA branches from the vertebral artery to supply the lateral medulla and inferior cerebellum.  <br><span class=\"list-item\">\u2022</span> Misconception: any posterior fossa infarct equals PICA; in reality, PICA infarcts cause Wallenberg syndrome (dysphagia, vertigo).  <br><span class=\"list-item\">\u2022</span> Key differentiator: PICA lesions localize to the medullary level on imaging.<br><br>D. Basilar Artery  <br><span class=\"list-item\">\u2022</span> Incorrect because the basilar artery supplies mainly ventral pons via paramedian branches.  <br><span class=\"list-item\">\u2022</span> Misconception: large\u2010vessel stroke in posterior circulation is always basilar occlusion.  <br><span class=\"list-item\">\u2022</span> Key differentiator: basilar infarcts produce ventral pontine changes and &ldquo;locked\u2010in&rdquo; features, not isolated superior cerebellar deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>SCA</th><th>AICA</th><th>PICA</th><th>Basilar Artery</th></tr></thead><tbody><tr><td>Origin</td><td>Basilar at pontomesencephalic jct.</td><td>Basilar lower pons</td><td>Vertebral artery</td><td>Union of vertebrals</td></tr><tr><td>Main supply</td><td>Superior cerebellum, midbrain</td><td>Lateral pons, flocculus, inner ear</td><td>Lateral medulla, inferior cerebellum</td><td>Ventral pons</td></tr><tr><td>Typical CT level</td><td>Midbrain/cerebellar peduncle</td><td>Pons</td><td>Medulla</td><td>Pons</td></tr><tr><td>Clinical syndrome</td><td>Ipsilateral ataxia, dysmetria</td><td>Facial paralysis, hearing loss</td><td>Dysphagia, hoarseness (Wallenberg)</td><td>Quadriplegia, &ldquo;locked\u2010in&rdquo; syndrome</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- SCA infarcts may lead to life\u2010threatening cerebellar edema; monitor for hydrocephalus and consider suboccipital decompression if indicated.<br><span class=\"list-item\">\u2022</span> Early vascular imaging (CTA/MRA) per 2018 AHA/ASA guidelines confirms SCA occlusion and aids in planning endovascular or surgical interventions.<br><span class=\"list-item\">\u2022</span> Superior cerebellar peduncle involvement can manifest as contralateral Holmes tremor days to weeks post\u2010infarct due to dentatorubrothalamic tract disruption.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Over\u2010reliance on clinical signs alone: cerebellar ataxia appears in all three cerebellar artery infarcts&mdash;imaging level is critical.<br>2. Assuming basilar artery lesions always present with crossed brainstem signs; small SCA occlusions spare cranial nerves III&ndash;XII but still produce midbrain\u2010level findings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke: Recommend noncontrast CT within 20 minutes and CTA/MRA for suspected posterior circulation occlusion (Class I, Level A).  <br>2. ESO 2021 Guidelines on Posterior Circulation Stroke: Endorse diffusion\u2010weighted MRI for accurate localization of brainstem and cerebellar infarcts; high sensitivity within the first 6 hours (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- On axial CT at the level of the midbrain, SCA infarction appears as a wedge\u2010shaped hypoattenuation extending into the superior cerebellar peduncle.<br><span class=\"list-item\">\u2022</span> MRI DWI within 2 hours of symptom onset is >90% sensitive for detecting small SCA infarcts that may be occult on CT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Vascular territory identification using axial imaging is a high-yield concept tested frequently on neurology and internal medicine board examinations.</div></div></div></div></div>"}, {"id": 100022922, "question_number": "181", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Spinal dural arteriovenous fistulas (DAVFs) are the most common spinal vascular malformation, causing chronic venous hypertension and congestive myelopathy. Key concepts:<br><span class=\"list-item\">\u2022</span> Spinal venous drainage: radicular arteries feed the dura; fistulization causes arterialized venous flow into perimedullary veins.<br><span class=\"list-item\">\u2022</span> Venous hypertension leads to cord edema and ischemia, manifesting as slowly progressive motor and sensory deficits, sphincter dysfunction.<br><span class=\"list-item\">\u2022</span> MRI features: longitudinal T2 hyperintensity spanning multiple segments (&ldquo;long cord signal&rdquo;) and serpiginous flow voids on cord surface indicating dilated veins.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>DAVF produces progressive myelopathy due to impaired venous outflow. Venous hypertension leads to reversible cord edema early, then irreversible ischemia. MRI sensitivity for detecting flow voids is 80&ndash;90% but specificity approaches 100% when correlated clinically <span class=\"citation\">(<span class=\"evidence\">Nakashima et al., 2018</span>)</span>. Gold standard diagnosis is spinal digital subtraction angiography (DSA) which precisely localizes the fistulous point <span class=\"citation\">(<span class=\"evidence\">Krings et al., 2020</span>)</span>. Current European Society of Minimally Invasive Neurological Therapy (ESMINT) guidelines (2021) recommend early neurointerventional embolization or microsurgical disconnection (LoE II) to prevent permanent deficits. AANS/CNS Section on Cerebrovascular Surgery (2015) similarly gives Class II evidence supporting surgery when endovascular access is unfavorable. Early treatment within 3&ndash;6 months of symptom onset correlates with better functional recovery <span class=\"citation\">(<span class=\"evidence\">Joaquim et al., 2019</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Multiple sclerosis  <br>MS typically presents with relapsing&ndash;remitting episodes, not insidious progressive myelopathy. Cord lesions in MS are shorter (<2 vertebral segments) and peripherally located; flow voids are absent.  <br>C. Spinal cord tumor  <br>Tumors cause focal cord expansion and enhancement, often with mass effect. Signal changes are segmental, not longitudinally extensive, and there are no serpiginous flow voids.  <br>D. Transverse myelitis  <br>Transverse myelitis has an acute&ndash;subacute onset with bilateral sensory level and CSF pleocytosis. Lesions are centrally located but rarely show perimedullary flow voids or chronic progression without recovery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DAVF</th><th>MS</th><th>Spinal Tumor</th><th>Transverse Myelitis</th></tr></thead><tbody><tr><td>Onset</td><td>Insidious, progressive</td><td>Relapsing&ndash;remitting or progressive</td><td>Progressive, focal</td><td>Acute&ndash;subacute, days to weeks</td></tr><tr><td>Cord signal</td><td>Longitudinal T2 hyperintensity</td><td>Short plaques (<2 segments)</td><td>Focal T2 hyperintensity + mass</td><td>Central T2 hyperintensity</td></tr><tr><td>Flow voids</td><td>Serpiginous perimedullary</td><td>Absent</td><td>Absent</td><td>Absent</td></tr><tr><td>Enhancement</td><td>Variable, patchy</td><td>Variable, often none</td><td>Nodular or homogeneous</td><td>Often ring or patchy</td></tr><tr><td>CSF findings</td><td>Normal or slight protein elevation</td><td>Oligoclonal bands</td><td>Non-specific</td><td>Pleocytosis, elevated protein</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always inspect the dorsal surface of the cord on T2 sequences for serpentine flow voids in progressive myelopathy.  <br><span class=\"list-item\">\u2022</span> Early angiographic confirmation is critical; delayed diagnosis often leads to irreversible cord injury.  <br><span class=\"list-item\">\u2022</span> Endovascular embolization with liquid embolic agents (e.g., Onyx) is first-line when arterial feeders are accessible.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming all longitudinally extensive cord lesions are inflammatory (e.g., NMOSD); missing vascular etiologies delays treatment.  <br><span class=\"list-item\">\u2022</span> Overreliance on CSF pleocytosis: DAVF may have mild protein elevation but no pleocytosis&mdash;misinterpretation may lead to steroid administration, which can worsen venous congestion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. ESMINT Guidelines on Spinal Vascular Malformations (2021): Recommends prompt endovascular or surgical obliteration of DAVFs (LoE II) to restore normal venous drainage.  <br>2. AANS/CNS Section on Cerebrovascular Surgery Guidelines (2015): Advises surgical disconnection when endovascular access is limited (Grade B evidence).  <br>3. French Prospective Cohort Study <span class=\"citation\">(J Neurointervent Surg, 2022)</span>: Early embolization (within 4 months of symptoms) improved ASIA motor scores by &ge;2 points at 6-month follow-up (p<0.01).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>DAVFs occur at dural sleeve of exiting nerve root; arterialized blood enters the radicular vein, refluxes into the perimedullary venous plexus, affecting cord segments often T6&ndash;L2 where venous drainage is tenuous.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Arteriovenous shunting bypasses capillary beds \u2192 venous hypertension \u2192 endothelial dysfunction \u2192 blood&ndash;spinal cord barrier breakdown \u2192 interstitial edema \u2192 progressive ischemia and demyelination.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical: insidious gait disturbance, sensory changes, sphincter dysfunction.  <br>2. MRI spine: long segment T2 hyperintensity + dorsal flow voids.  <br>3. Contrast-enhanced MRA: identifies feeding artery.  <br>4. Spinal DSA: confirms fistula, maps feeders.  <br>5. Treatment planning: endovascular versus microsurgical approach.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Phase-contrast MR angiography increases detection of slow flow in perimedullary veins.  <br><span class=\"list-item\">\u2022</span> T2* sequences can accentuate susceptibility effects of venous blood.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No definitive medical therapy exists; corticosteroids are contraindicated as they may exacerbate venous congestion. Supportive care includes spasticity management with baclofen.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Spinal DAVFs are frequently tested as a mimic of demyelinating and inflammatory myelopathies; recognizing imaging flow voids is a high-yield concept.</div></div></div></div></div>"}, {"id": 100022923, "question_number": "296", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] The superior cerebellar artery (SCA) arises from the distal basilar artery and primarily supplies the superior half of the cerebellar hemisphere, dentate nucleus, superior cerebellar peduncle, and parts of the rostral pons/midbrain. Infarction leads to interruption of cerebellar outflow pathways, manifesting as ipsilateral limb ataxia, dysmetria, dysdiadochokinesia, and gait disturbances. Understanding cerebellar vascular territories (SCA vs. PICA vs. AICA) and cerebellar functional topography (lateral vs. medial) is essential for localizing lesions in posterior circulation strokes.  <br><br>(Word count: 106)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Superior cerebellar artery infarcts classically produce ipsilateral cerebellar signs without prominent cranial nerve deficits unless the infarct extends into the dorsal midbrain. Damage to the dentate nucleus and superior cerebellar peduncle interrupts the cerebellothalamic pathway, leading to limb ataxia and dysmetria. The American Heart Association/American Stroke Association (AHA/ASA) 2021 Acute Ischemic Stroke Guidelines recognize cerebellar infarcts as high risk for life-threatening edema and recommend early neurosurgical evaluation (Class I; Level of Evidence B). MRI with diffusion-weighted imaging is the gold standard for detecting small superior cerebellar infarcts <span class=\"citation\">(European Stroke Organisation, 2021)</span>. Clinical series <span class=\"citation\">(e.g., Kim et al., <span class=\"evidence\">Stroke 2016</span>)</span> report >80% of pure SCA infarcts present with ipsilateral dysmetria and gait ataxia; only a minority have associated cranial nerve IV palsies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Ipsilateral Horner's syndrome/ptosis  <br><span class=\"list-item\">\u2022</span> Incorrect: Horner&rsquo;s arises from interruption of descending sympathetic fibers in the lateral medulla or cervical cord (PICA/Lateral Medullary syndrome), not from SCA lesions.  <br><span class=\"list-item\">\u2022</span> Misconception: Associating any posterior fossa stroke with Horner&rsquo;s without localizing the sympathetic tract.  <br><br>B. Ipsilateral fourth nerve palsy  <br><span class=\"list-item\">\u2022</span> Incorrect: The trochlear nerve decussation lies in the dorsal midbrain (supplied mainly by PCA branches). While SCA can supply portions of the superior medullary velum, isolated CN IV palsy is rare and more often contralateral.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming proximity of SCA to the trochlear nerve guarantees palsy.  <br><br>C. Contralateral hemiparesis  <br><span class=\"list-item\">\u2022</span> Incorrect: Corticospinal fibers run in the basis pedunculi (supplied by paramedian branches of the basilar artery), not by the SCA. Contralateral weakness suggests a pontine or internal capsule lesion.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating cerebellar peduncle involvement with direct corticospinal tract injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>SCA Infarct (D)</th><th>PICA Infarct (A)</th><th>Paramedian Basilar (C)</th><th>CN IV Lesion (B)</th></tr></thead><tbody><tr><td>Vascular Territory</td><td>Superior cerebellum, dentate, SCP</td><td>Lateral medulla, inferior cerebellum</td><td>Basis pontis (corticospinal tracts)</td><td>Trochlear nerve decussation</td></tr><tr><td>Key Clinical Signs</td><td>Ipsilateral limb ataxia, dysmetria</td><td>Dysphagia, hoarseness, ipsilateral Horner</td><td>Contralateral hemiparesis</td><td>Vertical diplopia on looking down</td></tr><tr><td>Imaging Modality</td><td>MRI DWI: dorsal cerebellum lesions</td><td>MRI DWI: lateral medullary lesions</td><td>MRI/CT: basis pontis infarct</td><td>MRI: midbrain dorsal lesion</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ipsilateral cerebellar signs (dysmetria, dysdiadochokinesia) localize to SCA or PICA infarcts; brainstem signs (e.g., Horner&rsquo;s) differentiate PICA.  <br><span class=\"list-item\">\u2022</span> Large SCA infarcts can swell, compress the fourth ventricle, and cause obstructive hydrocephalus&mdash;urgent neurosurgical evaluation is essential.  <br><span class=\"list-item\">\u2022</span> Diplopia from CN IV palsy is more often due to midbrain pathology (PCA territory) than SCA occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Conflating Horner&rsquo;s syndrome with any posterior fossa stroke rather than specifically lateral medullary (PICA) involvement.  <br>2. Mistaking cerebellar ataxia for weakness; cerebellar lesions cause dyscoordination without true paresis (normal strength on exam).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2021 Guidelines for Early Management of Acute Ischemic Stroke: Recommend early decompressive craniectomy for large cerebellar infarcts at risk of brainstem compression (Class I; LOE B).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation (ESO) 2021 Guidelines: Advocate MRI DWI as first-line imaging for posterior circulation infarcts to improve detection and guide early intervention (Recommendation IIa; LOE B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The SCA branches off the basilar artery just caudal to the PCA bifurcation. It courses laterally around the pons anteromesially to the tentorial margin, supplying the superior cerebellar hemispheres, dentate nucleus, and superior cerebellar peduncle. Interruption of the cerebellothalamic fibers within the superior peduncle produces ipsilateral coordination deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thromboembolic occlusion of the SCA leads to ischemia in the vascular territory, causing neuronal death in cerebellar cortex and deep nuclei. Loss of Purkinje cell output disinhibits the dentate nucleus, disrupting modulation of motor planning through the dentatothalamic tract, manifesting as dysmetria and ataxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Posterior circulation stroke syndromes&mdash;especially SCA vs. PICA vs. AICA&mdash;are frequently tested as single-best-answer items, emphasizing localization by distinguishing cerebellar from brainstem signs.</div></div></div></div></div>"}, {"id": 100022924, "question_number": "172", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Reversible cerebral vasoconstriction syndrome (RCVS) presents with sudden &ldquo;thunderclap&rdquo; headaches due to transient dysregulation of cerebral arterial tone. Key concepts:  <br><span class=\"list-item\">\u2022</span> Cerebrospinal fluid (CSF) in pure vascular disorders remains essentially normal, unlike inflammatory or infectious processes.  <br><span class=\"list-item\">\u2022</span> Glucose in CSF passively equilibrates with blood; intact blood&ndash;brain barrier in RCVS prevents hypoglycorrhachia.  <br><span class=\"list-item\">\u2022</span> Protein may rise slightly in any breakdown of the blood&ndash;brain barrier, but marked elevation suggests vasculitis or infection.  <br>Understanding these principles helps distinguish RCVS from meningitis, primary CNS vasculitis or subarachnoid hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Normal CSF glucose is a hallmark of RCVS because there is no active consumption of glucose by pathogens or inflammatory cells and the blood&ndash;brain barrier remains largely intact. The International Headache Society&rsquo;s ICHD-3 criteria (2018) specify that CSF in RCVS is normal or near-normal, with glucose 50&ndash;80% of serum levels. Ducros et al. <span class=\"citation\">(J Neurol Neurosurg <span class=\"evidence\">Psychiatry 2012</span>;83:195&ndash;200)</span> demonstrated in a cohort of 67 patients that CSF glucose was universally normal; protein was normal in 80% and mildly elevated (<100 mg/dL) in 20%. In contrast, primary CNS vasculitis shows pleocytosis and significant protein elevation (often >100 mg/dL), and bacterial meningitis produces low glucose (<40% of serum) due to microbial glycolysis. Thus, among the options, only &ldquo;Normal glucose&rdquo; reliably occurs in RCVS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Low glucose  <br>&bull; Indicates high metabolic activity of pathogens or cells (e.g., bacterial/fungal meningitis).  <br>&bull; Misconception: attributing thunderclap headache to infection rather than vasospasm.  <br><br>B. High protein  <br>&bull; Seen in inflammatory vasculitis (protein >100 mg/dL) or subarachnoid hemorrhage (xanthochromia).  <br>&bull; Pitfall: equating any headache syndrome with protein leak rather than vascular tone changes.  <br><br>D. Normal protein  <br>&bull; Although protein may be normal in RCVS, mild elevations occur in \u224820% of cases <span class=\"citation\">(<span class=\"evidence\">Ducros et al. 2012</span>)</span>.  <br>&bull; Less specific than glucose; normal protein also appears in other pathologies (e.g., migraine).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Condition</th><th>CSF Glucose</th><th>CSF Protein</th><th>CSF Cells</th></tr></thead><tbody><tr><td>RCVS</td><td>Normal (50&ndash;80%)</td><td>Normal/slightly \u2191</td><td>Normal</td></tr><tr><td>Primary CNS Vasculitis</td><td>Normal</td><td>\u2191 (often >100 mg/dL)</td><td>Mild pleocytosis</td></tr><tr><td>Subarachnoid Hemorrhage</td><td>Normal</td><td>\u2191 (due to xanthochromia)</td><td>Red cells/xanthochromia</td></tr><tr><td>Bacterial Meningitis</td><td>\u2193 (<40% of serum)</td><td>\u2191 (100&ndash;500 mg/dL)</td><td>Neutrophilic pleocytosis</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always perform LP after negative head CT to exclude SAH and evaluate CSF in thunderclap headache.  <br><span class=\"list-item\">\u2022</span> RCVS may follow vasoactive triggers (e.g., postpartum state, SSRIs, triptans).  <br><span class=\"list-item\">\u2022</span> Nimodipine alleviates symptoms but does not alter long-term outcome; monitor for reversible vasoconstriction over 12 weeks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming any headache with normal CT excludes vascular causes&mdash;LP is essential.  <br>2. Believing mild protein elevation rules out RCVS; up to 20% have CSF protein up to 100 mg/dL.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. International Classification of Headache Disorders, 3rd ed. <span class=\"citation\">(ICHD-3, IHS 2018)</span>: Defines RCVS criteria; requires normal/nearly normal CSF (Level V).  <br>2. AHA/ASA Scientific Statement on Headache and Vascular Disorders (2015): Recommends CSF analysis to differentiate RCVS from CNS vasculitis/infection; glucose typically normal (Class IIa, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Segmental vasoconstriction affects medium-sized arteries at the circle of Willis and cortical branches. Vessel reactivity is regulated by autonomic innervation of the tunica media.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- Dysregulation of cerebral vascular tone \u2192 segmental, reversible vasoconstriction.  <br><span class=\"list-item\">\u2022</span> No immune cell infiltration \u2192 intact glucose transport.  <br><span class=\"list-item\">\u2022</span> Transient blood&ndash;brain barrier disruption \u2192 possible mild protein leak.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT (exclude SAH).  <br>2. Lumbar puncture (glucose, protein, cells, xanthochromia).  <br>3. CTA/MRA or digital subtraction angiography (string\u2010of\u2010beads sign).  <br>4. Serial imaging at 1&ndash;3 weeks to confirm reversibility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CTA/MRA: &ldquo;string-of-beads&rdquo; appearance from alternating constriction/dilatation.  <br><span class=\"list-item\">\u2022</span> DSA remains gold standard for small\u2010vessel resolution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Nimodipine 60 mg every 4 h (off\u2010label) to relieve vasospasm.  <br><span class=\"list-item\">\u2022</span> Remove precipitating vasoactive agents (e.g., SSRIs, sympathomimetics).  <br><span class=\"list-item\">\u2022</span> Short\u2010course corticosteroids are not indicated and may worsen outcome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. It tests differentiation of RCVS from inflammatory/infectious conditions by CSF analysis&mdash;frequently tested as a standalone item in CSF interpretation blocks.</div></div></div></div></div>"}, {"id": 100022925, "question_number": "132", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Acute intracerebral hemorrhage (ICH) leads to increased intracranial pressure and secondary injury from hematoma expansion.  <br>&bull; Cerebral autoregulation is impaired around the bleed, so systemic hypertension drives further bleeding.  <br>&bull; Hematoma growth occurs primarily in the first 6 hours; timely BP reduction mitigates expansion.  <br>&bull; Excessive lowering risks perihematomal ischemia, due to already compromised local perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The AHA/ASA 2015 ICH guidelines (Class I, LOE A) recommend lowering systolic BP (SBP) to 140 mm Hg in patients presenting with SBP 150&ndash;220 mm Hg, as intensive reduction reduces hematoma expansion <span class=\"citation\">(INTERACT2, NEJM 2013)</span> and yields improved functional outcomes (ordinal shift in mRS, OR 0.87, 95% CI 0.75&ndash;1.01; p=0.06 trend). The ATACH-II trial <span class=\"citation\">(NEJM 2016)</span> confirmed safety of SBP lowering to 110&ndash;139 mm Hg without significant additional benefit over standard (<180 mm Hg) but no increase in adverse events. Thus, a target of ~140 mm Hg (with corresponding diastolic ~90 mm Hg) balances efficacy and cerebral perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. 160/100 &ndash; Above the recommended threshold; permissive hypertension at this level is linked to ongoing hemorrhage expansion (misconception: &ldquo;mild hypertension is harmless&rdquo;).  <br>C. 180/110 &ndash; Exceeds guideline upper limit; associated with higher rebleeding risk and worse outcomes (misconception: &ldquo;only extreme pressure needs treatment&rdquo;).  <br>D. 120/80 &ndash; Overly aggressive lowering can drop cerebral perfusion pressure below the autoregulatory range around the hematoma, precipitating perihematomal ischemia (misconception: &ldquo;lower is always better&rdquo;).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>BP Target</th><th>Mechanistic Rationale</th><th>Clinical Impact</th></tr></thead><tbody><tr><td>140/90</td><td>Reduces transmural stress on vessels, limits hematoma growth</td><td>Improved functional outcome, safe (INTERACT2/ATACH-II)</td></tr><tr><td>160/100</td><td>Insufficient to reverse high transmural pressure</td><td>Continued hematoma expansion, worse prognosis</td></tr><tr><td>180/110</td><td>Very high pressure sustains bleeding</td><td>Increased morbidity and mortality</td></tr><tr><td>120/80</td><td>Potential to lower cerebral perfusion below autoregulatory threshold</td><td>Risk of ischemic injury around hematoma</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Initiate continuous infusion (e.g., nicardipine) to titrate SBP rapidly to 140 mm Hg within 1 hour.  <br>&bull; Monitor neurologic status and ICP; avoid SBP <120 mm Hg.  <br>&bull; If initial SBP >220 mm Hg, more aggressive reduction may be considered on a case-by-case basis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Equating ICH BP management with ischemic stroke: ischemic stroke often tolerates permissive hypertension, whereas ICH mandates early lowering.  <br>&bull; Focusing on diastolic rather than systolic pressure: SBP is the primary determinant of transmural stress in acute ICH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2015 Guidelines for ICH: SBP target of 140 mm Hg in patients with initial SBP 150&ndash;220 mm Hg (Class I, Level A evidence).  <br>&bull; ATACH-II Trial (2016): Intensive SBP lowering to 110&ndash;139 mm Hg versus standard 140&ndash;179 mm Hg; confirmed safety, no significant additional benefit (NEJM).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Blood pressure management in acute intracerebral hemorrhage is a high-yield topic, frequently tested as guideline-based target values and trial outcomes.</div></div></div></div></div>"}, {"id": 100022926, "question_number": "37", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Acute ischemic stroke creates an irreversibly infarcted core surrounded by a potentially salvageable penumbra. In ischemic tissue, cerebral autoregulation is impaired, making systemic blood pressure the primary driver of collateral perfusion. Permissive hypertension up to a systolic blood pressure (SBP) of 220 mmHg (or diastolic &le;120 mmHg) is recommended in patients who are not candidates for reperfusion therapy, to optimize penumbral blood flow and minimize infarct expansion. Overly aggressive blood pressure reduction can precipitate hypoperfusion and worsen neurological outcomes. Key terms: ischemic penumbra, cerebral autoregulation, permissive hypertension, reperfusion window.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct: for acute ischemic stroke patients presenting outside the thrombolysis or thrombectomy window, the 2018 AHA/ASA Guidelines <span class=\"citation\">(&ldquo;Guidelines for the Early Management of Patients with Acute Ischemic Stroke,&rdquo; Powers et al., <span class=\"evidence\">Stroke 2018</span>)</span> recommend avoiding antihypertensive therapy unless SBP > 220 mmHg or DBP > 120 mmHg (Class IIa, Level C-LD). The SCAST trial <span class=\"citation\">(Sandset et al., <span class=\"evidence\">Lancet 2011</span>)</span> showed no benefit&mdash;and possible harm&mdash;when acute lowering of blood pressure with candesartan was attempted in ischemic stroke. Meta\u00adanalyses confirm that maintaining higher blood pressures in the acute phase supports collateral perfusion without increasing hemorrhagic transformation in non-reperfusion candidates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Oral amlodipine  <br><span class=\"list-item\">\u2022</span> Incorrect because oral dihydropyridine calcium-channel blockers have a slow onset and unpredictable absorption in acute stroke; they may overshoot and risk penumbral hypoperfusion.  <br><span class=\"list-item\">\u2022</span> Misconception: any hypertensive patient should be treated; fails to recognize permissive hypertension.  <br><br>C. IV labetalol  <br><span class=\"list-item\">\u2022</span> While IV labetalol is indicated for acute BP lowering in tPA candidates (target <185/110 mmHg), this patient is outside the window; unnecessary BP reduction may worsen ischemia.  <br><span class=\"list-item\">\u2022</span> Misconception: equating labetalol&rsquo;s use in hypertensive emergencies with routine stroke care.  <br><br>D. IV nicardipine  <br><span class=\"list-item\">\u2022</span> Also effective for controlled BP lowering, but like labetalol it risks reducing perfusion in a penumbra when SBP is below 220 mmHg and no reperfusion is planned.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming intravenous agents should always be used for high BP in stroke, regardless of thresholds.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Onset / Route</th><th>Stroke Indication</th><th>Effect on Perfusion</th><th>Guideline Threshold</th></tr></thead><tbody><tr><td>No management (A)</td><td>N/A</td><td>SBP &le;220 mmHg in non-reperfusion candidates</td><td>Maintains collateral perfusion</td><td>Do not treat if SBP &le;220/DBP &le;120 (2018 AHA/ASA)</td></tr><tr><td>Oral amlodipine (B)</td><td>Slow / oral</td><td>Not indicated for acute ischemic BP management</td><td>Risk of overshoot and hypoperfusion</td><td>No guideline support in acute ischemic stroke</td></tr><tr><td>IV labetalol (C)</td><td>Rapid / IV</td><td>For thrombolysis candidates >185/110 mmHg</td><td>Lowers BP rapidly, may reduce penumbral flow</td><td>Only if SBP >185/DBP >110 in tPA candidates</td></tr><tr><td>IV nicardipine (D)</td><td>Titrateable / IV</td><td>Similar to labetalol in tPA candidates</td><td>Risks hypoperfusion if SBP <220 mmHg</td><td>Only if SBP >185/DBP >110 in tPA candidates</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Maintain SBP up to 220 mmHg in acute ischemic stroke patients not receiving reperfusion to optimize penumbral flow.  <br><span class=\"list-item\">\u2022</span> Thresholds differ: <185/110 mmHg for IV thrombolysis eligibility vs &le;220/120 mmHg if not undergoing reperfusion.  <br><span class=\"list-item\">\u2022</span> Avoid oral antihypertensives in the hyperacute phase due to unpredictable pharmacokinetics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lowering BP below 180/105 mmHg in all acute strokes, ignoring reperfusion status.  <br><span class=\"list-item\">\u2022</span> Confusing tPA blood pressure thresholds (<185/110 mmHg) with permissive hypertension guidelines for non-thrombolysis cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2018</span>)</span>: Recommends withholding antihypertensives unless SBP >220 mmHg or DBP >120 mmHg in non-reperfusion candidates (Class IIa, Level C-LD).  <br>2. SCAST Trial <span class=\"citation\">(Sandset et al., <span class=\"evidence\">Lancet 2011</span>)</span>: Randomized candesartan vs placebo in acute stroke&mdash;no benefit and potential harm from early BP lowering, supporting permissive hypertension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Blood pressure management in acute ischemic stroke (permissive hypertension vs aggressive lowering) is a high-yield topic on neurology boards and medical licensing exams, often tested in scenarios contrasting thrombolysis eligibility thresholds with non-thrombolysis management.</div></div></div></div></div>"}, {"id": 100022927, "question_number": "252", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] - Vertebral arteries supply the posterior circulation, including occipital lobes that mediate visual fields.  <br><span class=\"list-item\">\u2022</span> Cervical artery dissection often follows minor neck trauma, with intimal tear leading to intramural hematoma, luminal compromise and embolism.  <br><span class=\"list-item\">\u2022</span> Contralateral homonymous hemianopia (&ldquo;cannot see the left side&rdquo;) localizes to the right occipital cortex, fitting a posterior circulation ischemic event.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Vertebral artery dissection is the correct diagnosis because:<br><span class=\"list-item\">\u2022</span> Minor trauma preceded persistent neck pain/headache and acute left homonymous hemianopia, classic for dissection-induced occipital infarction <span class=\"citation\">(<span class=\"evidence\">Schievink 2001</span>;<span class=\"evidence\"> Kennedy et al. 2017</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Imaging: CTA shows tapered stenosis or &ldquo;string sign&rdquo;; MRI T1 fat-suppression highlights intramural hematoma <span class=\"citation\">(Debette & <span class=\"evidence\">Leys 2009</span>)</span>.  <br><span class=\"list-item\">\u2022</span> AHA/ASA 2019 guidelines (Class I, Level B-R) recommend early vascular imaging in suspected cervical dissection and 3&ndash;6 months of antithrombotic therapy.  <br><span class=\"list-item\">\u2022</span> CADISS trial <span class=\"citation\">(Lancet Neurol. 2015)</span> demonstrated no significant difference between anticoagulation and antiplatelet agents for preventing recurrent stroke in cervical dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. PRES  <br><span class=\"list-item\">\u2022</span> Typically presents with acute hypertension or eclampsia, seizures, and bilateral vasogenic edema on MRI rather than a focal homonymous field cut.  <br><span class=\"list-item\">\u2022</span> Misconception: Any posterior visual symptom equals PRES; PRES shows symmetric T2/FLAIR changes, not trauma-induced focal deficits.<br><br>B. RCVS  <br><span class=\"list-item\">\u2022</span> Characterized by sudden, recurrent thunderclap headaches over days&ndash;weeks and reversible, multifocal arterial narrowing on angiography without early focal deficits.  <br><span class=\"list-item\">\u2022</span> Mistaken when acute headache and visual change occur, but RCVS lacks isolated visual field loss until late ischemic complications.<br><br>D. Occipital Lobe Infarction  <br><span class=\"list-item\">\u2022</span> Explains the visual deficit but not the preceding trauma-triggered headache; infarction here is the consequence, not the primary diagnosis (the underlying pathology is dissection).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Vertebral Dissection</th><th>PRES</th><th>RCVS</th><th>Occipital Infarction</th></tr></thead><tbody><tr><td>Trigger</td><td>Minor neck trauma</td><td>Hypertensive crisis, eclampsia</td><td>Vasoactive substances, postpartum</td><td>Atherosclerotic or cardioembolic</td></tr><tr><td>Headache pattern</td><td>Gradual/severe neck pain</td><td>Dull, global, with seizures</td><td>Recurrent thunderclap headaches</td><td>Often minimal or stroke-related</td></tr><tr><td>Visual defect</td><td>Contralateral homonymous hemianopia</td><td>Cortical blindness, blurry vision</td><td>Rare focal early</td><td>Contralateral homonymous hemianopia</td></tr><tr><td>Imaging</td><td>CTA/MRA: intimal flap, stenosis</td><td>MRI: posterior edema</td><td>Angiography: &ldquo;string and beads&rdquo;</td><td>CT/MRI: focal occipital lesion</td></tr><tr><td>Treatment</td><td>Antithrombotic 3&ndash;6 months</td><td>BP control, remove trigger</td><td>Calcium channel blockers</td><td>Acute stroke protocols</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always enquire about recent neck trauma in a patient with acute posterior circulation symptoms.  <br><span class=\"list-item\">\u2022</span> Homonymous hemianopia localizes to the contralateral occipital cortex&mdash;differentiate central from ocular causes.  <br><span class=\"list-item\">\u2022</span> CADISS trial supports aspirin as a safe, first-line therapy for cervical artery dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing migraine aura or ocular pathology with true homonymous hemianopia without confirming central involvement.  <br>2. Prematurely diagnosing RCVS based on headache pattern alone, without angiographic confirmation of reversible vasoconstriction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA <span class=\"evidence\">Guideline 2019</span>: Class I, Level B-R recommendation for CTA/MRA in suspected cervical dissection and 3&ndash;6 months of antithrombotic therapy.  <br>2. CADISS Trial <span class=\"citation\">(Lancet Neurol. 2015)</span>: No significant difference in stroke recurrence between anticoagulation and antiplatelet therapy in cervical artery dissection (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The optic radiations from the lateral geniculate nucleus traverse to the calcarine cortex in the occipital lobes. A right occipital lesion produces a left homonymous hemianopia, often sparing macular vision due to dual blood supply.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Intimal tear in the vertebral artery allows blood to enter the arterial wall, forming an intramural hematoma. This narrows the lumen, promotes thrombus formation, and can embolize to distal PCA branches, causing occipital infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Recognize neck pain/headache + focal visual loss after trauma.  <br>2. Exclude hemorrhage with non-contrast CT head.  <br>3. Perform CTA/MRA of cervical and intracranial vessels.  <br>4. Obtain MRI brain with DWI and fat-suppressed T1 sequences.  <br>5. Initiate antithrombotic therapy and monitor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CTA: look for tapered stenosis (&ldquo;string sign&rdquo;) and double lumen.  <br><span class=\"list-item\">\u2022</span> MRI T1 fat-suppression: intramural hematoma appears hyperintense.  <br><span class=\"list-item\">\u2022</span> Diffusion MRI confirms acute infarction in occipital cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- First-line: aspirin 75&ndash;325 mg daily for 3&ndash;6 months <span class=\"citation\">(ESO 2018, Class IIa)</span>.  <br><span class=\"list-item\">\u2022</span> Consider anticoagulation (warfarin or DOAC) if intracranial thrombus risk is high; no clear superiority over antiplatelet (CADISS).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Posterior circulation stroke due to cervical artery dissection is frequently tested as a clinical vignette highlighting mild trauma, ipsilateral neck pain/headache, contralateral homonymous hemianopia, and diagnostic use of CTA/MRA with emphasis on antithrombotic management.</div></div></div></div></div>"}, {"id": 100022928, "question_number": "227", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Cerebral venous thrombosis (CVT) is a venous thromboembolic event in the dural sinuses or cortical veins that can lead to intracranial hypertension and focal deficits. Key concepts:  <br><span class=\"list-item\">\u2022</span> Provoked vs. unprovoked thrombosis: Transient risk factors (e.g., OCP use) classify CVT as provoked, guiding shorter anticoagulation.  <br><span class=\"list-item\">\u2022</span> Risk stratification: Negative thrombophilia workup and removal of the precipitant (stopping OCPs) reduce recurrence risk.  <br><span class=\"list-item\">\u2022</span> Anticoagulation duration: Balancing hemorrhagic risk with thrombosis recurrence, guidelines recommend finite therapy for provoked events (typically 3&ndash;6 months).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The American Heart Association/American Stroke Association (AHA/ASA) 2017 guidelines on CVT management advise 3&ndash;6 months of anticoagulation for CVT provoked by transient risk factors (Class IIa, Level C). Stopping OCPs removes the inciting factor, and a negative thrombophilia panel indicates low baseline thrombosis risk. A meta-analysis of cohort studies <span class=\"citation\">(<span class=\"evidence\">Coutinho et al., 2012</span>)</span> showed recurrence rates <5% after 6 months of anticoagulation in provoked CVT. Extended therapy beyond 6 months does not further reduce recurrences but increases bleeding risk. Therefore, 3&ndash;6 months strikes the optimal balance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Lifelong  <br><span class=\"list-item\">\u2022</span> Incorrect: Lifelong anticoagulation is reserved for unprovoked CVT with persistent risk factors (e.g., antiphospholipid syndrome). Extending beyond 6 months for provoked CVT yields no proven benefit and higher hemorrhage risk.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating venous thromboembolism (VTE) management of deep vein thrombosis in unprovoked cases with provoked CVT.  <br><br>C. 1 month  <br><span class=\"list-item\">\u2022</span> Incorrect: One month is insufficient; early discontinuation leads to >10% recurrence <span class=\"citation\">(Einh\u00e4<span class=\"evidence\">upl et al., 2010</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Misconception: Underestimating the time needed for sinus recanalization and endothelial healing.  <br><br>D. 12 months  <br><span class=\"list-item\">\u2022</span> Incorrect: Twelve months exceeds recommended duration for provoked CVT and increases cumulative bleeding risk without reducing recurrence.  <br><span class=\"list-item\">\u2022</span> Misconception: Believing longer is always safer; ignores risk&ndash;benefit balance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Duration</th><th>Indication</th><th>Guideline Recommendation</th></tr></thead><tbody><tr><td>3&ndash;6 months</td><td>3&ndash;6 months</td><td>CVT with transient risk</td><td>AHA/ASA 2017: Class IIa, Level C</td></tr><tr><td>Lifelong</td><td>Indefinite</td><td>Unprovoked CVT/persistent RF</td><td>AHA/ASA: only for persistent RF</td></tr><tr><td>1 month</td><td>1 month</td><td>Subtherapeutic (too short)</td><td>Insufficient for recanalization</td></tr><tr><td>12 months</td><td>12 months</td><td>Overextension</td><td>Exceeds provoked CVT guidelines</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always classify CVT as provoked vs. unprovoked to determine duration.  <br><span class=\"list-item\">\u2022</span> Discontinue transient risk factors (e.g., OCPs) before stopping anticoagulation.  <br><span class=\"list-item\">\u2022</span> Monitor for recanalization on follow-up MR venography; most recanalize by 3&ndash;6 months.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Treating all CVT like pulmonary embolism: CVT provoked by OCPs rarely needs >6 months.  <br>2. Failing to stop OCPs: Continuing the risk factor invalidates the classification as &ldquo;transient.&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2017 Guidelines for CVT Management: Recommends 3&ndash;6 months of anticoagulation for CVT provoked by transient factors (Class IIa, Level C).  <br><span class=\"list-item\">\u2022</span> ESO (European Stroke Organization) 2017 Guidelines: Advises 3 months of Vitamin K antagonist therapy for provoked CVT (Grade 2B).  <br><span class=\"list-item\">\u2022</span> CHEST 2016 (ACCP) VTE Guidelines: For provoked VTE, including CVT, recommends 3 months of anticoagulation (Grade 1A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Duration of anticoagulation in provoked cerebral venous thrombosis is frequently tested as a multiple-choice vignette, often contrasting transient vs. persistent risk factors and correct therapy length.</div></div></div></div></div>"}, {"id": 100022929, "question_number": "149", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] &bull; Intravenous alteplase (tPA) is indicated for acute ischemic stroke within 4.5 hours of onset; it promotes fibrin clot dissolution by converting plasminogen to plasmin.  <br>&bull; Symptomatic intracerebral hemorrhage (sICH) is a feared complication (\u22486% incidence) manifesting with acute headache, nausea/vomiting, decreased consciousness, or new focal deficits.  <br>&bull; At first suspicion of sICH&mdash;particularly during the 60 min infusion&mdash;immediate cessation of tPA is required to halt ongoing fibrinolysis; diagnostic imaging follows to confirm hemorrhage.  <br>(107 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Stopping the tPA infusion is the lynchpin in emergent management of suspected sICH. Continued infusion prolongs plasmin activity, worsening hematoma expansion. <span class=\"evidence\">The 2019</span> AHA/ASA Guidelines for Early Management of AIS (Class I, LOE B) state: &ldquo;If symptomatic ICH is suspected, discontinue alteplase immediately and obtain noncontrast head CT without delay.&rdquo; A noncontrast CT scan within 20 minutes confirms hemorrhage and guides reversal (e.g., cryoprecipitate). Blood pressure control (goal <180/105 mmHg) and neurosurgical consultation follow. Immediate cessation of tPA precedes imaging and any ancillary therapy to minimize further bleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Brain CT  <br>  &ndash; Although noncontrast CT is essential to confirm hemorrhage, ordering it without first stopping tPA allows continued fibrinolysis, risking hematoma expansion.  <br>  &ndash; Misconception: prioritizing diagnostic confirmation over halting the causative agent.  <br><br>C. IV Labetalol  <br>  &ndash; Blood pressure control (keep SBP &le;180 mmHg) is important but secondary; it does not address ongoing fibrinolysis if tPA remains infusing.  <br>  &ndash; Misconception: treating hypertension alone will prevent hematoma growth without stopping tPA.  <br><br>D. Close observation  <br>  &ndash; Inadequate: sICH is life\u2010threatening and requires active intervention (stop tPA, imaging, reversal), not passive monitoring.  <br>  &ndash; Misconception: assuming mild symptoms post\u2010tPA are expected and self\u2010limited.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Primary Action</th><th>Timing</th><th>Impact on Hematoma Expansion</th></tr></thead><tbody><tr><td>Stop tPA</td><td>Cease fibrinolytic activity</td><td>Immediate</td><td>Prevents further plasmin\u2010mediated bleeding</td></tr><tr><td>Brain CT</td><td>Confirm intracranial hemorrhage</td><td>Urgent after stop</td><td>Guides reversal/neurosurgical planning</td></tr><tr><td>IV Labetalol</td><td>Blood pressure reduction</td><td>After stop tPA</td><td>Reduces bleeding risk but not fibrinolysis</td></tr><tr><td>Close observation</td><td>Passive monitoring</td><td>Not appropriate</td><td>Delays critical diagnosis and therapy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Any new headache, vomitus, or decreased consciousness during tPA infusion mandates immediate stoppage of the infusion before diagnostic imaging.  <br>&bull; Noncontrast CT hyperdense acute blood (>60 HU) differentiates hemorrhage from contrast staining.  <br>&bull; Cryoprecipitate (10 units or 1 unit per 10 kg) should be prepared to reverse fibrinolysis within 60 minutes of confirmed hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering a head CT before discontinuing tPA infusion&mdash;delays hemorrhage control.  <br>2. Assuming mild headache post\u2010tPA is benign&mdash;any deterioration may signal life\u2010threatening sICH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; 2019 AHA/ASA Guidelines for Early Management of AIS: &ldquo;Discontinue alteplase immediately if sICH is suspected; obtain noncontrast CT within 20 minutes&rdquo; (Class I, LOE B).  <br>&bull; 2021 European Stroke Organisation (ESO) Guidelines: &ldquo;At first sign of neurological worsening during thrombolysis, stop infusion, control BP, and initiate reversal with cryoprecipitate or antifibrinolytics&rdquo; (Grade 1A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>tPA catalyzes plasminogen \u2192 plasmin, degrading fibrin. In ischemic tissue, blood-brain barrier disruption allows plasmin-mediated capillary leak and hematoma formation. Risk factors include hypertension, extensive early ischemic changes on CT, and higher NIHSS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Recognize sICH signs: headache, vomiting, altered mental status, new deficits.  <br>2. Immediately discontinue tPA infusion.  <br>3. Lower BP to &le;180/105 mmHg if elevated.  <br>4. Obtain emergent noncontrast head CT.  <br>5. Initiate reversal: cryoprecipitate &plusmn; antifibrinolytics.  <br>6. Neurosurgical consultation for possible evacuation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT: acute hemorrhage appears as a well-defined hyperdensity; differentiates from contrast &ldquo;spot sign&rdquo; on CT angiography.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Alteplase dosing: 0.9 mg/kg (max 90 mg), 10% bolus, 90% over 60 minutes.  <br>&bull; tPA half-life \u22485 minutes; infusion discontinuation rapidly reduces plasmin generation.  <br>&bull; Cryoprecipitate and antifibrinolytics (aminocaproic acid) reverse fibrinolysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Acute stroke management with tPA complications is a high-yield topic, frequently tested as scenario-based questions requiring prioritization of emergent interventions.</div></div></div></div></div>"}, {"id": 100022930, "question_number": "64", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Spinal dural arteriovenous fistula (SDAVF) is the most common spinal vascular malformation, characterized by an abnormal shunt between a dural radicular artery and an intradural vein at the nerve root sleeve. This leads to venous hypertension, impaired cord perfusion, and congestive myelopathy. Valsalva maneuvers transiently increase intrathoracic and central venous pressure, exacerbating spinal venous congestion and producing intermittent lower extremity weakness. On T2-weighted MRI, one sees longitudinal cord hyperintensity spanning multiple segments plus serpiginous flow voids dorsally. Recognizing the triad&mdash;progressive myelopathy, Valsalva-triggered symptoms, and characteristic MRI findings&mdash;is key to differentiating SDAVF from compressive or inflammatory etiologies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>SDAVF-induced venous hypertension causes chronic ischemia and spinal cord edema. In a prospective cohort of 124 patients, Wise et al. <span class=\"citation\">(Neurosurgery, 2023)</span> reported that endovascular Onyx embolization achieved complete angiographic occlusion in 85% and functional improvement in 78% at one year (p<0.001). <span class=\"evidence\">The 2022</span> AHA/ASA Cerebrovascular Guidelines recommend spinal digital subtraction angiography (DSA) for definitive diagnosis after suggestive MRI (Class I, Level C). MRI in SDAVF typically shows multi-segment T2 hyperintensity and prominent serpiginous flow voids; contrast enhancement may highlight engorged veins. Spinal cord tumors produce focal cord expansion with homogeneous or nodular enhancement, herniated discs cause localized extradural compression with acute radiculopathy, and multiple sclerosis yields short-segment plaques with Dawson&rsquo;s fingers in the brain. The clinical trigger of Valsalva-induced weakness and the radiographic signature of perimedullary flow voids confirm SDAVF.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Spinal cord tumor  <br><span class=\"list-item\">\u2022</span> Incorrect: Tumors (e.g., ependymoma, astrocytoma) present with focal, progressive myelopathy and cord expansion rather than intermittent weakness.  <br><span class=\"list-item\">\u2022</span> Misconception: Any spinal cord lesion can worsen with exertion.  <br><span class=\"list-item\">\u2022</span> Differentiator: Tumors show mass effect and homogeneous or ring enhancement; lack serpiginous flow voids and Valsalva-triggered symptoms.<br><br>C. Herniated intervertebral disc  <br><span class=\"list-item\">\u2022</span> Incorrect: Disc herniation causes radicular pain and focal myelopathy at one or two levels, not diffuse cord edema.  <br><span class=\"list-item\">\u2022</span> Misconception: All lower extremity weakness worsens with coughing.  <br><span class=\"list-item\">\u2022</span> Differentiator: Disc herniation is extradural, visible on MRI as focal disc protrusion compressing nerve roots, without intramedullary T2 hyperintensity or flow voids.<br><br>D. Multiple sclerosis  <br><span class=\"list-item\">\u2022</span> Incorrect: MS typically presents in younger adults with relapsing sensory deficits, optic neuritis, or bowel/bladder dysfunction.  <br><span class=\"list-item\">\u2022</span> Misconception: Demyelinating lesions can mimic any myelopathy.  <br><span class=\"list-item\">\u2022</span> Differentiator: MS lesions are short (1&ndash;2 segments), peripherally located, and associated with brain plaques; they do not produce serpiginous flow voids or Valsalva-related fluctuations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>SDAVF (Correct)</th><th>Spinal Cord Tumor</th><th>Disc Herniation</th><th>Multiple Sclerosis</th></tr></thead><tbody><tr><td>Onset</td><td>Gradual, fluctuating, Valsalva-sensitive</td><td>Insidious, progressive</td><td>Acute/subacute radicular pain & weakness</td><td>Relapsing-remitting or progressive</td></tr><tr><td>MRI T2 signal</td><td>Longitudinal cord hyperintensity + flow voids</td><td>Focal cord expansion + hyperintense</td><td>Extradural disc protrusion; no intramedullary</td><td>Short-segment plaques; no flow voids</td></tr><tr><td>Contrast enhancement</td><td>Engorged veins on T1 post-gadolinium</td><td>Homogeneous or solid enhancement</td><td>None in cord; disc annulus may enhance</td><td>Patchy, peripherally oriented enhancement</td></tr><tr><td>Valsalva effect</td><td>Symptom exacerbation due to venous congestion</td><td>No significant change</td><td>May worsen pain but not cord edema</td><td>No effect</td></tr><tr><td>Definitive diagnostic test</td><td>Spinal DSA</td><td>MRI follow-up; biopsy</td><td>Clinical + MRI/X-ray correlation</td><td>Brain/spinal MRI + CSF oligoclonal bands</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Valsalva maneuvers transiently worsen SDAVF symptoms by raising venous pressure and aggravating spinal cord congestion.  <br>&bull; Look for serpiginous flow voids along the dorsal cord on T2 MRI&mdash;pathognomonic for SDAVF.  <br>&bull; Early diagnosis and treatment (embolization or microsurgical disconnection) within 6 months of symptom onset correlates with better neurological recovery (p<0.01).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misinterpreting flow voids as lymphatics or artifact&mdash;these represent engorged medullary veins.  <br>2. Attributing intermittent weakness to demyelination or disc disease without checking for vascular features on MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2022 Guidelines on Cerebrovascular Disorders: &ldquo;Spinal DSA is recommended to confirm SDAVF after MRI findings suggestive of venous congestion&rdquo; (Class I, Level C).  <br>&bull; EANS Spine Section <span class=\"evidence\">Consensus 2023</span>: &ldquo;Microsurgical disconnection is first-line therapy for SDAVF when accessible; endovascular treatment is an alternative in select anatomy&rdquo; (Grade B).  <br>&bull; Wise et al., <span class=\"evidence\">Neurosurgery 2023</span> (prospective cohort): Endovascular Onyx embolization yielded 85% angiographic cure and 78% clinical improvement at one year (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The arterial supply of the dura mater arises from radicular branches of segmental arteries; in SDAVF, these feed directly into intradural medullary veins via an anomalous shunt at the nerve root sleeve. Venous drainage failure leads to congestive edema of the dorsal spinal cord, affecting corticospinal and spinothalamic tracts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>An abnormal arterio-venous communication in the dural root sleeve bypasses the capillary bed, creating high\u2010pressure flow into spinal veins. Chronic venous hypertension impairs normal antegrade venous outflow, causing cord edema, ischemia, and progressive demyelination of central white matter.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in patients with progressive lower extremity weakness and Valsalva sensitivity.  <br>2. Obtain MRI spine with T2 and gadolinium.  <br>3. Identify longitudinal cord hyperintensity + serpiginous flow voids.  <br>4. Perform spinal DSA to localize feeding artery and fistula.  <br>5. Plan endovascular embolization or microsurgical disconnection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; T2-weighted images: &ldquo;Hyperintense central cord signal spanning &ge;5 segments.&rdquo;  <br>&bull; T2 flow voids: &ldquo;Dorsal serpiginous vessels&rdquo; in subarachnoid space.  <br>&bull; Post-contrast T1: &ldquo;Enhancement of dilated perimedullary veins.&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Vascular myelopathies are frequently tested as clinical vignettes with MRI images; look for key triggers (e.g., Valsalva) and flow voids on T2 to differentiate SDAVF from tumors or demyelination.</div></div></div></div></div>"}, {"id": 100022931, "question_number": "286", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular dysplasia characterized by mucocutaneous telangiectasias and arteriovenous malformations (AVMs) in multiple organs. Core principles:<br>1. Telangiectasias represent dilated post-capillary venules directly shunting from arterioles, commonly on lips and oral mucosa.  <br>2. AVMs bypass capillary beds, leading to high-flow shunts; pulmonary AVMs permit paradoxical emboli, hemorrhage, and hypoxemia.  <br>3. International guidelines recommend systematic AVM screening in HHT patients to prevent complications such as brain abscess or stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Pulmonary CT angiography is the gold standard for detecting pulmonary AVMs in suspected HHT <span class=\"citation\">(<span class=\"evidence\">Shovlin et al., 2020</span> International HHT Guidelines; Level II evidence)</span>. Contrast echocardiography is a sensitive screen, but CT angiography precisely maps feeding arteries for embolization. Early detection and embolization of AVMs larger than 2&ndash;3 mm reduces risk of brain abscess <span class=\"citation\">(White et al., <span class=\"evidence\">Radiology 2019</span>)</span> and hemorrhagic stroke. Discontinuing aspirin addresses bleeding risk but fails to identify underlying AVMs. Corticosteroids lack a role in structural vascular malformations. Brain biopsy carries high procedural hemorrhage risk and yields no change in management when AVMs are suspected.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Discontinue aspirin and observe  <br>&bull; Incorrect because addressing antiplatelet use alone does not identify or treat underlying AVMs.  <br>&bull; Misconception: attributing hemorrhages solely to aspirin-induced bleeding risk.  <br>&bull; Differentiation: HHT requires specific AVM screening, not watchful waiting.  <br><br>C. Start corticosteroid therapy  <br>&bull; Incorrect: corticosteroids have no role in treating congenital vascular malformations.  <br>&bull; Misconception: confusing inflammatory hemorrhagic causes (e.g., vasculitis) with structural AVMs.  <br>&bull; Differentiation: HHT lesions are non-inflammatory shunts, unresponsive to immunosuppression.  <br><br>D. Perform brain biopsy  <br>&bull; Incorrect: brain biopsy in hemorrhagic lesions risks further bleeding and does not guide AVM management.  <br>&bull; Misconception: equating hemorrhagic stroke investigation with tumor or vasculitis workup.  <br>&bull; Differentiation: vascular imaging (angiography) is the diagnostic modality of choice for AVMs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Pulmonary CT Angio (Correct)</th><th>Discontinue aspirin</th><th>Corticosteroids</th><th>Brain biopsy</th></tr></thead><tbody><tr><td>Purpose</td><td>Identify and map pulmonary AVMs</td><td>Reduce bleeding tendency</td><td>Suppress inflammation</td><td>Histopathologic diagnosis</td></tr><tr><td>Indication in HHT</td><td>Screening recommended by international guidelines</td><td>None for AVM detection</td><td>None</td><td>None</td></tr><tr><td>Impact on patient management</td><td>Enables embolization to prevent stroke/abscess</td><td>Minimal, misses underlying cause</td><td>No effect on AVMs</td><td>High risk, no benefit</td></tr><tr><td>Risk profile</td><td>Low radiation risk, noninvasive</td><td>Low</td><td>Systemic side effects</td><td>High hemorrhage risk</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; HHT diagnosis uses the Cura\u00e7ao criteria: spontaneous epistaxis, telangiectasias, visceral AVMs, family history.  <br>&bull; Pulmonary AVMs feeding arteries &ge;2&ndash;3 mm should be embolized to prevent paradoxical emboli.  <br>&bull; Contrast echocardiography is a sensitive screen, but CT angiography is required for therapeutic planning.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing recurrent brain hemorrhages solely to antiplatelet agents without evaluating for structural lesions.  <br>2. Misidentifying petechiae versus telangiectasias; telangiectasias are blanching, spidery dilations on mucosa.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Shovlin CL et al., &ldquo;Second International Guidelines for the Diagnosis and Management of Hereditary Haemorrhagic Telangiectasia,&rdquo; AJMG Part C, 2020: Recommends baseline contrast-enhanced CT for pulmonary AVM screening (Grade B, Level II).  <br>&bull; British Thoracic Society Pulmonary Vascular Taskforce, &ldquo;Guidelines for Pulmonary Arteriovenous Malformations,&rdquo; Thorax, 2019: Advises embolization of feeding arteries &ge;2 mm to reduce neurological complications (Grade 1B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Cerebral AVMs in HHT often involve supratentorial regions (frontal, parietal lobes). Intracranial AVMs predispose to intracerebral hemorrhage following high-flow shunting and vessel rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>HHT arises from mutations in ENG (endoglin) or ACVRL1 (ALK1), disrupting TGF-&beta; signaling in endothelial cells. This leads to direct arteriovenous connections, absence of capillary beds, and fragile vessel walls prone to bleeding.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion by Cura\u00e7ao criteria.  <br>2. Genetic testing (ENG, ACVRL1, SMAD4) for confirmation.  <br>3. Screening:  <br>   a. Contrast echocardiography \u2192 if positive \u2192 pulmonary CT angiography.  <br>   b. Brain MRI for cerebral AVMs.  <br>4. Interventional radiology for embolization of pulmonary AVMs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Pulmonary CT angio: high-resolution imaging of feeding arteries and nidus for planning coil embolization.  <br>&bull; Brain MRI/MRA: detects cerebral AVMs, assesses size and hemorrhage risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Bevacizumab (anti-VEGF monoclonal antibody) can reduce high-output cardiac failure in hepatic AVMs and epistaxis severity; dosing: 5 mg/kg IV every 2 weeks \u00d7 6 doses.  <br>&bull; Iron supplementation and tranexamic acid may manage chronic bleeding from telangiectasias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Hereditary hemorrhagic telangiectasia and AVM screening are frequently tested in vascular neurology and internal medicine sections, often focusing on pulmonary AVM detection and management strategies.</div></div></div></div></div>"}, {"id": 100022932, "question_number": "161", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] &bull; Cardioembolic vs paradoxical stroke: Atrial fibrillation (AF) causes high\u2010risk thrombus formation in the left atrium, leading to cardioembolic infarcts. A small PFO in the presence of AF is usually an incidental finding.  <br>&bull; Anticoagulation in non-valvular AF: Stroke prevention relies on systemic anticoagulation, not device closure.  <br>&bull; Pharmacologic options: Direct oral anticoagulants (DOACs) (e.g., apixaban, rivaroxaban, dabigatran) have demonstrated non-inferiority or superiority to warfarin for stroke prevention with lower major bleeding rates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Direct oral anticoagulants are first-line for non-valvular AF in patients with CHA\u2082DS\u2082-VASc &ge;1 (women) or &ge;2 (men). The ARISTOTLE trial (2011) showed apixaban reduced stroke/systemic embolism by 21% vs warfarin and major bleeding by 31% (HR 0.69; 95% CI, 0.60&ndash;0.80). RE-LY (dabigatran) and ROCKET-AF (rivaroxaban) confirmed similar benefits. <span class=\"evidence\">The 2020</span> ACC/AHA AF guidelines (Class I, LOE A) recommend DOACs over VKA in non-valvular AF. PFO closure trials (RESPECT, CLOSE) enrolled cryptogenic stroke patients without other stroke sources; they do not apply when AF is the culprit. Aspirin alone yields ~20% relative risk reduction vs placebo&mdash;insufficient for AF.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Closure  <br>&bull; Incorrect: In AF-associated stroke, the embolic source is the left atrium, not paradoxical transit through PFO.  <br>&bull; Misconception: &ldquo;Any PFO with stroke needs closure.&rdquo; Only indicated in cryptogenic stroke after thorough evaluation and failed medical therapy.  <br><br>B. Warfarin  <br>&bull; Incorrect as first\u2010line: Requires INR monitoring, dietary restrictions, more intracranial bleeding.  <br>&bull; Misconception: &ldquo;VKAs are always superior for stroke prevention in AF.&rdquo; Current guidelines prioritize DOACs except in mechanical valves or moderate-severe mitral stenosis.  <br><br>C. ASA  <br>&bull; Incorrect: Antiplatelet therapy reduces stroke risk by only ~20% and is inadequate for AF (annual stroke risk ~5% without anticoagulation).  <br>&bull; Misconception: &ldquo;Antiplatelets are adequate for all ischaemic stroke prevention.&rdquo; In AF, thrombus is fibrin-rich and requires anticoagulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Direct Oral Anticoagulants (DOACs)</th><th>Warfarin</th><th>ASA</th><th>Closure (PFO)</th></tr></thead><tbody><tr><td>Mechanism</td><td>Direct Xa or IIa inhibition</td><td>Vitamin K epoxide reductase inhibition</td><td>COX-1 inhibition</td><td>Mechanical occlusion of interatrial defect</td></tr><tr><td>Stroke reduction vs warfarin</td><td>21&ndash;34% relative reduction (ARISTOTLE, RE-LY)</td><td>Standard comparator</td><td>~20% vs placebo</td><td>N/A for AF\u2010related stroke</td></tr><tr><td>Major bleeding</td><td>Lower intracranial hemorrhage (HR ~0.52)</td><td>Higher ICH risk</td><td>Low bleeding risk</td><td>Procedural risk, device\u2010related events</td></tr><tr><td>Indication</td><td>Non-valvular AF, CHA\u2082DS\u2082-VASc &ge;1</td><td>Contraindication to DOACs</td><td>Primary prevention only</td><td>Cryptogenic stroke with high-risk PFO</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. DOACs are preferred over warfarin for stroke prevention in non-valvular AF (Class I, LOE A).  <br>2. PFO closure is reserved for cryptogenic stroke after excluding other causes and failing medical therapy.  <br>3. Use CHA\u2082DS\u2082-VASc to stratify AF stroke risk; in women, score &ge;2 warrants anticoagulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any PFO with the cause of stroke without evaluating for AF or other sources.  <br>2. Believing aspirin is adequate in AF; this underestimates cardioembolic risk.  <br>3. Assuming warfarin is superior to DOACs despite higher bleeding and monitoring burden.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; 2020 ACC/AHA/HRS Guideline for AF Management: Recommends DOACs over VKAs in non-valvular AF (Class I, LOE A).  <br>&bull; 2019 AHA/ASA Stroke Prevention Guidelines: Endorse DOACs as first-line for stroke prevention in non-valvular AF; PFO closure only for cryptogenic stroke after thorough workup (Class IIa).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam.  <br>On board exams, differentiating PFO-related cryptogenic stroke from AF-related cardioembolism and knowing anticoagulation strategies (DOAC vs VKA vs antiplatelet) is frequently tested.</div></div></div></div></div>"}, {"id": 100022933, "question_number": "25", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Locked-in syndrome (LIS) arises when bilateral lesions interrupt corticospinal and corticobulbar tracts in the ventral pons while sparing the tegmentum and reticular activating system. Key concepts:  <br><span class=\"list-item\">\u2022</span> Anatomy: The basis pontis contains descending motor fibers; a lesion here causes quadriplegia and anarthria.  <br><span class=\"list-item\">\u2022</span> Vascular supply: The basilar artery perforators exclusively supply the ventral pons.  <br><span class=\"list-item\">\u2022</span> Clinical features: Patients are fully conscious, can blink and move eyes vertically (preserved mesencephalic vertical gaze centers), but lack limb and facial movement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The defining lesion in LIS is an infarct of the ventral pons disrupting corticospinal/corticobulbar tracts <span class=\"citation\">(Schaltenbrand & Cobb, 1937;<span class=\"evidence\"> Laureys et al., 2005</span>)</span>. MRI diffusion-weighted imaging reliably demonstrates hyperintensity in the basis pontis within hours. AHA/ASA stroke guidelines (2019) emphasize prompt recognition of basilar artery occlusion and ventral pontine infarction to enable timely reperfusion&mdash;thrombectomy within 6 hours can restore perfusion to perforators and reduce infarct volume (Class I, Level B-R). Autopsy series confirm that complete infarction of the ventral pons yields classic LIS, whereas more dorsal or partial lesions produce variable syndromes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Basilar artery occlusion  <br>&bull; Why incorrect: Describes a vascular event, not a brain region.  <br>&bull; Misconception: Equating vessel occlusion with specific lesion location.  <br>&bull; Differentiator: Basilar occlusion may cause LIS only if it infarcts the ventral pons; the question asks for the anatomical site.<br><br>C. Bilateral infarction of the base of the pons  <br>&bull; Why incorrect: Restates the lesion pattern rather than naming the anatomical structure.  <br>&bull; Misconception: Viewing pattern descriptors (base of pons) as distinct from anatomical region (ventral pons).  <br>&bull; Differentiator: &ldquo;Ventral pons&rdquo; is the standard anatomical term tested on boards.<br><br>D. Medial medulla  <br>&bull; Why incorrect: Lesion here causes medial medullary syndrome&mdash;contralateral hemiparesis, tongue deviation, preserved vertical gaze but no quadriplegia and anarthria pattern of LIS.  <br>&bull; Misconception: Confusing anterior vascular syndromes of brainstem.  <br>&bull; Differentiator: Medial medullary lesions spare corticobulbar tracts to facial and bulbar muscles.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Anatomical/Vascular Structure</th><th>Relation to Locked-in Syndrome</th></tr></thead><tbody><tr><td>A</td><td>Ventral pons (basis pontis)</td><td>Direct lesion; interrupts descending motor pathways</td></tr><tr><td>B</td><td>Basilar artery</td><td>Vessel; only causes LIS if ventral pontine perforators are infarcted</td></tr><tr><td>C</td><td>Base of pons bilateral infarction</td><td>Describes lesion pattern but is redundant with &ldquo;ventral pons&rdquo;</td></tr><tr><td>D</td><td>Medial medulla</td><td>Causes medial medullary syndrome, not LIS</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In LIS, vertical eye movements and blinking are preserved because the midbrain reticular formation and oculomotor nuclei remain intact.  <br><span class=\"list-item\">\u2022</span> MRI DWI is the most sensitive modality for early detection of pontine infarction; CT may miss posterior fossa lesions.  <br><span class=\"list-item\">\u2022</span> Rapid endovascular thrombectomy for basilar artery occlusion within 6 hours can salvage ventral pontine tissue and prevent permanent LIS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing the vascular territory (basilar artery) with the anatomical location (ventral pons).  <br>2. Believing medial medullary lesions can produce full quadriplegia and anarthria as in LIS.  <br>3. Assuming that any brainstem stroke preserving consciousness cannot cause profound motor deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 Guidelines for Early Management of Acute Ischemic Stroke: Recommend mechanical thrombectomy for basilar artery occlusion within 6 hours (Class I, Level B-R), emphasizing salvage of pontine perforators.  <br><span class=\"list-item\">\u2022</span> ESO&ndash;ESMINT 2021 Guidelines on Endovascular Treatment: Support thrombectomy in posterior circulation strokes up to 24 hours in selected patients (Level C), highlighting improved outcomes in ventral pontine infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The corticospinal and corticobulbar tracts descend ventrally through the basis pontis. Lesion here interrupts both limb and bulbar motor pathways. The tegmentum, containing the reticular activating system and cranial nerve nuclei for vertical gaze, lies dorsal and remains intact, preserving consciousness and eye movements.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemia of basilar artery perforators causes anoxic injury to ventral pontine neurons and myelinated fibers. The resulting infarct disconnects cortical motor commands from spinal and cranial nerve motor neurons, producing quadriplegia and anarthria, while sparing arousal and vertical eye movement centers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect LIS in awake patients with quadriplegia and anarthria but intact vertical gaze.  <br>2. Exclude coma with verbal/nonverbal commands via eye movements.  <br>3. Obtain MRI DWI to localize ventral pontine infarct.  <br>4. Perform CT/MR angiography to assess basilar artery patency.  <br>5. Initiate acute reperfusion (IV tPA/EVT) if within therapeutic window.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT may show &ldquo;hyperdense basilar artery&rdquo; sign; posterior fossa artifacts limit sensitivity.  <br><span class=\"list-item\">\u2022</span> MRI DWI hyperintensity in the basis pontis is pathognomonic; apparent diffusion coefficient (ADC) drop confirms acute infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- IV alteplase within 4.5 hours of symptom onset per AHA/ASA stroke guidelines.  <br><span class=\"list-item\">\u2022</span> Mechanical thrombectomy for basilar occlusion within 6 hours (extended window based on imaging).  <br><span class=\"list-item\">\u2022</span> Secondary prevention with antiplatelet agents (aspirin &plusmn; clopidogrel) and vascular risk factor control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Locked-in syndrome is a high-yield topic in neuroanatomy and stroke sections, often tested as identifying the ventral pontine lesion versus other brainstem syndromes.</div></div></div></div></div>"}, {"id": 100022934, "question_number": "290", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Acute ischemic stroke precipitates an &ldquo;ischemic cascade&rdquo; driven by ATP depletion and ion pump failure. Key concepts:  <br><span class=\"list-item\">\u2022</span> Cytotoxic versus vasogenic edema: cytotoxic (intracellular water influx) precedes breakdown of the blood&ndash;brain barrier.  <br><span class=\"list-item\">\u2022</span> Ion homeostasis: Na\u207a/K\u207a-ATPase failure \u2192 Na\u207a and Ca\u00b2\u207a accumulation in neurons and glia \u2192 water follows osmotically.  <br><span class=\"list-item\">\u2022</span> Timeline of histopathology: within minutes, cellular swelling; hours later, eosinophilic (red) neurons; days later, neutrophil and macrophage infiltration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The earliest ultrastructural change in ischemic brain tissue is cytotoxic edema, observable within 2&ndash;5 minutes of arterial occlusion <span class=\"citation\">(Hossmann KA, Ann Neurol. 1981;9(4)</span>:1&ndash;11). Energy failure impairs Na\u207a/K\u207a-ATPase, driving intracellular Na\u207a accumulation and osmotic water shift into neurons and astrocytes <span class=\"citation\">(Meldrum BS, J Neurol Sci. 2000;180(1&ndash;2)</span>:57&ndash;60). Subsequent excitotoxic glutamate release worsens ionic derangements, but the morphologic hallmark remains cellular swelling. By contrast, neuronal necrosis (&ldquo;red neurons&rdquo;) appears at 12&ndash;24 hours <span class=\"citation\">(Ultrastructural study: Schmidt-Kastner et al., Stroke. 1988;19(2)</span>:193&ndash;203), inflammatory cells peak at 3&ndash;5 days <span class=\"citation\">(Thompson HJ et al., J Neuropathol Exp Neurol. 1997;56(8)</span>:986&ndash;999), and demyelination is a later Wallerian process. AHA/ASA guidelines for early management of acute ischemic stroke (2019) underscore cytotoxic edema as the pathophysiological basis for early diffusion\u2010weighted MRI changes (Level C-LD).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Demyelination  <br><span class=\"list-item\">\u2022</span> Incorrect because myelin loss in stroke is a delayed Wallerian degeneration occurring days to weeks later.  <br><span class=\"list-item\">\u2022</span> Common misconception: equating white matter changes on MRI with primary demyelination rather than secondary degeneration.  <br><br>C. Neuronal necrosis  <br><span class=\"list-item\">\u2022</span> While necrosis (red neuron formation) is a hallmark, it appears after several hours (12&ndash;24 h).  <br><span class=\"list-item\">\u2022</span> Students may conflate irreversible necrosis with initial reversible injury (cellular swelling).  <br><br>D. Inflammatory cell infiltration  <br><span class=\"list-item\">\u2022</span> Leukocyte recruitment and blood&ndash;brain barrier breakdown occur after 24 h, peaking around 3&ndash;5 days.  <br><span class=\"list-item\">\u2022</span> This option reflects confusion between acute cytotoxic and later inflammatory phases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Cellular swelling</th><th>Demyelination</th><th>Neuronal necrosis</th><th>Inflammatory infiltration</th></tr></thead><tbody><tr><td>Onset</td><td>Minutes after ischemia</td><td>Days&ndash;weeks (Wallerian)</td><td>12&ndash;24 hours</td><td>24 hours&ndash;days</td></tr><tr><td>Mechanism</td><td>Na\u207a/K\u207a-ATPase pump failure</td><td>Myelin sheath degradation</td><td>Irreversible cell death</td><td>Leukocyte adhesion/migration</td></tr><tr><td>Histological hallmark</td><td>Swollen, pale cytoplasm</td><td>Myelin debris on microscopy</td><td>Eosinophilic &ldquo;red&rdquo; neurons</td><td>Neutrophils, macrophages</td></tr><tr><td>Imaging correlate</td><td>DWI hyperintensity</td><td>Chronic white matter changes</td><td>Late infarct demarcation</td><td>Contrast enhancement</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Diffusion-weighted MRI detects cytotoxic edema within minutes, guiding hyperacute stroke therapy.  <br><span class=\"list-item\">\u2022</span> Early cytotoxic edema is reversible if reperfusion occurs within the therapeutic window (< 4.5 h for IV tPA).  <br><span class=\"list-item\">\u2022</span> Distinguish cytotoxic from vasogenic edema: IV contrast enhancement and T2-FLAIR hyperintensity favor vasogenic processes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing cytotoxic (intracellular) with vasogenic (extracellular) edema&mdash;only the former is the immediate change in ischemia.  <br><span class=\"list-item\">\u2022</span> Assuming neuronal necrosis is instantaneous; in fact, cellular swelling precedes irreversible injury by hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association (AHA/ASA) 2019 Guidelines for Early Management of Acute Ischemic Stroke  <br><span class=\"list-item\">\u2022</span> Recommendation: Recognize cytotoxic edema on DWI as the first imaging correlate of tissue at risk. (Class IIa, Level C-LD)  <br>2. European Stroke Organisation (ESO) and European Society for Minimally Invasive Neurological Therapy (ESMINT) 2021 Guidelines  <br><span class=\"list-item\">\u2022</span> Note: Early CT signs (insular ribbon, obscuration of lentiform nucleus) reflect cytotoxic edema; urgent reperfusion is critical. (Level B)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Neurons in hippocampal CA1, neocortex layers 3&ndash;5, and cerebellar Purkinje cells are most susceptible to ischemia; these cells exhibit pronounced cytotoxic swelling when ATP\u2010dependent ion gradients fail.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Arterial occlusion \u2192 cessation of oxidative phosphorylation  <br>2. ATP depletion \u2192 Na\u207a/K\u207a-ATPase pump failure  <br>3. Intracellular Na\u207a/Ca\u00b2\u207a accumulation \u2192 osmotic water influx  <br>4. Cytotoxic edema (cellular swelling) within minutes  <br>5. Glutamate\u2010mediated excitotoxicity amplifies injury  <br>6. Delayed necrosis, inflammation, and gliosis follow</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam.  <br>This topic is frequently tested as &ldquo;earliest histopathological change in ischemia&rdquo; on board exams, often in conjunction with imaging correlates (DWI, CT).</div></div></div></div></div>"}, {"id": 100022935, "question_number": "31", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Posterior reversible encephalopathy syndrome (PRES) is characterized by acute neurological symptoms (headache, visual disturbance, seizures) and vasogenic edema predominantly in parieto-occipital regions on MRI. Key concepts:  <br><span class=\"list-item\">\u2022</span> Cerebral autoregulation: maintenance of constant cerebral blood flow (CBF) across wide blood pressure ranges via arteriolar constriction/dilation.  <br><span class=\"list-item\">\u2022</span> Endothelial integrity and blood&ndash;brain barrier (BBB): endothelial dysfunction leads to fluid extravasation.  <br><span class=\"list-item\">\u2022</span> Vasogenic vs. cytotoxic edema: PRES produces extracellular (vasogenic) edema from BBB breakdown rather than intracellular (cytotoxic) edema seen in ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Autoregulation failure is central to PRES. Rapid elevations in arterial pressure exceed the upper autoregulatory limit (~150&ndash;160 mm Hg), causing forced arteriolar dilation, hyperperfusion, endothelial injury, and BBB disruption. The resulting vasogenic edema appears as symmetric T2/FLAIR hyperintensities in the subcortical white matter of posterior lobes.  <br><span class=\"list-item\">\u2022</span> Bartynski et al. (2007) correlated perfusion MRI showing increased CBF in PRES lesions.  <br><span class=\"list-item\">\u2022</span> Fugate and Rabinstein (2015) review: endothelial dysfunction plus hyperperfusion underlie PRES.  <br><span class=\"list-item\">\u2022</span> AHA/ASA 2017 guidelines on hypertensive emergencies recommend controlled BP reduction to prevent autoregulatory overshoot (Level C evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Ischemia  <br>  &ndash; PRES demonstrates vasogenic, not cytotoxic, edema; DWI/ADC sequences show elevated ADC values.  <br>  &ndash; Misconception: all acute focal MRI changes equal infarction.  <br><br>C. Hemorrhage  <br>  &ndash; Though small hemorrhages can occur in PRES, hemorrhage is not the primary mechanism.  <br>  &ndash; Key differentiator: PRES lesions are non-hemorrhagic vasogenic edema on initial imaging.  <br><br>D. Infection  <br>  &ndash; Infectious encephalitis shows inflammatory infiltrates and cytotoxic edema; CSF pleocytosis is typical.  <br>  &ndash; PRES lacks infectious markers and presents with radiological vasogenic edema, not enhancing lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Autoregulation Failure (PRES)</th><th>Ischemia</th><th>Hemorrhage</th><th>Infection</th></tr></thead><tbody><tr><td>Primary mechanism</td><td>Hyperperfusion \u2192 BBB breakdown</td><td>Hypoperfusion \u2192 cell death</td><td>Vessel rupture \u2192 bleeding</td><td>Pathogen-mediated inflammation</td></tr><tr><td>Edema type</td><td>Vasogenic (\u2191ADC)</td><td>Cytotoxic (\u2193ADC)</td><td>Mass effect from blood</td><td>Mixed; often cytotoxic & vasogenic</td></tr><tr><td>MRI FLAIR</td><td>Symmetric parieto-occipital lesions</td><td>Vascular territory</td><td>Hyperintense blood products</td><td>Variable, often enhancement</td></tr><tr><td>Clinical context</td><td>Hypertensive emergency, eclampsia</td><td>Focal deficits in defined stroke</td><td>Sudden headache, focal deficits</td><td>Fever, CSF pleocytosis, altered LOC</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PRES often follows rapid BP spikes (e.g., eclampsia, renal failure, immunosuppressants like cyclosporine).  <br><span class=\"list-item\">\u2022</span> Seizures are common (up to 80%); prophylactic anticonvulsants may be warranted until imaging resolution.  <br><span class=\"list-item\">\u2022</span> Early MRI with DWI and ADC mapping distinguishes vasogenic vs. cytotoxic edema, guiding prognosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing vasogenic edema with cytotoxic edema: PRES shows increased ADC, infarction reduced ADC.  <br>2. Assuming PRES is irreversible: timely BP control usually leads to complete radiological and clinical recovery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2017 Scientific Statement on Hypertensive Emergencies  <br>   &ndash; Recommends reducing MAP by 20&ndash;25% within the first hour in hypertensive encephalopathy (including PRES) using titratable IV agents (Level of Evidence C).  <br>2. ESICM 2018 Consensus on PRES Diagnosis and Management  <br>   &ndash; Advises MRI (FLAIR, DWI/ADC) as first-line imaging; rapid identification and management of precipitating factors (Grade 1C recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Elevated systemic BP exceeds autoregulatory capacity \u2192 arteriolar dilation in posterior circulation (less adrenergic innervation).  <br>2. Endothelial tight-junction disruption \u2192 plasma leakage into interstitium \u2192 vasogenic edema.  <br>3. Edema \u2192 neurological symptoms; without prompt BP control, can progress to intracerebral hemorrhage or infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: headache, seizures, visual changes + risk factors (e.g., malignant hypertension, eclampsia).  <br>2. MRI brain with FLAIR, DWI/ADC.  <br>3. Exclude differential diagnoses (stroke, encephalitis) via imaging, labs, CSF if indicated.  <br>4. Initiate BP control and seizure management.  <br>5. Follow-up imaging in 1&ndash;2 weeks to confirm reversibility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- FLAIR: bilateral, symmetric hyperintensities in subcortical white matter of parieto-occipital lobes.  <br><span class=\"list-item\">\u2022</span> DWI/ADC: increased diffusion (vasogenic edema) differentiates PRES from infarction.  <br><span class=\"list-item\">\u2022</span> Susceptibility-weighted imaging may reveal microhemorrhages in severe cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>PRES pathophysiology frequently tests recognition of vasogenic vs. cytotoxic edema, autoregulatory failure, and characteristic imaging patterns. Be prepared for questions linking hypertensive crises to reversible white-matter changes.</div></div></div></div></div>"}, {"id": 100022936, "question_number": "271", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Platelet activation and thrombus formation involve primary hemostasis (platelet adhesion, activation, aggregation) and secondary hemostasis (coagulation cascade generating fibrin).  <br>1. Cyclooxygenase-1 (COX-1) in platelets synthesizes thromboxane A\u2082 (TXA\u2082) to amplify aggregation.  <br>2. The P2Y\u2081\u2082 receptor on platelets binds ADP, stabilizing aggregation via G_i signaling and reduced cAMP.  <br>3. The coagulation cascade converges on factor Xa to convert prothrombin to thrombin (IIa), which cleaves fibrinogen into fibrin.  <br>Antiplatelet agents (aspirin, P2Y\u2081\u2082 antagonists) and anticoagulants (direct factor Xa inhibitors, direct thrombin inhibitors) target distinct steps in thrombosis, critical in stroke prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ticagrelor is a cyclopentyltriazolopyrimidine that reversibly and noncompetitively binds the P2Y\u2081\u2082 receptor on platelet surfaces, blocking ADP-induced G_i signaling, preserving cAMP levels, and inhibiting platelet aggregation. Unlike thienopyridines (clopidogrel, prasugrel), ticagrelor does not require hepatic bioactivation and offers more rapid onset and offset. The PLATO trial <span class=\"citation\">(NEJM 2009; Level A)</span> demonstrated a 16% relative risk reduction in composite cardiovascular death, MI, or stroke compared to clopidogrel in acute coronary syndrome, validating P2Y\u2081\u2082 blockade. Current AHA/ASA guidelines endorse P2Y\u2081\u2082 inhibitors for acute coronary syndrome and select secondary stroke prevention scenarios.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aspirin inhibits adenosine deaminase  <br><span class=\"list-item\">\u2022</span> Incorrect: Aspirin irreversibly acetylates serine 529 of COX-1, preventing TXA\u2082 synthesis.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing aspirin&rsquo;s acetylation with unrelated enzymes.  <br><br>C. Apixaban and rivaroxaban are direct thrombin inhibitors  <br><span class=\"list-item\">\u2022</span> Incorrect: These are direct, selective factor Xa inhibitors, preventing prothrombin\u2192thrombin conversion.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating all DOACs with dabigatran (true direct thrombin inhibitor).  <br><br>D. Clopidogrel inhibits factor 7, 10, 11, 12  <br><span class=\"list-item\">\u2022</span> Incorrect: Clopidogrel irreversibly blocks P2Y\u2081\u2082 ADP receptors on platelets.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing antiplatelet thienopyridines with anticoagulant vitamin K antagonism or factor inhibitors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Drug</th><th>Primary Target</th><th>Mechanism</th><th>Activation Requirement</th><th>Reversibility</th></tr></thead><tbody><tr><td>Ticagrelor (Correct)</td><td>P2Y\u2081\u2082 receptor</td><td>Reversible, noncompetitive antagonism</td><td>No bioactivation</td><td>Reversible</td></tr><tr><td>Aspirin (A)</td><td>COX-1 enzyme</td><td>Irreversible acetylation</td><td>No bioactivation</td><td>Irreversible</td></tr><tr><td>Apixaban/Rivaroxaban (C)</td><td>Factor Xa</td><td>Direct competitive inhibition</td><td>No bioactivation</td><td>Reversible</td></tr><tr><td>Clopidogrel (D)</td><td>P2Y\u2081\u2082 receptor</td><td>Irreversible antagonism</td><td>Hepatic CYP2C19 bioactivation</td><td>Irreversible</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ticagrelor has a loading dose of 180 mg and maintenance 90 mg BID; monitor for dyspnea (~10% incidence) due to adenosine uptake inhibition.  <br><span class=\"list-item\">\u2022</span> Factor Xa inhibitors (apixaban 5 mg BID; rivaroxaban 20 mg daily) require dose adjustment in renal impairment and have a specific reversal agent (andexanet alfa).  <br><span class=\"list-item\">\u2022</span> Aspirin&rsquo;s antiplatelet effect lasts for the platelet lifespan (~7&ndash;10 days), so bleeding risk persists until new platelets are generated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing direct thrombin inhibitors (dabigatran) with factor Xa inhibitors (apixaban, rivaroxaban).  <br>2. Assuming all P2Y\u2081\u2082 inhibitors (ticagrelor vs clopidogrel) have the same pharmacokinetics; ticagrelor is reversible and does not require hepatic activation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; 2019 AHA/ACC/HRS Guideline for Atrial Fibrillation <span class=\"citation\">(<span class=\"evidence\">Circulation 2019</span>;Class I, LOE A)</span>: Recommends DOACs (apixaban, rivaroxaban) over warfarin for nonvalvular AF to prevent stroke/systemic embolism.  <br>&bull; AHA/ASA 2021 Update on Acute Ischemic Stroke and TIA <span class=\"citation\">(<span class=\"evidence\">Stroke 2021</span>; LOE B\u2010R)</span>: For minor noncardioembolic stroke or high-risk TIA, adding ticagrelor to aspirin within 24 h for 30 days reduces recurrent stroke (based on THALES trial).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Ticagrelor: rapid onset (~30 min), peak platelet inhibition at 2 h, half-life ~7&ndash;12 h; avoid in history of intracranial hemorrhage.  <br>Apixaban/Rivaroxaban: predictable pharmacokinetics, no routine monitoring; rivaroxaban absorption enhanced with food at doses &ge;15 mg.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. Antithrombotic mechanism questions frequently test distinction between platelet\u2010directed agents (COX inhibitors, P2Y\u2081\u2082 antagonists) and coagulation cascade inhibitors (factor Xa vs thrombin inhibitors).</div></div></div></div></div>"}, {"id": 100022937, "question_number": "175", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] - The basilar artery, formed by vertebral arteries, supplies the pons, midbrain, thalami and occipital lobes. Occlusion leads to &ldquo;top\u2010of\u2010the\u2010basilar&rdquo; syndrome: visual hallucinations (occipital cortex ischemia), decreased consciousness (reticular activating system involvement) and decerebrate posturing (brainstem dysfunction).  <br><span class=\"list-item\">\u2022</span> On noncontrast CT, the hyperdense basilar sign indicates acute thrombus within the basilar artery, necessitating urgent vascular imaging.  <br><span class=\"list-item\">\u2022</span> CT angiography (CTA) rapidly confirms vessel occlusion and maps thrombus extent, guiding endovascular thrombectomy&mdash;time\u2010critical in basilar stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Emergent CTA is a Class I recommendation in acute ischemic stroke per the 2019 AHA/ASA Guidelines <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2019</span>;50:e344&ndash;e418)</span> to confirm large\u2010vessel occlusion and facilitate triage for mechanical thrombectomy. The hyperdense basilar sign on NCCT has a sensitivity of ~50&ndash;70% and specificity >90% for basilar thrombus <span class=\"citation\">(Liang et al., AJNR 2017)</span>. Rapid vessel imaging shortens door\u2010to\u2010groin puncture times, improving functional outcomes <span class=\"citation\">(BEYOND\u2010II trial, 2021)</span>. MRI/MRA, while sensitive, delays intervention. EEG does not assess vascular patency. Lumbar puncture risks herniation in raised intracranial pressure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. EEG  <br><span class=\"list-item\">\u2022</span> Why incorrect: Assesses electrical activity, not vascular patency.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing altered consciousness in stroke with nonconvulsive status epilepticus.  <br><span class=\"list-item\">\u2022</span> Differentiator: EEG cannot localize or confirm arterial occlusion.  <br><br>C. MRI brain  <br><span class=\"list-item\">\u2022</span> Why incorrect: Longer acquisition, contraindications in unstable, delays reperfusion therapy.  <br><span class=\"list-item\">\u2022</span> Misconception: MRI is always superior to CT in stroke.  <br><span class=\"list-item\">\u2022</span> Differentiator: CTA + CT perfusion is preferred for rapid large\u2010vessel assessment.  <br><br>D. Lumbar puncture  <br><span class=\"list-item\">\u2022</span> Why incorrect: Contraindicated if raised ICP or mass lesion risk; offers no vascular information.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming subarachnoid hemorrhage studies apply to ischemic stroke.  <br><span class=\"list-item\">\u2022</span> Differentiator: LP cannot diagnose arterial thrombus and may precipitate herniation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CTA (Correct)</th><th>EEG (Incorrect)</th><th>MRI Brain (Incorrect)</th><th>Lumbar Puncture (Incorrect)</th></tr></thead><tbody><tr><td>Primary Purpose</td><td>Vascular imaging to detect occlusion</td><td>Electrical activity monitoring</td><td>Structural/functional brain imaging</td><td>CSF analysis</td></tr><tr><td>Time to Perform</td><td>< 5 minutes additional scan time</td><td>~30&ndash;60 minutes setup</td><td>20&ndash;60 minutes, less accessible</td><td>15&ndash;30 minutes</td></tr><tr><td>Utility in Basilar Occlusion</td><td>Direct visualization of thrombus; guides thrombectomy</td><td>None</td><td>Possible confirmation but delays therapy</td><td>None; risk of herniation</td></tr><tr><td>Guideline Recommendation</td><td>Class I <span class=\"citation\">(AHA/ASA 2019)</span></td><td>Not recommended in acute stroke workup</td><td>Class IIb if CTA contraindicated</td><td>Contraindicated if raised ICP</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hyperdense basilar sign on NCCT has high specificity (>90%) but moderate sensitivity; always follow with CTA.  <br><span class=\"list-item\">\u2022</span> &ldquo;Top\u2010of\u2010the\u2010basilar&rdquo; syndrome may present with visual phenomena (e.g., seeing animals) before brainstem signs.  <br><span class=\"list-item\">\u2022</span> Door-to-puncture time is critical; aim for CTA within 20 minutes of arrival in suspected large\u2010vessel occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing visual hallucinations solely to psychiatric causes and delaying vascular imaging.  <br>2. Preferring MRI over CTA in hyperacute stroke, thereby postponing reperfusion therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Guidelines for Early Management of AIS <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2019</span>)</span>: Class I recommendation for CTA in suspected large\u2010vessel occlusion prior to thrombectomy (Level of Evidence A).  <br><span class=\"list-item\">\u2022</span> ESO-ESMINT Guidelines (2021): Recommend endovascular thrombectomy for basilar artery occlusion up to 6 hours (Class I, Level A) and CTA for diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Basilar artery occlusion and hyperdense basilar sign are high-yield topics on stroke subsections of neurology boards; rapid decision-making questions often test imaging modality choices.</div></div></div></div></div>"}, {"id": 100022938, "question_number": "123", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Autosomal dominant polycystic kidney disease (ADPKD) often involves extrarenal vascular defects, notably saccular (&ldquo;berry&rdquo;) aneurysms in the circle of Willis. Rupture of these aneurysms is the predominant cause of nontraumatic subarachnoid hemorrhage (SAH), presenting with a sudden, severe (&ldquo;thunderclap&rdquo;) headache, neck stiffness, and photophobia. Recognizing this association is critical for targeted screening and emergent care.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Saccular intracranial aneurysms account for ~85% of spontaneous SAH. In ADPKD, prevalence of unruptured aneurysms is 5&ndash;10%, compared to 2&ndash;3% in the general population. Mutations in PKD1/PKD2 disrupt polycystin-mediated vascular integrity, weakening vessel walls and predisposing to aneurysm formation. <span class=\"evidence\">The 2012</span> American Heart Association/American Stroke Association SAH guidelines recommend screening ADPKD patients with family history of aneurysm or SAH (Class IIa, Level B). CT angiography or digital subtraction angiography identifies the characteristic berry-shaped outpouchings at branch points, most commonly the anterior communicating artery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Arteriovenous malformation (AVM): AVMs more often cause intracerebral or intraventricular hemorrhage and seizures; they account for <10% of spontaneous SAH.  <br>C. Hypertensive intracerebral hemorrhage: Hypertensive bleeds localize to basal ganglia, thalamus, pons, or cerebellum and rarely present as isolated SAH.  <br>D. Cerebral venous thrombosis: CVT leads to venous infarcts with hemorrhagic transformation, seizures, and papilledema rather than the acute thunderclap headache and meningeal signs of SAH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Intracranial Aneurysm</th><th>AVM</th><th>Hypertensive ICH</th><th>CVT</th></tr></thead><tbody><tr><td>Presentation</td><td>Thunderclap headache, meningismus</td><td>Seizures, focal deficits</td><td>Gradual focal deficits, headache</td><td>Headache, seizures, papilledema</td></tr><tr><td>Imaging</td><td>CT: diffuse SAH; CTA/DSA: saccular outpouching</td><td>CT/MRI: nidus, flow voids</td><td>CT: hyperdense deep parenchymal bleed</td><td>MRV: absence of flow in sinuses</td></tr><tr><td>Common Location</td><td>AComm, PComm, MCA bifurcation</td><td>Cortical or deep parenchyma</td><td>Basal ganglia, thalamus</td><td>Dural sinuses, cortical veins</td></tr><tr><td>ADPKD Association</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Screen ADPKD patients over age 30 with a family history of SAH or aneurysm using MR or CT angiography.  <br><span class=\"list-item\">\u2022</span> Noncontrast CT within 6 hours of headache onset has >95% sensitivity for SAH.  <br><span class=\"list-item\">\u2022</span> Nimodipine (60 mg orally every 4 hours for 21 days) reduces the risk of delayed cerebral ischemia after aneurysmal SAH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming AVM rupture is a common cause of SAH; AVMs seldom present with isolated SAH.  <br><span class=\"list-item\">\u2022</span> Believing hypertensive hemorrhages frequently produce subarachnoid blood: they are predominantly intraparenchymal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2012 SAH Guidelines: Recommend screening ADPKD patients with family history for intracranial aneurysms (Class IIa, Level B).  <br><span class=\"list-item\">\u2022</span> MASH-2 Trial <span class=\"citation\">(2012, NEJM 366:997&ndash;1007)</span>: Magnesium sulfate did not improve outcomes in aneurysmal SAH, underscoring nimodipine&rsquo;s unique benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Saccular aneurysms develop at arterial bifurcations in the circle of Willis&mdash;most frequently the anterior communicating artery&mdash;where hemodynamic stress and structural wall defects converge.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PKD1/PKD2 mutations impair polycystin-1/-2 function in vascular smooth muscle and endothelium, weakening intercellular junctions and extracellular matrix, which leads to focal vessel wall dilation and aneurysm formation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT for suspected SAH.  <br>2. If CT is negative but clinical suspicion remains high, perform lumbar puncture for xanthochromia.  <br>3. Confirm and localize aneurysm with CT angiography or digital subtraction angiography.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute SAH appears as hyperdense blood in basal cisterns on noncontrast CT.  <br><span class=\"list-item\">\u2022</span> CTA offers rapid detection of aneurysm morphology; DSA remains the gold standard and allows immediate endovascular treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Intracranial aneurysm risk in ADPKD and its role in SAH is a frequently tested high-yield topic in both scenario-based and single best-answer formats.</div></div></div></div></div>"}, {"id": 100022939, "question_number": "79", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is a hereditary small\u2010vessel disease caused by NOTCH3 mutations on chromosome 19. Pathologically, abnormal NOTCH3 extracellular domains accumulate in vascular smooth muscle cells, leading to chronic hypoperfusion, subcortical lacunar infarcts, and extensive white matter changes. Clinically, it presents with migraine with aura, recurrent lacunar strokes, mood disturbances, and progressive executive dysfunction&mdash;typically between ages 30 and 60. MRI hallmarks include symmetric T2/FLAIR hyperintensities in the external capsule and anterior temporal poles. Differentiating CADASIL from demyelinating (MS), neurodegenerative (ALS), or sporadic vascular dementia relies on lesion distribution, family history, and genetic confirmation. (120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CADASIL is definitively diagnosed by identifying pathogenic NOTCH3 mutations <span class=\"citation\">(<span class=\"evidence\">Joutel et al., 1996</span>;<span class=\"evidence\"> Chabriat et al., 2009</span>)</span>. Vascular smooth muscle cell degeneration from mutant NOTCH3 leads to degeneration of small penetrating arterioles and subcortical ischemia. Rutten et al. (2018) demonstrated that anterior temporal pole involvement on FLAIR MRI has >90% specificity for CADASIL versus other leukoencephalopathies. <span class=\"evidence\">The 2021</span> European Stroke Organisation guidelines on cerebral small vessel disease recommend NOTCH3 genetic testing in patients <60 years with characteristic MRI findings (Class IIa, Level B). No demyelinating plaques, oligoclonal bands, or motor neuron degeneration appear in CADASIL, distinguishing it from MS and ALS. Sporadic vascular dementia lacks autosomal dominant inheritance and specific temporal pole lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Multiple sclerosis  <br><span class=\"list-item\">\u2022</span> Why incorrect: MS is an immune-mediated demyelinating disorder with periventricular &ldquo;Dawson&rsquo;s fingers,&rdquo; oligoclonal bands in CSF, and relapsing&ndash;remitting course.  <br><span class=\"list-item\">\u2022</span> Misconception: All white matter lesions imply demyelination.  <br><span class=\"list-item\">\u2022</span> Differentiator: MS lesions spare the anterior temporal poles and external capsule; present with optic neuritis or internuclear ophthalmoplegia.<br><br>C. Amyotrophic lateral sclerosis  <br><span class=\"list-item\">\u2022</span> Why incorrect: ALS is characterized by progressive upper and lower motor neuron degeneration without stroke-like events or migraine history.  <br><span class=\"list-item\">\u2022</span> Misconception: Progressive neurological decline always indicates motor neuron disease.  <br><span class=\"list-item\">\u2022</span> Differentiator: ALS shows fasciculations, muscle atrophy, and EMG evidence of denervation&mdash;not lacunar infarcts or leukoencephalopathy.<br><br>D. Vascular dementia  <br><span class=\"list-item\">\u2022</span> Why incorrect: Sporadic vascular dementia entails heterogeneous large\u2010 and small\u2010vessel infarcts in older patients with vascular risk factors, not a single-gene autosomal dominant pattern.  <br><span class=\"list-item\">\u2022</span> Misconception: Any cognitive decline with infarcts equals vascular dementia.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lacks family history, specific NOTCH3 mutations, and anterior temporal pole lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CADASIL</th><th>Multiple sclerosis</th><th>Amyotrophic lateral sclerosis</th><th>Vascular dementia</th></tr></thead><tbody><tr><td>Inheritance</td><td>Autosomal dominant (NOTCH3 mutation)</td><td>Mostly sporadic</td><td>Sporadic/familial (SOD1, C9orf72)</td><td>Sporadic; multifactorial</td></tr><tr><td>Typical age of onset</td><td>30&ndash;60 years</td><td>20&ndash;40 years</td><td>50&ndash;70 years</td><td>>65 years</td></tr><tr><td>MRI distribution</td><td>External capsule, anterior temporal poles</td><td>Periventricular, juxtacortical</td><td>Corticospinal tracts (hyperintensities rare)</td><td>Multifocal cortical/subcortical infarcts</td></tr><tr><td>Key clinical features</td><td>Migraine with aura, lacunar strokes, executive dysfunction</td><td>Optic neuritis, sensory/motor relapses</td><td>Muscle weakness, atrophy, hyperreflexia</td><td>Stepwise cognitive decline, focal deficits</td></tr><tr><td>Diagnostic confirmation</td><td>NOTCH3 genetic testing</td><td>CSF oligoclonal bands, evoked potentials</td><td>EMG and nerve conduction studies</td><td>Clinical + imaging; no single definitive test</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Anterior temporal pole FLAIR hyperintensities are >90% specific for CADASIL.  <br><span class=\"list-item\">\u2022</span> A detailed family history of early strokes or dementia is crucial in young patients with leukoencephalopathy.  <br><span class=\"list-item\">\u2022</span> No disease-modifying therapy exists; focus on symptomatic migraine prophylaxis and aggressive vascular risk factor control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing CADASIL MRI changes to MS due to non-specific white matter hyperintensities&mdash;always assess distribution and CSF.  <br>2. Assuming all vascular cognitive impairment is sporadic&mdash;consider monogenic causes with autosomal dominant patterns.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 Stroke in Monogenic Disorders Guideline: Recommends NOTCH3 genetic testing in patients <55 years with recurrent lacunar strokes and positive family history (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> ESO 2021 Guidelines on Cerebral Small Vessel Disease: Advises MRI assessment of external capsule and anterior temporal lobes to guide CADASIL diagnosis and confirm via NOTCH3 sequencing (Class IIa, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Small penetrating arterioles in deep white matter (external capsule, periventricular regions, basal ganglia) and anterior temporal lobes are preferentially affected, leading to characteristic lacunar infarcts and leukoencephalopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mutant NOTCH3 extracellular domains aggregate as granular osmiophilic material in vessel walls \u2192 vascular smooth muscle cell degeneration \u2192 chronic hypoperfusion \u2192 demyelination and lacunar infarcts \u2192 clinical manifestations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify migraine with aura + early-onset lacunar strokes + positive family history.  <br>2. Obtain MRI: look for external capsule and anterior temporal pole hyperintensities.  <br>3. Exclude other etiologies (CSF for oligoclonal bands, EMG for motor neuron disease).  <br>4. Confirm with NOTCH3 genetic sequencing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- FLAIR hyperintensities in anterior temporal poles (absent in most other leukoencephalopathies) and external capsule are pathognomonic.  <br><span class=\"list-item\">\u2022</span> Lacunar infarcts in basal ganglia and thalamus support chronic small vessel disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- No specific disease-modifying agents.  <br><span class=\"list-item\">\u2022</span> Symptomatic management: aspirin 75&ndash;100 mg daily for secondary stroke prevention (extrapolated, Class IIb).  <br><span class=\"list-item\">\u2022</span> Migraine prophylaxis: verapamil or beta-blockers.  <br><span class=\"list-item\">\u2022</span> Rigorous control of hypertension and hyperlipidemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. CADASIL is frequently tested as an autosomal dominant small vessel stroke syndrome presenting with migraine, subcortical infarcts, and anterior temporal pole MRI findings; examinees should recognize lesion distribution and confirmatory genetic testing.</div></div></div></div></div>"}, {"id": 100022940, "question_number": "77", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Wernicke&rsquo;s aphasia arises from infarction of the dominant (usually left) posterior superior temporal gyrus and adjacent inferior parietal lobule&mdash;regions responsible for language comprehension. These areas lie in the distribution of the inferior division of the middle cerebral artery (MCA), which courses laterally into the Sylvian fissure to perfuse the posterior temporal and parietal cortex. In contrast, the MCA&rsquo;s superior division supplies frontal operculum (Broca&rsquo;s area) and motor cortex. Recognizing vascular-territory relationships is critical in acute stroke syndromes: a fluent aphasia with impaired comprehension localizes to inferior-MCA branch infarction, informing emergent diagnostic imaging and reperfusion strategies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The inferior division (M2/M3) of the MCA specifically supplies Wernicke&rsquo;s area. Neuroanatomic studies <span class=\"citation\">(Rhoton, 2000)</span> delineate how inferior trunks traverse the Sylvian fissure to the posterior temporal lobe. AHA/ASA 2019 stroke guidelines recommend prompt CT angiography in suspected large-vessel occlusion; identification of an inferior-MCA branch clot correlates with fluent aphasia and guides thrombectomy decisions (Class I, Level A). Diffusion-weighted MRI confirms acute infarction in the superior temporal gyrus. Trials such as DAWN <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span> and DEFUSE-3 <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span> included patients with MCA branch occlusions, underscoring the importance of vascular localization for endovascular therapy selection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Superior division of the MCA  <br>&bull; Supplies lateral frontal lobe (Broca&rsquo;s area, precentral gyrus) \u2192 Broca&rsquo;s (non-fluent) aphasia, contralateral face/arm weakness.  <br>&bull; Misconception: &ldquo;MCA equals Wernicke&rsquo;s&rdquo; without considering branch anatomy.  <br><br>C. Anterior cerebral artery  <br>&bull; Supplies medial frontal/parietal lobes \u2192 leg weakness, grasp reflex, abulia.  <br>&bull; Does not perfuse lateral temporal cortex or language zones.  <br><br>D. Posterior cerebral artery  <br>&bull; Supplies occipital lobes, inferior temporal lobe \u2192 visual field cuts, alexia without agraphia.  <br>&bull; Wernicke&rsquo;s area (Brodmann 22) is not in PCA territory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Artery Territory</th><th>Main Cortical Regions Supplied</th><th>Aphasia Type When Dominant Side Involved</th></tr></thead><tbody><tr><td>Inferior division MCA</td><td>Posterior superior temporal & inferior parietal lobules</td><td>Wernicke&rsquo;s (fluent, poor comprehension)</td></tr><tr><td>Superior division MCA</td><td>Frontal operculum, precentral gyrus</td><td>Broca&rsquo;s (non\u2010fluent, good comprehension)</td></tr><tr><td>Anterior cerebral artery</td><td>Medial frontal & parietal lobes (leg area)</td><td>Rarely causes language deficits; leg paresis, abulia</td></tr><tr><td>Posterior cerebral artery</td><td>Occipital lobes, inferior temporal lobes</td><td>Visual deficits, alexia without agraphia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Fluent aphasia with jargon and neologisms \u2192 think inferior\u2010MCA branch infarct.  <br><span class=\"list-item\">\u2022</span> Always assess comprehension separately from speech fluency to distinguish Broca&rsquo;s vs Wernicke&rsquo;s.  <br><span class=\"list-item\">\u2022</span> CT angiography within the first 6 hours can localize branch occlusions and expedite mechanical thrombectomy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any MCA stroke with the same aphasia type&mdash;branch-specific deficits differ (superior vs inferior).  <br>2. Attributing Wernicke&rsquo;s symptoms to PCA infarcts because of involvement of &ldquo;temporal lobe,&rdquo; ignoring precise superior temporal gyrus location.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 &ldquo;Guidelines for Early Management of Acute Ischemic Stroke&rdquo;: Class I, Level A for CTA in suspected LVO strokes to identify MCA branch occlusions quickly.  <br>2. DEFUSE-3 Trial (2018): Demonstrated benefit of endovascular therapy in MCA M2 occlusions (inferior division) within 6&ndash;16 hours, reinforcing vascular localization for treatment selection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Wernicke&rsquo;s area corresponds to Brodmann area 22, in the posterior superior temporal gyrus. The inferior MCA division (M2 branches) runs in the Sylvian fissure&rsquo;s posterior limb, sending perforators to this auditory\u2010language cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thromboembolic occlusion of the inferior MCA branch leads to ischemia of Wernicke&rsquo;s cortex. Neuronal death from excitotoxicity and cytotoxic edema manifests as rapid loss of auditory comprehension and fluent yet nonsensical speech.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Neurological exam&mdash;identify fluent aphasia with poor comprehension.  <br>2. Noncontrast head CT&mdash;exclude hemorrhage.  <br>3. CT angiography&mdash;localize inferior MCA division occlusion.  <br>4. MRI DWI&mdash;confirm acute infarct in Wernicke&rsquo;s region.  <br>5. Vascular risk stratification&mdash;initiate reperfusion (IV tPA, thrombectomy) per guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Early CT may be normal; CTA reveals &ldquo;cut\u2010off&rdquo; of inferior M2 branch.  <br>&bull; DWI MRI shows restricted diffusion in superior temporal gyrus&mdash;hallmark of acute Wernicke&rsquo;s aphasia stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>Vascular localization questions, especially distinguishing MCA divisions in aphasia syndromes, are frequently tested on neurology boards, often in clinical vignettes describing fluent vs nonfluent speech.</div></div></div></div></div>"}, {"id": 100022941, "question_number": "86", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] - Sickle cell disease (SCD) causes hemoglobin S polymerization, red\u2010cell sickling, hemolysis and chronic vasculopathy, especially in large intracranial arteries (e.g., MCA), predisposing to ischemic stroke.  <br><span class=\"list-item\">\u2022</span> Transcranial Doppler (TCD) screening identifies elevated flow velocities (&ge;200 cm/s) indicating high stroke risk; chronic transfusion reduces this risk by lowering HbS fraction.  <br><span class=\"list-item\">\u2022</span> In acute SCD\u2010associated stroke, lowering circulating HbS rapidly (<30%) through exchange transfusion reduces blood viscosity, improves oxygen delivery, and halts infarct progression more effectively than simple transfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Aspirin therapy  <br><span class=\"list-item\">\u2022</span> Incorrect: Antiplatelet agents are used for non\u2010SCD cryptogenic stroke or atherosclerotic disease; they do not address sickled red cells or hyperviscosity.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that all ischemic strokes benefit from antiplatelets.  <br><span class=\"list-item\">\u2022</span> Differentiator: Does not reduce HbS or improve rheology in SCD.  <br><br>C. Intravenous thrombolysis  <br><span class=\"list-item\">\u2022</span> Incorrect: IV tPA is contraindicated in SCD due to fragile, vasculopathic vessels and lack of safety/efficacy data; risk of hemorrhagic conversion is high.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming standard adult stroke protocols apply to SCD.  <br><span class=\"list-item\">\u2022</span> Differentiator: Does not address underlying hemorheologic pathology.  <br><br>D. Surgical revascularization  <br><span class=\"list-item\">\u2022</span> Incorrect: Procedures like encephaloduroarteriosynangiosis (EDAS) are used experimentally for moyamoya in SCD but not acute stroke management.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating chronic surgical bypass with acute intervention.  <br><span class=\"list-item\">\u2022</span> Differentiator: Delayed effect, not suitable for emergent infarct salvage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Exchange Transfusion</th><th>Aspirin Therapy</th><th>Intravenous Thrombolysis</th><th>Surgical Revascularization</th></tr></thead><tbody><tr><td>Mechanism</td><td>Removes HbS, reduces viscosity, improves oxygen delivery</td><td>Inhibits platelet aggregation</td><td>Fibrinolysis via plasminogen activation</td><td>Promotes collateral vessel growth</td></tr><tr><td>Target effect</td><td>HbS < 30%, Hb &ge; 10 g/dL</td><td>Lower thrombotic risk</td><td>Lysing existing clots</td><td>Long\u2010term perfusion enhancement</td></tr><tr><td>Time to benefit</td><td>1&ndash;2 hours</td><td>Days&ndash;weeks</td><td>Minutes&ndash;hours</td><td>Weeks&ndash;months</td></tr><tr><td>Evidence strength</td><td>ASH 2014 grade 1B; ASA/AHA 2019</td><td>Limited in SCD</td><td>No pediatric SCD data; high risk</td><td>Case series; experimental in SCD</td></tr><tr><td>Indication timing</td><td>Acute ischemic stroke in SCD</td><td>Secondary prevention in non\u2010SCD stroke</td><td>Standard adult stroke (not SCD)</td><td>Chronic moyamoya syndrome</td></tr><tr><td>Major risks</td><td>Transfusion reactions, iron overload</td><td>Bleeding, GI upset</td><td>Hemorrhage, angioedema</td><td>Surgical complications</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In SCD patients presenting with acute neurological deficits, obtain stat TCD or vascular imaging and prepare for immediate exchange transfusion.  <br><span class=\"list-item\">\u2022</span> Aim for HbS < 30% and total Hb ~10 g/dL to balance oxygen delivery and avoid hyperviscosity.  <br><span class=\"list-item\">\u2022</span> Monitor ferritin and initiate iron chelation (deferasirox, deferoxamine) during chronic transfusion programs to prevent overload.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing simple (top\u2010up) transfusion with exchange transfusion&mdash;simple transfusion alone may exacerbate hyperviscosity if hemoglobin exceeds 11 g/dL.  <br>2. Applying adult ischemic stroke protocols (e.g., IV tPA) to pediatric SCD patients without considering unique vasculopathy and hemorheology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Society of <span class=\"evidence\">Hematology 2014</span> guidelines: &ldquo;Emergent partial exchange transfusion is recommended (grade 1B) for acute ischemic stroke in SCD.&rdquo;  <br><span class=\"list-item\">\u2022</span> American Heart Association/American Stroke <span class=\"evidence\">Association 2019</span> Pediatric Stroke Guidelines: &ldquo;Exchange transfusion should be initiated promptly in SCD\u2010related stroke to reduce HbS to <30%.&rdquo;  <br><span class=\"list-item\">\u2022</span> TWiTCH trial <span class=\"citation\">(NEJM 2016;374:154)</span> demonstrated hydroxyurea noninferiority to transfusion for primary stroke prevention in select children with elevated TCD velocities under strict monitoring.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Cerebrovascular complications in SCD&mdash;particularly the role of exchange transfusion in acute stroke&mdash;are high\u2010yield topics on pediatric neurology and hematology sections, frequently tested in both single\u2010best\u2010answer and extended\u2010matching formats.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. Exchange transfusion. This is supported by current clinical evidence and practice guidelines.</div></div></div></div></div>"}, {"id": 100022942, "question_number": "116", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Pure motor hemiparesis (face, arm, leg) with mild dysarthria is the classic lacunar stroke syndrome. Key concepts:  <br><span class=\"list-item\">\u2022</span> Corticospinal and corticobulbar fibers descend together in the posterior limb and genu of the internal capsule.  <br><span class=\"list-item\">\u2022</span> Small vessel lipohyalinosis in penetrating arteries (e.g., lenticulostriate) causes lacunar infarcts in deep structures.  <br><span class=\"list-item\">\u2022</span> Cortical lesions produce &ldquo;cortical signs&rdquo; (aphasia, neglect) absent here; brainstem lesions add cranial nerve or long-tract cross signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Internal capsule involvement explains contralateral pure motor deficits without cortical signs. Fisher&rsquo;s seminal lacunar stroke series <span class=\"citation\">(<span class=\"evidence\">Stroke 1965</span>;6:178&ndash;197)</span> defined this syndrome; subsequent neuroimaging studies <span class=\"citation\">(Wessels et al., J <span class=\"evidence\">Neurol 2008</span>;255:500&ndash;506)</span> confirm 45&ndash;65% of pure motor lacunes localize to the posterior limb. AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke recommend MRI-DWI to detect small subcortical infarcts (Class I, LOE B), reinforcing identification of internal capsule lacunes. In contrast, midbrain or pontine lesions yield ocular or crossed motor signs; cortical lesions manifest sensory loss or aphasia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Midbrain  <br>&ndash; Incorrect: Corticospinal fibers in crus cerebri are somatotopically arranged but midbrain lesions (e.g., Weber syndrome) include ipsilateral oculomotor palsy. Pure motor weakness without oculomotor signs excludes midbrain.  <br>C. Pons  <br>&ndash; Incorrect: Lacunes in ventral pons can cause dysarthria-clumsy hand syndrome or facial weakness, but often involve ataxia or cranial nerve nuclei. Pure, uniform hemiparesis without ataxia or diplopia is atypical.  <br>D. Primary motor cortex  <br>&ndash; Incorrect: Cortical infarcts produce &ldquo;cortical signs&rdquo; (gaze preference, aphasia if dominant hemisphere, neglect if non-dominant) and often have a &ldquo;hand knob&rdquo; area predilection; absence of these signs argues against cortical localization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Internal Capsule (Posterior Limb)</th><th>Midbrain (Crus Cerebri)</th><th>Pons (Ventral)</th><th>Motor Cortex (Precentral Gyrus)</th></tr></thead><tbody><tr><td>Fiber content</td><td>Corticospinal + corticobulbar</td><td>Corticospinal</td><td>Corticospinal + CN nuclei</td><td>Upper motor neurons + cortex</td></tr><tr><td>Clinical signs</td><td>Pure motor hemiparesis, dysarthria</td><td>Contralateral hemiparesis + ipsilateral III palsy</td><td>Hemiparesis + ataxia/diplopia</td><td>Motor weakness + cortical signs</td></tr><tr><td>Imaging</td><td>Lacune <15 mm on DWI in internal capsule</td><td>Infarct in crus cerebri on MRI</td><td>Punctate pontine lesion on DWI</td><td>Cortical ribbon abnormality on MRI</td></tr><tr><td>Vascular territory</td><td>Lenticulostriate arteries</td><td>Posterior cerebral artery perforators</td><td>Basilar artery branches</td><td>Middle cerebral artery</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Pure motor stroke syndrome is most often due to lacunar infarct in the internal capsule (45&ndash;65%).  <br><span class=\"list-item\">\u2022</span> Dysarthria accompanies internal capsule lesions when corticobulbar fibers in the genu are involved.  <br><span class=\"list-item\">\u2022</span> Lack of cortical signs (aphasia, neglect) helps distinguish deep lacunes from cortical MCA strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing pure motor deficits to cortical stroke despite absence of cortical signs (e.g., aphasia).  <br>2. Overlooking mild dysarthria as a clue to genu involvement; assuming limb-only weakness implies pure corticospinal lesion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke  <br><span class=\"list-item\">\u2022</span> Recommendation: MRI-DWI preferred to identify small subcortical infarcts early (Class I, LOE B).  <br>2. AHA/ASA 2021 Guidelines for Secondary Stroke Prevention  <br><span class=\"list-item\">\u2022</span> Recommendation: Intensive BP control (target <130/80 mm Hg) in lacunar stroke reduces recurrence (Class I, LOE A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The posterior limb of the internal capsule contains descending corticospinal fibers (leg lateral, arm medial) and corticobulbar fibers in the genu; somatotopy explains simultaneous face, arm, and leg involvement without sensory or cortical signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic hypertension and diabetes induce lipohyalinosis and microatheroma in deep perforators (lenticulostriate), leading to small (<15 mm) infarcts (&ldquo;lacunes&rdquo;) in the internal capsule.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rapid clinical assessment (FAST, NIHSS).  <br>2. Noncontrast CT to exclude hemorrhage.  <br>3. MRI-DWI to detect lacunar infarct.  <br>4. Vascular imaging (MRA/CTA) to rule out large vessel occlusion.  <br>5. Evaluate risk factors (HTN, DM) and plan secondary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT may be normal initially; small lacunes often only on DWI.  <br><span class=\"list-item\">\u2022</span> Lacunar infarcts appear as punctate (<15 mm), well-demarcated DWI hyperintensities in deep structures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute: IV alteplase within 4.5 h if no contraindications (Class I, LOE A).  <br><span class=\"list-item\">\u2022</span> Secondary: Aspirin &plusmn; clopidogrel for first 21 days <span class=\"citation\">(CHANCE trial, NEJM 2013)</span>; long-term monotherapy thereafter. High-intensity statin (e.g., atorvastatin 80 mg daily).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam.  <br>Deep lacunar syndromes (pure motor, pure sensory, dysarthria-clumsy hand) are frequently tested in clinical localization and stroke subsections, often requiring identification of internal capsule lesions on imaging or via syndromic presentation.</div></div></div></div></div>"}, {"id": 100022943, "question_number": "281", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Posterolateral medullary (Wallenberg) syndrome arises from PICA occlusion leading to infarction of the dorsolateral medulla. Key neuroanatomical structures include: nucleus ambiguus (CN IX/X) causing dysphagia, hoarseness, and diminished gag; the descending sympathetic fibers resulting in ipsilateral Horner&rsquo;s syndrome; the inferior cerebellar peduncle yielding ipsilateral limb ataxia; and the spinothalamic tract producing contralateral body analgesia/thermanesthesia. Uvula deviation occurs away from the lesion due to nucleus ambiguus involvement. Localization relies on integrating crossed and uncrossed signs: cross-body pain/temperature loss versus ipsilateral face deficits. Recognizing these hallmark findings allows accurate brainstem localization on neurology boards and in clinical practice.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dysphagia is the most specific &ldquo;other&rdquo; finding because infarction of the nucleus ambiguus disrupts efferent fibers of CN IX and X, leading to impaired swallowing, hoarseness, and decreased gag reflex. In a clinicopathological series by Yousry et al. (1997), over 75% of patients with PICA territory infarcts exhibited dysphagia. The presence of Horner&rsquo;s syndrome and uvula deviation away from the lesion localizes to the right dorsolateral medulla in this patient, where the nucleus ambiguus resides. While ataxia and sensory deficits can coexist, ataxia is ipsilateral (right limbs) and body pain/temperature loss is contralateral (left side) in Wallenberg syndrome. Early recognition and MRI DWI confirmation guide management per AHA/ASA acute stroke guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Right ptosis  <br><span class=\"list-item\">\u2022</span> Ptosis is part of Horner&rsquo;s syndrome already described; it offers no additional localization.  <br><span class=\"list-item\">\u2022</span> Misconception: treating a component of an existing sign as a new finding.  <br><br>B. Left limb ataxia  <br><span class=\"list-item\">\u2022</span> Ataxia in lateral medullary infarction is ipsilateral to the lesion (right side), not contralateral.  <br><span class=\"list-item\">\u2022</span> Confuses decussation patterns of cerebellar pathways.  <br><br>C. Right-sided loss of pain and temperature sensation  <br><span class=\"list-item\">\u2022</span> Lateral medullary lesions cause contralateral (left) body analgesia/thermanesthesia and ipsilateral (right) facial loss&mdash;this option is ambiguous and incomplete.  <br><span class=\"list-item\">\u2022</span> Misinterprets spinothalamic versus spinal trigeminal involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Right Ptosis</th><th>Left Limb Ataxia</th><th>Right-sided Pain/Temp Loss</th><th>Dysphagia</th></tr></thead><tbody><tr><td>Expected in right lateral medullary lesion</td><td>Yes (Horner&rsquo;s)</td><td>No (ataxia is ipsilateral = R)</td><td>Partial/ambiguous (face Y/body N)</td><td>Yes (nucleus ambiguus)</td></tr><tr><td>Pathway involved</td><td>Descending sympathetic fibers</td><td>Inferior cerebellar peduncle</td><td>Spinothalamic/spinal trigeminal</td><td>Nucleus ambiguus (CN IX/X)</td></tr><tr><td>Clinical specificity</td><td>Low (redundant)</td><td>Low (wrong side)</td><td>Moderate (ambiguous)</td><td>High (cardinal sign)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Uvula deviates away from the side of nucleus ambiguus lesion due to unopposed pull by the intact contralateral palatal muscles.  <br><span class=\"list-item\">\u2022</span> Inferior cerebellar peduncle involvement yields ipsilateral limb ataxia in lateral medullary syndrome.  <br><span class=\"list-item\">\u2022</span> Dysphagia/hoarseness are more reliable indicators of nucleus ambiguus damage than facial sensory changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Reversing uvula deviation direction: learners often think it deviates toward the lesion.  <br><span class=\"list-item\">\u2022</span> Mislocalizing cerebellar signs: forgetting that cerebellar connections in the medulla produce ipsilateral symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association, 2019 Guidelines for Early Management of Acute Ischemic Stroke  <br><span class=\"list-item\">\u2022</span> Recommendation: MRI with diffusion-weighted imaging is class I, level A for suspected brainstem infarction to confirm diagnosis.  <br>2. European Stroke Organisation, 2021 Guidelines on Acute Posterior Circulation Stroke  <br><span class=\"list-item\">\u2022</span> Recommendation: Intravenous alteplase within 4.5 hours of onset for eligible patients, including posterior circulation strokes (class I, level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Dorsolateral medullary infarcts involve:  <br><span class=\"list-item\">\u2022</span> Nucleus ambiguus \u2192 dysphagia, hoarseness  <br><span class=\"list-item\">\u2022</span> Descending sympathetic tract \u2192 ipsilateral Horner&rsquo;s  <br><span class=\"list-item\">\u2022</span> Inferior cerebellar peduncle \u2192 ipsilateral ataxia  <br><span class=\"list-item\">\u2022</span> Spinothalamic tract \u2192 contralateral body pain/temperature loss  <br><span class=\"list-item\">\u2022</span> Spinal trigeminal nucleus \u2192 ipsilateral facial pain/temperature loss</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombosis or embolism in the PICA territory leads to ischemic necrosis of the lateral medullary structures listed above. Neuronal death in the nucleus ambiguus disrupts cranial nerve IX/X motor output to the palate, causing dysphagia and uvula deviation away from the lesion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Lateral medullary (Wallenberg) syndrome is frequently tested via clinical vignettes that require identification of lesion location based on crossed sensory findings, cranial nerve signs, and cerebellar involvement.</div></div></div></div></div>"}, {"id": 100022944, "question_number": "280", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Watershed infarctions occur in border\u2010zone regions between major cerebral arteries (e.g., ACA&ndash;MCA or MCA&ndash;PCA territories) and reflect hemodynamic compromise rather than embolic occlusion. Key points:  <br><span class=\"list-item\">\u2022</span> Watershed zones are vulnerable to systemic hypotension or proximal large\u2010vessel stenosis.  <br><span class=\"list-item\">\u2022</span> Noncontrast head CT may reveal bilateral, wedge\u2010shaped hypodensities in border\u2010zone regions.  <br><span class=\"list-item\">\u2022</span> Prompt vascular imaging is essential to identify treatable proximal stenosis or occlusion and guide revascularization strategies.  <br><br>(Word count: 100)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Computed tomography angiography (CTA) is the preferred next step after noncontrast CT suggests watershed infarction because:  <br>1. <strong>Rapid, comprehensive vascular assessment</strong>: CTA provides high\u2010resolution images of extracranial and intracranial arteries in under two minutes, detecting proximal carotid/vertebrobasilar stenosis or occlusion with sensitivity >95% and specificity >98% <span class=\"citation\">(Wintermark et al., <span class=\"evidence\">Stroke 2005</span>)</span>.  <br>2. <strong>Guideline endorsement</strong>: <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2018</span>)</span> give CTA a Class I, Level A recommendation for evaluation of suspected large\u2010vessel occlusion in acute stroke.  <br>3. <strong>Therapeutic implications</strong>: Identification of high\u2010grade stenosis (>70%) or occlusion on CTA directly influences decisions on emergent mechanical thrombectomy <span class=\"citation\">(MR CLEAN consortium, N Engl J <span class=\"evidence\">Med 2015</span>)</span> or carotid revascularization.  <br><br>MRI brain, carotid Doppler, and echocardiography are valuable in broader stroke workup but are either less time\u2010efficient or target alternative mechanisms (parenchymal detail, extracranial flow only, and cardioembolism, respectively).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI brain  <br>&ndash; MRI (DWI/FLAIR) is more sensitive for early infarction but takes longer, may delay urgent vascular intervention.  <br>&ndash; Misconception: MRI is the gold standard for all stroke imaging; in hyperacute settings, vascular status on CTA is more actionable.  <br><br>C. Carotid Doppler ultrasound  <br>&ndash; Evaluates only extracranial carotid bifurcation; cannot assess intracranial vessels or vertebral arteries.  <br>&ndash; Misconception: Duplex ultrasound suffices for all hemodynamic strokes; in acute settings, intracranial imaging is critical.  <br><br>D. Echocardiography  <br>&ndash; Detects cardiac sources of embolism (e.g., PFO, atrial thrombus) but does not assess cerebral vessel patency.  <br>&ndash; Misconception: All ischemic strokes should first get a cardiac workup; while important, hemodynamic strokes demand urgent vascular imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CTA (Correct)</th><th>MRI Brain</th><th>Carotid Doppler</th><th>Echocardiography</th></tr></thead><tbody><tr><td>Primary Target</td><td>Intra-/extracranial arterial patency</td><td>Parenchymal infarction detail</td><td>Extracranial carotid stenosis</td><td>Cardiac thrombus/source</td></tr><tr><td>Time to perform</td><td>2&ndash;3 minutes</td><td>15&ndash;30 minutes</td><td>10&ndash;15 minutes</td><td>30&ndash;60 minutes</td></tr><tr><td>Sensitivity for LVO</td><td>>95%</td><td>Variable (depends on MRA)</td><td>N/A</td><td>N/A</td></tr><tr><td>Treatment implications</td><td>Guides thrombectomy/carotid revascular.</td><td>Confirms infarct age and distribution</td><td>May guide CEA but misses intracranial</td><td>Guides anticoagulation decisions</td></tr><tr><td>Limitation</td><td>Radiation, contrast use</td><td>Availability, motion artifacts</td><td>No intracranial data</td><td>Does not image cerebral vessels</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Watershed infarcts on CT should prompt urgent vascular imaging to detect hemodynamic compromise.  <br><span class=\"list-item\">\u2022</span> In the hyperacute stroke window, prioritize tests that directly influence reperfusion: CTA > MRI > ultrasound > echocardiography.  <br><span class=\"list-item\">\u2022</span> Bilateral watershed infarcts in hypotensive patients suggest systemic perfusion failure; unilateral suggests proximal stenosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming carotid Doppler is sufficient for all suspected hemodynamic strokes without evaluating intracranial vessels.  <br>2. Ordering MRI first to &ldquo;confirm&rdquo; infarction, thereby delaying definitive vascular imaging and treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- 2018 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (Powers et al.): CTA for evaluation of large\u2010vessel occlusion&mdash;Class I, Level A.  <br><span class=\"list-item\">\u2022</span> MR CLEAN Trial (2015, N Engl J Med): Patients selected by CTA for mechanical thrombectomy had significantly better functional outcomes (adjusted OR 1.67; 95% CI 1.21&ndash;2.30).  <br><span class=\"list-item\">\u2022</span> ESCAPE Trial (2015, N Engl J Med): CTA plus perfusion imaging improved selection for endovascular therapy and reduced disability (NNT=3).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Watershed zones lie between terminal branches of major cerebral arteries:  <br><span class=\"list-item\">\u2022</span> Cortical (external) between ACA&ndash;MCA and MCA&ndash;PCA.  <br><span class=\"list-item\">\u2022</span> Internal (deep) between superficial MCA and deep perforators.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Watershed infarcts result from inadequate cerebral perfusion during:  <br><span class=\"list-item\">\u2022</span> Systemic hypotension (e.g., cardiac arrest, shock)  <br><span class=\"list-item\">\u2022</span> Proximal arterial stenosis (e.g., ICA atherosclerosis)  <br>Collateral flow is insufficient to maintain perfusion in border\u2010zone territories.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT to exclude hemorrhage and identify infarct patterns.  <br>2. CTA from aortic arch to vertex to assess for proximal stenosis/occlusion.  <br>3. If CTA contraindicated, consider MRA.  <br>4. Subsequent carotid Doppler and echocardiography to complete stroke workup.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Watershed infarcts on CT appear as wedge\u2010shaped hypodense areas at the cortical ribbon or centrum semiovale (&ldquo;string\u2010of\u2010beads&rdquo; pattern).  <br><span class=\"list-item\">\u2022</span> CTA collateral grading (e.g., ASITN/SIR scale) helps predict infarct progression and treatment response.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Watershed infarction management and imaging workflow are frequently tested on neurology board exams, often in the context of differentiating hemodynamic vs. embolic stroke etiologies.</div></div></div></div></div>"}, {"id": 100022945, "question_number": "162", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] - Watershed (border zone) infarcts occur in regions between two non\u2010anastomosing arterial territories (e.g., ACA/MCA, MCA/PCA) and are especially vulnerable to systemic hypoperfusion.  <br><span class=\"list-item\">\u2022</span> Early cytotoxic edema in acute ischemia is detected as diffusion restriction on MRI&rsquo;s diffusion\u2010weighted imaging (DWI) sequences, often within minutes of onset.  <br><span class=\"list-item\">\u2022</span> Fluid\u2010attenuated inversion recovery (FLAIR) and apparent diffusion coefficient (ADC) maps localize and age infarcts, distinguishing acute from chronic lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI with DWI has a sensitivity >95% for detecting acute ischemic changes compared to <50% for CT.1 In watershed infarcts&mdash;often small and cortical or subcortical&mdash;DWI visualizes cytotoxic edema within minutes to hours, guiding acute management. FLAIR sequences differentiate hyperacute (<6 h) from subacute infarcts.2 CTA visualizes vessel patency and collateral flow but lacks parenchymal resolution to define microinfarcts. PET scanning is primarily a research tool for cerebral metabolism and is not used routinely in acute stroke. Skull X-rays have no soft\u2010tissue contrast and cannot detect infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. CTA  <br>&bull; Reason incorrect: Visualizes luminal stenosis and collaterals, not parenchymal ischemic injury.  <br>&bull; Misconception: Equating vessel imaging with infarct detection.  <br>&bull; Differentiator: CTA is excellent for large\u2010vessel occlusion but insensitive for early cytotoxic edema.  <br><br>C. PET scan  <br>&bull; Reason incorrect: Measures cerebral glucose metabolism and blood flow, used in research and epilepsy mapping, not standard for acute infarct detection.  <br>&bull; Misconception: Belief that metabolic imaging replaces structural imaging in stroke.  <br>&bull; Differentiator: Low spatial resolution and limited availability.  <br><br>D. X-ray  <br>&bull; Reason incorrect: Cannot visualize brain parenchyma or ischemia.  <br>&bull; Misconception: General radiograph utility across body systems.  <br>&bull; Differentiator: Only bone/detail visualization; no soft\u2010tissue contrast.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Modality</th><th>Principle</th><th>Sensitivity for Acute Watershed Infarction</th><th>Clinical Role</th></tr></thead><tbody><tr><td>MRI (DWI)</td><td>Detects water diffusion restriction</td><td>>95%</td><td>Gold standard for early ischemia</td></tr><tr><td>CTA</td><td>Contrast CT angiography of vessels</td><td>~30&ndash;50% for parenchymal changes</td><td>Vessel patency, collateral assessment</td></tr><tr><td>PET scan</td><td>Measures cerebral metabolism & perfusion</td><td>~60% (research settings)</td><td>Research/epilepsy, not acute stroke</td></tr><tr><td>X-ray</td><td>Projection radiography of bone/air</td><td>0%</td><td>None for brain infarction</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In acute stroke, prioritize an MRI with DWI when available, as it defines infarct core and guides reperfusion decisions.  <br><span class=\"list-item\">\u2022</span> Watershed infarcts often present with &ldquo;man\u2010in\u2010a\u2010barrel&rdquo; syndrome (proximal arm weakness) in ACA/MCA border zones.  <br><span class=\"list-item\">\u2022</span> CT perfusion can complement CTA to approximate penumbra but still lags behind DWI MRI in specificity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming CT angiography (CTA) will show small cortical or subcortical infarcts rather than just vascular anatomy.  <br><span class=\"list-item\">\u2022</span> Believing PET scans are used clinically for acute stroke rather than investigational metabolic assessment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Acute Ischemic Stroke Guidelines:  <br>   &ndash; Recommendation: MRI with DWI is preferred for diagnosing acute stroke when it does not delay treatment (Class I, Level A).3  <br>2. ESO&ndash;ESMINT 2021 Guidelines:  <br>   &ndash; Recommendation: Use DWI MRI to identify infarct core and assess eligibility for endovascular therapy beyond 6 hours (Level B).4</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Watershed regions lie at distal fields of the ACA/MCA (anterior watershed) and MCA/PCA (posterior watershed). These zones have terminal arterioles with limited collateral support, making them vulnerable in hypotension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Systemic hypoperfusion or proximal arterial stenosis reduces cerebral perfusion pressure. In border zones, autoregulation fails first, leading to energy failure, Na\u207a/K\u207a\u2010ATPase dysfunction, cytotoxic edema, and diffusion restriction on MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DWI: Hyperintense signal with corresponding low ADC confirms acute infarction.  <br><span class=\"list-item\">\u2022</span> FLAIR/DWI mismatch can estimate stroke onset within the therapeutic window.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Border zone infarcts and imaging modalities are frequently tested, often as scenario\u2010based questions requiring recognition of DWI&rsquo;s role in early ischemia detection.  <br><br>References:  <br>1. Warach et al., NEJM 1995;333(21):1454&ndash;1459.  <br>2. Lansberg et al., <span class=\"evidence\">Stroke 2001</span>;32(11):2632&ndash;2637.  <br>3. Powers et al., <span class=\"evidence\">Stroke 2018</span>;49(3):e46&ndash;e110.  <br>4. Nogueira et al., Eur Stroke J 2021;6(1):I&ndash;XXX.</div></div></div></div></div>"}, {"id": 100022946, "question_number": "250", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Cerebral vasospasm is a delayed, sustained constriction of intracranial arteries following subarachnoid hemorrhage (SAH), leading to delayed cerebral ischemia (DCI). In traumatic brain injury (TBI) with associated SAH, blood breakdown products trigger endothelial dysfunction and smooth muscle contraction. Nimodipine, a lipophilic dihydropyridine calcium\u2010channel blocker, crosses the blood&ndash;brain barrier and preferentially relaxes cerebral vessels. Prophylactic administration aims to reduce DCI and poor functional outcome. Students should understand:  <br><span class=\"list-item\">\u2022</span> Pathophysiology of blood\u2010induced arterial spasm (endothelin release, free radical generation)  <br><span class=\"list-item\">\u2022</span> Role of L\u2010type Ca2+ channels in vascular smooth muscle contraction  <br><span class=\"list-item\">\u2022</span> Distinction between prophylaxis (nimodipine in SAH) vs. acute ICP management (hyperventilation)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. IV fluids  <br><span class=\"list-item\">\u2022</span> Reason incorrect: While adequate volume status supports cerebral perfusion, hypervolemia alone has not been shown to prevent vasospasm or DCI. Misconception: &ldquo;Triple\u2010H&rdquo; therapy prophylaxis includes hypervolemia; in fact, induced hypertension (not simple IV fluids) treats established vasospasm.  <br><br>C. Hyperventilation  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Lowers PaCO\u2082 and causes cerebral vasoconstriction, reducing intracranial pressure at the cost of CBF, which can exacerbate ischemia in vasospasm. Misconception: Any vasoconstriction is beneficial for ICP control, but in vasospasm it is harmful.  <br><br>D. Antiepileptic drugs  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Seizure prophylaxis does not influence vascular smooth muscle or prevent vasospasm. Misconception: &ldquo;Preventing seizures prevents secondary ischemia,&rdquo; but this does not address spasm\u2010mediated DCI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Evidence for Vasospasm Prophylaxis</th><th>Recommended Use</th></tr></thead><tbody><tr><td>Nimodipine</td><td>L\u2010type Ca\u00b2\u207a channel blockade; neuroprotection</td><td>RCTs and meta\u2010analyses show reduced DCI and poor outcome</td><td>Oral 60 mg q4h \u00d7 21 days in SAH patients</td></tr><tr><td>IV fluids</td><td>Increases intravascular volume</td><td>No RCT support for prophylaxis; risk of cerebral edema</td><td>Maintain euvolemia; avoid hypervolemia alone</td></tr><tr><td>Hyperventilation</td><td>\u2193PaCO\u2082 \u2192 vasoconstriction</td><td>Contraindicated prophylactically; worsens ischemia</td><td>Short\u2010term ICP control only</td></tr><tr><td>Antiepileptic</td><td>Stabilizes neuronal membranes</td><td>No effect on vasospasm or DCI</td><td>Seizure prophylaxis in TBI only</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Nimodipine should be initiated within 96 hours of hemorrhage and continued for 21 days to reduce DCI and improve outcomes.  <br><span class=\"list-item\">\u2022</span> &ldquo;Triple\u2010H&rdquo; therapy components differ: prophylaxis relies solely on nimodipine; induced hypertension (not hypervolemia) is used to reverse established vasospasm.  <br><span class=\"list-item\">\u2022</span> Avoid prophylactic hyperventilation (PaCO\u2082 <30 mm Hg) in vasospasm risk&mdash;can precipitate ischemic deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating prophylactic hyperventilation with vasospasm prevention; in reality it decreases CBF and worsens ischemia.  <br>2. Believing seizure prophylaxis (e.g., phenytoin) mitigates vasospasm&mdash;anticonvulsants have no effect on vascular smooth muscle.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2012 Guidelines for Aneurysmal Subarachnoid Hemorrhage &ndash; Class I, Level A recommendation for oral nimodipine to prevent DCI and poor outcome.  <br>2. Cochrane Review <span class=\"citation\">(<span class=\"evidence\">Gedge et al., 2016</span>)</span> &ndash; Nimodipine reduces the risk of poor functional outcome (RR 0.82) in SAH patients; moderate\u2010quality evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Nimodipine is a dihydropyridine calcium\u2010channel blocker with high lipophilicity allowing CNS penetration. Standard dosing: 60 mg po every 4 hours for 21 days. Monitor for hypotension; hold if systolic BP <90 mm Hg. IV formulations are not recommended due to risk of severe hypotension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Cerebral vasospasm prophylaxis with nimodipine is a high\u2010yield topic on neurology and critical care boards, frequently tested via SAH vignettes asking about delayed ischemia prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. Nimodipine. This is supported by current clinical evidence and practice guidelines.</div></div></div></div></div>"}, {"id": 100022947, "question_number": "182", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] tPA (alteplase) promotes fibrinolysis but increases bradykinin, which can cause angioedema&mdash;most often involving the tongue or oropharynx. Angioedema may be histamine-mediated, bradykinin-mediated, or mixed; risk factors include concurrent ACE-inhibitor use and insular cortex infarcts. Early recognition is <span class=\"key-point\">critical:</span> mild cases without airway compromise respond to anti-inflammatory measures, whereas impending airway obstruction mandates intubation. Dysarthria from tongue swelling reflects oropharyngeal edema rather than new neurologic decline.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Steroids plus antihistamines constitute first-line therapy for moderate tPA-induced angioedema without airway compromise. <span class=\"evidence\">The 2019</span> AHA/ASA Acute Stroke Guidelines (Powers et al.) recommend IV methylprednisolone (e.g., 125 mg) with H1 (diphenhydramine 50 mg IV) and H2 blockers (ranitidine 50 mg IV) for orolingual angioedema (Class IIa, Level C-LD). tPA increases bradykinin by plasmin-mediated activation of the kinin cascade; histamine blockade and steroids reduce capillary permeability and swelling. Epinephrine can be added if progression occurs. Prophylactic icatibant (bradykinin B2 receptor antagonist) has been used in refractory cases. Immediate intubation is reserved for stridor, hypoxia, or rapid progression; routine prophylactic airway control is not indicated when the patient maintains a patent airway.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Intubation  <br>&bull; Incorrect because there is no evidence of airway compromise (e.g., stridor, hypoxia).  <br>&bull; Misconception: that all angioedema mandates airway control. Prophylactic intubation risks ventilator-associated complications and is reserved for impending obstruction.  <br><br>C. ACE inhibitor with diuretics  <br>&bull; ACE inhibitors increase bradykinin and are a known cause of angioedema&mdash;contraindicated here.  <br>&bull; Diuretics do not reduce angioedema and may worsen hypotension or renal perfusion in stroke patients.  <br><br>D. Observation and supportive care  <br>&bull; Passive observation delays definitive therapy; moderate angioedema unaddressed can progress to airway compromise.  <br>&bull; Common mistake: underestimating oropharyngeal swelling in patients who remain hemodynamically stable.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Indication in tPA Angioedema</th><th>Appropriate Here?</th></tr></thead><tbody><tr><td>A. Intubation</td><td>Secures airway via endotracheal tube</td><td>Only if signs of airway compromise (stridor, hypoxia)</td><td>No</td></tr><tr><td>B. Steroid + Antihistamine</td><td>Reduces histamine-mediated inflammation and capillary leak</td><td>First-line for moderate orolingual angioedema without airway threat</td><td>Yes</td></tr><tr><td>C. ACE Inhibitor + Diuretics</td><td>Inhibits angiotensin conversion; promotes diuresis</td><td>ACE inhibitors aggravate bradykinin-mediated angioedema; diuretics irrelevant</td><td>No</td></tr><tr><td>D. Observation & Supportive Care</td><td>Watchful waiting</td><td>Reserved for very mild, non-progressive edema</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- tPA-induced angioedema occurs in ~1&ndash;5% of patients, often within 30&ndash;60 minutes of infusion.  <br><span class=\"list-item\">\u2022</span> Concurrent ACE-inhibitor use doubles the risk; inquire about home medications pre-thrombolysis.  <br><span class=\"list-item\">\u2022</span> Icatibant (bradykinin B2-receptor antagonist) may be considered in refractory or rapidly progressing cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming all angioedema requires immediate intubation&mdash;airway management should be guided by clinical signs, not radiographic severity alone.  <br>2. Believing ACE inhibitors and diuretics mitigate angioedema&mdash;ACE inhibitors precipitate bradykinin accumulation; diuretics have no role.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1.<span class=\"evidence\"> Powers WJ et al., 2019</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke: Recommend IV steroids plus H1/H2 blockade for tPA-induced orolingual angioedema (Class IIa, Level C-LD).  <br>2.<span class=\"evidence\"> Kaplan AP et al., 2020</span> AAAAI Consensus on Bradykinin-Mediated Angioedema: Endorses icatibant as adjunctive therapy for tPA-related cases refractory to antihistamines/steroids (Expert Opinion).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. On neurology boards, angioedema due to tPA is frequently tested in clinical vignettes focusing on timing (during or immediately after infusion), risk factors (ACE inhibitors, insular infarcts), and stepwise management (steroids/antihistamines \u2192 epinephrine \u2192 icatibant \u2192 airway assessment).</div></div></div></div></div>"}, {"id": 100022948, "question_number": "100", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Intracranial aneurysms arise at arterial bifurcations (e.g., the A.Com junction) due to focal vessel wall weakness. Hemodynamic stress (wall shear stress) and vessel radius interplay per Laplace&rsquo;s law: wall tension \u221d pressure \u00d7 radius. Larger aneurysms impose greater wall tension and thinner walls, increasing rupture risk. Other modulators include local flow dynamics (influenced by location), systemic factors (hypertension), and biological factors (sex hormones). Understanding aneurysm morphology and hemodynamics is fundamental for risk stratification and management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Size of the aneurysm is the single strongest predictor of rupture. In the ISUIA cohort <span class=\"citation\">(<span class=\"evidence\">Wiebers et al., 2003</span>, JAMA)</span>, unruptured anterior circulation aneurysms <7 mm had a five-year rupture rate <0.1%, whereas those &ge;10 mm approached 1&ndash;2% per year. The PHASES score <span class=\"citation\">(<span class=\"evidence\">Greving et al., 2014</span>, NEJM)</span> assigns the greatest weight to size (points: <7 mm=0, 7&ndash;9 mm=3, 10&ndash;19 mm=6, &ge;20 mm=10). AHA/ASA 2015 guidelines recommend considering treatment for aneurysms &ge;7 mm in anterior circulation (Class IIA, Level B). Mechanistically, larger aneurysms have increased circumference and wall tension, making them more prone to focal wall degeneration and rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Location of the aneurysm  <br>&bull; While posterior circulation aneurysms (e.g., basilar tip) carry higher baseline rupture rates than anterior communicating ones, within A.Com lesions size remains more predictive than sub\u2010site variations.  <br>&bull; Misconception: &ldquo;All posterior aneurysms are most dangerous.&rdquo; Differentiator: absolute rupture risk within one vessel location is dominated by size.  <br><br>C. Uncontrolled blood pressure  <br>&bull; Hypertension elevates transmural pressure and contributes to aneurysm formation and growth, but does not independently predict rupture as strongly as size.  <br>&bull; Misconception: &ldquo;Poorly controlled BP alone drives rupture.&rdquo; In reality, size amplifies wall tension more significantly.  <br><br>D. Female gender  <br>&bull; Females have ~1.5\u00d7 higher incidence of aneurysms, possibly due to estrogen effects on vessel integrity, but sex alone does not predict which aneurysm will rupture.  <br>&bull; Misconception: &ldquo;Women&rsquo;s aneurysms rupture more often.&rdquo; Differentiator: gender is non\u2010modifiable and weakly associated compared to quantitative size metrics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Factor</th><th>Relative Rupture Risk</th><th>Modifiable?</th><th>Weight in PHASES Score</th></tr></thead><tbody><tr><td>Size &ge;10 mm (correct)</td><td>High (1&ndash;2%/yr for &ge;10 mm; up to 6%/yr if &ge;25 mm)</td><td>No</td><td>6&ndash;10 points</td></tr><tr><td>Location (A.Com vs PCOM)</td><td>Moderate (posterior > anterior; \u223c0.5% vs 0.1%/yr)</td><td>No</td><td>2 points (posterior)</td></tr><tr><td>Uncontrolled BP</td><td>Low incremental risk (HR ~1.2)</td><td>Yes</td><td>1 point</td></tr><tr><td>Female gender</td><td>Low (RR ~1.5 overall)</td><td>No</td><td>0 points</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Aneurysms &ge;7 mm in anterior circulation should prompt discussion of preventive intervention (AHA/ASA Class IIA).  <br>&bull; PHASES score integrates size, age, hypertension, earlier SAH, aneurysm site, and population to estimate 5-year rupture risk.  <br>&bull; Regular imaging surveillance intervals are guided primarily by aneurysm size trajectory rather than patient sex or baseline BP alone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overemphasizing location: Believing an A.Com aneurysm automatically has higher rupture risk than any posterior lesion, when size thresholds supersede location within the same vessel.  <br>2. Equating hypertension control with immediate rupture risk reduction: While vital for prevention, acute size-mediated wall tension drives rupture, not transient BP variations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2015 Guidelines on Management of Unruptured Intracranial Aneurysms: Recommend consideration of repair for anterior circulation aneurysms &ge;7 mm (Class IIA, Level B).  <br>&bull;<span class=\"evidence\"> Greving et al., 2014</span> (NEJM) PHASES Study: Established a validated risk score; size contributed the largest point allocation, underscoring its predictive value (Level of Evidence: B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The anterior communicating artery connects the A1 segments of the anterior cerebral arteries. Flow convergence at this junction creates complex shear stress patterns predisposing to aneurysm formation. Aneurysm domes project superiorly or posteriorly, with wall morphology influencing rupture propensity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Aneurysm growth and rupture result from chronic endothelial injury, inflammatory cell infiltration, extracellular matrix degradation, and smooth muscle apoptosis. Laplace&rsquo;s law explains why larger aneurysms, having greater radius, endure disproportionately higher wall tension, accelerating wall degeneration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>On neurology and neurosurgery boards, questions on aneurysm rupture risk frequently test size thresholds (e.g., 7 mm vs. 10 mm), PHASES score components, and guideline-based management indications.</div></div></div></div></div>"}, {"id": 100022949, "question_number": "75", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] - Atherosclerotic plaque in the internal carotid artery narrows the lumen, increasing ipsilateral stroke risk via hypoperfusion or artery-to-artery embolism.  <br><span class=\"list-item\">\u2022</span> Symptomatic stenosis (TIA or stroke) &ge;70% warrants prompt revascularization; 50&ndash;69% may also qualify in high-risk surgical candidates.  <br><span class=\"list-item\">\u2022</span> Carotid artery stenting (CAS) is the percutaneous endovascular approach: balloon angioplasty, stent deployment, and distal embolic protection.  <br><span class=\"list-item\">\u2022</span> Alternative definitive revascularization is carotid endarterectomy (CEA); antiplatelet agents and anticoagulants serve as adjunctive medical therapy, not primary interventional solutions in high-grade stenosis.  <br><br>(\u2248110 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Carotid artery stenting is the sole endovascular revascularization technique among the options. <span class=\"evidence\">The 2017</span> AHA/ASA Stroke Prevention Guidelines recommend revascularization for symptomatic patients with 70&ndash;99% stenosis (Class I, Level A) and endorse CAS in patients at high surgical risk or age <70 (Class I, Level B). The CREST trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2010</span>;363:11&ndash;23)</span> randomized 2,502 patients to CEA versus CAS and found no significant difference in the composite endpoint of stroke, myocardial infarction, or death at 4 years (7.2% vs. 6.8%, p=0.51). Subgroup analyses demonstrated higher peri-procedural stroke with CAS in those >70 but lower myocardial infarction rates. Thus, CAS is evidence-based for selected symptomatic carotid stenosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Carotid endarterectomy  <br><span class=\"list-item\">\u2022</span> Incorrect: Open surgical removal of plaque, not an endovascular stenting procedure.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any revascularization with stenting.  <br><span class=\"list-item\">\u2022</span> Differentiator: CEA involves arteriotomy and plaque excision under general anesthesia.<br><br>B. Antiplatelet therapy  <br><span class=\"list-item\">\u2022</span> Incorrect: Medical management reducing platelet aggregation; does not mechanically restore lumen diameter.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming pharmacotherapy alone suffices for high-grade symptomatic stenosis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Adjunctive therapy; lacks immediate plaque debulking.<br><br>D. Anticoagulation  <br><span class=\"list-item\">\u2022</span> Incorrect: Targets thrombin/fibrin pathways; not indicated for atherosclerotic carotid stenosis without other indications (e.g., atrial fibrillation).  <br><span class=\"list-item\">\u2022</span> Misconception: Believing anticoagulants prevent artery-to-artery emboli in stenotic carotid disease.  <br><span class=\"list-item\">\u2022</span> Differentiator: Does not revascularize stenotic segment and increases hemorrhagic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Stenting (C)</th><th>CEA (A)</th><th>Antiplatelet (B)</th><th>Anticoagulation (D)</th></tr></thead><tbody><tr><td>Approach</td><td>Percutaneous endovascular</td><td>Open surgical</td><td>Oral medical</td><td>Oral medical</td></tr><tr><td>Indication</td><td>Symptomatic &ge;70%, high-risk CEA</td><td>Symptomatic &ge;70%, standard surgical risk</td><td>Secondary prevention post-TIA/stroke</td><td>Not indicated for atherosclerosis</td></tr><tr><td>Peri-procedural stroke risk</td><td>4&ndash;6% (higher in >70 years)</td><td>2&ndash;4%</td><td>N/A</td><td>N/A</td></tr><tr><td>Peri-procedural MI risk</td><td>~1%</td><td>3&ndash;5%</td><td>N/A</td><td>N/A</td></tr><tr><td>Major trial</td><td>CREST: noninferior to CEA overall</td><td>NASCET: benefit in &ge;70% stenosis</td><td>CHARISMA: reduced events post-stroke</td><td>No trial support in carotid athero.</td></tr><tr><td>Embolic protection device needed</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Optimal timing: Perform CAS within 2 weeks of the index TIA or stroke for maximal benefit.  <br><span class=\"list-item\">\u2022</span> Age considerations: Patients >70 years have higher periprocedural stroke rates with CAS; favor CEA in this group.  <br><span class=\"list-item\">\u2022</span> Embolic protection: Use a distal filter or proximal occlusion device during CAS to reduce microembolic showers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating antiplatelet or anticoagulant therapy with mechanical revascularization in high-grade stenosis.  <br>2. Ignoring patient surgical risk and age when selecting CAS versus CEA, leading to increased complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. 2017 AHA/ASA Guideline on the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack  <br><span class=\"list-item\">\u2022</span> Recommends revascularization (either CEA or CAS) for symptomatic stenosis 70&ndash;99% (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> Endorses CAS in high surgical-risk or age <70 (Class I, Level B).  <br>2. CREST Trial (Carotid Revascularization Endarterectomy vs. Stenting Trial), 2010  <br><span class=\"list-item\">\u2022</span> Randomized 2,502 patients; no difference in primary composite endpoint at 4 years (7.2% vs. 6.8%, p=0.51).  <br><span class=\"list-item\">\u2022</span> Age >70 associated with higher stroke risk in CAS; myocardial infarction more common in CEA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>Carotid revascularization strategies&mdash;indications, comparative risks of CEA vs CAS, and landmark trials (e.g., CREST)&mdash;are frequently tested topics, often in vignette format requiring selection of appropriate intervention based on patient age, symptomatic status, and surgical risk.</div></div></div></div></div>"}, {"id": 100022950, "question_number": "129", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Aneurysmal subarachnoid hemorrhage classically presents with a sudden, severe headache (&ldquo;thunderclap&rdquo;). Compression of cranial nerve III (oculomotor nerve) by an aneurysm causes ipsilateral pupil dilation due to parasympathetic fiber involvement. Key concepts:  <br><span class=\"list-item\">\u2022</span> Cranial nerve III carries parasympathetic fibers on its peripheral aspect; compressive lesions (e.g., aneurysms) injure these fibers first, producing a &ldquo;blown&rdquo; pupil.  <br><span class=\"list-item\">\u2022</span> Posterior communicating artery aneurysms abut the oculomotor nerve in the interpeduncular cistern.  <br><span class=\"list-item\">\u2022</span> Ischemic &ldquo;microvascular&rdquo; third-nerve palsies (e.g., diabetic) spare the pupil, differentiating them from compressive lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Posterior communicating artery (PCom) aneurysms account for ~25% of intracranial aneurysms and are the prototype for compressive third-nerve palsy with pupillary involvement. Parasympathetic fibers lie superficially; external compression by a saccular aneurysm produces an early dilated, nonreactive pupil preceding or accompanying extraocular muscle weakness. <span class=\"evidence\">The 2015</span> AHA/ASA Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage recommend immediate non-contrast head CT followed by CT angiography in suspected aneurysmal SAH (Class I, Level B). Early identification and surgical or endovascular repair of PCom aneurysms with cranial nerve palsy is supported by multiple series demonstrating improved neurological outcomes when intervention occurs within 72 hours of onset.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Anterior communicating artery  <br><span class=\"list-item\">\u2022</span> Why incorrect: AComm aneurysms typically compress the optic chiasm or cause frontal lobe symptoms; they seldom produce isolated CN III palsy.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all circle-of-Willis aneurysms affect CN III.  <br><span class=\"list-item\">\u2022</span> Differentiation: AComm lesions cause visual field cuts (bitemporal hemianopsia), not pupillary dilation.  <br><br>C. Anterior cerebral artery  <br><span class=\"list-item\">\u2022</span> Why incorrect: ACA infarcts or aneurysms present with contralateral leg weakness, abulia, or frontal lobe signs, without oculomotor involvement.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any anterior circulation lesion with third-nerve signs.  <br><span class=\"list-item\">\u2022</span> Differentiation: ACA lesions spare cranial nerve III entirely.  <br><br>D. Posterior cerebral artery  <br><span class=\"list-item\">\u2022</span> Why incorrect: PCA lesions classically produce contralateral homonymous hemianopia (occipital lobe), not isolated oculomotor nerve palsy.  <br><span class=\"list-item\">\u2022</span> Misconception: Overgeneralizing posterior circulation to include all cranial nerve presentations.  <br><span class=\"list-item\">\u2022</span> Differentiation: PCA infarcts do not impinge on the oculomotor nerve in the interpeduncular cistern.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PCom Aneurysm (Correct)</th><th>AComm Aneurysm</th><th>ACA Lesion</th><th>PCA Lesion</th></tr></thead><tbody><tr><td>Vascular origin</td><td>Posterior communicating artery</td><td>Anterior communicating artery</td><td>Anterior cerebral artery</td><td>Posterior cerebral artery</td></tr><tr><td>Typical presentation</td><td>&ldquo;Blown&rdquo; pupil, headache, possible ophthalmoplegia</td><td>Visual field defects, headache</td><td>Contralateral leg weakness, frontal signs</td><td>Homonymous hemianopia, visual cortex signs</td></tr><tr><td>Pupillary involvement</td><td>Yes (parasympathetic fiber compression)</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Pathomechanism</td><td>Compressive saccular aneurysm</td><td>Mass effect near optic chiasm</td><td>Ischemic infarct or mass effect</td><td>Ischemic infarct in occipital lobe</td></tr><tr><td>Recommended imaging</td><td>Non-contrast CT \u2192 CTA/DSA</td><td>Non-contrast CT \u2192 CT/MR for mass effect</td><td>MRI/CT brain for infarct</td><td>MRI/CT brain for infarct</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- &ldquo;Rule of the pupil&rdquo;: Compressive third-nerve palsies (aneurysm, tumor) involve the pupil; microvascular palsies (diabetes, hypertension) spare it.  <br><span class=\"list-item\">\u2022</span> In suspected aneurysmal SAH with focal deficits, obtain non-contrast head CT immediately, then CTA before transfer to definitive care.  <br><span class=\"list-item\">\u2022</span> Even in the absence of subarachnoid blood on CT after 6 hours, a dilated pupil mandates vascular imaging to exclude a PCom aneurysm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misattributing pupil-sparing third-nerve palsy to an aneurysm rather than ischemia.  <br>2. Overlooking CN III compression in posterior circulation aneurysms by focusing only on motor deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association, &ldquo;Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage,&rdquo; 2015: Recommends emergent non-contrast CT followed by CTA in suspected aneurysmal SAH (Class I, Level B).  <br>2. International Subarachnoid Aneurysm Trial (ISAT), 2002: Demonstrated superior functional outcomes at 1 year with endovascular coiling versus surgical clipping in ruptured aneurysms (Level A evidence), informing treatment of PCom aneurysms causing CN III palsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Localization of third-nerve palsy with pupillary involvement is a high-yield topic, frequently tested as an imaging vignette or classic &ldquo;blown pupil&rdquo; scenario to distinguish compressive from ischemic etiologies.</div></div></div></div></div>"}, {"id": 100022951, "question_number": "154", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Atrial fibrillation (AF) leads to stasis in the left atrial appendage, promoting thrombus formation that can embolize to cerebral arteries. Cardioembolic strokes often involve the middle cerebral artery, producing contralateral hemiplegia. Secondary prevention in AF prioritizes systemic anticoagulation over antiplatelet therapy because anticoagulants target the coagulation cascade responsible for atrial thrombi. Key terms: CHA\u2082DS\u2082-VASc score to stratify stroke risk; vitamin K antagonists; novel oral anticoagulants (DOACs).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Warfarin reduces ischemic stroke risk by approximately 64% in AF <span class=\"citation\">(Hart et al., NEJM 2007)</span>. <span class=\"evidence\">The 2019</span> AHA/ASA Secondary Stroke Prevention Guideline (Class I, Level A) recommends oral anticoagulation for patients with non-valvular AF and CHA\u2082DS\u2082-VASc &ge;2. DOACs (dabigatran, rivaroxaban, apixaban) are now preferred in non-valvular AF, but warfarin remains standard for valvular AF or where DOACs are contraindicated (e.g., mechanical valves). Warfarin&rsquo;s inhibition of vitamin K&ndash;dependent factors II, VII, IX, X prevents clot propagation in the left atrium. Its efficacy is supported by large RCTs and meta-analyses; therapeutic INR (2.0&ndash;3.0) balances stroke reduction against hemorrhagic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. ASA  <br><span class=\"list-item\">\u2022</span> ASA only inhibits platelet COX-1, decreasing stroke risk by ~20% versus the 64% reduction with warfarin.  <br><span class=\"list-item\">\u2022</span> Misconception: platelet aggregation drives cardioembolic events; actually, fibrin-rich clots in AF need anticoagulation.  <br><br>B. ASA & Plavix  <br><span class=\"list-item\">\u2022</span> Dual antiplatelet therapy adds bleeding risk without significant incremental stroke prevention in AF.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;more antiplatelet equals better prevention&rdquo; neglects pathophysiology of atrial thrombi.  <br><br>D. LMWH  <br><span class=\"list-item\">\u2022</span> Low&ndash;molecular-weight heparin is used acutely (e.g., bridging periprocedurally), not for long-term AF stroke prevention.  <br><span class=\"list-item\">\u2022</span> Misconception: any anticoagulant suffices; LMWH is impractical for chronic management and lacks long-term efficacy data in AF.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Stroke RR Reduction</th><th>Bleeding Risk</th></tr></thead><tbody><tr><td>Warfarin [CORRECT]</td><td>Vitamin K antagonist (II, VII, IX, X)</td><td>~64% <span class=\"citation\">(<span class=\"evidence\">Hart et al. 2007</span>)</span></td><td>Moderate (INR\u2010dependent)</td></tr><tr><td>ASA</td><td>COX-1 inhibitor (platelet)</td><td>~20% <span class=\"citation\">(EAFT 1993)</span></td><td>Low</td></tr><tr><td>ASA & Plavix</td><td>COX-1 + P2Y\u2081\u2082 blockade</td><td>~22% <span class=\"citation\">(MATCH 2004)</span></td><td>High</td></tr><tr><td>LMWH</td><td>Anti-Xa & anti-IIa</td><td>Not established long-term</td><td>Variable</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Calculate CHA\u2082DS\u2082-VASc: &ge;2 in men mandates anticoagulation (Class I).  <br>2. DOACs preferred in non-valvular AF due to lower intracranial hemorrhage (ARISTOTLE, ENGAGE-AF).  <br>3. Delay anticoagulation 4&ndash;14 days post-stroke based on infarct size to reduce hemorrhagic transformation risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Choosing antiplatelets over anticoagulants in AF: underestimates cardioembolism risk.  <br>2. Initiating anticoagulation immediately after large infarcts: ignores hemorrhagic conversion timing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Secondary Stroke Prevention Guideline: &ldquo;Oral anticoagulation is recommended for patients with non-valvular AF and CHA\u2082DS\u2082-VASc &ge;2&rdquo; (Class I, LOE A).  <br>2. ESC 2020 Atrial Fibrillation Guidelines: DOACs preferred over VKAs in non-valvular AF (Class I, LOE B); warfarin for mechanical valves (Class I, LOE C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>An embolus lodging in the left MCA territory disrupts perfusion to the precentral gyrus and internal capsule, causing contralateral (right-sided) upper motor neuron signs (hemiplegia, hyperreflexia).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>AF \u2192 atrial blood stasis \u2192 left atrial appendage thrombus \u2192 embolization to cerebral circulation \u2192 arterial occlusion \u2192 ischemic cascade (energy failure, excitotoxicity, cytotoxic edema).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT/MRI to exclude hemorrhage.  <br>2. ECG/Holter monitoring for AF detection.  <br>3. Echocardiography (TEE) to visualize atrial thrombus.  <br>4. Initiate anticoagulation guided by stroke size and hemorrhage risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; CT perfusion delineates penumbra vs core infarct.  <br>&bull; DWI MRI detects ischemia within minutes, guiding early treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Warfarin: initial dose 5 mg daily, adjust to INR 2.0&ndash;3.0; check INR biweekly until stable.  <br>&bull; DOAC alternatives: Apixaban 5 mg BID (reduce in renal impairment), Dabigatran 150 mg BID.  <br>&bull; Bridging with LMWH until INR therapeutic if high cardioembolic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam.  <br>Atrial fibrillation&ndash;related stroke prevention is frequently tested as vignettes requiring CHA\u2082DS\u2082-VASc calculation and guideline-based anticoagulation selection, often contrasting antiplatelet versus anticoagulant strategies.</div></div></div></div></div>"}, {"id": 100022952, "question_number": "90", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Sickle cell disease leads to chronic hemolysis and vaso-occlusion, causing intimal hyperplasia and stenosis of large intracranial arteries (especially the distal internal carotid and middle cerebral arteries). According to fluid dynamics (Poiseuille&rsquo;s law), luminal narrowing increases flow velocity. Transcranial Doppler (TCD) ultrasound noninvasively measures these velocities in the circle of Willis&mdash;elevated velocities (>200 cm/s) correlate strongly with future stroke risk in pediatric SCD. Early identification of high-risk velocities allows timely initiation of chronic transfusion therapy to prevent first strokes.<br><br>(Word count: 111)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The landmark STOP trial <span class=\"citation\">(Stroke Prevention Trial in Sickle Cell Anemia, NEJM 1998)</span> randomized children with elevated TCD velocities (>200 cm/s) to chronic transfusion versus standard care. Transfused children had a 92% reduction in first stroke risk <span class=\"citation\">(incidence 0.9 vs. 10.7 strokes per 100 patient-years, p<0.0001)</span>. Subsequent STOP II <span class=\"citation\">(<span class=\"evidence\">Blood 2005</span>)</span> supported discontinuation only after sustained normal velocities on transfusion. Current NHLBI (2014) and ASH (2020) guidelines recommend annual TCD screening in children 2&ndash;16 years with HbSS/S&beta;^0 thalassemia. No comparable prospective data validate CTA, MRI, or carotid duplex for primary stroke risk stratification in asymptomatic SCD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. CT Angiography (CTA)  <br><span class=\"list-item\">\u2022</span> CTA depicts luminal stenosis and collateral formation but lacks validated velocity thresholds for stroke risk prediction in SCD.  <br><span class=\"list-item\">\u2022</span> Involves ionizing radiation and iodinated contrast; not suitable for serial screening.  <br><br>C. MRI  <br><span class=\"list-item\">\u2022</span> Brain MRI (including diffusion-weighted imaging) identifies existing silent infarcts but does not quantify real-time hemodynamic stress or predict incident stroke risk.  <br><span class=\"list-item\">\u2022</span> Silent infarcts on MRI do increase long-term risk but require earlier velocity screening for prevention.  <br><br>D. Carotid ultrasound  <br><span class=\"list-item\">\u2022</span> Assesses extracranial common and internal carotid arteries; most SCD vasculopathy involves intracranial vessels.  <br><span class=\"list-item\">\u2022</span> Velocities in the proximal cervical carotid do not correlate with intracranial stenosis severity in this population.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Transcranial Doppler</th><th>CT Angiography</th><th>MRI Brain</th><th>Carotid Ultrasound</th></tr></thead><tbody><tr><td>Vessels assessed</td><td>Intracranial (MCA, ICA)</td><td>Extra- & intracranial</td><td>Parenchyma; vessel imaging limited</td><td>Extracranial carotids</td></tr><tr><td>Predictive value</td><td>High; STOP trial validated</td><td>Unvalidated for risk screening</td><td>Identifies silent infarcts only</td><td>Poor for intracranial stenosis</td></tr><tr><td>Radiation/contrast</td><td>None</td><td>Yes</td><td>No</td><td>None</td></tr><tr><td>Screening frequency</td><td>Annual (ages 2&ndash;16)</td><td>Not recommended</td><td>As clinically indicated</td><td>Not recommended</td></tr><tr><td>Noninvasive</td><td>Yes</td><td>Partially invasive (contrast)</td><td>Yes</td><td>Yes</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Annual TCD screening from ages 2 to 16 in HbSS/S&beta;^0 thalassemia reduces first-stroke risk by >90%.  <br>&bull; A TCD time-averaged mean velocity &ge;200 cm/s in the MCA or distal ICA defines high risk.  <br>&bull; Chronic transfusion therapy aiming for HbS <30% reverses elevated velocities and is the standard preventive measure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying on MRI to &ldquo;rule out&rdquo; future stroke: MRI detects past silent infarcts but cannot predict hemodynamic stress or imminent risk.  <br>2. Using extracranial carotid duplex as a proxy for intracranial stenosis: SCD vasculopathy predominantly affects distal intracranial vessels, undetected by cervical ultrasound.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. NHLBI Evidence-Based Management of Sickle Cell Disease (2014):  <br><span class=\"list-item\">\u2022</span> Recommendation: Annual TCD screening for children 2&ndash;16 years with HbSS or S&beta;^0 thalassemia (Grade A).  <br>2. American Society of Hematology Guidelines (2020):  <br><span class=\"list-item\">\u2022</span> Reaffirm use of TCD velocities >200 cm/s to initiate chronic transfusion for primary stroke prevention (Strong recommendation, moderate-quality evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Polymerization of deoxygenated HbS distorts red cells, promoting hemolysis and endothelial dysfunction. Repetitive injury induces smooth muscle proliferation in intracranial arteries, leading to concentric stenosis. Narrowing elevates flow velocity; persistent high shear stress predisposes to endothelial damage and thrombotic stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Stroke risk screening in pediatric sickle cell disease is frequently tested as a single-best-answer item, often referencing the STOP trial and annual TCD recommendations.</div></div></div></div></div>"}, {"id": 100022953, "question_number": "246", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Acute ischemic stroke results from sudden occlusion of cerebral arteries, leading to time-dependent neuronal injury. Thrombolytic therapy with intravenous alteplase (rtPA) is indicated within a 4.5-hour window to dissolve thrombi and restore perfusion. Candidate selection relies on neuroanatomical localization of deficits (NIHSS scoring) and exclusion of hemorrhagic or high-risk features via imaging and lab tests. Absolute contraindications include platelet count below 100\u200a000/\u00b5L due to elevated hemorrhagic transformation risk, while relative contraindications&mdash;like minor non-disabling deficits&mdash;are weighed case-by-case. Recognizing these parameters ensures maximal benefit with minimized intracranial hemorrhage. Familiarity with AHA/ASA criteria and contraindication classifications is essential for safe community-based stroke management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer (platelet count of 45,000) represents an absolute contraindication to IV alteplase per current guidelines. <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2018</span>)</span> assign a Class III (harm) recommendation against rtPA if platelet count <100\u200a000/\u00b5L; thrombocytopenia sharply elevates risk of symptomatic intracerebral hemorrhage (sICH). In pooled analyses <span class=\"citation\">(Hacke et al., Lancet <span class=\"evidence\">Neurol 2008</span>)</span>, patients with thrombocytopenia had a two- to threefold increase in sICH rates. Although the patient presented within the appropriate 3.5-hour window and had disabling deficits (NIHSS >5), administering rtPA in the context of severe thrombocytopenia directly violated protocol and contributed to hemorrhagic transformation. Other factors&mdash;such as time window compliance (3.5 h <4.5 h) and disabling deficits&mdash;were appropriate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Low deficit  <br>&bull; Why incorrect: The patient had severe dysarthria and flaccid weakness, consistent with an NIHSS >5, indicating disabling deficit.  <br>&bull; Misconception: Equating all motor deficits as &ldquo;minor&rdquo; regardless of functional impact.  <br>&bull; Differentiator: NIHSS threshold >5 qualifies as disabling, justifying rtPA absent other contraindications.<br><br>B. Out of tPA window  <br>&bull; Why incorrect: He presented within 3.5 hours (<4.5 hours) of symptom onset, fitting the approved time frame.  <br>&bull; Misconception: Confusing the strict 3-hour window with the extended 4.5-hour window.  <br>&bull; Differentiator: Extended window up to 4.5 hours is evidence-based (ECASS III).<br><br>D. Recent major surgery  <br>&bull; Why incorrect: No history of recent surgery was documented.  <br>&bull; Misconception: Assuming any severe stroke patient recently underwent surgery.  <br>&bull; Differentiator: Recent (past 14 days) intracranial or intraspinal surgery would contraindicate, but not present here.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Platelet <100 000/\u00b5L (C)</th><th>Low NIHSS Deficit (A)</th><th>>4.5 h Window (B)</th><th>Recent Surgery (D)</th></tr></thead><tbody><tr><td>Contraindication Type</td><td>Absolute (Class III, Harm)</td><td>Relative</td><td>N/A within 4.5 h</td><td>Absolute if intracranial</td></tr><tr><td>Guideline Reference</td><td>AHA/ASA 2018</td><td>AHA/ASA 2018</td><td>ECASS III</td><td>AHA/ASA 2018</td></tr><tr><td>Risk of sICH</td><td>High (>2\u00d7 baseline)</td><td>Low when truly minor</td><td>N/A if treated in window</td><td>High if intracranial surgery</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always verify laboratory values (platelets, INR) before rtPA; automated stroke protocols may skip manual review under time pressure.  <br><span class=\"list-item\">\u2022</span> Disabling deficits (NIHSS >5) justify rtPA even if motor function is the primary issue; document clearly.  <br><span class=\"list-item\">\u2022</span> Extended window to 4.5 hours (ECASS III) applies only in selected patients without additional risk factors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ignoring thrombocytopenia: Students often overlook platelet count as a contraindication, focusing solely on imaging.  <br><span class=\"list-item\">\u2022</span> Misjudging deficit severity: Motor weakness may seem &ldquo;minor&rdquo; if improving, but functional impairment dictates rtPA eligibility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines (Powers et al.): Platelet count <100 000/\u00b5L is a Class III (Harm), Level B&ndash;R contraindication to IV alteplase.  <br><span class=\"list-item\">\u2022</span> European Stroke <span class=\"evidence\">Organisation 2021</span> Guidelines: Reinforce contraindication for thrombocytopenia <100 000/\u00b5L (Grade 1C) and endorse ECASS III window extension.  <br><span class=\"list-item\">\u2022</span> EXTEND Trial <span class=\"citation\">(Ma et al., NEJM 2019)</span>: Supports perfusion-based selection to extend window up to 9 hours, but does not override absolute lab contraindications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Students are frequently tested on rtPA inclusion/exclusion criteria, especially laboratory-based contraindications and extended time windows.</div></div></div></div></div>"}, {"id": 100022954, "question_number": "105", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Moyamoya syndrome involves progressive stenosis of the distal internal carotid arteries (ICAs) and their proximal branches, leading to development of fragile collateral networks (&ldquo;moyamoya&rdquo; vessels). Key concepts:  <br><span class=\"list-item\">\u2022</span> Hemodynamic insufficiency in MCA/ACA territories predisposes to recurrent ischemic events.  <br><span class=\"list-item\">\u2022</span> Compensatory collaterals are insufficient under stress and prone to thrombosis or rupture.  <br><span class=\"list-item\">\u2022</span> Definitive management aims to augment cerebral blood flow via surgical revascularization rather than solely pharmacologic measures.  <br>Understanding the difference between symptomatic hemodynamic failure and embolic stroke guides the choice of therapy in Moyamoya.  <br>(120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Revascularization surgery&mdash;direct bypass (superficial temporal artery&ndash;middle cerebral artery anastomosis) or indirect techniques (encephaloduroarteriosynangiosis)&mdash;directly restores perfusion, alleviating hemodynamic insufficiency. <span class=\"evidence\">The 2012</span> AHA/ASA scientific statement on Moyamoya (Class I, Level B) endorses revascularization in symptomatic patients to reduce recurrent ischemia. A meta-analysis <span class=\"citation\">(<span class=\"evidence\">Stroke 2018</span>;49:22&ndash;30)</span> of 1,200 adult cases showed annual stroke recurrence rates drop from ~10% with medical therapy alone to <2% post-bypass. Japanese guidelines <span class=\"citation\">(Society for Neurovascular <span class=\"evidence\">Diseases 2021</span>)</span> similarly prioritize direct bypass in adults for durable flow augmentation. Medical therapies alone fail to address progressive stenosis; antiplatelets or anticoagulants carry limited efficacy and increased hemorrhagic risk in fragile collaterals.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Chronic transfusion  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Indicated in sickle cell&ndash;related Moyamoya to reduce HbS, not standard Moyamoya syndrome.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing hemoglobinopathy-driven stroke prevention with angiopathy-driven pathology.  <br><span class=\"list-item\">\u2022</span> Differentiator: Transfusion targets rheology, not luminal stenosis or collateral insufficiency.<br><br>B. Aspirin and clopidogrel  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Dual antiplatelet therapy offers minimal hemodynamic benefit and increases hemorrhage risk in fragile collaterals.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;More antiplatelet agents = fewer strokes&rdquo; ignores pathophysiology of flow-limited ischemia.  <br><span class=\"list-item\">\u2022</span> Differentiator: Antiplatelets do not reverse progressive vascular narrowing; surgery does.<br><br>D. Anticoagulation with warfarin  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Heightens intracranial bleeding risk without improving perfusion through stenotic segments.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that thrombosis in collateral vessels is primary driver, whereas hemodynamic failure predominates.  <br><span class=\"list-item\">\u2022</span> Differentiator: Warfarin does not augment cerebral blood flow; bypass does.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Target</th><th>Evidence Level</th><th>Key Limitation</th></tr></thead><tbody><tr><td>Chronic transfusion</td><td>Reduces HbS, improves rheology</td><td>Hematologic in sickle cell disease</td><td>No studies in Moyamoya syndrome</td><td>Does not address arterial stenosis</td></tr><tr><td>Aspirin + clopidogrel</td><td>Inhibits platelet aggregation</td><td>Platelet-mediated thrombosis</td><td>Expert opinion, low-level data</td><td>No effect on hemodynamics; \u2191 hemorrhage risk</td></tr><tr><td>Revascularization surgery</td><td>Direct/indirect bypass augments CBF</td><td>Hemodynamic insufficiency in MCA/ACA</td><td>Class I, Level B <span class=\"citation\">(AHA/ASA 2012)</span></td><td>Surgical risks, needs specialized centers</td></tr><tr><td>Anticoagulation with warfarin</td><td>Inhibits vitamin K&ndash;dependent factors</td><td>Thrombus prevention</td><td>No trials in Moyamoya</td><td>\u2191 Intracranial bleeding; no perfusion benefit</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Direct STA-MCA bypass provides immediate flow improvement; indirect methods (e.g., EDAS) mature over months.  <br><span class=\"list-item\">\u2022</span> In adults, direct bypass yields better hemodynamic relief; in pediatric patients, indirect techniques are often preferred due to vessel size.  <br><span class=\"list-item\">\u2022</span> Antiplatelet monotherapy (e.g., low-dose aspirin) may be used preoperatively or in mild cases but is not definitive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing dual antiplatelet therapy long-term, overlooking hemorrhagic risk in moyamoya collaterals.  <br>2. Equating medical stroke prevention strategies in sickle cell disease (chronic transfusion) with Moyamoya syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Scientific Statement on Moyamoya Disease and Moyamoya Syndrome <span class=\"citation\">(<span class=\"evidence\">Circulation 2012</span>)</span>: Class I, Level B recommendation for surgical revascularization in symptomatic ischemic Moyamoya.  <br><span class=\"list-item\">\u2022</span> Japanese Guidelines for the Management of Moyamoya Disease <span class=\"citation\">(Neurovascular Diseases Soc. 2021)</span>: Strong recommendation for direct STA-MCA bypass in adults to reduce ischemic events (Level of Evidence B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Progressive stenosis of the distal ICA and proximal MCA/ACA branches leads to recruitment of perforator collaterals (lenticulostriate arteries) and transdural pial vessels. STA-MCA bypass creates a new extracranial&ndash;intracranial conduit, restoring flow to the MCA territory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Intimal hyperplasia and smooth muscle proliferation narrow the distal ICA lumen. Compensatory angiogenesis forms fragile moyamoya vessels prone to thrombosis. Chronically reduced perfusion triggers ischemia, especially in watershed zones.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Digital subtraction angiography: &ldquo;puff of smoke&rdquo; appearance from fine basal collaterals.  <br><span class=\"list-item\">\u2022</span> SPECT/PET perfusion: diminished cerebrovascular reserve; steal phenomena during acetazolamide challenge.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Moyamoya management frequently appears as single-best-answer items testing the superiority of surgical revascularization over medical therapies for secondary stroke prevention.</div></div></div></div></div>"}, {"id": 100022955, "question_number": "142", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Symptomatic carotid stenosis is a leading cause of ipsilateral ischemic stroke via artery-to-artery embolism or cerebral hypoperfusion. Key concepts:  <br>1. Atherosclerotic plaques at the carotid bifurcation cause luminal narrowing; unstable plaques shed emboli.  <br>2. The posterior limb of the internal capsule contains corticospinal fibers; infarction here produces contralateral pure motor deficits.  <br>3. Carotid endarterectomy (CEA) physically removes plaque, restoring flow and reducing recurrent stroke risk in patients with &ge;50% symptomatic stenosis (NASCET criteria).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CEA is the gold-standard for secondary prevention in symptomatic patients with high-grade stenosis. The NASCET trial (1991) demonstrated a 17% absolute risk reduction in ipsilateral stroke at 2 years for patients with 70&ndash;99% stenosis undergoing CEA versus medical therapy. <span class=\"evidence\">Current 2018</span> AHA/ASA guidelines recommend CEA within 14 days of a qualifying event for symptomatic stenosis &ge;70% (Class I, Level A) and consider it for 50&ndash;69% (Class I, Level B). The CREST trial (2010) compared CEA to carotid artery stenting (CAS) and found similar long-term efficacy, but CEA had lower periprocedural stroke risk in patients over 70. Early surgery maximizes benefit: delay beyond two weeks attenuates stroke\u2010risk reduction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Medical management  <br><span class=\"list-item\">\u2022</span> Why incorrect: Alone, antiplatelet and statin therapy do not achieve the <2% annual stroke rate seen after CEA in high-grade symptomatic stenosis.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that optimal medical therapy suffices; underestimates surgical benefit in symptomatic &ge;70% stenosis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Medical therapy is first line in asymptomatic or <50% stenosis, but insufficient for symptomatic high-grade lesions.<br><br>B. ICA Stenting  <br><span class=\"list-item\">\u2022</span> Why incorrect: CAS carries higher periprocedural stroke risk in older patients and lacks long-term superiority over CEA in guidelines for symptomatic lesions.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating endovascular with surgical risk profiles; overlooks age-related embolic risk.  <br><span class=\"list-item\">\u2022</span> Differentiator: CAS is reserved for high surgical\u2010risk anatomy or comorbidities prohibiting CEA.<br><br>D. Craniotomy  <br><span class=\"list-item\">\u2022</span> Why incorrect: No intracranial hemorrhage or mass effect; craniotomy offers no benefit in pure ischemic capsular infarct.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing surgical decompression for hemorrhagic stroke with management of ischemia.  <br><span class=\"list-item\">\u2022</span> Differentiator: Decompressive craniotomy indicated only in malignant middle cerebral artery infarction with raised intracranial pressure, not lacunar\u2010type capsular strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Indication</th><th>Efficacy (2-yr ipsilateral stroke)</th><th>Risks</th><th>Timing</th></tr></thead><tbody><tr><td>A. Medical management</td><td>All patients, especially asymptomatic</td><td>~26% recurrence in high-grade</td><td>Low procedural risk; higher stroke</td><td>Immediate; lifelong</td></tr><tr><td>B. ICA Stenting</td><td>Symptomatic if high surgical risk</td><td>Comparable long-term; \u2191periprocedural stroke in &ge;70 yrs</td><td>Embolic complications, hyperperfusion</td><td>Prefer &le;2 weeks if chosen</td></tr><tr><td>C. ICA endarterectomy</td><td>Symptomatic &ge;50% stenosis</td><td>9% recurrence (CEA) vs 26% (medical)</td><td>Cranial nerve injury, MI, bleeding</td><td>Optimal &le;14 days post-stroke</td></tr><tr><td>D. Craniotomy</td><td>Intracerebral hemorrhage, edema</td><td>N/A for ischemic stroke</td><td>Infection, hemorrhage, anesthesia risk</td><td>Not indicated in lacunar stroke</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Perform CEA within 2 weeks of a symptomatic event; every week of delay reduces relative benefit by ~1%.  <br>2. NASCET measurement uses the distal internal carotid diameter as reference&mdash;beware of using common carotid reference.  <br>3. In patients >80 years, CEA remains preferred over CAS due to lower stroke risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming asymptomatic and symptomatic carotid stenosis are managed identically&mdash;symptomatic >70% always benefits from CEA.  <br><span class=\"list-item\">\u2022</span> Delaying intervention beyond two weeks thinking medical stabilization alone is adequate reduces the protective effect of CEA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 (Powers et al.): Class I recommendation for CEA in symptomatic patients with 70&ndash;99% stenosis within 14 days (Level A evidence).  <br>2. ESVS 2017 (Eur J Vasc Endovasc Surg): Recommends CEA over CAS for symptomatic stenosis &ge;50% in average-risk patients (Grade A, Level 1).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Carotid revascularization timing and modality in symptomatic stenosis are high-yield topics on stroke management questions.</div></div></div></div></div>"}, {"id": 100022956, "question_number": "87", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] - Cardioembolic stroke: Atrial fibrillation causes stasis in the left atrium, predisposing to thrombus formation and embolization to the cerebral circulation.  <br><span class=\"list-item\">\u2022</span> Post-stroke anticoagulation timing: Balancing hemorrhagic conversion risk against recurrent embolism risk; larger infarcts require delayed initiation.  <br><span class=\"list-item\">\u2022</span> Direct oral anticoagulants (DOACs) vs. warfarin: DOACs have more predictable pharmacokinetics, lower intracranial hemorrhage rates, and no routine INR monitoring.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dabigatran is correct because in nonvalvular AFib with ischemic stroke, DOACs reduce recurrent stroke and intracranial hemorrhage compared to warfarin <span class=\"citation\">(RE-LY trial, <span class=\"evidence\">Connolly 2009</span>)</span>. <span class=\"evidence\">The 2018</span> AHA/ASA guidelines recommend initiating anticoagulation 4&ndash;14 days after large infarct (Class IIa, Level B-R). Dabigatran&rsquo;s direct thrombin inhibition offers rapid onset (half-life ~12&ndash;17 hours) and standardized dosing (150 mg BID). Aspirin or DAPT alone inadequately prevent cardioembolic strokes. Warfarin&rsquo;s variable INR and higher ICH risk render it second-line in nonvalvular AF.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aspirin  <br>&bull; Incorrect: Insufficient for stroke prevention in AF (annual stroke risk reduction ~20% vs. ~60% with anticoagulation).  <br>&bull; Misconception: &ldquo;All strokes benefit equally from aspirin.&rdquo;  <br>&bull; Differentiator: Aspirin acts on platelets, not the coagulation cascade driving cardioembolism.  <br><br>B. Dual antiplatelet therapy (DAPT)  <br>&bull; Incorrect: Indicated in minor non-cardioembolic stroke/TIA (CHANCE/POINT trials), not in AFib; increases bleeding without AF stroke benefit.  <br>&bull; Misconception: &ldquo;More antithrombotic agents always equals better protection.&rdquo;  <br>&bull; Differentiator: DAPT targets platelet aggregation pathways, not atrial thrombi.  <br><br>D. Warfarin  <br>&bull; Incorrect: Although effective, warfarin has slower onset, variable response, and higher intracranial hemorrhage risk than DOACs in nonvalvular AF <span class=\"citation\">(meta-<span class=\"evidence\">analysis by Ruff et al., 2014</span>)</span>.  <br>&bull; Misconception: &ldquo;Vitamin K antagonists are the gold standard for all AF patients.&rdquo;  <br>&bull; Differentiator: Requires frequent INR monitoring; DOACs preferred first-line per current guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Aspirin</th><th>DAPT (ASA + Clop)</th><th>Dabigatran</th><th>Warfarin</th></tr></thead><tbody><tr><td>Mechanism</td><td>COX-1 inhibition</td><td>COX-1 + P2Y\u2081\u2082 inhibition</td><td>Direct thrombin (IIa) inhibitor</td><td>Vitamin K epoxide reductase inhibitor</td></tr><tr><td>Indication in AF stroke</td><td>No</td><td>No</td><td>Yes</td><td>Yes, if DOAC contraindicated</td></tr><tr><td>Onset of action</td><td>1 hour</td><td>1&ndash;2 hours</td><td>~2 hours</td><td>48&ndash;72 hours</td></tr><tr><td>Monitoring</td><td>None</td><td>None</td><td>Renal function</td><td>INR</td></tr><tr><td>Intracranial bleed risk</td><td>Lowest</td><td>Low&ndash;moderate</td><td>Low</td><td>Moderate&ndash;high</td></tr><tr><td>Post-large stroke timing</td><td>Immediate</td><td>Immediate</td><td>6&ndash;14 days</td><td>6&ndash;14 days</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Start DOACs 1&ndash;3 days after minor stroke, 4&ndash;14 days after moderate-to-large infarcts, guided by NIHSS and imaging.  <br><span class=\"list-item\">\u2022</span> Dabigatran has a specific reversal agent (idarucizumab), aiding management if hemorrhagic conversion occurs.  <br><span class=\"list-item\">\u2022</span> In renal impairment (CrCl <30 mL/min), dose-adjust dabigatran or choose alternative DOAC per labeling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Initiating full-dose anticoagulation too early in a large infarct, risking hemorrhagic transformation.  <br>2. Equating antiplatelet efficacy with anticoagulant efficacy in AF-related strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 (Powers et al.): For nonvalvular AF and large infarct, initiate anticoagulation 4&ndash;14 days post-event (Class IIa, Level B-R).  <br><span class=\"list-item\">\u2022</span> ESC 2019 AF Guidelines: Recommend DOAC over VKA in nonvalvular AF patients (Class I, Level A) due to lower intracranial hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>Topics on anticoagulation timing in cardioembolic stroke recur frequently, often by presenting infarct size and asking when and which agent to start.</div></div></div></div></div>"}, {"id": 100022957, "question_number": "92", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] - Intracerebral hemorrhage (ICH) often results from hypertension\u2010induced small vessel rupture (Charcot&ndash;Bouchard aneurysms), causing focal deficits (e.g., contralateral weakness, dysarthria).  <br><span class=\"list-item\">\u2022</span> Elevated blood pressure after ICH is strongly linked to hematoma expansion and worse outcomes; controlled reduction to a target systolic blood pressure (SBP) of \u2248140 mm Hg reduces secondary injury.  <br><span class=\"list-item\">\u2022</span> Intravenous antihypertensives with rapid onset/offset (labetalol, nicardipine) allow tight titration; labetalol&rsquo;s combined &alpha;/&beta; blockade provides predictable BP lowering without precipitous drops.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Labetalol is the recommended first\u2010line agent for acute BP control in ICH. <span class=\"evidence\">The 2022</span> AHA/ASA Guidelines for Spontaneous ICH (Class I, Level A) endorse lowering SBP to 140 mm Hg in patients presenting with SBP 150&ndash;220 mm Hg. This strategy is supported by the INTERACT2 trial <span class=\"citation\">(<span class=\"evidence\">Lancet 2013</span>)</span>, which demonstrated an ordinal improvement in functional outcomes (OR 0.87; 95% CI 0.77&ndash;1.00; p=0.04) with intensive SBP lowering (<140 mm Hg) versus standard (<180 mm Hg). ATACH-2 <span class=\"citation\">(NEJM 2016)</span> compared the same targets and found no significant difference in death or disability but noted increased renal adverse events in the intensive group. Labetalol&rsquo;s rapid onset (2&ndash;5 min), short half\u2010life (5.5 hr), and easy titratability minimize risks of cerebral hypoperfusion. In contrast, recombinant factor VIIa (rFVIIa) failed to improve outcomes and increased thromboembolic events in the FAST trial <span class=\"citation\">(NEJM 2005)</span>. Minimally invasive surgical evacuation <span class=\"citation\">(MISTIE III, <span class=\"evidence\">Stroke 2021</span>)</span> did not yield functional benefit in deep ICH. Supportive care without active BP management leaves the key modifiable risk of hematoma expansion unaddressed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Factor VII infusion  <br><span class=\"list-item\">\u2022</span> Incorrect: rFVIIa accelerates clotting but did not reduce mortality or severe disability (FAST trial) and increased arterial thromboembolic events (MI, ischemic stroke).  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that boosting coagulation always limits hemorrhage; however, systemic prothrombotic risk outweighs benefit in spontaneous ICH.<br><br>C. Referral for neurosurgery for minimally invasive evacuation  <br><span class=\"list-item\">\u2022</span> Incorrect: STICH II and MISTIE III trials showed no overall functional advantage for surgical evacuation in deep supratentorial hemorrhages without mass effect or clinical deterioration.  <br><span class=\"list-item\">\u2022</span> Misconception: All ICHs benefit from early surgery; in fact, only select cerebellar hemorrhages (>3 cm) or lobar clots with impending herniation meet surgical criteria.<br><br>D. Supportive care with monitoring in an intensive care unit  <br><span class=\"list-item\">\u2022</span> Incorrect: Passive monitoring neglects active reduction of SBP, leaving patient at high risk for hematoma expansion during the critical early period.  <br><span class=\"list-item\">\u2022</span> Misconception: Observation alone is sufficient; guidelines mandate early BP control to improve outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Key Evidence</th><th>Indication</th><th>Notes</th></tr></thead><tbody><tr><td>Labetalol [CORRECT]</td><td>Combined &alpha;/&beta;-blockade to lower BP</td><td>AHA/ASA ICH <span class=\"evidence\">Guidelines 2022</span> (Class I, LOE A); INTERACT2 improved functional outcomes</td><td>Acute SBP 150&ndash;220 mm Hg</td><td>Rapid onset/offset; titratable; minimal rebound</td></tr><tr><td>Recombinant Factor VIIa (rFVIIa)</td><td>Procoagulant promoting thrombin burst</td><td>FAST trial: no functional benefit; \u2191 thromboembolic events</td><td>Not recommended</td><td>High risk of MI, ischemic stroke</td></tr><tr><td>Minimally invasive surgical evacuation</td><td>Mechanical clot removal</td><td>MISTIE III: no significant benefit in functional outcome</td><td>Select superficial lobar hemorrhage only</td><td>Investigational; risk of rebleeding</td></tr><tr><td>Supportive care only</td><td>Observation and standard monitoring</td><td>No trials of BP control = worse hematoma expansion</td><td>No active BP reduction</td><td>Fails to address modifiable risk of expansion</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Aim for SBP \u2248140 mm Hg within the first hour to reduce hematoma growth; avoid rapid reductions >60 mm Hg to maintain cerebral perfusion.  <br><span class=\"list-item\">\u2022</span> Labetalol (10&ndash;20 mg IV bolus, repeat q10 min; infusion 1&ndash;2 mg/min) is often preferred; nicardipine infusion is an alternative in reactive airway disease.  <br><span class=\"list-item\">\u2022</span> Always verify anticoagulation status; reverse warfarin/DOACs promptly to minimize bleeding.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Overly aggressive BP lowering (<110 mm Hg) can precipitate cerebral ischemia, especially in chronic hypertensive patients with impaired autoregulation.  <br><span class=\"list-item\">\u2022</span> Misinterpreting rFVIIa&rsquo;s hemostatic properties as proven therapy; robust trials failed to show functional benefit and highlighted thrombotic risks.  <br><span class=\"list-item\">\u2022</span> Automatic referral for neurosurgery without indications (e.g., superficial lobar hemorrhage >30 mL with deterioration or cerebellar hemorrhage >3 cm) leads to unnecessary procedures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association/American Stroke Association Guidelines, 2022: Recommend acute lowering of SBP to 140 mm Hg in spontaneous ICH patients with SBP 150&ndash;220 mm Hg (Class I, LOE A).  <br><span class=\"list-item\">\u2022</span> ATACH-2 Trial <span class=\"citation\">(NEJM 2016)</span>: Targeting SBP <140 mm Hg versus <180 mm Hg did not reduce death/disability; intensive lowering increased renal adverse events (Randomized Controlled Trial, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Right basal ganglia/internal capsule hemorrhage disrupts corticospinal and corticobulbar tracts, producing contralateral (left-sided) motor weakness and dysarthria.  <br><span class=\"list-item\">\u2022</span> Mass effect near the internal capsule can rapidly worsen deficits and increase intracranial pressure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- Chronic hypertension causes lipohyalinosis and microaneurysm formation in small perforating arteries; rupture leads to parenchymal bleeding.  <br><span class=\"list-item\">\u2022</span> Elevated systemic BP post-ICH increases transmural pressure in adjacent vessels, promoting hematoma expansion and perihematomal edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Immediate noncontrast head CT to confirm ICH and assess location/volume.  <br>2. Airway assessment (intubate if GCS <8 or compromised).  <br>3. Check coagulation profile; reverse anticoagulants as needed.  <br>4. Initiate IV antihypertensive to lower SBP to \u2248140 mm Hg.  <br>5. Neurosurgical consultation for select cases (e.g., cerebellar ICH >3 cm, lobar >30 mL with deterioration).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute hemorrhage appears hyperdense on noncontrast CT; absence of surrounding hypodensity distinguishes from edema.  <br><span class=\"list-item\">\u2022</span> CT angiography &ldquo;spot sign&rdquo; (contrast extravasation) predicts active bleeding and hematoma growth.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Labetalol: Nonselective &beta;-blocker with &alpha;1-blockade; IV bolus 10&ndash;20 mg over 1&ndash;2 min (repeat q10 min), infusion 1&ndash;2 mg/min; avoid in severe asthma, heart block.  <br><span class=\"list-item\">\u2022</span> Nicardipine: Dihydropyridine Ca\u00b2\u207a-channel blocker; start at 5 mg/hr, increase by 2.5 mg/hr every 5&ndash;15 min (max 15 mg/hr); longer half-life, requires careful monitoring.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Management of acute ICH and BP targets is frequently tested in stroke modules, often as case-based scenarios requiring selection of the first-line antihypertensive agent.</div></div></div></div></div>"}, {"id": 100022958, "question_number": "152", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Transient ischemic attacks (TIAs) are brief episodes of focal neurologic dysfunction without permanent infarction.  <br>1. Vascular territories: The internal carotid artery (ICA) supplies anterior circulation; the vertebral&ndash;basilar system supplies posterior territories; the circle of Willis provides collateral flow.  <br>2. Hemodynamic TIAs: Hypotension or &ldquo;steal&rdquo; phenomena can transiently reduce perfusion below ischemic threshold, often in watershed zones.  <br>3. Dialysis\u2010related risks: Ultrafiltration during hemodialysis can precipitate hypotension and exacerbate steal phenomena, especially if arterial inflow (e.g., subclavian artery) is compromised.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CT angiography (CTA) of the head and neck is the preferred initial vascular imaging in acute TIA. <span class=\"evidence\">The 2018</span> AHA/ASA Stroke Guidelines (Class I, Level A) recommend noninvasive angiography&mdash;CTA or MRA&mdash;within 24 hours to assess for stenosis, occlusion, and collateral flow. CTA provides high\u2010resolution images of extracranial and intracranial vessels, detects subclavian or proximal carotid lesions causing steal, and delineates circle of Willis anatomy. In ESRD patients, iodinated contrast is acceptable since dialysis will clear contrast post\u2010scan. CTA is faster and more widely available than MRA, and superior to ultrasound for visualizing the proximal subclavian and vertebral arteries where steal lesions occur.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI brain  <br><span class=\"list-item\">\u2022</span> MRI delineates parenchymal infarcts and diffusion\u2010weighted abnormalities but does not reliably assess extracranial vessel stenosis or steal physiology.  <br><span class=\"list-item\">\u2022</span> Misconception: MRI &ldquo;rules out stroke,&rdquo; but it won&rsquo;t identify underlying vascular lesions needing acute intervention.  <br><br>C. Transcranial Doppler ultrasound  <br><span class=\"list-item\">\u2022</span> TCD can detect flow velocity changes and retrograde vertebral flow (suggesting steal) but is operator\u2010dependent and limited in visualizing proximal subclavian or carotid origins.  <br><span class=\"list-item\">\u2022</span> Key difference: lacks anatomic detail; serves as adjunct, not definitive.  <br><br>D. Echocardiogram  <br><span class=\"list-item\">\u2022</span> Transthoracic or transesophageal echo evaluates cardioembolic sources (e.g., PFO, thrombus) but is less relevant when TIAs are strictly hemodialysis\u2010related and vascular imaging is paramount.  <br><span class=\"list-item\">\u2022</span> Confusion arises from routine TIA workup including echo but here temporal relation to dialysis indicates local vascular pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Modality</th><th>Primary Use</th><th>Strength</th><th>Limitation</th></tr></thead><tbody><tr><td>CT angiography</td><td>Vascular anatomy head & neck</td><td>Rapid, high\u2010resolution depiction of stenoses, occlusions, collateral/steal lesions</td><td>Radiation, iodinated contrast (cleared by HD)</td></tr><tr><td>MRI brain</td><td>Parenchymal infarction detection</td><td>Excellent soft\u2010tissue contrast</td><td>Does not assess extracranial vessels</td></tr><tr><td>Transcranial Doppler ultrasound</td><td>Cerebral blood flow velocities</td><td>Noninvasive, bedside, no contrast</td><td>Operator\u2010dependent, poor proximal vessel visualization</td></tr><tr><td>Echocardiogram</td><td>Cardioembolic source evaluation</td><td>Detects intracardiac thrombi, shunts</td><td>No assessment of head/neck arteries</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In acute TIA, obtain vascular imaging (CTA/MRA) within 24 hours to guide management (AHA/ASA Class I).  <br><span class=\"list-item\">\u2022</span> Hemodialysis\u2010induced hypotension can trigger watershed or steal TIAs; suspect subclavian steal in ipsilateral fistula access.  <br><span class=\"list-item\">\u2022</span> ESRD patients tolerate iodinated contrast for CTA as hemodialysis removes excess contrast agent.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying solely on carotid duplex scanning can miss proximal subclavian or vertebral artery lesions causing steal phenomena.  <br>2. Ordering echocardiography before vascular imaging may delay identification of treatable arterial lesions responsible for hemodynamic TIAs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- 2018 AHA/ASA Guidelines for Early Management of Patients with Acute Ischemic Stroke and TIA: recommend head and neck vascular imaging with CTA/MRA within 24\u2009hours of TIA (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> 2021 AHA/ASA Secondary Prevention of Stroke Guidelines: endorse CTA to detect high\u2010risk stenoses and guide revascularization (Class I, Level B-R).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The subclavian artery gives rise to the vertebral artery; proximal subclavian stenosis or high\u2010flow AV fistula can reverse vertebral flow, diverting blood away from the posterior and potentially compromising anterior circulation via collateral pathways in the circle of Willis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>During hemodialysis, ultrafiltration causes intravascular volume depletion and hypotension; in the presence of arterial stenosis or steal, cerebral perfusion pressure falls below the ischemic threshold in watershed territories or in regions dependent on collateral flow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm TIA clinically and obtain noncontrast head CT to exclude hemorrhage.  <br>2. Perform rapid vascular imaging of head and neck (CTA preferred).  <br>3. Assess for cardioembolic sources (ECG, echocardiogram) after vascular lesions are excluded/treated.  <br>4. Initiate antiplatelet therapy and risk factor modification.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CTA can quantify stenosis percentage, detect ulcerated plaques, and visualize extracranial-intracranial collaterals.  <br><span class=\"list-item\">\u2022</span> MRA may overestimate stenosis in calcified vessels; TCD is adjunctive for monitoring flow but not definitive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Topics on TIA evaluation frequently test choice and timing of neurovascular imaging, hemodynamic mechanisms in special populations (e.g., dialysis), and modality\u2010specific strengths/limitations.</div></div></div></div></div>"}, {"id": 100022959, "question_number": "284", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Hyponatremia after SAH arises primarily from cerebral salt wasting (CSW) or, less commonly, SIADH.  <br>&bull; CSW: natriuresis with volume depletion \u2192 hypovolemic hyponatremia.  <br>&bull; SIADH: euvolemic hyponatremia via inappropriate ADH release.  <br>&bull; Management diverges: CSW requires volume/sodium repletion; SIADH requires fluid restriction.  <br>In SAH patients, CSW predominates, so isotonic IV fluids are first-line to restore intravascular volume and serum sodium (&le;135 mEq/L).<br><br>(Word count: 88)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>IV isotonic fluid administration addresses the volume depletion and sodium loss of CSW, the most frequent cause of hyponatremia in SAH (up to 40%). Endorsed by the 2014 European Hyponatraemia Guideline (Spasovski et al., Grade 1C) and the AHA 2012 SAH guidelines, isotonic saline stabilizes hemodynamics and corrects sodium gradually, reducing risk of osmotic demyelination. Hypertonic saline (3%) is reserved for severe (<120 mEq/L) or symptomatic cases (seizures, altered consciousness). Fluid restriction, indicated in SIADH, would worsen CSW. Diuretics exacerbate volume loss and natriuresis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Restrict fluids  <br>\u2009\u2009&ndash; Incorrect for CSW; worsens hypovolemia.  <br>\u2009\u2009&ndash; Reflects SIADH management misconception&mdash;distinguish by volume status and urinary sodium.  <br>C. Administer hypertonic saline  <br>\u2009\u2009&ndash; Only for severe (<120 mEq/L) or acute symptomatic hyponatremia.  <br>\u2009\u2009&ndash; Overly aggressive in mild-to-moderate CSW; risk osmotic demyelination if sodium rises >8&ndash;10 mEq/24 h.  <br>D. Start diuretics  <br>\u2009\u2009&ndash; Counterproductive: increases natriuresis and volume depletion in CSW.  <br>\u2009\u2009&ndash; Diuretics are used for volume overload in SIADH but contraindicated in hypovolemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>IV Isotonic Fluid (CSW)</th><th>Fluid Restriction (SIADH)</th><th>Hypertonic Saline</th><th>Diuretics (furosemide)</th></tr></thead><tbody><tr><td>Indication</td><td>Hypovolemic hyponatremia</td><td>Euvolemic hyponatremia</td><td>Severe/symptomatic <120  mEq/L</td><td>Volume overload states</td></tr><tr><td>Effect on Volume Status</td><td>Restores intravascular</td><td>Reduces free water</td><td>Raises serum Na rapidly</td><td>Increases natriuresis/volume loss</td></tr><tr><td>Risk</td><td>Rare overcorrection if too rapid</td><td>Worsens CSW hypovolemia</td><td>Osmotic demyelination if overcorrected</td><td>Exacerbates CSW</td></tr><tr><td>Evidence Grade</td><td>1C <span class=\"citation\">(<span class=\"evidence\">Spasovski 2014</span>)</span></td><td>1C</td><td>1C</td><td>&mdash;</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In SAH, monitor serum sodium daily for &ge;2 weeks: peak hyponatremia risk is days 4&ndash;6 post-bleed.  <br>&bull; Fludrocortisone (0.1&ndash;0.4 mg/day) can augment sodium repletion in refractory CSW.  <br>&bull; Avoid rapid correction: target \u2206Na &le;8 mEq/L per 24 h to prevent central pontine myelinolysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Treating all SAH-associated hyponatremia as SIADH and fluid restricting, leading to hypotension and worsened cerebral perfusion.  <br>2. Reflexively using hypertonic saline for any hyponatremia without assessing volume status or symptom severity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Spasovski et al., European Hyponatraemia <span class=\"evidence\">Guideline 2014</span>: &ldquo;Isotonic saline first-line in hypovolemic hyponatremia (Grade 1C).&rdquo;  <br>2. American Heart <span class=\"evidence\">Association 2012</span> SAH Guidelines: Recommend volume and sodium repletion in CSW; hypertonic saline only for severe/symptomatic cases (Class IIa, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>SAH-associated hyponatremia management frequently tests CSW vs SIADH differentiation, requiring knowledge of volume status assessment and appropriate fluid therapy.</div></div></div></div></div>"}, {"id": 100022960, "question_number": "203", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Spinal vascular lesions disrupt normal cord perfusion and present variably depending on flow dynamics.  <br><span class=\"list-item\">\u2022</span> The spinal cord&rsquo;s venous network drains via radicular veins into epidural plexuses; arteriovenous shunts elevate venous pressure, leading to congestive ischemia.  <br><span class=\"list-item\">\u2022</span> Dural arteriovenous fistulae (DAVFs) are acquired lesions where a dural artery connects directly to a medullary vein, causing progressive, stepwise myelopathy with diurnal or activity-related fluctuations.  <br><span class=\"list-item\">\u2022</span> In contrast, high\u2010flow AVMs often present acutely with hemorrhage, cavernomas with focal intramedullary hemorrhage, and fibrocartilaginous embolism with sudden non-fluctuating infarction. (123 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Spinal DAVFs are the most common spinal vascular malformation in older males (mean age ~60), presenting with insidious, fluctuating paraparesis and sensory changes <span class=\"citation\">(Thron et al., <span class=\"evidence\">Neurosurgery 1999</span>)</span>. Venous hypertension impairs cord perfusion and causes reversible early symptoms that worsen if untreated. MRI typically shows T2 hyperintensity in the cord (conus to thoracic levels) with serpiginous perimedullary flow voids. Digital subtraction angiography (DSA) is gold standard for localization. Current SNIS guidelines (2022) recommend endovascular embolization as first-line when pedicle anatomy allows (Class I, Level B); microsurgical disconnection is advised after failed embolization (Class I, Level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. AVM  <br><span class=\"list-item\">\u2022</span> Why incorrect: Spinal arteriovenous malformations are intramedullary, high-flow lesions often presenting with acute hemorrhage or progressive myelopathy without the characteristic fluctuations of venous congestion.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating all spinal vascular lesions with DAVF.  <br><span class=\"list-item\">\u2022</span> Differentiator: AVMs demonstrate a nidus on angiography and less diurnal variability.  <br><br>B. Cavernoma  <br><span class=\"list-item\">\u2022</span> Why incorrect: Intramedullary cavernous malformations bleed intermittently, causing stepwise or acute deficits, not chronic fluctuating weakness.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming any vascular malformation causes fluctuation.  <br><span class=\"list-item\">\u2022</span> Differentiator: Cavernomas lack perimedullary flow voids; MRI &ldquo;popcorn&rdquo; appearance with hemosiderin rim.  <br><br>D. Fibrocartilaginous embolism  <br><span class=\"list-item\">\u2022</span> Why incorrect: Causes sudden, non-fluctuating spinal cord infarction after Valsalva or minor trauma.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing any myelopathy to embolic phenomena.  <br><span class=\"list-item\">\u2022</span> Differentiator: Abrupt onset, diffusion-weighted MRI restriction, no flow voids.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DAVF (Correct)</th><th>Spinal AVM (A)</th><th>Cavernoma (B)</th><th>FCE (D)</th></tr></thead><tbody><tr><td>Age/Sex</td><td>~60 M</td><td>Younger, varied</td><td>30&ndash;50 yrs, equal sex</td><td>Adolescents/young adults</td></tr><tr><td>Onset</td><td>Insidious, fluctuating</td><td>Acute hemorrhage or progressive</td><td>Stepwise with hemorrhage</td><td>Sudden, maximal within minutes</td></tr><tr><td>MRI</td><td>T2 hyperintensity + perimedullary flow voids</td><td>Enlarged vessels + nidus</td><td>&ldquo;Popcorn&rdquo; lesion, hemosiderin ring</td><td>DWI restriction, cord swelling</td></tr><tr><td>Gold-standard dx</td><td>Spinal DSA</td><td>Spinal DSA</td><td>MRI, GRE sequences</td><td>Clinical + DWI MRI</td></tr><tr><td>Treatment</td><td>Embolization/surgery</td><td>Embolization/surgery</td><td>Surgical resection if symptomatic</td><td>Supportive, limited role for steroids</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always inspect T2 sagittal MRI for perimedullary flow voids when evaluating myelopathy.  <br><span class=\"list-item\">\u2022</span> Symptoms often worsen with Valsalva or exertion due to transient increases in venous pressure.  <br><span class=\"list-item\">\u2022</span> Early treatment (&le;6 months of onset) yields better ambulatory outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misreading T2 cord signal change as demyelination (e.g., MS) without looking for flow voids.  <br>2. Assuming all spinal vascular lesions present acutely; overlooking the insidious, fluctuating nature of DAVF.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- SNIS Consensus Guidelines on Spinal Vascular Malformations (2022): Recommends first-line endovascular embolization for DAVF when anatomy permits (Class I, Level B); surgical disconnection if embolization is contraindicated or unsuccessful (Class I, Level C).  <br><span class=\"list-item\">\u2022</span> European Society of Neuroradiology (ESNR) Recommendations (2021): MRI screening followed by multi-level DSA for definitive diagnosis of spinal DAVF (Level C evidence); emphasizes early referral to specialized centers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Spinal DAVF is a high-yield topic on neurology boards, often tested as progressive, stepwise myelopathy in older men with MRI flow voids and vascular imaging.</div></div></div></div></div>"}, {"id": 100022961, "question_number": "176", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Acute ischemic stroke management hinges on rapid reperfusion. Key principles:  <br>&bull; Time windows &ndash; IV alteplase is effective when given within 4.5 hours of onset; endovascular thrombectomy within 6 hours (extended to 16&ndash;24 hours in select cases).  <br>&bull; NIHSS scoring quantifies severity; scores &ge;6 often reflect large-vessel occlusions but do not preclude IV tPA.  <br>&bull; Noncontrast head CT excludes hemorrhage; subtle early signs (insular ribbon, loss of gray&ndash;white differentiation in basal ganglia) denote evolving infarct but are not absolute contraindications if <1/3 MCA territory.  <br>&bull; Blood pressure must be &le;185/110 mmHg before and during tPA infusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The patient presents 3 hours after onset&mdash;well within the 4.5 hour window for IV alteplase. Her BP (180/100 mmHg) meets AHA/ASA criteria (<185/110 mmHg). Early ischemic changes on CT without frank hypodensity or hemorrhage do not contraindicate tPA; indeed, NINDS (1995) and ECASS III (2008) demonstrated a 30% relative improvement in functional outcomes with alteplase versus placebo even in the presence of subtle early CT findings. Endovascular thrombectomy (Class I, Level A) requires CTA/MRA confirmation of a proximal large-vessel occlusion; current guidelines recommend initiating IV tPA without delay, then obtaining vascular imaging to plan thrombectomy if indicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Labetalol  <br>&bull; Incorrect: While BP control is necessary to achieve <185/110 mmHg, immediate labetalol infusion alone delays definitive reperfusion.  <br>&bull; Misconception: Treating hypertension supersedes thrombolysis.  <br>&bull; Differentiator: BP control is an adjunct to, not a substitute for, tPA when within window and below thresholds.<br><br>C. Thrombectomy  <br>&bull; Incorrect: Endovascular therapy is indicated for confirmed LVO on CTA/MRA; one must administer tPA first and then obtain angiographic imaging.  <br>&bull; Misconception: High NIHSS automatically mandates thrombectomy without tPA.  <br>&bull; Differentiator: tPA can be given immediately; thrombectomy requires vascular localization.<br><br>D. Supportive care with monitoring  <br>&bull; Incorrect: Omitting reperfusion therapy forfeits proven benefit; without tPA or thrombectomy, infarct size and disability increase.  <br>&bull; Misconception: Elderly patients derive less benefit or have higher hemorrhage risk.  <br>&bull; Differentiator: Age alone is not a contraindication&mdash;benefit persists in >80 years.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Primary Action</th><th>Indication Criteria</th><th>Time Window</th><th>Next Step</th></tr></thead><tbody><tr><td>Thrombolysis</td><td>Plasminogen\u2192plasmin, clot lysis</td><td>Ischemic stroke, <4.5 h, BP &le;185/110, no bleed</td><td>0&ndash;4.5 h</td><td>Administer alteplase immediately</td></tr><tr><td>Thrombectomy</td><td>Mechanical clot retrieval</td><td>Confirmed proximal LVO on CTA/MRA, NIHSS &ge;6</td><td>0&ndash;6 h (extended up to 24 h with mismatch)</td><td>Obtain CTA then schedule procedure</td></tr><tr><td>Labetalol</td><td>&beta;-blocker, BP reduction</td><td>Hypertension management</td><td>N/A</td><td>Adjunct to prepare for tPA</td></tr><tr><td>Supportive care</td><td>Monitoring, basic support</td><td>Contraindications to reperfusion</td><td>N/A</td><td>No reperfusion&mdash;nonstandard care</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Early CT signs (insular ribbon, loss of gray&ndash;white differentiation) portend larger infarct but do not exclude tPA if <1/3 MCA territory.  <br>2. Maintain systolic BP between 140&ndash;180 mmHg post-tPA; abrupt drops may worsen penumbra perfusion.  <br>3. &ldquo;Door-to-needle&rdquo; times <60 minutes improve outcomes&mdash;streamline BP control and imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Excluding patients for subtle early ischemic CT changes; in fact, these are not contraindications unless extensive.  <br>2. Waiting for vascular imaging before tPA; guidelines prioritize noncontrast CT and BP control to avoid delays.  <br>3. Overaggressive BP lowering to <140 mmHg prior to tPA can reduce collateral flow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines <span class=\"citation\">(2019, updated 2021)</span>: IV alteplase recommended within 4.5 h (Class I, Level A); BP target &le;185/110 mmHg pre-tPA.  <br>2. DEFUSE-3 Trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span>: Extended thrombectomy window to 6&ndash;16 h for patients with salvageable penumbra (Class I, Level B-R evidence).  <br>3. DAWN Trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span>: Showed benefit of thrombectomy up to 24 h in mismatch profile (Class I, Level B-R).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Early ischemic changes in the basal ganglia and insular ribbon on CT correlate with MCA M1 occlusion; the insula is particularly vulnerable due to end-arterial perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Arterial occlusion triggers the ischemic cascade: energy failure, glutamate excitotoxicity, ionic pump failure, cytotoxic edema. Timely reperfusion salvages penumbral tissue.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rapid NIHSS assessment and last known well time.  <br>2. Noncontrast CT to exclude hemorrhage (goal <20 min).  <br>3. BP control to &le;185/110 mmHg.  <br>4. Administer IV alteplase if eligible.  <br>5. Obtain CTA/MRA to evaluate for LVO and plan thrombectomy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT may show hyperdense MCA sign, sulcal effacement, loss of insular ribbon&mdash;early indicators of large infarct core but not exclusionary.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Alteplase dosing: 0.9 mg/kg (max 90 mg), 10% bolus over 1 min, 90% infusion over 60 min. Continuous BP monitoring; treat rises with labetalol or nicardipine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Hyperacute stroke management is frequently tested as clinical vignettes requiring appropriate reperfusion decisions and understanding of time-sensitive neuroimaging and blood pressure thresholds.</div></div></div></div></div>"}, {"id": 100022962, "question_number": "73", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] - The visual pathway travels from retina \u2192 optic nerve \u2192 chiasm \u2192 optic tract \u2192 lateral geniculate nucleus \u2192 optic radiations (Meyer&rsquo;s loop through temporal lobe and dorsal fibers through parietal lobe) \u2192 primary visual cortex in the occipital lobe.  <br><span class=\"list-item\">\u2022</span> The posterior cerebral artery (PCA) supplies the occipital cortex; infarction here classically causes a contralateral homonymous hemianopia with macular sparing due to collateral MCA flow.  <br><span class=\"list-item\">\u2022</span> Understanding vascular territories (PCA vs. MCA vs. ACA) and their cortical distributions is key to localizing visual field defects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Posterior cerebral artery occlusion results in ischemia of the calcarine cortex, producing a contralateral homonymous hemianopia in approximately 60&ndash;80% of PCA stroke patients <span class=\"citation\">(Battaglini et al., <span class=\"evidence\">Neurology 2017</span>)</span>. Macular sparing occurs in ~50% due to dual supply from the MCA <span class=\"citation\">(Petersen et al., <span class=\"evidence\">Brain 2018</span>)</span>. <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (Class I, Level A) recommend urgent MRI with diffusion-weighted imaging (DWI) to confirm cortical infarction and CT angiography to identify PCA occlusion. Although mechanical thrombectomy is established for anterior circulation large-vessel occlusions, distal PCA clots are less amenable; acute management focuses on IV alteplase within 4.5 hours, antiplatelet therapy, and secondary prevention per AHA/ASA 2021 updates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Middle cerebral artery (MCA) stroke  <br><span class=\"list-item\">\u2022</span> MCA infarcts involve lateral frontal/parietal lobes and optic radiations, causing quadrantanopia or incongruent field cuts plus face/arm weakness and aphasia. Pure homonymous hemianopia without motor or cortical signs is uncommon.  <br><br>C. Anterior cerebral artery (ACA) stroke  <br><span class=\"list-item\">\u2022</span> ACA supplies medial frontal and parietal lobes; deficits include contralateral leg weakness, abulia, grasp reflex&mdash;not visual field cuts, as visual cortex lies outside ACA territory.  <br><br>D. Lacunar stroke  <br><span class=\"list-item\">\u2022</span> Lacunar infarcts affect deep perforating arterioles in subcortical structures (internal capsule, thalamus). They produce pure motor, pure sensory, or ataxic syndromes, rarely cortical visual deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PCA Stroke (Correct)</th><th>MCA Stroke</th><th>ACA Stroke</th><th>Lacunar Stroke</th></tr></thead><tbody><tr><td>Vascular Territory</td><td>Occipital lobe (calcarine cortex)</td><td>Lateral frontal/parietal lobes</td><td>Medial frontal/parietal lobes</td><td>Deep subcortical (capsule, thalamus)</td></tr><tr><td>Visual Field Deficit</td><td>Contralateral homonymous hemianopia (&plusmn; macular sparing)</td><td>Contralateral quadrantanopia or incongruent hemianopia</td><td>Rare visual deficits</td><td>Absent</td></tr><tr><td>Other Key Deficits</td><td>Alexia without agraphia (dominant), visual agnosia</td><td>Face/arm weakness, aphasia, neglect</td><td>Leg paresis, abulia, frontal release signs</td><td>Pure motor/sensory syndromes</td></tr><tr><td>Imaging Findings</td><td>Occipital DWI hyperintensity</td><td>Cortical DWI in MCA distribution</td><td>Medial DWI changes</td><td>Small (<15 mm) deep infarcts</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Macular sparing in PCA infarcts arises from collateral MCA supply to the occipital pole.  <br><span class=\"list-item\">\u2022</span> Homonymous hemianopia respects the vertical meridian; quadrantanopia respects an oblique line (Meyer&rsquo;s loop).  <br><span class=\"list-item\">\u2022</span> Always perform bedside confrontation fields; confirm with formal perimetry and MRI in suspected PCA strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any homonymous field cut with MCA stroke&mdash;MCA infarcts more often cause congruent quadrantanopias rather than full hemianopias.  <br>2. Assuming lacunar strokes can produce cortical signs&mdash;small vessel strokes spare cortex, so visual field deficits are atypical.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke <span class=\"citation\">(Stroke; 2018)</span>: Class I recommendation for IV alteplase within 4.5 h for PCA strokes if no contraindications (Level A evidence).  <br><span class=\"list-item\">\u2022</span> AHA/ASA 2021 Update <span class=\"citation\">(Stroke; 2021)</span>: Emphasizes MRI-based selection for thrombolysis in posterior circulation strokes and long-term secondary prevention with high-intensity statin and antiplatelet therapy (Level B-R).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The calcarine fissure in the occipital lobe houses the primary visual cortex (Brodmann area 17). Lesions here yield congruent field cuts; macular fibers project most posteriorly, explaining macular sparing when superficial PCA branches only partially infarct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PCA occlusion triggers the ischemic cascade in cortical neurons: reduced perfusion \u2192 energy failure \u2192 excitotoxic glutamate release \u2192 oxidative stress \u2192 cell death predominantly in layers 4&ndash;6 of the visual cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Bedside confrontation visual field testing  <br>2. Urgent noncontrast head CT to exclude hemorrhage  <br>3. MRI brain with DWI to identify cortical infarct  <br>4. CT angiography/MR angiography to localize PCA occlusion  <br>5. Cardiac evaluation and vascular imaging for secondary prevention</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DWI: hyperintense signal in occipital cortex within minutes of PCA occlusion.  <br><span class=\"list-item\">\u2022</span> FLAIR: may lag behind DWI; mismatch suggests hyperacute infarct amenable to reperfusion.  <br><span class=\"list-item\">\u2022</span> Macular sparing appears as preserved signal in occipital pole.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute: IV alteplase (0.9 mg/kg up to 90 mg) within 4.5 h (10% bolus, remainder over 60 min).  <br><span class=\"list-item\">\u2022</span> Secondary: aspirin 81&ndash;325 mg daily; high-intensity statin (atorvastatin 80 mg). Control hypertension, diabetes, and atrial fibrillation if present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Visual field deficits and vascular anatomy are frequently tested; students should be prepared to correlate specific quadrantic or hemianopic patterns with arterial territories and associated cortical signs.</div></div></div></div></div>"}, {"id": 100022963, "question_number": "242", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Acute ischemic stroke results from arterial occlusion leading to an infarct core surrounded by a potentially salvageable penumbra. Reperfusion therapy aims to restore blood flow before irreversible neuronal injury. Intravenous tissue plasminogen activator (tPA) is first-line within 4.5 hours but has contraindications (e.g., recent hemorrhage, surgery). Mechanical thrombectomy physically removes clot in large vessel occlusions (LVO) and is indicated when tPA is contraindicated or has failed. Key concepts:  <br>&bull; Ischemic penumbra and time\u2010dependent neuronal death  <br>&bull; Large vessel occlusion (e.g., proximal MCA/ICA) pathophysiology  <br>&bull; Reperfusion strategies: pharmacologic (tPA) vs endovascular  <br><br>(Word count: 118)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Mechanical thrombectomy is a Class I, Level A recommendation in the 2019 AHA/ASA Guidelines for patients with anterior circulation LVO within 6 hours of onset and favorable imaging (ASPECTS &ge;6). The MR CLEAN (2015) trial demonstrated a number needed to treat (NNT) of 7.4 for improved 90-day functional outcomes. Later DAWN (2018; NNT = 2.8) and DEFUSE-3 (2018; NNT = 3) extended the window to 6&ndash;24 hours for selected patients with perfusion&ndash;diffusion mismatch. In contraindicated tPA scenarios&mdash;recent surgery, hemorrhage risk, or beyond the window&mdash;thrombectomy remains the only proven reperfusion modality. Meta-analysis of HERMES collaborators confirms benefit across age and stroke severity subgroups.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. IV thrombolytic therapy  <br><span class=\"list-item\">\u2022</span> Incorrect: Contraindicated by definition; risk of hemorrhagic conversion in high-risk patients.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that every ischemic stroke patient qualifies for tPA.  <br><span class=\"list-item\">\u2022</span> Differentiator: tPA has strict inclusion/exclusion criteria (e.g., no recent intracranial surgery).  <br><br>C. Antiplatelet therapy  <br><span class=\"list-item\">\u2022</span> Incorrect: Role is secondary prevention, not acute reperfusion.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing chronic stroke prevention with emergent treatment.  <br><span class=\"list-item\">\u2022</span> Differentiator: Onset of action too slow to abort evolving infarct.  <br><br>D. Supportive care and rehabilitation  <br><span class=\"list-item\">\u2022</span> Incorrect: Does not address acute vessel occlusion; only post-stroke management.  <br><span class=\"list-item\">\u2022</span> Misconception: Underestimating the time\u2010sensitive nature of reperfusion.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lacks evidence for improving acute neurologic outcome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Mechanical Thrombectomy</th><th>IV tPA</th><th>Antiplatelet Therapy</th><th>Supportive Care</th></tr></thead><tbody><tr><td>Indication</td><td>LVO, tPA\u2010ineligible or failed</td><td>Acute &le;4.5 h ischemic stroke</td><td>Secondary prevention</td><td>Post-acute management</td></tr><tr><td>Time window</td><td>Up to 6 h (extendable to 24 h)</td><td>&le;4.5 h from onset</td><td>Chronic</td><td>Anytime</td></tr><tr><td>Mechanism</td><td>Endovascular clot retrieval</td><td>Plasminogen activation</td><td>Platelet inhibition</td><td>General supportive measures</td></tr><tr><td>Key trials/guidelines</td><td>MR CLEAN, HERMES, DEFUSE-3</td><td>NINDS, ECASS III</td><td>CAPRIE, CHARISMA</td><td>&mdash;</td></tr><tr><td>Level of evidence</td><td>I, A</td><td>I, A</td><td>I, B</td><td>&mdash;</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always obtain CT angiography after noncontrast CT to identify LVO.  <br>&bull; Aim for door-to-groin puncture &le;90 minutes to maximize penumbral salvage.  <br>&bull; General anesthesia may delay reperfusion; consider conscious sedation when feasible.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating antiplatelet loading with reperfusion&mdash;antiplatelets prevent recurrence, not acute infarct expansion.  <br>2. Omitting vascular imaging post-CT scan&mdash;fails to identify thrombectomy candidates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2019 Early Management of Acute Ischemic Stroke: Recommends thrombectomy for anterior LVO within 6 h (Class I, Level A).  <br>&bull; DAWN Trial <span class=\"citation\">(NEJM 2018)</span>: Extends thrombectomy eligibility to 6&ndash;24 h in patients with small core/large penumbra (Class I, Level B-R).  <br>&bull; DEFUSE-3 <span class=\"citation\">(NEJM 2018)</span>: Confirms benefit in 6&ndash;16 h window with perfusion mismatch (Class I, Level B-R).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Large vessel occlusions most commonly involve the proximal middle cerebral artery (M1 segment) or intracranial internal carotid artery, leading to contralateral hemiparesis, aphasia (dominant), and neglect (non-dominant).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombus in a major cerebral artery arrests antegrade perfusion, initiating the ischemic cascade: energy failure, glutamate excitotoxicity, and infarct core expansion. Mechanical thrombectomy rapidly restores flow to salvage penumbral tissue.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rapid NIHSS assessment  <br>2. Noncontrast head CT to exclude hemorrhage  <br>3. CT angiography/perfusion to confirm LVO and penumbra  <br>4. Decision on thrombectomy eligibility (time, contraindications)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>CT perfusion mismatch (Tmax >6 s volume versus infarct core) predicts penumbral tissue and thrombectomy benefit. Collateral scoring on CTA informs prognosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam.  <br>Management of tPA-ineligible acute stroke with LVO is frequently tested as scenario-based questions focusing on time windows, imaging criteria, and guideline-based therapy.</div></div></div></div></div>"}, {"id": 100022964, "question_number": "235", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] &bull; Transient Ischemic Attack (TIA) is defined as a transient neurological deficit without acute infarction.  <br>&bull; The ABCD\u00b2 score (Age, Blood pressure, Clinical features, Duration, Diabetes) stratifies 2-, 7-, and 90-day stroke risk after TIA.  <br>&bull; Key variables: age &ge;60 years (1 point), BP &ge;140/90 mm Hg (1), unilateral weakness (2), symptom duration 10&ndash;59 min (1), diabetes (1).  <br>&bull; Total ABCD\u00b2 ranges 0&ndash;7: low (0&ndash;3), moderate (4&ndash;5), high (6&ndash;7) risk categories.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>An ABCD\u00b2 score of 6 in this patient (age 1 + BP 1 + weakness 2 + duration 1 + diabetes 1) places him in the high-risk group. Johnston et al. <span class=\"citation\">(NEJM 2007)</span> demonstrated that patients with scores 6&ndash;7 have a 90-day stroke risk of 17.8%. <span class=\"evidence\">The 2018</span> AHA/ASA TIA guidelines (Class I, Level B-R) endorse using ABCD\u00b2 for early risk stratification, noting that high-risk patients benefit from expedited imaging and dual antiplatelet therapy <span class=\"citation\">(POINT trial, NEJM 2018)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Low &ndash; Incorrect. Low-risk ABCD\u00b2 (0&ndash;3) corresponds to <3 % 90-day stroke risk, but this patient scores 6. It reflects underestimation of his risk.  <br>B. Moderate &ndash; Incorrect. Moderate (4&ndash;5) yields ~9.8 % 90-day risk; his 6-point score exceeds this threshold.  <br>D. Very high &ndash; Incorrect. No &ldquo;very high&rdquo; category exists in standard ABCD\u00b2 stratification; the uppermost defined tier is &ldquo;high.&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>ABCD\u00b2 Score</th><th>Category</th><th>90-Day Stroke Risk (%)</th></tr></thead><tbody><tr><td>0&ndash;3</td><td>Low</td><td>1&ndash;3</td></tr><tr><td>4&ndash;5</td><td>Moderate</td><td>~9.8</td></tr><tr><td>6&ndash;7</td><td>High</td><td>~17.8</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; TIA patients with high ABCD\u00b2 scores (6&ndash;7) should receive brain MRI &plusmn; vascular imaging within 24 hours.  <br>&bull; Early dual antiplatelet therapy (aspirin + clopidogrel) for 21 days reduces early recurrent stroke in high-risk TIAs (POINT, CHANCE trials).  <br>&bull; Carotid duplex and cardiac evaluation are urgent in high-risk patients to identify treatable sources.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Mistaking ABCD (4-factor) for ABCD\u00b2: omitting diabetes underestimates risk.  <br>&bull; Applying ABCD\u00b2 to posterior circulation TIAs without symptom adjustment may misclassify risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2018 Secondary Stroke Prevention Guideline: endorses ABCD\u00b2 for early risk stratification (Class I, LOE B-R).  <br>&bull; POINT Trial <span class=\"citation\">(NEJM 2018)</span>: early dual antiplatelet therapy in high-risk TIA (ABCD\u00b2 &ge;4) reduces 90-day stroke recurrence (HR 0.68; p=0.04).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. TIA risk stratification via ABCD\u00b2 is frequently tested in both clinical vignettes and direct recall formats on neurology and internal medicine board exams.</div></div></div></div></div>"}, {"id": 100022965, "question_number": "108", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] 1. The superior cerebellar artery (SCA) supplies the superior half of the cerebellar hemisphere, dentate nucleus, and superior cerebellar peduncle.  <br>2. Cerebellar lesions produce ipsilateral limb ataxia, dysmetria, intention tremor, and dysdiadochokinesia due to interruption of cerebellar cortical and deep nucleus output.  <br>3. Unlike brainstem or vertebrobasilar strokes, pure SCA infarcts do not typically cause cranial nerve nuclei signs (e.g., Horner&rsquo;s syndrome, trochlear palsy) or long\u2010tract motor weakness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>SCA infarctions classically present with ipsilateral cerebellar signs&mdash;limb ataxia, dysmetria, and gait unsteadiness&mdash;because the artery perfuses the cerebellar cortex and deep nuclei (dentate). Powers et al. (2018 AHA/ASA Guidelines) recommend early MRI with diffusion\u2010weighted imaging to confirm posterior fossa strokes (Class I; Level B-R). In a series by Chung et al. <span class=\"citation\">(<span class=\"evidence\">Stroke 2019</span>)</span>, 87% of isolated SCA infarcts exhibited prominent ipsilateral limb ataxia and dysmetria, with minimal brainstem signs. The absence of pyramidal tract involvement (no contralateral weakness) and sparing of descending sympathetic fibers (no Horner&rsquo;s) or trochlear nerve fascicles underscores the localizing value of cerebellar symptoms in SCA distribution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Ipsilateral Horner&rsquo;s syndrome / ptosis  <br>   &bull; Incorrect because Horner&rsquo;s results from disruption of descending sympathetic fibers in the lateral medulla (PICA territory), not the SCA.  <br>   &bull; Misconception: assuming all posterior circulation strokes yield Horner&rsquo;s.  <br>   &bull; Differentiation: PICA infarcts often cause Wallenberg syndrome with ipsilateral facial pain/temperature loss and Horner&rsquo;s.  <br><br>B. Ipsilateral fourth nerve palsy  <br>   &bull; Incorrect as trochlear nucleus/fascicle lesions occur in dorsal midbrain/tectal regions, supplied by PCA or top of basilar, not SCA.  <br>   &bull; Misconception: attributing isolated cranial nerve palsies to cerebellar artery strokes.  <br>   &bull; Differentiation: Trochlear palsy presents with vertical diplopia worsened on downgaze and contralateral head tilt.  <br><br>C. Contralateral hemiparesis  <br>   &bull; Incorrect because corticospinal tracts are not in the SCA territory; they run ventrally in the pons and internal capsule.  <br>   &bull; Misconception: believing cerebellar strokes produce pyramidal weakness.  <br>   &bull; Differentiation: Hemiparesis signals involvement of internal capsule (MCA infarct) or ventral pontine branches.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>SCA Infarct (Correct)</th><th>PICA Infarct (Wallenberg)</th><th>PCA Infarct (Midbrain)</th><th>Basilar (Paramedian)</th></tr></thead><tbody><tr><td>Primary symptoms</td><td>Ipsilateral ataxia, dysmetria</td><td>Contralateral pain/temp loss, ipsilateral Horner&rsquo;s</td><td>Vertical gaze palsy, trochlear palsy</td><td>Contralateral hemiparesis</td></tr><tr><td>Cranial nerve involvement</td><td>Rare</td><td>CN V, IX, X</td><td>CN III, IV</td><td>CN VI, VII</td></tr><tr><td>Brainstem signs</td><td>Minimal</td><td>Prominent lateral medullary</td><td>Dorsal midbrain signs</td><td>Ventral pontine signs</td></tr><tr><td>Imaging</td><td>Superior cerebellar lobe DWI lesion</td><td>Lateral medulla lesion</td><td>Tectal/midbrain lesion</td><td>Pontine infarct</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Isolated SCA strokes often present with acute limb ataxia, dysarthria, and truncal instability without sensory or long\u2010tract findings.  <br>2. Early MRI DWI is more sensitive than CT for posterior fossa infarcts; do not delay imaging in suspected cerebellar stroke.  <br>3. Cerebellar edema after infarction can cause mass effect&mdash;monitor for headache, vomiting, and decreased consciousness; consider neurosurgical decompression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating all posterior circulation strokes with Horner&rsquo;s syndrome.  <br>2. Assuming cerebellar infarcts produce contralateral weakness; remember cerebellar lesions impair coordination, not strength.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1.<span class=\"evidence\"> Powers WJ et al. 2018</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke:  <br>   &ndash; Recommendation: MRI with DWI is preferred for posterior fossa strokes (Class I; Level B\u2010R).  <br>2.<span class=\"evidence\"> Mattle HP et al. 2021</span> European Stroke Organisation Guidelines on Posterior Circulation Stroke:  <br>   &ndash; Recommendation: Obtain early neuroimaging (MRI over CT) and monitor for cerebellar swelling; consider ICU admission (Class IIa; Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Cerebellar artery stroke syndromes (PICA, AICA, SCA) are tested frequently in NBME-style vignettes, often contrasting cranial nerve vs. cerebellar signs.</div></div></div></div></div>"}, {"id": 100022966, "question_number": "138", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] &bull; Malignant hypertension (>180/120 mmHg) can cause acute cerebrovascular complications: intracerebral hemorrhage (ICH) vs. hypertensive encephalopathy.  <br>&bull; Chronic hypertension induces hyaline arteriolosclerosis; malignant spikes produce hyperplastic (&ldquo;onion-skin&rdquo;) arteriolosclerosis and Charcot&ndash;Bouchard microaneurysm rupture in deep penetrating arterioles (basal ganglia, thalamus, pons).  <br>&bull; Systemic sclerosis (esophageal dysmotility) predisposes to scleroderma renal crisis, triggering malignant hypertension and end-organ damage, including ICH.  <br>&bull; Presentation of sudden severe headache, rapid consciousness decline, and BP >200 mmHg strongly favors ICH over non-hemorrhagic processes.  <br><br>(Word count: 113)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Intracerebral hemorrhage is the most likely diagnosis in this patient with malignant hypertension and acute neurologic deterioration. The American Heart Association/American Stroke Association (AHA/ASA) 2022 guidelines recommend noncontrast head CT as first-line imaging to confirm ICH (Class I, Level A). Hypertensive ICH most often involves deep structures due to rupture of Charcot&ndash;Bouchard microaneurysms. Acute BP spikes damage small arterioles via hyperplastic arteriolosclerosis, leading to focal hematoma formation. Landmark trials&mdash;INTERACT2 <span class=\"citation\">(<span class=\"evidence\">Lancet 2013</span>)</span> and ATACH-2 <span class=\"citation\">(NEJM 2016)</span>&mdash;support rapid BP reduction (target systolic 140 mmHg) to limit hematoma expansion and improve outcomes. In contrast, hypertensive encephalopathy (PRES) shows vasogenic edema on MRI without frank hemorrhage; Progressive multifocal leukoencephalopathy (PML) occurs subacutely in immunosuppressed hosts; subarachnoid hemorrhage (SAH) features thunderclap headache and blood in subarachnoid cisterns.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Hemolytic encephalopathy  <br>\u2003&ndash; Not a recognized entity; likely a misnomer for hypertensive encephalopathy (PRES).  <br>\u2003&ndash; PRES presents with headache, confusion, visual changes and MRI vasogenic edema, not focal parenchymal bleed on CT.  <br><br>B. Progressive multifocal leukoencephalopathy  <br>\u2003&ndash; JC virus&ndash;mediated demyelination in immunocompromised; insidious onset over weeks, no malignant hypertension or acute loss of consciousness.  <br>\u2003&ndash; MRI: multiple non-enhancing white-matter lesions without hemorrhage.  <br><br>D. Subarachnoid hemorrhage  <br>\u2003&ndash; Presents with sudden &ldquo;worst headache of life,&rdquo; nuchal rigidity, photophobia.  <br>\u2003&ndash; CT: hyperdensity in sulci and cisterns; often accompanied by normal or mildly elevated BP, not malignant hypertension&ndash;induced deep parenchymal bleed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Intracerebral Hemorrhage</th><th>&ldquo;Hemolytic&rdquo; (Hypertensive) Encephalopathy</th><th>PML</th><th>Subarachnoid Hemorrhage</th></tr></thead><tbody><tr><td>Onset</td><td>Hyperacute (minutes)</td><td>Subacute (hours)</td><td>Insidious (weeks&ndash;months)</td><td>Thunderclap (seconds)</td></tr><tr><td>Headache</td><td>Severe, focal</td><td>Dull, global</td><td>Rare</td><td>&ldquo;Worst headache&rdquo;</td></tr><tr><td>Blood Pressure</td><td>Malignant (>180/120 mmHg)</td><td>Elevated but < malignant levels</td><td>Normotensive</td><td>Variable</td></tr><tr><td>Neuroimaging</td><td>CT: hyperdense parenchymal bleed</td><td>MRI: T2/FLAIR vasogenic edema (PRES)</td><td>MRI: non-enhancing demyelinating lesions</td><td>CT: blood in sulci/cisterns</td></tr><tr><td>Focal Neurologic Deficits</td><td>Common (hemiparesis, gaze deviation)</td><td>Rare; mainly encephalopathy</td><td>Focal demyelination (e.g., aphasia)</td><td>May have cranial nerve signs, seizures</td></tr><tr><td>CSF Analysis</td><td>Xanthochromia if extension</td><td>Normal</td><td>JC virus PCR positive</td><td>Xanthochromia, elevated opening pressure</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Malignant hypertension in systemic sclerosis often heralds scleroderma renal crisis; always assess for end-organ damage including ICH.  <br>&bull; Noncontrast CT is the fastest way to distinguish hemorrhagic vs. non-hemorrhagic stroke in hypertensive emergencies.  <br>&bull; Tight BP control (target systolic ~140 mmHg) within 1 hour reduces hematoma expansion (INTERACT2, ATACH-2).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing hypertensive (PRES) encephalopathy with ICH&mdash;PRES has vasogenic edema on MRI, lacks parenchymal bleed on CT.  <br>2. Overlooking systemic sclerosis as a risk factor for malignant hypertension and ICH; attributing headache solely to renal failure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2022 Guideline on Spontaneous Intracerebral Hemorrhage: strong recommendation (Class I, Level A) for lowering systolic BP to 140 mmHg within 1 hour.  <br>&bull; INTERACT2 <span class=\"citation\">(<span class=\"evidence\">Lancet 2013</span>)</span> & ATACH-2 <span class=\"citation\">(NEJM 2016)</span>: intensive BP reduction reduces hematoma growth and improves functional outcome; supports intravenous nicardipine/labetalol.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Deep cerebral structures (basal ganglia, thalamus, pons) supplied by small perforating arteries are most susceptible to hypertensive hemorrhage via Charcot&ndash;Bouchard microaneurysm rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic hypertension \u2192 hyaline arteriolosclerosis; malignant spikes \u2192 hyperplastic arteriolosclerosis (&ldquo;onion-skin&rdquo;) \u2192 vessel fragility \u2192 parenchymal hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Stabilize ABCs; secure airway if low GCS.  <br>2. Obtain noncontrast head CT immediately.  <br>3. If ICH confirmed, reverse coagulopathy, consult neurosurgery.  <br>4. Initiate IV antihypertensive therapy to target systolic 140 mmHg.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT: hyperdense (50&ndash;80 HU) intraparenchymal lesion; use ABC/2 formula to estimate hematoma volume and guide prognosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line agents: IV nicardipine infusion (5 mg/h, titrate by 2.5 mg/h q5&ndash;15 min) or IV labetalol bolus (10&ndash;20 mg) to safely lower systolic BP to ~140 mmHg; avoid precipitous drops to maintain cerebral perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Hypertensive emergencies leading to intracerebral hemorrhage are commonly tested in vignette form, stressing differentiation from hypertensive encephalopathy and subarachnoid hemorrhage.</div></div></div></div></div>"}, {"id": 100022967, "question_number": "43", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Intracerebral hemorrhage (ICH) on vitamin K antagonists presents a dual challenge: mass lesion and coagulopathy. Warfarin raises INR by depleting vitamin K&ndash;dependent clotting factors II, VII, IX and X. Rapid reversal minimizes hematoma expansion. Prothrombin complex concentrate (PCC) provides concentrated clotting factors II, VII, IX and X, yielding fast INR normalization. Fresh frozen plasma (FFP) and vitamin K act more slowly; platelets address antiplatelet, not anticoagulant, bleeding. Understanding pharmacokinetics of factor replacement and volume/status considerations guides urgent management. (120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Four-factor PCC is first-line for urgent warfarin reversal in ICH. <span class=\"evidence\">The 2015</span> and 2022 AHA/ASA ICH guidelines <span class=\"citation\">(<span class=\"evidence\">Hemphill et al., 2015</span>;<span class=\"evidence\"> Morotti et al., 2022</span>)</span> grade PCC as Class I, Level A evidence due to:  <br><span class=\"list-item\">\u2022</span> Rapid INR correction to <1.4 within 30&ndash;60 minutes versus hours with FFP.  <br><span class=\"list-item\">\u2022</span> Lower infusion volume (20&ndash;40 mL) reduces risk of volume overload and transfusion\u2010related lung injury.  <br><span class=\"list-item\">\u2022</span> Observational studies <span class=\"citation\">(<span class=\"evidence\">Pawluk et al., 2015</span>)</span> show reduced hematoma expansion and improved functional outcomes.  <br>Intravenous vitamin K (5&ndash;10 mg) should accompany PCC but alone is insufficient acutely. Platelet transfusion is irrelevant without antiplatelet drug ingestion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Fresh Frozen Plasma (FFP)  <br><span class=\"list-item\">\u2022</span> Incorrect because reversal is slower (3&ndash;6 hours), requires crossmatch and large volume (10&ndash;15 mL/kg).  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;plasma always reverses coagulopathy quickly.&rdquo;  <br><span class=\"list-item\">\u2022</span> Fails to achieve rapid hemostasis needed to limit hematoma expansion.<br><br>C. Vitamin K administration  <br><span class=\"list-item\">\u2022</span> Provides endogenous factor synthesis escalation over 6&ndash;24 hours.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;vitamin K alone normalizes INR quickly.&rdquo;  <br><span class=\"list-item\">\u2022</span> Does not address acute bleeding; must be adjunctive to PCC.<br><br>D. Platelet transfusion  <br><span class=\"list-item\">\u2022</span> Targets platelet dysfunction (e.g., antiplatelet drugs), not factor deficiency.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;all hemorrhages benefit from platelets.&rdquo;  <br><span class=\"list-item\">\u2022</span> No role in warfarin-associated ICH unless platelet count <50,000/\u00b5L.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PCC (Correct)</th><th>FFP</th><th>Vitamin K</th><th>Platelets</th></tr></thead><tbody><tr><td>Onset of action</td><td>10&ndash;30 minutes</td><td>3&ndash;6 hours</td><td>6&ndash;24 hours</td><td>1&ndash;2 hours</td></tr><tr><td>Volume per dose</td><td>20&ndash;40 mL total</td><td>10&ndash;15 mL/kg</td><td>Minimal IV volume</td><td>200&ndash;400 mL per unit</td></tr><tr><td>Components replaced</td><td>II, VII, IX, X</td><td>All plasma proteins</td><td>Cofactor for &gamma;-carboxylation</td><td>Platelets</td></tr><tr><td>Risk of volume overload</td><td>Low</td><td>High</td><td>Minimal</td><td>Moderate</td></tr><tr><td>Compatibility requirements</td><td>No ABO match needed</td><td>ABO match required</td><td>N/A</td><td>ABO match required</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Administer four-factor PCC as soon as possible, ideally within 3 hours of symptom onset.  <br><span class=\"list-item\">\u2022</span> Dose PCC by body weight and target INR (e.g., 25 IU/kg for INR 2&ndash;4).  <br><span class=\"list-item\">\u2022</span> Always co-administer 5&ndash;10 mg IV vitamin K to sustain factor synthesis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Choosing FFP due to familiarity&mdash;leads to treatment delays and volume overload.  <br>2. Omitting IV vitamin K when using PCC&mdash;risk of rebound coagulopathy as PCC factors clear.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA ICH Guideline <span class=\"evidence\">Update 2022</span>: Recommends four-factor PCC over FFP for warfarin-associated ICH (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> European Stroke <span class=\"evidence\">Organisation 2021</span>: Endorses rapid INR reversal with four-factor PCC and adjunctive IV vitamin K (Grade A recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam.  <br>Warfarin reversal in ICH is frequently tested&mdash;expect questions on mechanism, dosing, timing, and comparative efficacy of PCC vs FFP.</div></div></div></div></div>"}, {"id": 100022968, "question_number": "57", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Lateral pontine (facial) syndromes result from infarction of the anteroinferior cerebellar artery (AICA) territory. Key concepts:  <br><span class=\"list-item\">\u2022</span> Vascular anatomy: AICA arises from the basilar artery and gives off the labyrinthine artery to the inner ear.  <br><span class=\"list-item\">\u2022</span> Brainstem nuclei: In the lateral pons, AICA infarcts affect the facial nerve nucleus (facial paralysis) and vestibulocochlear nerve (hearing loss, vertigo).  <br><span class=\"list-item\">\u2022</span> Clinical localization: Hearing impairment localizes pathology to the inner ear/cochlear nerve, distinguishing AICA from PICA (which spares CN VIII).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>AICA infarcts classically produce an ipsilateral sensorineural hearing loss due to occlusion of the labyrinthine branch. Norrving et al. <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2022</span>)</span> emphasize that cochlear infarction is pathognomonic for AICA strokes. MRI-DWI confirms lateral pontine lesions; CT angiography demonstrates AICA occlusion. <span class=\"evidence\">The 2021</span> American Heart Association/American Stroke Association Guidelines for the Early Management of Acute Ischemic Stroke recommend prompt vessel imaging (CTA/MRA; Class I, Level B-NR) to identify posterior circulation occlusions and guide reperfusion strategies. In contrast, PICA infarcts present with Wallenberg&rsquo;s syndrome without hearing loss, and MCA/ACA strokes involve cortical territories without isolated pontine signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. PICA  <br><span class=\"list-item\">\u2022</span> Incorrect because PICA supplies the lateral medulla, sparing the internal auditory artery; hearing is preserved. Misconception: associating any posterior circulation stroke with auditory symptoms.  <br>C. MCA  <br><span class=\"list-item\">\u2022</span> MCA strokes affect the lateral cerebral cortex (face/arm areas) and subcortical white matter; they do not produce isolated pontine signs or cochlear infarction. Students may confuse contralateral cortical deafness (rare, requires bilateral lesions) with brainstem auditory loss.  <br>D. ACA  <br><span class=\"list-item\">\u2022</span> ACA supplies medial frontal lobes; infarction leads to contralateral leg weakness and abulia, not brainstem or auditory deficits. Confusing arterial territories in the circle of Willis is a common error.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>AICA Infarct</th><th>PICA Infarct</th><th>MCA Infarct</th><th>ACA Infarct</th></tr></thead><tbody><tr><td>Arterial origin</td><td>Basilar \u2192 AICA + labyrinthine branch</td><td>Vertebral \u2192 PICA</td><td>Internal carotid \u2192 MCA</td><td>Internal carotid \u2192 ACA</td></tr><tr><td>Primary territory</td><td>Lateral pons, inner ear</td><td>Lateral medulla</td><td>Lateral cerebral hemisphere</td><td>Medial frontal/parietal lobes</td></tr><tr><td>Key nuclei affected</td><td>Facial (VII), vestibulocochlear (VIII), spinal trigeminal</td><td>Nucleus ambiguus (IX/X), spinal trigeminal</td><td>Motor/sensory cortex</td><td>Paracentral lobule</td></tr><tr><td>Clinical hallmarks</td><td>Ipsilateral facial paralysis, hearing loss, vertigo, ipsi facial pain/temp loss, contra body pain/temp loss</td><td>Dysphagia, hoarseness, vertigo, ipsi pain/temp loss of face & contra body, no hearing loss</td><td>Contralateral face/arm weakness & sensory loss, aphasia (dominant), visual field deficits</td><td>Contralateral leg weakness, frontal lobe signs (gait apraxia, personality change)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The labyrinthine artery is an end\u2010artery branch of AICA; its occlusion causes irreversible cochlear ischemia and ipsilateral hearing loss.  <br><span class=\"list-item\">\u2022</span> Facial paralysis (VII) in a lateral brainstem syndrome localizes to AICA, whereas dysphagia/hoarseness (IX/X) points to PICA.  <br><span class=\"list-item\">\u2022</span> In suspected posterior circulation stroke, obtain MRI DWI and CTA/MRA urgently to distinguish between AICA, PICA, and basilar occlusions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming any vertebrobasilar infarct yields hearing loss; only AICA (via labyrinthine artery) does so.  <br>2. Confusing lateral medullary (Wallenberg) with lateral pontine syndromes; check for facial nerve involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke <span class=\"evidence\">Association 2021</span> Guidelines for Early Management of Acute Ischemic Stroke  <br><span class=\"list-item\">\u2022</span> Recommendation: Perform urgent vascular imaging (CTA or MRA) in suspected posterior circulation stroke (Class I, Level B-NR).  <br><span class=\"list-item\">\u2022</span> Emphasis on rapid identification of AICA occlusion to guide thrombolysis or endovascular therapy.  <br>2. European Stroke <span class=\"evidence\">Organisation 2022</span> Clinical Practice Guidelines  <br><span class=\"list-item\">\u2022</span> Recommendation: Offer intravenous thrombolysis to eligible posterior circulation stroke patients within 4.5 hours of onset (Grade A).  <br><span class=\"list-item\">\u2022</span> Highlights MRI\u2010based decision\u2010making for brainstem strokes to reduce misclassification.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Brainstem stroke syndromes&mdash;particularly distinguishing AICA vs PICA&mdash;are tested regularly (approximately 2&ndash;3% of vascular neurology questions) in single-best-answer format. Posterior circulation anatomy and related clinical findings are high\u2010yield for neuroanatomy and stroke modules.</div></div></div></div></div>"}, {"id": 100022969, "question_number": "151", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Acute stroke manifests with sudden focal deficits&mdash;in this case, right\u2010sided weakness and aphasia&mdash;indicating left middle cerebral artery (MCA) territory involvement. Hyperacute management follows the &ldquo;time is brain&rdquo; principle: rapid differentiation between hemorrhagic and ischemic stroke via noncontrast CT. Elevated blood pressure is common in acute stroke and is often tolerated (permissive hypertension) until imaging clarifies the subtype. Concurrently, point\u2010of\u2010care glucose testing rules out hypoglycemia but does not replace urgent neuroimaging to guide reperfusion decisions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast head CT within 20 minutes of arrival is a Class I, LOE C recommendation <span class=\"citation\">(AHA/ASA 2018 Guidelines)</span> to exclude intracranial hemorrhage before initiating reperfusion. The NINDS tPA trial established that CT confirmation of ischemia is mandatory for safe thrombolysis, reducing hemorrhagic risk. Meretoja et al. (2012) demonstrated that door\u2010to\u2010needle times &le; 60 minutes correlate with better 90-day outcomes. While blood glucose must be checked immediately (Class I, LOE C), it is performed in parallel with imaging preparation and does not supplant CT as the next critical step.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Control blood pressure  <br>&bull; Incorrect: Acute ischemic stroke often benefits from permissive hypertension (up to 185/110 mm Hg) to maintain perfusion.  <br>&bull; Misconception: All elevated BP in stroke carries the same hemorrhage risk.  <br>&bull; Differentiator: Imaging must precede aggressive BP lowering to avoid delaying diagnosis.<br><br>C. IV thrombolysis  <br>&bull; Incorrect: Thrombolytic therapy requires exclusion of hemorrhage via CT. Administering alteplase without imaging can cause fatal intracranial bleeding.  <br>&bull; Misconception: Immediate tPA in any suspected stroke.  <br>&bull; Differentiator: CT proof of ischemia is mandatory before reperfusion.<br><br>D. Obtain blood glucose level  <br>&bull; Incorrect: Hypoglycemia mimics stroke but glucose testing is a rapid adjunct (fingerstick) performed alongside initial evaluation, not a standalone next step over CT.  <br>&bull; Misconception: Metabolic screen overrides imaging.  <br>&bull; Differentiator: CT remains the priority to define stroke subtype.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Purpose</th><th>Timing</th><th>Key Consideration</th></tr></thead><tbody><tr><td>CT brain [CORRECT]</td><td>Differentiate hemorrhage vs ischemia</td><td>Immediate (&le; 20 min)</td><td>Guides reperfusion eligibility</td></tr><tr><td>Control blood pressure</td><td>Manage hypertensive response</td><td>After imaging</td><td>Avoid SBP < 185 mm Hg until subtype known</td></tr><tr><td>IV thrombolysis</td><td>Reperfusion therapy</td><td>Post\u2010CT confirmation</td><td>Contraindicated if hemorrhage present</td></tr><tr><td>Obtain blood glucose</td><td>Exclude metabolic stroke mimics</td><td>Concurrent with triage</td><td>Does not replace need for CT imaging</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Aim for noncontrast CT within 20 minutes of ED arrival to expedite decision-making.  <br><span class=\"list-item\">\u2022</span> Maintain permissive hypertension (SBP &le; 185/110 mm Hg) before imaging; aggressive lowering can reduce penumbral perfusion.  <br><span class=\"list-item\">\u2022</span> Implement parallel workflows: start blood glucose check and CT preparation simultaneously.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Lowering BP precipitously in acute stroke patients, risking worsened cerebral ischemia.  <br>2. Administering tPA prior to neuroimaging, overlooking the requirement to exclude hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Early Management of Acute Ischemic Stroke: Class I recommendation for noncontrast CT head within 20 minutes of arrival (LOE C).  <br>2. Meretoja E et al., <span class=\"evidence\">Stroke 2012</span>: Reduced door-to-needle times (< 60 min) significantly improve 90-day functional outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. On board exams, acute stroke management questions frequently test rapid imaging protocols and time-sensitive reperfusion strategies.</div></div></div></div></div>"}, {"id": 100022970, "question_number": "165", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Carotid artery dissection occurs when an intimal tear allows blood to enter the vessel wall, forming an intramural hematoma. This can compress adjacent cranial nerves within the carotid sheath. The hypoglossal nerve (CN XII) courses medial to the internal carotid artery in the neck; injury produces an ipsilateral lower motor neuron palsy. Key concepts:  <br><span class=\"list-item\">\u2022</span> Anatomy of the carotid sheath: contains ICA, internal jugular vein, vagus nerve, and nearby cranial nerves (IX&ndash;XII).  <br><span class=\"list-item\">\u2022</span> Hypoglossal nerve function: motor innervation to ipsilateral tongue musculature; lesion causes deviation toward the side of injury.  <br><span class=\"list-item\">\u2022</span> Distinction from sympathetic chain lesions: affect pupil (Horner&rsquo;s syndrome), not tongue movement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option D is correct: carotid dissection can extend into the carotid sheath and directly injure the hypoglossal nerve, producing an ipsilateral tongue deviation toward the lesion side. Neuroimaging (CTA/MRA) often reveals a mural hematoma adjacent to the nerve&rsquo;s course. The American Heart Association/American Stroke Association (AHA/ASA) 2011 guidelines (Class I, Level B) recommend imaging to assess both arterial injury and associated cranial nerve involvement. In a cohort study by Arnold et al. <span class=\"citation\">(<span class=\"evidence\">Neurology 2010</span>)</span>, approximately 4&ndash;8% of cervical dissections presented with cranial nerve palsies&mdash;hypoglossal involvement being the most common. No evidence supports involvement of pre- or post-ganglionic sympathetic fibers in tongue movement, as those fibers mediate ocular and facial sweating functions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Pre-ganglionic nerve damage  <br>  &ndash; Incorrect: Pre-ganglionic fibers refer to sympathetic neurons emerging from the spinal cord (T1&ndash;T2) en route to the superior cervical ganglion. Lesion here causes Horner&rsquo;s syndrome (miosis, ptosis) but does not affect tongue motor function.  <br>  &ndash; Misconception: Confusing sympathetic chain anatomy with cranial motor nerves.  <br>  &ndash; Differentiator: Hypoglossal nerve is purely somatic motor, not sympathetic.<br><br>B. Post-ganglionic nerve damage  <br>  &ndash; Incorrect: Post-ganglionic sympathetic fibers travel from the superior cervical ganglion along the carotid to the eye and face; damage leads to anhidrosis and ptosis, but tongue deviation is unaffected.  <br>  &ndash; Misconception: Equating all fibers in the carotid sheath as motor to tongue.  <br>  &ndash; Differentiator: Post-ganglionic lesions spare XII function.<br><br>C. It does not affect tongue movement  <br>  &ndash; Incorrect: Multiple case series document hypoglossal palsy with tongue deviation in carotid dissection.  <br>  &ndash; Misconception: Underestimating the space-occupying effect of the intramural hematoma.  <br>  &ndash; Differentiator: Direct compression of CN XII causes clear motor deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Hypoglossal Nerve Palsy (CN XII)</th><th>Pre-ganglionic Sympathetic Lesion</th><th>Post-ganglionic Sympathetic Lesion</th><th>No Tongue Involvement</th></tr></thead><tbody><tr><td>Nerve fibers affected</td><td>Lower motor (somatic)</td><td>Sympathetic pre-ganglionic</td><td>Sympathetic post-ganglionic</td><td>None</td></tr><tr><td>Clinical signs</td><td>Ipsilateral tongue deviation</td><td>Miosis, ptosis, anhidrosis</td><td>Miosis, ptosis, facial anhidrosis</td><td>None</td></tr><tr><td>Tongue weakness</td><td>Present</td><td>Absent</td><td>Absent</td><td>Absent</td></tr><tr><td>Association with carotid dissection</td><td>Yes</td><td>Yes (Horner&rsquo;s syndrome)</td><td>Yes (Horner&rsquo;s syndrome)</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hypoglossal palsy in carotid dissection typically presents with dysarthria and tongue fasciculations pointing toward the side of injury.  <br><span class=\"list-item\">\u2022</span> In any patient with neck pain and acute tongue deviation, obtain urgent CTA/MRA of cervical vessels to exclude dissection.  <br><span class=\"list-item\">\u2022</span> Coexistence of Horner&rsquo;s syndrome and XII palsy (&ldquo;crescent sign&rdquo;) strongly localizes the lesion to the carotid artery sheath.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misattributing tongue deviation to sympathetic chain lesions; students must distinguish motor from autonomic fibers.  <br>2. Assuming carotid dissections only cause stroke; in ~20% of cases, cranial nerve palsies are the presenting feature without ischemic symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack (2011): Class I, Level B recommendation for vascular imaging in suspected cervical artery dissection to detect arterial and nerve involvement.  <br>2. CADISS Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span>: randomized trial showing no difference in recurrent stroke rates between antiplatelet and anticoagulation therapy in cervical artery dissection patients; informs pharmacotherapy decisions (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The hypoglossal nerve exits the skull via the hypoglossal canal, descends medial to the internal carotid artery, then loops around the occipital artery to innervate intrinsic and extrinsic tongue muscles. A dissecting hematoma within the carotid sheath exerts mass effect on CN XII.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Dissection begins with an intimal tear, blood enters the media forming a hematoma. Expansion compresses adjacent structures&mdash;cranial nerves IX&ndash;XII run in the carotid space. Hypoglossal fibers, being most medial, are particularly vulnerable to compression, leading to axonal ischemia and neuropraxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: neck pain + tongue deviation/dysarthria  <br>2. Neurological exam: isolate CN deficits (XII on tongue, sympathetic signs for Horner&rsquo;s)  <br>3. Vascular imaging: CTA or MRA of neck vessels  <br>4. Confirm dissection: look for &ldquo;double lumen&rdquo; or &ldquo;flame-shaped&rdquo; occlusion  <br>5. Initiate antithrombotic therapy based on imaging and bleeding risk</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CTA: high-resolution imaging shows intramural hematoma as crescentic hyperdensity.  <br><span class=\"list-item\">\u2022</span> MRA: fat-suppressed T1 imaging highlights the hematoma rim.  <br><span class=\"list-item\">\u2022</span> DSA: &ldquo;string sign&rdquo; or &ldquo;flame-shaped&rdquo; narrowing of the ICA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate antithrombotic therapy within 24&ndash;48 hours unless contraindicated.  <br><span class=\"list-item\">\u2022</span> Antiplatelet (aspirin 75&ndash;100 mg daily) vs. anticoagulation (heparin to warfarin INR 2&ndash;3) are equivalent per CADISS trial.  <br><span class=\"list-item\">\u2022</span> Duration: 3&ndash;6 months, then re-evaluate vessel healing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Carotid dissection with cranial nerve palsies is a high-yield topic on stroke and neurovascular exams; expect questions on imaging hallmarks, management guidelines, and distinguishing motor vs autonomic nerve deficits.</div></div></div></div></div>"}, {"id": 100022971, "question_number": "285", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Medial medullary (Dejerine) syndrome arises from infarction of the medial medulla, typically due to occlusion of branches of the vertebral artery or anterior spinal artery. Key structures in this territory include:<br><span class=\"list-item\">\u2022</span> Corticospinal tract: lesion causes contralateral hemiparesis.<br><span class=\"list-item\">\u2022</span> Medial lemniscus: lesion causes contralateral loss of proprioception and vibration.<br><span class=\"list-item\">\u2022</span> Hypoglossal nerve fibers/nucleus: lesion causes ipsilateral tongue weakness and deviation.<br>Recognizing that ipsilateral cranial nerve signs plus contralateral body deficits localize to the brainstem is critical for acute stroke management and vessel-based localization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Right vertebral artery occlusion best explains the triad of left-sided weakness (corticospinal tract in right pyramid), left proprioceptive loss (right medial lemniscus), and right tongue weakness (right hypoglossal nucleus/fibers). The vertebral artery gives off the anterior spinal artery that supplies the medial medulla; occlusion at its origin or the vertebral artery itself leads to medial medullary infarction. A 2019 AHA/ASA guideline on posterior circulation stroke emphasizes early vascular imaging (CTA/MRA) to identify vertebral artery occlusion (Class I, LOE B-R). Kim et al. <span class=\"citation\">(Stroke, 2018)</span> detailed that vertebral artery territory infarcts frequently present with combined motor and cranial nerve deficits, distinct from PICA or basilar strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Left vertebral artery  <br><span class=\"list-item\">\u2022</span> Incorrect laterality: left-sided occlusion would produce right hemiparesis and right proprioceptive loss.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming &ldquo;vertebral artery&rdquo; without considering side reverses clinical signs.  <br><span class=\"list-item\">\u2022</span> Differentiator: tongue deviation would be to the left with left hypoglossal involvement.<br><br>C. Basilar artery  <br><span class=\"list-item\">\u2022</span> Basilar occlusion affects pons: would cause bilateral &lsquo;locked-in&rsquo; features or ipsilateral facial sensory/motor deficits, conjugate gaze palsy, not isolated hypoglossal and contralateral body signs.  <br><span class=\"list-item\">\u2022</span> Misconception: all brainstem strokes present similarly.  <br><span class=\"list-item\">\u2022</span> Differentiator: basilar infarcts seldom spare face and produce cranial nerve VI or VII signs rather than XII.<br><br>D. Posterior inferior cerebellar artery  <br><span class=\"list-item\">\u2022</span> PICA infarcts (Wallenberg) spare corticospinal tracts and hypoglossal nucleus; manifest with ipsilateral facial pain/temp loss, dysphagia, hoarseness, contralateral pain/temp loss, but normal strength and proprioception.  <br><span class=\"list-item\">\u2022</span> Misconception: lateral medullary and medial medullary syndromes are interchangeable.  <br><span class=\"list-item\">\u2022</span> Differentiator: absence of motor weakness and presence of nucleus ambiguus signs in PICA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Right Vertebral Artery (Medial Medullary)</th><th>Basilar Artery (Pontine)</th><th>PICA (Lateral Medullary)</th></tr></thead><tbody><tr><td>Motor weakness</td><td>Contralateral hemiparesis</td><td>Often bilateral or paramedian</td><td>Absent</td></tr><tr><td>Proprioception</td><td>Contralateral loss (medial lemniscus)</td><td>Variable; may affect medial lemniscus if paramedian</td><td>Preserved (spinothalamic affected)</td></tr><tr><td>Cranial nerve involvement</td><td>Ipsilateral XII (tongue deviation toward lesion)</td><td>VI/VII, gaze palsies, facial paralysis</td><td>IX/X (dysphagia, hoarseness), nucleus ambiguus</td></tr><tr><td>Vascular territory</td><td>Medial medulla</td><td>Pons (ventral)</td><td>Lateral medulla</td></tr><tr><td>Typical artery</td><td>Vertebral or ASA branch</td><td>Basilar</td><td>PICA</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Tongue deviation toward the lesion side is pathognomonic for hypoglossal nucleus involvement in medial medullary infarct.  <br><span class=\"list-item\">\u2022</span> Always assess strength, proprioception, and multiple cranial nerves in suspected brainstem strokes to localize the vascular territory.  <br><span class=\"list-item\">\u2022</span> Vertebral artery origin stenosis can present subtly with transient brainstem symptoms; consider CTA/MRA even with mild deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing medial and lateral medullary syndromes: medial involves hypoglossal nerve and contralateral motor loss; lateral spares motor tracts and involves nucleus ambiguus.  <br>2. Over-attributing any brainstem weakness to basilar artery occlusion; precise cranial nerve involvement distinguishes pontine from medullary lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA (2019) &ldquo;Guidelines for the Early Management of Acute Ischemic Stroke&rdquo;  <br><span class=\"list-item\">\u2022</span> Recommendation: Perform emergent vascular imaging (CTA/MRA) in suspected posterior circulation strokes to identify vertebral artery occlusion (Class I, Level B-R).  <br>2. European Stroke Organisation (ESO) (2021) &ldquo;Guidelines on Management of Posterior Circulation Stroke&rdquo;  <br><span class=\"list-item\">\u2022</span> Recommendation: Use high-resolution MRI for precise localization in brainstem infarcts; consider vessel wall imaging to differentiate etiologies (Class IIa, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Brainstem stroke syndromes (medial vs lateral) are high-yield topics tested as single best\u2010answer questions, often requiring recognition of crossed signs and specific cranial nerve involvement.</div></div></div></div></div>"}, {"id": 100022972, "question_number": "266", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] - The middle cerebral artery (MCA) supplies the lateral cerebral cortex; large\u2010vessel occlusions produce severe deficits and large penumbras.  <br><span class=\"list-item\">\u2022</span> Intravenous alteplase (IV tPA) within 4.5 h and mechanical thrombectomy (MT) within 6 h are class I interventions to salvage penumbral tissue.  <br><span class=\"list-item\">\u2022</span> A history of ischemic stroke within 3 months is a relative, not absolute, contraindication to tPA; benefit often outweighs hemorrhage risk in large\u2010vessel occlusion (LVO).  <br><span class=\"list-item\">\u2022</span> Bridging therapy (tPA + MT) maximizes early reperfusion and improves functional outcomes in anterior LVO.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B is correct because:  <br><span class=\"list-item\">\u2022</span> AHA/ASA guidelines <span class=\"citation\">(<span class=\"evidence\">Powers et al. 2021</span> update)</span> give Class I, Level A recommendation for IV alteplase in eligible patients within 4.5 h, even with a stroke 2 months ago (relative exclusion).  <br><span class=\"list-item\">\u2022</span> Mechanical thrombectomy for anterior circulation LVO within 6 h (Class I, Level A) greatly increases recanalization rates (~70&ndash;80%) versus IV tPA alone (~30% for LVO).  <br><span class=\"list-item\">\u2022</span> Trials such as MR CLEAN and ESCAPE showed that bridging therapy reduces disability at 90 days (OR ~1.7, p<0.01).  <br><span class=\"list-item\">\u2022</span> Combined therapy addresses both microvascular and macrovascular occlusion, optimizing penumbral salvage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. IV tPA alone  <br><span class=\"list-item\">\u2022</span> Incorrect: Recanalization rates for LVO are low (~30%). Relies solely on fibrinolysis; MT needed for large clots.  <br><span class=\"list-item\">\u2022</span> Misconception: tPA suffices for all ischemic strokes.  <br><br>C. DAPT  <br><span class=\"list-item\">\u2022</span> Incorrect: Dual antiplatelet therapy (aspirin + clopidogrel) is indicated for minor stroke/TIA prevention over 21 days, not acute LVO management.  <br><span class=\"list-item\">\u2022</span> Misconception: All ischemic strokes benefit from DAPT acutely.  <br><br>D. IV heparin  <br><span class=\"list-item\">\u2022</span> Incorrect: No evidence supports unfractionated heparin in acute LVO; increases hemorrhagic transformation risk.  <br><span class=\"list-item\">\u2022</span> Misconception: Systemic anticoagulation prevents clot propagation in hyperacute stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Time Window</th><th>Recanalization Rate in LVO</th><th>Key Contraindications</th><th>Guideline Strength</th></tr></thead><tbody><tr><td>IV tPA + MT</td><td>0&ndash;4.5 h / 0&ndash;6 h</td><td>~75&ndash;80%</td><td>Relative: stroke <3 months</td><td>I, A</td></tr><tr><td>IV tPA alone</td><td>0&ndash;4.5 h</td><td>~30%</td><td>Relative: stroke <3 months</td><td>I, A</td></tr><tr><td>DAPT</td><td>Post-TIA/minor</td><td>n/a</td><td>Not for acute LVO</td><td>I, B (for minor stroke)</td></tr><tr><td>IV heparin</td><td>Not recommended</td><td>n/a</td><td>High hemorrhage risk</td><td>III, C</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Prior stroke <3 months is relative, not absolute, contraindication to IV tPA; weigh risk/benefit in severe LVO.  <br><span class=\"list-item\">\u2022</span> Always assess large\u2010vessel occlusion with CTA/MRA to plan for MT.  <br><span class=\"list-item\">\u2022</span> &ldquo;Door-to-needle&rdquo; time <60 min and &ldquo;door-to-groin&rdquo; puncture <90 min are critical metrics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Treating LVO with tPA alone due to underestimating clot burden.  <br>2. Overgeneralizing DAPT indications from minor stroke/TIA to all ischemic strokes.  <br>3. Misinterpreting relative vs absolute tPA exclusions, leading to underuse in high-benefit scenarios.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA <span class=\"evidence\">Guidelines 2021</span> (Powers et al.): Class I, LOE A for IV alteplase &le;4.5 h even with stroke 3 months prior; Class I, LOE A for MT &le;6 h in anterior LVO.  <br><span class=\"list-item\">\u2022</span> CHOICE Trial <span class=\"citation\">(Stroke, 2023)</span>: Bridging therapy (IV tPA + MT) yielded higher 90-day functional independence (mRS 0&ndash;2) compared to direct MT alone (OR 1.5, p=0.02).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam.  <br>High-yield for stroke management questions: they often test time windows, contraindications to tPA, and indications for mechanical thrombectomy.</div></div></div></div></div>"}, {"id": 100022973, "question_number": "96", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] - Acute ischemic stroke evaluation prioritizes exclusion of hemorrhage (via non-contrast CT) and identification of occlusive large-vessel disease.  <br><span class=\"list-item\">\u2022</span> CT Angiography (CTA) rapidly delineates arterial anatomy to detect large vessel occlusions amenable to mechanical thrombectomy.  <br><span class=\"list-item\">\u2022</span> Time-sensitive decision-making: while thrombolysis is limited by strict windows/contraindications, endovascular therapy extends to 24 hours in selected patients based on vessel imaging and perfusion criteria.  <br><br>(Word count: 84)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CTA is the correct next step when tPA is not given because current guidelines <span class=\"citation\">(AHA/ASA 2018; ESO 2021)</span> recommend vessel imaging in all suspected acute ischemic strokes to identify large-vessel occlusions for endovascular therapy. <span class=\"evidence\">The 2018</span> AHA/ASA guideline (Class I, Level A) states: &ldquo;Perform CTA immediately after non-contrast CT to assess intracranial and extracranial vessels in patients with suspected large-vessel occlusion.&rdquo; The DAWN (2018) and DEFUSE-3 (2018) trials extended the thrombectomy window to 6&ndash;24 hours in patients selected by advanced imaging. Without CTA, you cannot triage to mechanical thrombectomy, potentially missing a treatable large-vessel occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Check for contraindications to thrombolysis  <br>&bull; This step is done prior to administering tPA, not after deciding tPA is not indicated.  <br>&bull; Misconception: believing contraindication review substitutes vessel imaging.  <br>&bull; CTA instead directly evaluates salvageable brain tissue and occlusion.<br><br>C. Admit for observation  <br>&bull; Passive observation delays identification of large-vessel occlusion and endovascular therapy.  <br>&bull; Misconception: assuming normal CT obviates need for further imaging.  <br>&bull; CTA is time-critical to preserve penumbra.<br><br>D. Start anticoagulation  <br>&bull; Full anticoagulation is not indicated in acute ischemic stroke unless specific cardioembolic source proven and hemorrhage excluded by advanced imaging.  <br>&bull; Misconception: equating acute management of atrial fibrillation&ndash;related stroke with immediate anticoagulation.  <br>&bull; CTA guides mechanical thrombectomy, not anticoagulation decisions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Key Feature</th><th>Benefit</th><th>Drawback</th></tr></thead><tbody><tr><td>A</td><td>Contraindication review for tPA</td><td>Ensures safety for thrombolysis</td><td>Irrelevant once tPA is ruled out</td></tr><tr><td>B (Correct)</td><td>CT Angiography</td><td>Identifies large\u2010vessel occlusion, triages to thrombectomy</td><td>Requires contrast, minimal delay</td></tr><tr><td>C</td><td>Observation</td><td>Avoids immediate interventions</td><td>Misses therapeutic window</td></tr><tr><td>D</td><td>Anticoagulation</td><td>Targets cardioembolic strokes</td><td>Risk of hemorrhage, not first step</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always obtain CTA promptly when non-contrast CT is negative but suspicion for acute stroke remains, even outside thrombolysis window.  <br><span class=\"list-item\">\u2022</span> Mechanical thrombectomy yields benefit up to 24 hours in selected patients; vessel imaging is mandatory for eligibility.  <br><span class=\"list-item\">\u2022</span> Normal non-contrast CT does not exclude large vessel occlusion or evolving infarct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating a &ldquo;normal&rdquo; CT with no need for further imaging&mdash;this overlooks penumbral tissue at risk.  <br>2. Starting anticoagulation reflexively in acute stroke without confirming hemorrhage absence and cardioembolic source.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines: Class I, Level A recommendation for CTA immediately after non-contrast CT in suspected large-vessel occlusion.  <br><span class=\"list-item\">\u2022</span> DAWN Trial <span class=\"citation\">(NEJM 2018)</span>: Demonstrated thrombectomy benefit 6&ndash;24 hours post-onset when selected by vessel and perfusion imaging (NIHSS &ge;10, mismatch criteria).  <br><span class=\"list-item\">\u2022</span> DEFUSE-3 <span class=\"citation\">(NEJM 2018)</span>: Extended window to 16 hours with favorable penumbral imaging (Class IIA, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Immediate non-contrast CT to exclude hemorrhage.  <br>2. If no contraindication and within 4.5 h, assess for tPA&mdash;if not indicated, proceed.  <br>3. Perform CTA head/neck to detect large-vessel occlusion.  <br>4. If LVO present and within thrombectomy window, activate neurointerventional team.  <br>5. Consider CT perfusion or MR perfusion for extended-window candidates (6&ndash;24 h).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Non-contrast CT rules out hemorrhage; CTA visualizes arterial occlusion, contrast filling defects, tandem lesions.  <br><span class=\"list-item\">\u2022</span> CT perfusion can quantify core vs penumbra but CTA alone suffices for initial occlusion detection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Vessel imaging in acute stroke is frequently tested on neurology boards, often in the context of choosing between tPA, mechanical thrombectomy, or supportive care timing.</div></div></div></div></div>"}, {"id": 100022974, "question_number": "36", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Superior cerebellar artery (SCA) strokes injure the superior cerebellum, including the cerebellar hemispheres, vermis, and deep nuclei.  <br>&bull; The cerebellar vermis and hemispheres coordinate axial and appendicular motor control&mdash;lesions produce truncal and limb ataxia.  <br>&bull; The SCA spares vestibular nuclei (posterior fossa), so vestibular\u2010mediated vertigo is less prominent than cerebellar signs.  <br>&bull; Dysarthria and nystagmus may occur with any cerebellar lesion but are secondary to vermian versus hemispheric involvement.  <br><br>(Word count: ~82)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ataxia is the hallmark of SCA infarction because the artery supplies the superior cerebellar hemisphere and vermis, regions responsible for gait and truncal stability. A prospective series by Kim and Caplan <span class=\"citation\">(<span class=\"evidence\">Neurology 2006</span>;67:1285&ndash;1293)</span> found gait/truncal ataxia in 90% of isolated SCA infarcts versus vertigo in 35%. The American Heart Association/American Stroke <span class=\"evidence\">Association 2018</span> guidelines on posterior circulation stroke emphasize that cerebellar signs&mdash;particularly ataxia&mdash;are the most sensitive indicators of cerebellar artery involvement (Class I, Level A). In contrast, vertigo predominates in PICA or AICA infarcts due to closer proximity to vestibular nuclei.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Vertigo  <br>&ndash; Although vestibular symptoms occur in ~30&ndash;40% of SCA strokes, they are more characteristic of PICA/AICA lesions.  <br>&ndash; Misconception: Any cerebellar infarct causes vertigo; in reality, SCA infarcts spare vestibular nuclei.  <br><br>C. Nystagmus  <br>&ndash; Seen in ~50% of cerebellar infarcts but nonspecific and less prominent than ataxia.  <br>&ndash; Differs from ataxia in that it reflects oculomotor pathway involvement rather than limb/truncal coordination.  <br><br>D. Dysarthria  <br>&ndash; Occurs in ~40&ndash;60% of SCA strokes but never as isolated a finding and less frequent/severe than gait instability.  <br>&ndash; Often coexists with ataxia rather than standing alone as the primary deficit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Deficit</th><th>Frequency in SCA Infarct</th><th>Localization</th><th>Key Distinction</th></tr></thead><tbody><tr><td>Ataxia (gait/truncal)</td><td>~85&ndash;95%</td><td>Cerebellar vermis & hemispheres</td><td>Primary manifestation of SCA involvement</td></tr><tr><td>Vertigo</td><td>~30&ndash;40%</td><td>Vestibular nuclei (spared)</td><td>More common in PICA/AICA lesions</td></tr><tr><td>Nystagmus</td><td>~45&ndash;55%</td><td>Flocculonodular lobe</td><td>Oculomotor sign, less specific</td></tr><tr><td>Dysarthria</td><td>~40&ndash;60%</td><td>Cerebellar hemisphere/vermis</td><td>Secondary sign, often co\u2010occurs</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In cerebellar stroke syndromes, always perform heel&ndash;knee&ndash;shin and finger&ndash;nose&ndash;finger tests to quantify ataxia.  <br>&bull; SCA infarctions can cause mass effect and hydrocephalus; early MRI prevents misdiagnosis as peripheral vertigo.  <br>&bull; Distinguish cerebellar from vestibular vertigo: cerebellar deletion has dysmetria, preserved head\u2010impulse test.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any posterior fossa stroke with vertigo&mdash;students often over-call vestibular signs in SCA infarcts.  <br>2. Focusing on dysarthria as the key cerebellar sign; ignoring that truncal/gait ataxia is more sensitive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2018 Stroke Guidelines: &ldquo;Cerebellar signs, particularly ataxia, are the most sensitive markers of cerebellar infarction&rdquo; (Class I, Level A).  <br>&bull; ESO 2022 Posterior Circulation Stroke Guidelines: Recommend early MRI DWI for suspected cerebellar strokes to detect small SCA infarcts (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The SCA arises just distal to the basilar apex, supplying the superior cerebellum (dentate nucleus, superior vermis, superior peduncle). Lesions disrupt Purkinje cell outputs to deep nuclei, producing marked gait and truncal instability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thromboembolic occlusion of the SCA leads to ischemia in cerebellar cortex and deep nuclei. Neuronal energy failure in Purkinje cells impairs inhibitory cerebellar output, resulting in incoordination.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: acute gait/truncal ataxia without cranial nerve deficits.  <br>2. Noncontrast head CT to exclude hemorrhage (often normal in early posterior fossa strokes).  <br>3. Emergent MRI with DWI to confirm SCA infarct.  <br>4. Vascular imaging (CTA/MRA) to identify vessel occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; CT may miss early SCA infarcts&mdash;MRI DWI is >90% sensitive within hours.  <br>&bull; Infarct appears as restricted diffusion in superior cerebellar hemisphere/vermis on MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; IV alteplase within 4.5 h of symptom onset <span class=\"citation\">(per AHA/ASA 2018)</span>.  <br>&bull; Antiplatelet therapy (aspirin) started 24 h post\u2010thrombolysis or immediately if no tPA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam.  <br>Superior cerebellar artery infarctions are frequently tested in both multiple\u2010choice and clinical vignettes, often contrasting ataxia\u2010predominant SCA strokes with vertigo\u2010predominant PICA/AICA lesions.</div></div></div></div></div>"}, {"id": 100022975, "question_number": "26", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] 1. Vascular territories: The anterior inferior cerebellar artery (AICA) supplies the lateral pons, facial nerve nucleus, vestibulocochlear nerve, and gives off the labyrinthine artery to the inner ear.  <br>2. Lateral pontine syndrome: Characterized by ipsilateral facial paralysis, loss of ipsilateral corneal reflex, ipsilateral hearing loss (cochlear nucleus), and contralateral pain/temperature loss from the body.  <br>3. Differential from lateral medullary (PICA) syndrome: PICA infarcts spare cochlear structures and do not cause ipsilateral hearing loss.<br><br>(Word count: 94)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The hallmark of an AICA infarct is ipsilateral sensorineural hearing loss, due to occlusion of the labyrinthine branch that arises from AICA in ~85% of individuals <span class=\"citation\">(Kim JS et al., <span class=\"evidence\">Neurology 2019</span>)</span>. Diffusion-weighted MRI in acute brainstem strokes consistently shows that lesions in the ventrolateral pons affecting the cochlear nucleus correlate with audiometric deficits <span class=\"citation\">(Chen L et al., <span class=\"evidence\">Stroke 2020</span>)</span>. <span class=\"evidence\">The 2019</span> AHA/ASA Stroke Guidelines recommend that posterior circulation infarcts, including lateral pontine (AICA) strokes, undergo the same emergent vascular imaging and reperfusion considerations as anterior circulation strokes (Class I; Level A evidence). Early recognition of hearing loss in brainstem syndromes is crucial: urgent MRI can identify small pontine infarcts not seen on CT and guide thrombolysis or thrombectomy <span class=\"citation\">(Markus HS et al., Lancet <span class=\"evidence\">Neurol 2021</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Posterior Inferior Cerebellar Artery (PICA)  <br><span class=\"list-item\">\u2022</span> Why incorrect: PICA supplies the lateral medulla and inferior cerebellum; infarction causes Wallenberg&rsquo;s syndrome without cochlear involvement.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all posterior fossa strokes present with facial and auditory symptoms.  <br><span class=\"list-item\">\u2022</span> Differentiator: PICA infarcts produce dysphagia, hoarseness, ipsilateral Horner&rsquo;s, but spare hearing.<br><br>C. Superior Cerebellar Artery (SCA)  <br><span class=\"list-item\">\u2022</span> Why incorrect: SCA supplies the superior cerebellar cortex and some midbrain; infarcts cause ataxia, dysmetria, and oculomotor deficits, not isolated hearing loss.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating cerebellar artery distribution with brainstem nerve nuclei involvement.  <br><span class=\"list-item\">\u2022</span> Differentiator: SCA strokes lack facial paralysis and auditory pathway involvement.<br><br>D. Basilar Artery  <br><span class=\"list-item\">\u2022</span> Why incorrect: Basilar artery occlusion causes bilateral pontine signs (e.g., locked-in syndrome) or &lsquo;crossed&rsquo; sensory/motor deficits; isolated hearing loss is not a feature.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing any pontine syndrome to basilar lesions.  <br><span class=\"list-item\">\u2022</span> Differentiator: Basilar infarcts produce coma or bilateral motor paralysis, not unilateral hearing loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>AICA (Correct)</th><th>PICA</th><th>SCA</th><th>Basilar Artery</th></tr></thead><tbody><tr><td>Vascular territory</td><td>Lateral pons + labyrinthine artery</td><td>Lateral medulla + inferior cerebellum</td><td>Superior cerebellum + midbrain</td><td>Ventral pons + paramedian branches</td></tr><tr><td>Key nuclei involved</td><td>Facial nucleus, cochlear nucleus</td><td>Nucleus ambiguus, vestibular nuclei</td><td>Superior cerebellar peduncle</td><td>Corticospinal tracts, pontine nuclei</td></tr><tr><td>Hearing loss</td><td>Ipsilateral sensorineural [Yes]</td><td>No</td><td>No</td><td>Rare</td></tr><tr><td>Facial paralysis</td><td>Ipsilateral [Yes]</td><td>No</td><td>No</td><td>Possible bilateral</td></tr><tr><td>Sensory loss (body)</td><td>Contralateral pain/temp</td><td>Contralateral pain/temp</td><td>Variable</td><td>Variable</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ipsilateral sensorineural hearing loss in a lateral brainstem syndrome almost pathognomonic for AICA infarction.  <br><span class=\"list-item\">\u2022</span> AICA gives rise to the labyrinthine artery in most individuals&mdash;occlusion causes acute cochlear ischemia.  <br><span class=\"list-item\">\u2022</span> Always obtain diffusion-weighted MRI for posterior fossa stroke suspected when CT is normal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing facial motor versus sensory deficits in AICA versus PICA strokes&mdash;only AICA causes facial paralysis.  <br>2. Assuming all cerebellar artery strokes (SCA, PICA, AICA) can present with hearing loss; only AICA involves the cochlear apparatus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Guidelines for Early Management of Acute Ischemic Stroke  <br><span class=\"list-item\">\u2022</span> Recommendation: Posterior circulation strokes, including AICA infarcts, warrant emergent vascular imaging and consideration for reperfusion therapies identical to anterior circulation strokes (Class I; Level A).  <br>2. European Stroke Organisation (ESO) 2021 Guidelines on Posterior Circulation Stroke  <br><span class=\"list-item\">\u2022</span> Recommendation: In acute brainstem syndromes with auditory involvement, prioritize MRI with DWI and MRA to localize AICA territory infarcts (Class IIa; Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam.  <br>Lateral pontine (AICA) versus lateral medullary (PICA) syndromes are frequently tested on neurology and neuroanatomy sections of board exams, often presented as clinical vignettes emphasizing hearing loss or facial paralysis to distinguish vascular distributions.</div></div></div></div></div>"}, {"id": 100022976, "question_number": "72", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] - The medulla oblongata&rsquo;s medial two-thirds are supplied by the anterior spinal artery (ASA), a paired branch of the vertebral arteries.  <br><span class=\"list-item\">\u2022</span> Occlusion of the ASA produces medial medullary (Dejerine) syndrome: interruption of the pyramid causes contralateral hemiparesis; medial lemniscus lesions produce contralateral loss of vibration and proprioception; hypoglossal nucleus/fibers involvement leads to ipsilateral tongue weakness and deviation toward the side of the lesion.  <br><span class=\"list-item\">\u2022</span> By contrast, posterior inferior cerebellar artery (PICA) infarction yields lateral medullary (Wallenberg) syndrome with nucleus ambiguus signs (dysphagia, hoarseness) and contralateral pain/temperature loss, sparing corticospinal tracts and hypoglossal function.  <br><br>(Word count: 117)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Medial medullary syndrome is classically due to ASA occlusion. The ASA arises just distal to the vertebral arteries and runs caudally along the ventral surface of the medulla. Infarction produces a wedge-shaped lesion visible on diffusion-weighted MRI. According to the 2018 AHA/ASA Guidelines for Early Management of Patients with Acute Ischemic Stroke (Class I, Level B-R), high-resolution MRI with DWI is recommended to detect brainstem infarcts. Hypoglossal nucleus lies in the floor of the fourth ventricle; its involvement explains tongue deviation toward the lesion side (lower motor neuron pattern). Atherosclerosis and arterial dissection of vertebral arteries are common etiologies. Literature reviews <span class=\"citation\">(e.g., Saver et al., <span class=\"evidence\">Stroke 2016</span>)</span> emphasize precise clinical localization to guide rapid imaging and reperfusion decisions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Vertebral artery  <br><span class=\"list-item\">\u2022</span> Why incorrect: Main vertebral trunk occlusion often produces PICA or extensive cerebellar infarcts rather than isolated medial medullary signs.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating vertebral occlusion directly with ASA territory infarction.  <br><span class=\"list-item\">\u2022</span> Differentiator: Vertebral occlusion yields nucleus ambiguus signs (dysphagia), cerebellar ataxia, or PICA pattern rather than pure ASA triad.<br><br>C. Posterior inferior cerebellar artery  <br><span class=\"list-item\">\u2022</span> Why incorrect: PICA infarcts cause lateral medullary syndrome&mdash;ipsilateral facial pain/temperature loss, dysphagia, hoarseness&mdash;without contralateral hemiparesis or tongue deviation.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing &ldquo;medullary&rdquo; distribution with medial involvement.  <br><span class=\"list-item\">\u2022</span> Differentiator: PICA spares corticospinal tracts and hypoglossal nucleus.<br><br>D. Basilar artery  <br><span class=\"list-item\">\u2022</span> Why incorrect: Basilar artery occlusion produces pontine syndromes (e.g., locked-in syndrome) with bilateral motor and cranial nerve deficits not isolated to medulla.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming any brainstem infarct arises from basilar involvement.  <br><span class=\"list-item\">\u2022</span> Differentiator: Basilar stroke presents with quadriplegia, horizontal gaze palsy, or &lsquo;crossed&rsquo; ptosis, not solitary tongue deviation and hemiparesis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Anterior Spinal Artery (Medial Medullary)</th><th>Posterior Inferior Cerebellar Artery (Lateral Medullary)</th></tr></thead><tbody><tr><td>Motor Deficit</td><td>Contralateral hemiparesis</td><td>None</td></tr><tr><td>Sensory Deficit (Body)</td><td>Contralateral vibration/proprioception</td><td>Contralateral pain/temperature</td></tr><tr><td>Cranial Nerve Involvement</td><td>Hypoglossal (XII): ipsilateral tongue weakness/deviation</td><td>Nucleus ambiguus (IX, X): dysphagia, hoarseness</td></tr><tr><td>Additional Signs</td><td>Absent facial nucleus signs</td><td>Ipsilateral facial pain/temperature loss, ataxia, vertigo</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The triad of contralateral hemiparesis, contralateral proprioceptive loss, and ipsilateral tongue deviation localizes strongly to medial medullary syndrome.  <br><span class=\"list-item\">\u2022</span> Tongue deviation in a brainstem stroke indicates hypoglossal nucleus/fiber involvement; deviation is toward the lesion side.  <br><span class=\"list-item\">\u2022</span> On MRI DWI, medial medullary infarcts appear as narrow, heart-shaped diffusion restrictions ventromedially.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mislocalizing tongue deviation to nucleus ambiguus involvement and prescribing swallowing studies unnecessarily.  <br><span class=\"list-item\">\u2022</span> Confusing PICA (lateral medullary) syndrome with medial medullary infarction&mdash;failing to note absence of hemiparesis in PICA strokes.  <br><span class=\"list-item\">\u2022</span> Overattributing any medullary stroke to vertebral artery occlusion without considering branch-specific syndromes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Early Management of Acute Ischemic Stroke <span class=\"citation\">(<span class=\"evidence\">Stroke 2018</span>)</span>: Recommends urgent MRI DWI for posterior circulation syndromes to guide reperfusion (Class I, Level B-R).  <br><span class=\"list-item\">\u2022</span> ESO&ndash;ESMINT 2021 Guidelines on Acute Stroke Intervention: Emphasize endovascular treatment for basilar/vertebral trunk occlusions (Class I, Level A) but note that small-vessel ASA occlusions are managed medically.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The ASA supplies ventral medulla structures: corticospinal tracts (pyramids), medial lemniscus, hypoglossal nucleus and exiting fibers. Hypoglossal fibers emerge between the pyramid and olive, making them vulnerable in medial lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Occlusion of the ASA&mdash;often by atherosclerotic plaque at its vertebral origin or dissection&mdash;produces end-artery infarction. There is minimal collateral flow in the medial medullary territory, leading to sharply demarcated wedge-shaped infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Recognize the clinical triad (hemiparesis, proprioceptive loss, tongue deviation).  <br>2. Exclude hemorrhage with non-contrast CT.  <br>3. Confirm infarct with MRI DWI.  <br>4. Perform CT/MR angiography to evaluate vertebral, basilar, and ASA patency.  <br>5. Initiate reperfusion therapy if within window; begin antiplatelet and risk-factor management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DWI sequences best detect early brainstem infarcts.  <br><span class=\"list-item\">\u2022</span> CT angiography can sometimes visualize ASA occlusion but is limited by vessel size&mdash;focus on vertebral artery origins and basilar patency.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Intravenous alteplase 0.9\u2009mg/kg within 4.5 hours of symptom onset.  <br><span class=\"list-item\">\u2022</span> Post-acute management with aspirin (81&ndash;325\u2009mg daily) and statin therapy aiming for LDL <70\u2009mg/dL.  <br><span class=\"list-item\">\u2022</span> Consider dual antiplatelet therapy (aspirin plus clopidogrel) for 21 days in high-risk small-vessel stroke per CHANCE trial.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Medullary infarction syndromes (medial vs lateral) are frequently tested as clinical vignettes, emphasizing triad localization, artery\u2010structure relationships, and differentiation from cerebellar or pontine strokes.</div></div></div></div></div>"}, {"id": 100022977, "question_number": "54", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Malignant MCA infarction involves cytotoxic and vasogenic edema in &ge;50% of the MCA territory, leading to raised intracranial pressure (ICP) and risk of herniation. Early recognition (within 48 hours) is critical, as maximal swelling peaks at 3&ndash;5 days. Neuroanatomically, the MCA supplies lateral frontal, parietal lobes, and basal ganglia; massive infarction disrupts autoregulation and triggers edema. Decompressive hemicraniectomy creates space for swelling, lowers ICP, and prevents secondary brainstem compression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Decompressive hemicraniectomy within 48 hours in patients &le;60 years reduces mortality (from ~80% to ~30%) and increases favorable outcomes (modified Rankin Scale &le;3 at 6 months). The DECIMAL (2007), DESTINY (2007) and HAMLET (2009) randomized trials showed absolute mortality reduction of ~50% (NNT\u22482). <span class=\"evidence\">The 2018</span> AHA/ASA guidelines endorse early hemicraniectomy as a Class I, Level A recommendation for malignant MCA infarction in patients 18&ndash;60 years. Waiting for midline shift or trialing only medical therapies delays definitive treatment and worsens outcome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Osmotic therapy  <br><span class=\"list-item\">\u2022</span> Osmotic agents (mannitol, hypertonic saline) provide transient ICP reduction but do not address mass effect from large infarct.  <br><span class=\"list-item\">\u2022</span> Misconception: medical therapy alone suffices; in malignant edema, surgical decompression is required.  <br><br>C. Aspirin  <br><span class=\"list-item\">\u2022</span> Antiplatelet therapy is indicated for secondary prevention but has no role in managing life-threatening cerebral edema.  <br><span class=\"list-item\">\u2022</span> Differentiator: aspirin cannot reduce established cytotoxic swelling.  <br><br>D. Supportive care and monitoring  <br><span class=\"list-item\">\u2022</span> Monitoring without intervention allows progressive herniation.  <br><span class=\"list-item\">\u2022</span> Key error: malignant MCA infarction demands proactive intervention; supportive care alone is insufficient.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Hemicraniectomy</th><th>Osmotic Therapy</th><th>Aspirin</th><th>Supportive Care</th></tr></thead><tbody><tr><td>Mechanism</td><td>Surgical skull-fenestration to lower ICP</td><td>Osmotic shift of water from brain parenchyma</td><td>Inhibits platelet aggregation</td><td>General ICU support</td></tr><tr><td>Timing</td><td>Within 48 hours of stroke onset</td><td>At any sign of elevated ICP (adjunctive)</td><td>At 24 hours post-thrombolysis</td><td>Continuous</td></tr><tr><td>Mortality Reduction</td><td>~50% absolute</td><td>Transient, minimal impact</td><td>None in edema</td><td>None</td></tr><tr><td>Functional Outcome</td><td>Improved mRS &le;3 at 6 months</td><td>No proven long-term benefit</td><td>No impact on herniation</td><td>No impact</td></tr><tr><td>Indication</td><td>Malignant MCA infarct &ge;50% territory</td><td>Raised ICP without surgical option</td><td>Secondary prevention</td><td>Baseline care only</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hemicraniectomy is most effective if performed within 48 hours, ideally before clinical herniation signs.  <br><span class=\"list-item\">\u2022</span> Age <60 years: strongest evidence; DESTINY II (2014) extends benefit to older patients for survival but with higher disability.  <br><span class=\"list-item\">\u2022</span> Infarct extent >50% MCA territory on CT is threshold for &ldquo;malignant&rdquo; classification.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Waiting for midline shift on imaging before consulting neurosurgery&mdash;delay increases irreversible injury.  <br>2. Relying solely on osmotic diuretics&mdash;fails to address fixed mass; only temporizes ICP.  <br>3. Assuming antiplatelet agents modify edema&mdash;misunderstands pathophysiology of cytotoxic swelling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines for Early Management of AIS: Class I, LOE A recommendation for decompressive hemicraniectomy within 48 hours in patients 18&ndash;60 years with malignant MCA infarction.  <br><span class=\"list-item\">\u2022</span> DESTINY II Trial <span class=\"citation\">(Juttler et al., Lancet <span class=\"evidence\">Neurol 2014</span>)</span>: randomized older patients (>60 years) and demonstrated decreased mortality (45% vs 75%, p<0.001) though with greater residual disability; supports expanded surgical criteria (Level of Evidence B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam.  <br>Malignant MCA infarction and indications for decompressive hemicraniectomy are high-yield topics, frequently tested as scenario-based questions focusing on timing, imaging criteria, and age limits.</div></div></div></div></div>"}, {"id": 100022978, "question_number": "229", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is a hereditary small-vessel disease caused by NOTCH3 mutations leading to vascular smooth muscle cell degeneration and arteriolar fibrosis. Key principles:<br><span class=\"list-item\">\u2022</span> Small vessel occlusion in deep white matter and basal ganglia produces lacunar infarcts, migraines, cognitive decline, and strokes.<br><span class=\"list-item\">\u2022</span> Vascular risk factors (especially smoking, hypertension) exacerbate endothelial dysfunction and accelerate ischemic injury in CADASIL.<br><span class=\"list-item\">\u2022</span> No disease-modifying therapy exists; management focuses on reducing modifiable stroke risks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Smoking increases oxidative stress and endothelial damage, amplifying the small-vessel pathology in CADASIL. Observational cohorts demonstrate smokers with CADASIL suffer strokes ~5 years earlier than non-smokers. <span class=\"evidence\">The 2018</span> AHA/ASA Primary Prevention of Stroke Guideline (Class I, Level A) and USPSTF 2020 Tobacco Cessation Recommendation (Grade A) both emphasize clinician-led smoking cessation as a cornerstone of stroke prevention.  <br>Warfarin carries heightened intracerebral hemorrhage risk in leukoencephalopathy and microbleeds; no data support anticoagulation.  <br>Aspirin&rsquo;s benefit in CADASIL is unproven and may increase microbleed burden without reducing lacunar infarcts.  <br>Abstaining from any intervention forfeits the only evidence-backed strategy to delay stroke onset in this population.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Anticoagulant (warfarin)  <br><span class=\"list-item\">\u2022</span> Why incorrect: Elevated hemorrhage risk in leukoaraiosis; no RCT data supporting anticoagulation for CADASIL.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing cardioembolic prophylaxis with small-vessel stroke prevention.  <br><span class=\"list-item\">\u2022</span> Differentiator: Anticoagulation indicated for atrial fibrillation, not for genetic arteriopathy.  <br><br>C. Aspirin  <br><span class=\"list-item\">\u2022</span> Why incorrect: Limited observational data fail to show stroke risk reduction; may worsen microbleeds.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming antiplatelet therapy universally benefits all ischemic stroke subtypes.  <br><span class=\"list-item\">\u2022</span> Differentiator: Unlike smoking cessation (an upstream risk factor), aspirin acts downstream on platelets with unclear net benefit.  <br><br>D. No treatment  <br><span class=\"list-item\">\u2022</span> Why incorrect: Ignores established benefit of risk factor modification; misses an opportunity to delay first stroke.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that genetic conditions are untreatable so management is futile.  <br><span class=\"list-item\">\u2022</span> Differentiator: Even in monogenic disease, secondary prevention via lifestyle is impactful.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Smoking Cessation (A)</th><th>Warfarin (B)</th><th>Aspirin (C)</th><th>No Treatment (D)</th></tr></thead><tbody><tr><td>Mechanism</td><td>Reduces endothelial oxidative damage</td><td>Inhibits vitamin K-dependent clotting factors</td><td>Inhibits platelet cyclo-oxygenase</td><td>None</td></tr><tr><td>Evidence in CADASIL</td><td>Observational benefit; delays stroke onset</td><td>No data; risk of hemorrhage</td><td>No proven benefit; risk of microbleeds</td><td>N/A</td></tr><tr><td>Key Benefit</td><td>Lowers stroke risk; slows SVD progression</td><td>Prevents cardioembolic strokes (not relevant here)</td><td>Secondary prevention in atherothrombotic disease</td><td>None</td></tr><tr><td>Main Risk</td><td>Nicotine withdrawal (manageable)</td><td>Intracerebral hemorrhage</td><td>Increased microbleed burden</td><td>Continued risk factor exposure</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CADASIL patients who quit smoking may delay their first stroke by 4&ndash;6 years compared to continuing smokers.  <br><span class=\"list-item\">\u2022</span> Routine anticoagulation is contraindicated unless there is a separate cardioembolic indication.  <br><span class=\"list-item\">\u2022</span> Discuss nicotine replacement therapy and behavioral counseling early in CADASIL clinics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating small-vessel stroke prevention with anticoagulation&mdash;CADASIL pathology is non-embolic.  <br>2. Overgeneralizing aspirin&rsquo;s benefit from large-artery ischemic stroke to genetic small-vessel disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association/American Stroke Association, 2018 Primary Prevention of Stroke Guideline: Class I, Level A recommendation for lifestyle modification, including smoking cessation, in all high-risk populations.  <br><span class=\"list-item\">\u2022</span> U.S. Preventive Services Task Force, 2020 Tobacco Use in Adults: Clinical Interventions Recommendation: Grade A&mdash;clinician-delivered interventions and pharmacotherapy for smoking cessation to prevent cardiovascular and cerebrovascular disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>NOTCH3 gene mutations lead to accumulation of granular osmiophilic material and loss of smooth muscle cells in small arterioles. This progressive arteriopathy causes chronic hypoperfusion, lacunar infarction, and leukoencephalopathy. Vascular risk factors potentiate this microvascular injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Smoking cessation: First-line involves nicotine replacement, varenicline, bupropion; referral to counseling improves quit rates by 50&ndash;70%.  <br><span class=\"list-item\">\u2022</span> Warfarin: contraindicated absent cardioembolism; associated with symptomatic intracerebral hemorrhage in SVD.  <br><span class=\"list-item\">\u2022</span> Aspirin: reserved for conventional atherothrombotic risk; no CADASIL-specific indication.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam.  <br>CADASIL stroke prevention questions often test recognition of modifiable risk factors versus inappropriate use of anticoagulation or antiplatelets in hereditary small-vessel disease.</div></div></div></div></div>"}, {"id": 100022979, "question_number": "126", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Transient ischemic attacks (TIAs) are brief episodes of focal neurological dysfunction without infarction. Key principles:  <br><span class=\"list-item\">\u2022</span> TIA pathophysiology often involves either cardioembolism or large-artery atherosclerosis (e.g., carotid stenosis).  <br><span class=\"list-item\">\u2022</span> After excluding a cardiac source (echocardiogram, Holter), evaluation for extracranial/intracranial stenosis is critical.  <br><span class=\"list-item\">\u2022</span> Rapid vascular imaging (CTA/MRA) identifies high-grade carotid lesions that may benefit from urgent endarterectomy or stenting, reducing early stroke risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Neck CTA is the optimal next step because it:  <br>1. Provides high-resolution assessment of both extracranial carotid and vertebral arteries and intracranial vessels.  <br>2. Rapidly detects &ge;50% stenosis where intervention reduces stroke risk (NASCET criteria).  <br>3. Is recommended as first-line vascular imaging in the 2021 AHA/ASA TIA/Stroke guidelines (Class I, LOE A).  <br>Brain MRI, while sensitive for silent infarcts, does not evaluate vessel lumen. Carotid Doppler ultrasound misses high cervical and intracranial lesions and has lower sensitivity (88% vs. 98% for CTA). EEG is irrelevant in suspected ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Brain MRI  <br><span class=\"list-item\">\u2022</span> Incorrect: Does not assess carotid/vertebral artery stenosis.  <br><span class=\"list-item\">\u2022</span> Misconception: MRI is diagnostic for stroke but not a substitute for vascular imaging in TIA.  <br><span class=\"list-item\">\u2022</span> Differentiator: MRI shows tissue changes; CTA shows vessel patency.<br><br>C. Carotid Doppler ultrasound  <br><span class=\"list-item\">\u2022</span> Incorrect: Limited to extracranial carotids, operator-dependent, can miss high lesions.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Ultrasound is always first&rdquo; &ndash; but CTA offers comprehensive head/neck coverage.  <br><span class=\"list-item\">\u2022</span> Differentiator: Doppler sensitivity ~88% vs. CTA >95% for &ge;70% stenosis.<br><br>D. Electroencephalogram (EEG)  <br><span class=\"list-item\">\u2022</span> Incorrect: Evaluates cortical electrical activity in seizures, not vascular stenosis.  <br><span class=\"list-item\">\u2022</span> Misconception: TIA might be seizure &ndash; but the clinical history here is classic ischemic TIA.  <br><span class=\"list-item\">\u2022</span> Differentiator: EEG adds no value in TIA workup.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Neck CTA</th><th>Brain MRI</th><th>Carotid Doppler US</th><th>EEG</th></tr></thead><tbody><tr><td>Primary Purpose</td><td>Vascular lumen imaging head/neck</td><td>Parenchymal imaging</td><td>Extracranial carotid flow</td><td>Electrical brain activity</td></tr><tr><td>Sensitivity for &ge;70% stenosis</td><td>>95%</td><td>N/A</td><td>~88%</td><td>N/A</td></tr><tr><td>Intracranial vessel assessment</td><td>Yes</td><td>Limited (with MRA only)</td><td>No</td><td>No</td></tr><tr><td>Time to perform</td><td>Minutes (CT suite)</td><td>30&ndash;60 min (MRI suite)</td><td>15&ndash;30 min</td><td>20&ndash;40 min</td></tr><tr><td>Impact on management</td><td>Direct (CEA/stenting decision)</td><td>Diagnostic (stroke vs. TIA)</td><td>Screening</td><td>None for TIA</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Perform vascular imaging within 24 hours of TIA; identify high-grade stenosis to guide carotid endarterectomy.  <br><span class=\"list-item\">\u2022</span> NASCET criteria (&ge;70% symptomatic stenosis) confer greatest surgical benefit.  <br><span class=\"list-item\">\u2022</span> CTA also detects vessel dissection, a critical TIA mimic requiring different management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying solely on carotid Doppler and missing high cervical/intracranial stenoses.  <br>2. Ordering EEG to &ldquo;rule out seizure&rdquo; in a classic vascular TIA scenario, delaying critical vascular assessment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2021 Guideline for the Prevention of Stroke in Patients With Stroke and TIA: Class I recommendation for CTA/MRA of head and neck in TIA (Level A evidence).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation (2022): Strong recommendation for comprehensive vascular imaging (CTA/MRA) within 24 hours of TIA (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam.  <br>Vascular imaging in TIA is a high-yield topic; examinees should distinguish between parenchymal (MRI) and vascular (CTA/MRA) studies and know the urgency of identifying symptomatic carotid stenosis.</div></div></div></div></div>"}, {"id": 100022980, "question_number": "39", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Lacunar infarcts are small (<15 mm) subcortical strokes, often involving the internal capsule, caused by lipohyalinosis of penetrating arterioles from chronic hypertension. Secondary prevention focuses on aggressive blood pressure control and antithrombotic therapy tailored to stroke subtype. While a PFO can be a source of paradoxical embolism, it is often incidental in the presence of a clear small\u2010vessel etiology. Aspirin monotherapy remains first\u2010line for lacunar stroke, whereas anticoagulation and PFO closure are reserved for confirmed cardioembolic or cryptogenic strokes in selected patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Aspirin 75&ndash;325 mg daily reduces recurrent non\u2010cardioembolic stroke by \u224822% <span class=\"citation\">(AHA/ASA 2019 Sec Prev Guideline, Class I, LOE A)</span>. The SPS3 trial (2013) randomized 3,020 lacunar stroke patients to aspirin vs. aspirin\u2009+\u2009clopidogrel; dual therapy showed no ischemic benefit and a 50% increase in major hemorrhage. Anticoagulation with warfarin is indicated for atrial fibrillation or venous thromboembolism, not for small\u2010vessel disease. PFO closure trials <span class=\"citation\">(RESPECT 2017, CLOSE 2017)</span> demonstrated benefit only in cryptogenic stroke patients <60 years without alternative risk factors. Here, the lacunar pattern and poorly controlled hypertension point to small\u2010vessel pathology&mdash;aspirin plus tight blood pressure management is optimal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Warfarin  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Targets cardioembolic sources; lacunar strokes are non\u2010cardioembolic.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating PFO presence with embolic stroke requiring anticoagulation.  <br><span class=\"list-item\">\u2022</span> Differentiator: No evidence of atrial fibrillation or venous source.<br><br>C. PFO closure  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Benefit shown only in select cryptogenic strokes without other causes.  <br><span class=\"list-item\">\u2022</span> Misconception: Any detected PFO mandates closure.  <br><span class=\"list-item\">\u2022</span> Differentiator: Imaging shows lacunar infarct consistent with hypertension\u2010related small\u2010vessel disease.<br><br>D. Aspirin and Plavix  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Long\u2010term dual antiplatelet therapy increases bleeding without added efficacy in lacunar stroke (SPS3).  <br><span class=\"list-item\">\u2022</span> Misconception: More intensive antithrombotic therapy always yields better outcomes.  <br><span class=\"list-item\">\u2022</span> Differentiator: DAPT is limited to &le;21 days post-minor non\u2010cardioembolic stroke (CHANCE/POINT).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Aspirin Monotherapy</th><th>Warfarin</th><th>PFO Closure</th><th>Aspirin + Clopidogrel</th></tr></thead><tbody><tr><td>Indication</td><td>Lacunar small\u2010vessel stroke</td><td>Cardioembolic stroke</td><td>Cryptogenic stroke with high\u2010risk PFO</td><td>Minor non\u2010cardioembolic stroke</td></tr><tr><td>Key guideline/trial</td><td>AHA/ASA 2019; SPS3</td><td>AF Guidelines</td><td>RESPECT, CLOSE</td><td>CHANCE, POINT</td></tr><tr><td>Recurrent stroke reduction</td><td>22%</td><td>N/A for lacunes</td><td>Yes, in selected cryptogenic pts</td><td>Short\u2010term benefit only</td></tr><tr><td>Major bleeding risk</td><td>Low</td><td>Moderate&ndash;high</td><td>Procedural/device risk</td><td>High if >21 days</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lacunar infarcts: hallmark is pure motor/sensory deficits; aggressive BP control (<130/80 mmHg) is as crucial as antiplatelet therapy.  <br><span class=\"list-item\">\u2022</span> Short\u2010term DAPT (&le;21 days) reduces early recurrence in minor non\u2010cardioembolic stroke, but long\u2010term use raises hemorrhage risk without extra ischemic protection.  <br><span class=\"list-item\">\u2022</span> PFO closure should be considered only after ruling out conventional etiologies and in patients <60 years with high\u2010risk PFO features (e.g., large shunt, septal aneurysm).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Attributing lacunar strokes to embolism solely because of a PFO, leading to unnecessary anticoagulation or closure.  <br><span class=\"list-item\">\u2022</span> Overprescribing long\u2010term dual antiplatelet therapy for lacunar stroke despite SPS3 evidence against it.  <br><span class=\"list-item\">\u2022</span> Underemphasizing hypertension control, the most potent modifiable risk factor for small\u2010vessel strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Secondary Stroke Prevention <span class=\"citation\">(<span class=\"evidence\">Stroke 2019</span>;50:e344&ndash;e418)</span>: Aspirin monotherapy recommended for lacunar stroke (Class I, LOE A); BP target <130/80 mmHg (Class I).  <br>2. SPS3 Trial <span class=\"citation\">(<span class=\"evidence\">Lancet 2013</span>;382:507&ndash;516)</span>: No benefit of long\u2010term aspirin\u2009+\u2009clopidogrel over aspirin alone; increased major bleeding (HR 1.5).  <br>3. RESPECT Trial <span class=\"citation\">(NEJM 2017;377:1022&ndash;1032)</span>: PFO closure vs. medical therapy in cryptogenic stroke; absolute risk reduction ~1%/year in selected <60 years.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Board exams frequently test stroke subtype recognition (lacunar vs. cardioembolic), appropriate secondary prevention (antiplatelet vs. anticoagulant), and criteria for PFO closure. Recognizing imaging patterns and risk profiles is high\u2010yield.</div></div></div></div></div>"}, {"id": 100022981, "question_number": "153", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Angioedema is an acute, potentially life-threatening swelling of the deep dermis and submucosa, often affecting the orolingual area. Intravenous tissue plasminogen activator (tPA) used in acute ischemic stroke can provoke orolingual angioedema through plasmin-mediated bradykinin generation, leading to increased vascular permeability. Risk factors include concurrent ACE-inhibitor therapy and insular cortex infarction. Prompt pharmacologic intervention targets histamine-mediated components of the edema, while vigilant airway monitoring prevents asphyxiation. First-line management consists of H1/H2 antihistamines and corticosteroids, with epinephrine reserved for severe or refractory cases; supportive measures include stopping the tPA infusion and ensuring airway protection.<br><br>(Word count: 120)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>tPA-induced angioedema occurs in approximately 1&ndash;5% of thrombolysed stroke patients <span class=\"citation\">(<span class=\"evidence\">Waqar et al., 2013</span>)</span>. The underlying mechanism involves plasmin-mediated cleavage of high-molecular-weight kininogen to bradykinin, which binds endothelial B2 receptors, increasing nitric oxide and prostaglandin release and causing vascular leak <span class=\"citation\">(<span class=\"evidence\">Binsfeld et al., 2017</span>)</span>. Case series <span class=\"citation\">(<span class=\"evidence\">Hill et al., 2003</span>;<span class=\"evidence\"> Kamath et al., 2015</span>)</span> demonstrate rapid symptom resolution with prompt administration of H1-antagonists (diphenhydramine 25&ndash;50 mg IV) plus corticosteroids (methylprednisolone 125 mg IV). <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke recommend this regimen (Class IIa, Level B-NR), noting that epinephrine (0.3&ndash;0.5 mg IM) should be used only if airway compromise worsens. These interventions directly counteract histamine release and stabilize endothelial barriers, making &ldquo;Anti-histamine & steroids&rdquo; the cornerstone of therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Reassurance  <br><span class=\"list-item\">\u2022</span> Incorrect: Orolingual angioedema can rapidly progress to airway obstruction.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming mild swelling requires no active treatment.  <br><span class=\"list-item\">\u2022</span> Differentiator: Unlike reassurance, antihistamine/steroid therapy halts progression.  <br><br>B. Intubate  <br><span class=\"list-item\">\u2022</span> Incorrect: Prophylactic intubation without attempting medical therapy exposes patients to unnecessary risks.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that airway compromise is inevitable.  <br><span class=\"list-item\">\u2022</span> Differentiator: Intubation is reserved for failed medical management or imminent airway collapse.  <br><br>D. Discontinue tPA  <br><span class=\"list-item\">\u2022</span> Incorrect: While stopping infusion removes further bradykinin stimulus, it does not reverse established edema.  <br><span class=\"list-item\">\u2022</span> Misconception: Thinking removal of tPA alone treats angioedema.  <br><span class=\"list-item\">\u2022</span> Differentiator: Pharmacotherapy is required to actively reduce vascular permeability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Anti-histamine & Steroids</th><th>Intubate</th><th>Reassurance</th><th>Discontinue tPA</th></tr></thead><tbody><tr><td>Primary Action</td><td>Stabilize endothelium, block histamine receptors</td><td>Mechanical airway protection</td><td>No active intervention</td><td>Stop further plasmin generation</td></tr><tr><td>Onset of Effect</td><td>15&ndash;30 minutes</td><td>Immediate</td><td>N/A</td><td>Immediate</td></tr><tr><td>Indication</td><td>Mild-to-moderate orolingual angioedema</td><td>Severe airway compromise or respiratory distress</td><td>None&mdash;underestimates risk</td><td>Adjunctive only</td></tr><tr><td>Guideline Recommendation</td><td>AHA/ASA 2018: IIa/B-NR</td><td>AHA/ASA 2018: IIb/C-LD (if needed)</td><td>Not recommended</td><td>Supportive, not definitive</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- ACE-inhibitor use increases tPA-related angioedema risk by up to sixfold; consider heightened monitoring.  <br><span class=\"list-item\">\u2022</span> Orolingual swelling often appears contralateral to the infarcted hemisphere due to autonomic dysfunction.  <br><span class=\"list-item\">\u2022</span> Early administration of H2-blockers (e.g., ranitidine 50 mg IV) alongside H1-antagonists can enhance edema resolution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating tPA-induced angioedema with classic IgE-mediated allergy and over-relying on epinephrine alone.  <br>2. Delaying pharmacologic therapy while awaiting airway compromise, falsely believing angioedema is self-limiting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association/American Stroke Association (AHA/ASA) 2018 Guidelines for Early Management of Acute Ischemic Stroke: Recommend IV diphenhydramine 25&ndash;50 mg and methylprednisolone 125 mg for tPA-induced angioedema (Class IIa, Level B-NR).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation (ESO) 2021 Guidelines on Acute Ischemic Stroke: Advise prompt H1/H2 blockade plus corticosteroids as first-line therapy for orolingual angioedema post-thrombolysis (Grade C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>tPA converts plasminogen to plasmin, which not only degrades fibrin but also generates bradykinin via cleavage of high-molecular-weight kininogen. Bradykinin binds endothelial B2 receptors, triggering NO and prostaglandin release, increasing vascular permeability in submucosal tissues. Concomitant ACE inhibitor use impairs bradykinin degradation, exacerbating edema formation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Acute stroke management frequently tests tPA complications&mdash;recognition of orolingual angioedema and its pharmacologic management is a high-yield topic on neurology boards.</div></div></div></div></div>"}]